0000059478-18-000256.txt : 20181106 0000059478-18-000256.hdr.sgml : 20181106 20181106103510 ACCESSION NUMBER: 0000059478-18-000256 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181106 DATE AS OF CHANGE: 20181106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LILLY ELI & CO CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 181161888 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1112 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1112 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 10-Q 1 lly-9302018x10q.htm 10-Q Document


 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
Quarterly Report Under Section 13 or 15(d) of the
Securities Exchange Act of 1934
FOR THE QUARTER ENDED SEPTEMBER 30, 2018
COMMISSION FILE NUMBER 001-6351
ELI LILLY AND COMPANY
(Exact name of Registrant as specified in its charter)
INDIANA
 
35-0470950
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
 
Identification No.)
LILLY CORPORATE CENTER, INDIANAPOLIS, INDIANA 46285
(Address of principal executive offices)
Registrant’s telephone number, including area code (317) 276-2000
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days.
Yes ý No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes ý No o
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of a “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ý
  
 
 
 
  
Accelerated filer o
Non-accelerated filer o
  
 
  
Smaller reporting company o
 
  
 
 
 
 
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes o No ý
The number of shares of common stock outstanding as of November 2, 2018:
Class
 
Number of Shares Outstanding
Common
 
1,059,322,255

 



Eli Lilly and Company
Form 10-Q
For the Quarter Ended September 30, 2018
Table of Contents
 
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

2


Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act). Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “intend,” “anticipate,” “plan,” “continue” or similar expressions.
In particular, information appearing under “Management's Discussion and Analysis of Results of Operations and Financial Condition” includes forward-looking statements. Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those projected in these statements. Where, in any forward-looking statement, we (Lilly or the company) express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:
•
the timing of anticipated regulatory approvals and launches of new products;
•
market uptake of recently launched products;
•
competitive developments affecting current products;
•
the expiration of intellectual property protection for certain of our products;
•
our ability to protect and enforce patents and other intellectual property;
•
the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals;
•
regulatory compliance problems or government investigations;
•
regulatory actions regarding currently marketed products;
•
unexpected safety or efficacy concerns associated with our products;
•
issues with product supply stemming from manufacturing difficulties or disruptions;
•
regulatory changes or other developments;
•
changes in patent law or regulations related to data-package exclusivity;
•
litigation involving past, current, or future products as we are largely self-insured;
•
unauthorized disclosure or misappropriation of trade secrets or other confidential data stored in our information systems, networks, and facilities, or those of third parties with whom we share our data;
•
changes in tax law;
•
changes in foreign currency exchange rates, interest rates, and inflation;
•
asset impairments and restructuring charges;
•
changes in accounting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC);
•
acquisitions and business development transactions and related integration costs;
•
information technology system inadequacies or operating failures;
•
reliance on third-party relationships and outsourcing arrangements;
•
the impact of global macroeconomic conditions; and
•
uncertainties and risks related to timing and potential value to both Elanco and Lilly of the planned separation of the Elanco animal health business, including business, industry, and market risks, as well as risks involving realizing the anticipated tax-free nature of the separation.
More information on factors that could cause actual results or events to differ materially from those anticipated is included from time to time in our reports filed with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2017, particularly under the caption “Risk Factors”, and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2018 and June 30, 2018.
All forward-looking statements herein speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this report. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report.

3


PART I. Financial Information
Item 1. Financial Statements
Consolidated Condensed Statements of Operations
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars and shares in millions, except per-share data)
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Revenue
$
6,061.9

 
$
5,658.0

 
$
18,117.1

 
$
16,710.6

Costs, expenses, and other:
 
 
 
 
 
 
 
Cost of sales
1,562.3

 
1,586.3

 
4,836.3

 
4,505.9

Research and development
1,343.3

 
1,340.0

 
3,853.3

 
3,870.4

Marketing, selling, and administrative
1,616.6

 
1,578.5

 
4,770.3

 
4,876.6

Acquired in-process research and development (Note 3)
30.0

 
205.0

 
1,654.5

 
1,062.6

Asset impairment, restructuring, and other special charges (Note 5)
83.3

 
406.5

 
236.0

 
670.4

Other–net, (income) expense (Note 11)
15.4

 
(49.9
)
 
(90.1
)
 
(188.6
)
 
4,650.9


5,066.4


15,260.3


14,797.3

Income before income taxes
1,411.0


591.6


2,856.8


1,913.3

Income taxes (Note 7)
261.5

 
36.0

 
749.8

 
460.5

Net income
$
1,149.5


$
555.6


$
2,107.0


$
1,452.8

 
 
 
 
 
 
 
 
Earnings per share:
 
 
 
 
 
 
 
Basic
$
1.13

 
$
0.53

 
$
2.04

 
$
1.38

Diluted
$
1.12

 
$
0.53

 
$
2.03

 
$
1.37

Shares used in calculation of earnings per share:
 
 
 
 
 
 
 
Basic
1,020.4

 
1,053.4

 
1,033.2

 
1,054.8

Diluted
1,026.3

 
1,056.0

 
1,037.8

 
1,057.0

See notes to consolidated condensed financial statements.

4


Consolidated Condensed Statements of Comprehensive Income
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Net income
$
1,149.5

 
$
555.6

 
$
2,107.0

 
$
1,452.8

Other comprehensive income, net of tax (Note 10) (1)
660.2

 
167.7

 
375.3

 
651.2

Comprehensive income
$
1,809.7


$
723.3


$
2,482.3


$
2,104.0

(1) Other comprehensive income for the three and nine months ended September 30, 2018 was all attributable to controlling interest. Other comprehensive income for the three and nine months ended September 30, 2017 consisted of $165.5 million and $664.6 million, respectively, of other comprehensive income attributable to controlling interest and $2.2 million and $(13.4) million of other comprehensive income (loss) attributable to noncontrolling interest during the same periods.
See notes to consolidated condensed financial statements.


5


Consolidated Condensed Balance Sheets
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)

 
September 30, 2018
 
December 31, 2017
Assets
(Unaudited)
 
 
Current Assets
 
 
 
Cash and cash equivalents (Note 6)
$
8,960.0

 
$
6,536.2

Short-term investments (Note 6)
76.1

 
1,497.9

Accounts receivable, net of allowances of $34.0 (2018) and $38.7 (2017)
4,859.4

 
4,546.3

Other receivables
793.2

 
715.9

Inventories
4,118.0

 
4,458.3

Prepaid expenses and other
1,879.2

 
1,447.5

Total current assets
20,685.9

 
19,202.1

Other Assets
 
 
 
Investments (Note 6)
2,005.8

 
5,678.8

Goodwill
4,358.4

 
4,370.1

Other intangibles
3,619.4

 
4,029.2

Deferred tax assets
3,132.3

 
1,166.4

Sundry
2,009.2

 
1,707.9

Total other assets
15,125.1

 
16,952.4

Property and equipment, net of accumulated depreciation of $9,671.7 (2018) and $9,264.6 (2017)
8,814.1

 
8,826.5

Total assets
$
44,625.1

 
$
44,981.0

Liabilities and Equity
 
 
 
Current Liabilities
 
 
 
Short-term borrowings and current maturities of long-term debt
$
1,002.2

 
$
3,706.6

Accounts payable
1,281.2

 
1,410.7

Employee compensation
858.5

 
997.9

Sales rebates and discounts
5,129.4

 
4,465.1

Dividends payable
—

 
590.6

Income taxes payable
409.2

 
532.9

Other current liabilities
2,146.2

 
2,832.1

Total current liabilities
10,826.7

 
14,535.9

Other Liabilities
 
 
 
Long-term debt
11,674.7

 
9,940.5

Accrued retirement benefits (Note 8)
2,684.5

 
3,513.9

Long-term income taxes payable
3,740.5

 
3,776.5

Other noncurrent liabilities
1,547.8

 
1,546.3

Total other liabilities
19,647.5

 
18,777.2

Commitments and Contingencies (Note 9)
 
 
 
Eli Lilly and Company Shareholders’ Equity
 
 
 
Common stock
667.1

 
687.9

Additional paid-in capital
6,522.9

 
5,817.8

Retained earnings
14,408.7

 
13,894.1

Employee benefit trust
(3,013.2
)
 
(3,013.2
)
Accumulated other comprehensive loss (Note 10)
(5,439.5
)
 
(5,718.6
)
Cost of common stock in treasury
(69.4
)
 
(75.8
)
Total Eli Lilly and Company shareholders’ equity
13,076.6

 
11,592.2

Noncontrolling interests (Note 3)
1,074.3

 
75.7

Total equity
14,150.9

 
11,667.9

Total liabilities and equity
$
44,625.1

 
$
44,981.0

See notes to consolidated condensed financial statements.

6


Consolidated Condensed Statements of Equity
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)

 
Equity of Eli Lilly and Company Shareholders
 
 
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions, shares in thousands)
Common Stock
 
Additional
Paid-in
Capital
 
Retained
Earnings
 
Employee Benefit Trust
 
Accumulated Other Comprehensive Loss
 
Common Stock in Treasury
 
Noncontrolling Interest
Shares
 
Amount
Shares
 
Amount
Balance at July 1, 2017
1,101,646

 
$
688.5

 
$
5,686.1

 
$
15,590.1

 
$
(3,013.2
)
 
$
(4,774.9
)
 
664

 
$
(75.8
)
 
$
68.9

Net income


 


 


 
555.6

 


 


 


 


 
0.3

Other comprehensive income, net of tax


 


 


 


 


 
165.5

 


 


 
2.2

Issuance of stock under employee stock plans, net
26

 


 
(1.2
)
 


 


 


 


 


 


Stock-based compensation


 


 
69.8

 


 


 


 


 


 


Other


 


 


 
(0.2
)
 


 


 


 


 
(1.1
)
Balance at September 30, 2017
1,101,672

 
$
688.5

 
$
5,754.7

 
$
16,145.5

 
$
(3,013.2
)
 
$
(4,609.4
)
 
664

 
$
(75.8
)
 
$
70.3

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at July 1, 2018
1,077,548

 
$
673.5

 
$
5,825.7

 
$
14,247.3

 
$
(3,013.2
)
 
$
(6,108.7
)
 
604

 
$
(69.4
)
 
$
65.6

Net income (loss)


 


 


 
1,149.5

 


 


 


 


 
(5.2
)
Other comprehensive income, net of tax


 


 


 


 


 
660.2

 


 


 


Retirement of treasury shares
(10,191
)
 
(6.4
)
 


 
(993.7
)
 


 


 
(10,191
)
 
1,000.0

 


Purchase of treasury shares (1)


 


 


 


 


 


 
10,191

 
(1,000.0
)
 


Issuance of stock under employee stock plans, net
17

 


 
(0.5
)
 


 


 


 


 


 


Stock-based compensation


 


 
68.5

 


 


 


 


 


 


Sale of Elanco stock (Note 3)


 


 
629.2

 


 


 
9.0

 


 


 
1,017.2

Other


 


 


 
5.6

 


 


 


 


 
(3.3
)
Balance at September 30, 2018
1,067,374

 
$
667.1

 
$
6,522.9

 
$
14,408.7

 
$
(3,013.2
)
 
$
(5,439.5
)
 
604

 
$
(69.4
)
 
$
1,074.3

(1) As of September 30, 2018, there was $7.00 billion remaining under our $8.00 billion share repurchase program authorized in June 2018.
See notes to consolidated condensed financial statements.


























7


Consolidated Condensed Statements of Equity (Continued)
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)

 
Equity of Eli Lilly and Company Shareholders
 
 
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions, shares in thousands)
Common Stock
 
Additional
Paid-in
Capital
 
Retained
Earnings
 
Employee Benefit Trust
 
Accumulated Other Comprehensive Loss
 
Common Stock in Treasury
 
Noncontrolling Interest
Shares
 
Amount
Shares
 
Amount
Balance at January 1, 2017
1,101,586

 
$
688.5

 
$
5,640.6

 
$
16,046.3

 
$
(3,013.2
)
 
$
(5,274.0
)
 
711

 
$
(80.5
)
 
$
72.8

Net income


 


 


 
1,452.8

 


 


 


 


 
14.3

Other comprehensive income (loss), net of tax


 


 


 


 


 
664.6

 


 


 
(13.4
)
Cash dividends declared per share: $1.04


 


 


 
(1,095.7
)
 


 


 


 


 


Retirement of treasury shares
(3,191
)
 
(2.0
)
 


 
(257.9
)
 


 


 
(3,191
)
 
259.9

 


Purchase of treasury shares


 


 
60.0

 


 


 


 
3,191

 
(259.9
)
 


Issuance of stock under employee stock plans, net
3,277

 
2.0

 
(155.0
)
 


 


 


 
(47
)
 
4.7

 


Stock-based compensation


 


 
209.1

 


 


 


 


 


 


Other


 


 


 


 


 


 


 


 
(3.4
)
Balance at September 30, 2017
1,101,672

 
$
688.5

 
$
5,754.7

 
$
16,145.5

 
$
(3,013.2
)
 
$
(4,609.4
)
 
664

 
$
(75.8
)
 
$
70.3

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at January 1, 2018
1,100,672

 
$
687.9

 
$
5,817.8

 
$
13,894.1

 
$
(3,013.2
)
 
$
(5,718.6
)
 
664

 
$
(75.8
)
 
$
75.7

Net income (loss)


 


 


 
2,107.0

 


 


 


 


 
(0.6
)
Other comprehensive income, net of tax


 


 


 


 


 
375.3

 


 


 


Cash dividends declared per share: $1.13


 


 


 
(1,148.6
)
 


 


 


 


 


Retirement of treasury shares
(36,014
)
 
(22.5
)
 


 
(3,028.2
)
 


 


 
(36,014
)
 
3,050.7

 


Purchase of treasury shares (1)


 


 


 


 


 


 
36,014

 
(3,050.7
)
 


Issuance of stock under employee stock plans, net
2,716

 
1.7

 
(130.8
)
 


 


 


 
(60
)
 
6.4

 


Stock-based compensation


 


 
206.7

 


 


 


 


 


 


Adoption of new accounting standards (Note 2)


 


 


 
2,584.4

 


 
(105.2
)
 


 


 


Sale of Elanco stock (Note 3)


 


 
629.2

 


 


 
9.0

 


 


 
1,017.2

Other


 


 


 


 


 


 


 


 
(18.0
)
Balance at September 30, 2018
1,067,374

 
$
667.1

 
$
6,522.9

 
$
14,408.7

 
$
(3,013.2
)
 
$
(5,439.5
)
 
604

 
$
(69.4
)
 
$
1,074.3

(1) As of September 30, 2018, there was $7.00 billion remaining under our $8.00 billion share repurchase program authorized in June 2018.
See notes to consolidated condensed financial statements.



8


Consolidated Condensed Statements of Cash Flows
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
 
 
Nine Months Ended
September 30,
 
2018
 
2017
Cash Flows from Operating Activities
 
Net income
$
2,107.0

 
$
1,452.8

Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
 
 
 
Depreciation and amortization
1,263.5

 
1,155.4

Change in deferred income taxes
161.6

 
151.7

Stock-based compensation expense
206.7

 
209.1

Acquired in-process research and development
1,654.5

 
1,062.6

Other changes in operating assets and liabilities, net of acquisitions
(1,638.2
)
 
(525.2
)
Other non-cash operating activities, net
320.7

 
365.7

Net Cash Provided by Operating Activities
4,075.8

 
3,872.1

Cash Flows from Investing Activities
 
 
 
Net purchases of property and equipment
(816.3
)
 
(633.3
)
Proceeds from sales and maturities of short-term investments
2,535.5

 
2,320.2

Purchases of short-term investments
(112.2
)
 
(2,973.8
)
Proceeds from sales of noncurrent investments
3,444.7

 
1,686.9

Purchases of noncurrent investments
(719.7
)
 
(3,739.6
)
Cash paid for acquisitions, net of cash acquired (Note 3)
—

 
(882.1
)
Purchase of in-process research and development (Note 3)
(1,578.2
)
 
(1,036.8
)
Other investing activities, net
(188.8
)
 
(178.0
)
Net Cash Provided by (Used for) Investing Activities
2,565.0

 
(5,436.5
)
Cash Flows from Financing Activities
 
 
 
Dividends paid
(1,739.2
)
 
(1,643.8
)
Net change in short-term borrowings
(2,297.1
)
 
1,226.8

Proceeds from issuance of long-term debt
2,477.7

 
2,232.0

Repayments of long-term debt
(1,001.5
)
 
(630.6
)
Purchases of common stock
(3,050.7
)
 
(199.9
)
Net proceeds from Elanco initial public offering (Note 3)
1,659.7

 
—

Other financing activities, net
(314.1
)
 
(299.6
)
Net Cash Provided by (Used for) Financing Activities
(4,265.2
)
 
684.9

Effect of exchange rate changes on cash and cash equivalents
48.2

 
21.7

 
 
 
 
Net increase (decrease) in cash and cash equivalents
2,423.8

 
(857.8
)
Cash and cash equivalents at January 1
6,536.2

 
4,582.1

Cash and Cash Equivalents at September 30
$
8,960.0

 
$
3,724.3

See notes to consolidated condensed financial statements.



9


Notes to Consolidated Condensed Financial Statements
(Tables present dollars in millions, except per-share data)
Note 1: Basis of Presentation and Revenue
We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2017. We issue our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing.
All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of incremental shares from our stock-based compensation programs.
Adoption of Revenue Accounting Standard
Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers and other related updates (see Note 2 for additional discussion). The new standard has been applied to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don’t believe the effect of applying this practical expedient resulted in material differences. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for the three and nine months ended September 30, 2018 do not differ materially from amounts that would have resulted from application of the previous standards.
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Net product revenue
$
5,664.5

 
$
5,323.8

 
$
16,905.6

 
$
15,841.5

Collaboration and other revenue (1)
397.4

 
334.2

 
1,211.5

 
869.1

Revenue
$
6,061.9

 
$
5,658.0

 
$
18,117.1

 
$
16,710.6

(1) Collaboration and other revenue associated with prior year transfers of intellectual property was $76.2 million and $258.4 million during the three and nine months ended September 30, 2018, respectively, and $36.7 million and $105.5 million during the three and nine months ended September 30, 2017, respectively.
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta™ and Jardiance® families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Net Product Revenue
Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 75 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a

10


financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates and discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.
Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates and discounts and returns. The following describe the most significant of these judgments:
Sales Rebates and Discounts - Background and Uncertainties
•
Most of our pharmaceutical products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. Most of our animal health products are sold to wholesale distributors. We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.
•
The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.
•
The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback contracts in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.
•
Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.
Sales Returns - Background and Uncertainties
•
When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuances, or a changing competitive environment. We maintain a returns policy that allows U.S. pharmaceutical customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.

11


•
As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products sold to major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.
•
Actual product returns have been less than 2 percent of our net revenue over each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market.
Adjustments to Revenue
Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended September 30, 2018, for product shipped in previous years were not material.
Disaggregation of Revenue
Our disaggregated revenue is disclosed in Note 12.
Collaborations and Other Arrangements
We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers.
•
Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.
•
Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date.
•
Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.
•
Royalty revenue from licensees, which is based on sales to third parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.
•
For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.
•
Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval.

12


•
We have entered into arrangements whereby we transferred rights to products and committed to supply for a period of time. For those arrangements for which we concluded that the obligations were not distinct, any amounts received upfront are being amortized to revenue as net product revenue over the period of the supply arrangement as the performance obligation is satisfied.
Contract Liabilities
Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales rebates, discounts, and returns. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.
We have the following amounts recorded for contract liabilities:
 
September 30, 2018
 
December 31, 2017
Contract liabilities
$
308.6

 
$
335.2

The contract liabilities amount disclosed above as of September 30, 2018, is primarily related to:
•
The remaining license period of symbolic intellectual property, and
•
Obligations to supply product for a defined period of time.
Revenue recognized from contract liabilities as of January 1, 2018, during the three and nine months ended September 30, 2018, was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.
Note 2: Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:
Standard
 
Description
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers
 
This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.
 
Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 12.
Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities
 
This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.
 
Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.

13


Standard
 
Description
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory
 
This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified
retrospective approach to adoption.
 
Upon adoption, the cumulative effect of applying the standard resulted in an increase to deferred tax assets and retained earnings of approximately $2.5 billion. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.
Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost
 
This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component.
 
Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. The application of the new standard resulted in reclassification to other income of $63.8 million for the three months ended September 30, 2017, while increasing cost of sales by $20.2 million, marketing, selling, and administrative expenses by $23.0 million, and research and development expenses by $20.6 million for the same period. The application of the new standard resulted in reclassification to other income of $191.3 million for the nine months ended September 30, 2017, while increasing cost of sales by $60.5 million, marketing, selling, and administrative expenses by $69.0 million, and research and development expenses by $61.8 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.

The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on our financial statements:
Standard
 
Description
 
Effective Date
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases
 
This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.
 
This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt on that date.
 
We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.

14


Note 3: Divestiture and Acquisitions
Divestiture
Formation of Elanco and Initial Public Offering
On September 24, 2018, Elanco Animal Health Incorporated (Elanco) completed an initial public offering (the IPO) resulting in the issuance of 72.3 million shares of its common stock, which represents 19.8 percent of Elanco's outstanding shares, at $24 per share. Elanco shares began trading on the New York Stock Exchange under the symbol "ELAN" in September 2018.
In connection with the completion of the IPO, through a series of equity and other transactions, we transferred to Elanco the animal health businesses that form its business going forward. In exchange, Elanco transferred to us, or will transfer to us, consideration of approximately $4.2 billion, which consists primarily of the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco in August 2018, and the term loan facility entered into by Elanco during the period (see Note 6). The consideration that we receive is intended to be used for debt repayment, dividends, and/or share repurchases. The excess of the net proceeds from the IPO over the net book value of our divested interest was $629.2 million and was recorded in additional paid-in capital. Of our consolidated cash and cash equivalents as of September 30, 2018, approximately $300 million is retained by Elanco for working capital purposes.
We continue to consolidate Elanco, as we retain control over Elanco. The earnings attributable to the divested, noncontrolling interest for the period from IPO until September 30, 2018 were not material for the three and nine months ended September 30, 2018. As of September 30, 2018, the noncontrolling interest of $1.02 billion associated with Elanco is reflected in noncontrolling interests in the consolidated condensed balance sheet.
Acquisitions
On January 3, 2017, we completed the acquisition of Boehringer Ingelheim Vetmedica, Inc.'s United States (U.S.) feline, canine, and rabies vaccine portfolio and other related assets (BIVIVP). This transaction, as further discussed in this note below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition have been included in our consolidated condensed financial statements from the date of acquisition.
In addition to the acquisition of BIVIVP, we acquired assets in development in the nine months ended September 30, 2018, which are further discussed in this note below in Asset Acquisitions. Upon acquisition, the acquired in-process research and development (IPR&D) charges related to these products were immediately expensed because the products had no alternative future use. We incurred acquired IPR&D charges of $30.0 million and $1.65 billion for the three and nine months ended September 30, 2018, respectively, and $205.0 million and $1.06 billion for the three and nine months ended September 30, 2017, respectively.

15


Acquisition of a Business
Boehringer Ingelheim Vetmedica, Inc. Vaccine Portfolio Acquisition
Overview of Transaction
In 2017, we acquired BIVIVP in an all-cash transaction for $882.1 million. Under the terms of the agreement, we acquired a manufacturing and research and development site and a U.S. vaccine portfolio, including vaccines used for the treatment of bordetella, Lyme disease, rabies, and parvovirus, among others.
Assets Acquired and Liabilities Assumed
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at January 3, 2017
Inventories
$
108.6

Marketed products (1)
297.0

Property and equipment
148.2

Other assets and liabilities - net
8.2

Total identifiable net assets
562.0

Goodwill (2)
320.1

Total consideration transferred - net of cash acquired
$
882.1

(1) These intangible assets, which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 10 years.
(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy animal health business, future unidentified projects and products, and the assembled workforce of BIVIVP. The goodwill associated with this acquisition is deductible for tax purposes.
Asset Acquisitions
The following table and narrative summarize our asset acquisitions during the nine months ended September 30, 2018 and September 30, 2017.
Counterparty
Compound(s) or Therapy
Acquisition Month
 
Phase of Development (1)
 
Acquired IPR&D Expense
Sigilon Therapeutics (Sigilon)
Encapsulated cell therapies for the potential treatment of type 1 diabetes
April 2018
 
Pre-clinical
 
$
66.9

AurKa Pharma, Inc. (AurKa)
AK-01, an Aurora kinase A inhibitor
June 2018
 
Phase I
 
81.8

ARMO Biosciences, Inc. (ARMO)
Cancer therapy - pegilodecakin
June 2018
 
Phase III
 
1,475.8

Anima Biotech (Anima)
Translation inhibitors for selected neuroscience targets
July 2018
 
Pre-clinical
 
30.0

 
 
 
 
 
 
 
CoLucid Pharmaceuticals, Inc. (CoLucid)
Oral therapy for the acute treatment of migraine - lasmiditan
March 2017
 
Phase III
 
857.6

KeyBioscience AG (KeyBioscience)
Multiple molecules for treatment of metabolic disorders
July 2017
 
Phase II
 
55.0

Nektar Therapeutics (Nektar)
Immunological therapy - NKTR-358
August 2017
 
Phase I
 
150.0

(1) The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.
In connection with the arrangements described herein, our partners may be entitled to future royalties and/or commercial milestones based on sales should these products be approved for commercialization and/or milestones based on the successful progress of the compounds through the development process.

16


We entered into a collaboration agreement with Sigilon to develop encapsulated cell therapies for the potential treatment of type 1 diabetes. Sigilon will create proprietary products comprised of induced pluripotent stem cells engineered into differentiated insulin-producing pancreatic beta cells and encapsulated using Sigilon's Afibromer technology. We will receive an exclusive worldwide license to Sigilon's Afibromer technology for islet cell encapsulation. Under the terms of the agreement, we paid an upfront fee of $62.5 million and made an equity investment in Sigilon.
We acquired AK-01 through the acquisition of AurKa. Under the terms of the agreement, we acquired all shares of AurKa for a cash purchase price of $81.3 million, net of cash acquired, plus net accrued liabilities assumed of $0.5 million. Substantially all the value of AurKa was related to AK-01, its only significant asset. The acquired IPR&D expense was not tax deductible.
We acquired pegilodecakin through the acquisition of ARMO. Under the terms of the agreement, we acquired all shares of ARMO for a cash purchase price of $1.40 billion, net of cash acquired, plus net accrued liabilities assumed of $75.8 million. Substantially all of the value of ARMO was related to pegilodecakin, its only significant asset. The acquired IPR&D expense was not tax deductible.
We entered into a collaboration agreement with Anima for the discovery and development of translation inhibitors for several target proteins by using Anima's translation control therapeutics platform. Under the terms of the agreement, we paid an upfront fee of $30.0 million. Anima will use its technology platform to discover lead candidates that are translation inhibitors of our selected neuroscience targets. We will be responsible for all clinical development and commercialization activities and costs related to the collaboration.
We acquired lasmiditan through the acquisition of CoLucid. Under the terms of the agreement, we acquired all shares of CoLucid for a cash purchase price of $831.8 million, net of cash acquired, plus net accrued liabilities assumed of $25.8 million. Substantially all of the value of CoLucid was related to lasmiditan, its only significant asset. The acquired IPR&D expense was not tax deductible.
Our collaboration agreement with KeyBioscience provides us with access to KeyBioscience's Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of treatments for metabolic disorders such as type 2 diabetes, along with multiple molecules. Prior to entering into the agreement, KeyBioscience had initiated Phase II development of the lead molecule. The other assets included in the collaboration range from pre-clinical to Phase I development. Under the terms of the agreement, we receive worldwide rights to develop and commercialize these molecules.
Our collaboration with Nektar is to co-develop Nektar's compound which has the potential to treat a number of autoimmune and other chronic inflammatory conditions. Under the terms of the agreement, we are responsible for all costs of global commercialization. Nektar will have an option to co-promote in the U.S. under certain conditions.
In September 2018, we announced a license agreement with Chugai Pharmaceutical Company for OWL833, an oral non-peptidic GLP-1 receptor agonist. OWL833 is a preclinical asset that is being studied for the treatment of type 2 diabetes. Under the terms of the agreement, we will acquire worldwide development and commercialization rights to OWL833 for a cash purchase price of $50.0 million and success-based milestones and royalties. The transaction is expected to close in the fourth quarter of 2018, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. We expect an acquired IPR&D charge of $50.0 million in the fourth quarter of 2018.
In October 2018, we announced a global license and research agreement with Dicerna Pharmaceuticals (Dicerna) for the discovery, development, and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration, and pain. Under terms of the agreement, we will pay an upfront fee of $100.0 million and make an equity investment in Dicerna. The transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Upon closing, we will record an acquired IPR&D expense of approximately $135 million.
In October 2018, we acquired a Priority Review Voucher from SIGA Technologies, Inc. for a cash purchase price of $80.0 million. We intend to utilize the voucher to fast track a product application for an existing R&D project, although the specific project has not yet been determined. As a result of this transaction, we will record an acquired IPR&D expense of $80.0 million in the fourth quarter of 2018.

17


In November 2018, we entered into a collaboration agreement with NextCure, Inc. (NextCure) for the discovery and development of immuno-oncology cancer therapies. NextCure will apply its discovery platform technology to identify novel, functional immune-related targets and we will develop antibodies to these targets. The parties will be able to exclusively license antibodies resulting from the collaboration. Under terms of the agreement, we will pay an upfront fee of $25.0 million and make an equity investment in NextCure. As a result of this transaction, we will record an acquired IPR&D expense of approximately $30 million in the fourth quarter of 2018.
Note 4: Collaborations and Other Arrangements
We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the collaboration partner. See Note 1 for amounts of collaboration and other revenue recognized from these types of arrangements.
Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.
Boehringer Ingelheim Diabetes Collaboration
We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim’s oral diabetes products: Trajenta, Jentadueto®, Jardiance, Glyxambi®, and Synjardy®, as well as our basal insulin: Basaglar®.
The table below summarizes significant regulatory and commercialization events and milestones (deferred) capitalized for the compounds included in this collaboration:
 
 
Year Launched
 
Milestones
(Deferred) Capitalized (1)
Product Family
 
U.S.
 
Europe
 
Japan
 
Year
Amount
Trajenta (2)
 
2011
 
2011
 
2011
 
Cumulative (4) - all prior to 2017
$
446.4

Jardiance (3)
 
2014
 
2014
 
2015
 
Cumulative (4) - all prior to 2017
299.5

Basaglar
 
2016
 
2015
 
2015
 
Cumulative (4) - all prior to 2017
(250.0
)
(1) In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration.
(2) Jentadueto is included in the Trajenta product family. The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
(3) Glyxambi and Synjardy are included in the Jardiance product family. The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
(4) The cumulative amount represents the total initial amounts that were (deferred) or capitalized from the start of this collaboration through the end of the reporting period.
In the most significant markets, we and Boehringer Ingelheim share equally the ongoing development costs, commercialization costs, and agreed upon gross margin for any product resulting from the collaboration. We record our portion of the gross margin associated with Boehringer Ingelheim's compounds as collaboration and other revenue. We record our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company is entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments result in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may be reduced by any performance payments we make related to these products. Similarly, performance payments we may receive related to Basaglar effectively reduce Boehringer Ingelheim's share of the gross margin, which reduces our cost of sales.

18


The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Basaglar
$
201.2

 
$
145.7

 
$
569.0

 
$
278.3

Jardiance
166.9

 
127.2

 
465.1

 
304.3

Trajenta
135.7

 
153.3

 
418.5

 
408.2

Erbitux® 
We have several collaborations with respect to Erbitux. The most significant collaborations are or, where applicable, were in Japan, and prior to the transfer of commercialization rights in the fourth quarter of 2015, the U.S. and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). Certain rights to Erbitux outside the U.S. and Canada (collectively, North America) will remain with Merck KGaA (Merck) upon expiration of that agreement.
The following table summarizes our revenue recognized with respect to Erbitux:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Net product revenue
$
133.7

 
$
137.6

 
$
397.0

 
$
403.3

Collaboration and other revenue
25.8

 
25.9

 
78.5

 
73.7

Revenue
$
159.5


$
163.5


$
475.5


$
477.0

Bristol-Myers Squibb Company
Pursuant to commercial agreements with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), we had been co-developing Erbitux in North America exclusively with BMS. On October 1, 2015, BMS transferred their commercialization rights to us with respect to Erbitux in North America pursuant to a modification of our existing arrangement, and we began selling Erbitux at that time. This modification did not affect our rights with respect to Erbitux in other jurisdictions. In connection with the modification of terms, we provided consideration to BMS based upon a tiered percentage of net sales of Erbitux in North America estimated to average 38 percent through September 2018. The transfer of the commercialization rights was accounted for as an acquisition of a business. The consideration to be paid to BMS was accounted for as contingent consideration liability. See Note 6 for discussion regarding the estimation of this liability.
Merck KGaA
A development and license agreement grants Merck exclusive rights to market Erbitux outside of North America until December 2018. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. This agreement was amended in 2015 to grant Merck exclusive commercialization rights in Japan but did not result in any changes to our rights.
Merck manufactures Erbitux for supply in its territory as well as for Japan. We receive a royalty on the sales of Erbitux outside of North America, which is included in collaboration and other revenue as the underlying sales occur. Royalties due to third parties are recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties.
Olumiant® 
We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte) which provides us the development and commercialization rights to its Janus tyrosine kinase inhibitor compound, now known as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. Incyte exercised its option to co-develop Olumiant in rheumatoid arthritis in 2010 and psoriatic arthritis, atopic dermatitis, alopecia areata, and systemic lupus erythematosus (SLE) in 2017. The

19


agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones.
The following table summarizes our milestones achieved:
Year
Event
Classification
Amount
2016
Regulatory submissions in the U.S. and Europe
R&D expense
$
55.0

2017
Regulatory approval in Europe
Intangible asset
65.0

Regulatory approval in Japan
Intangible asset
15.0

Began Phase III testing for atopic dermatitis
R&D expense
30.0

2018
Regulatory approval in the U.S.
Intangible asset
100.0

Began Phase III testing for SLE
R&D Expense
20.0

As of September 30, 2018, Incyte is eligible to receive up to $130.0 million of additional payments from us contingent upon certain development and success-based regulatory milestones. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones.
Effient® 
We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. Marketing rights for major territories are shown below. We and Daiichi Sankyo each have exclusive marketing rights in certain other territories.
Territory
 
Marketing Rights
 
Selling Party
U.S.
 
Co-promotion
 
Lilly
Major European markets
 
Co-promotion
 
Daiichi Sankyo
Japan
 
Exclusive
 
Daiichi Sankyo
While major European markets are a co-promotion territory under the terms of our arrangement, Daiichi Sankyo exclusively promotes Effient in these markets.
The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories, including the major European markets.
We record net product revenue in our exclusive and co-promotion territories where we are the selling party. Profit-share payments due to Daiichi Sankyo for co-promotion countries where we are the selling party are recorded as marketing, selling, and administrative expenses. Any profit-share payments due to us from Daiichi Sankyo for the major European markets are recorded as collaboration and other revenue. We also record our share of the expenses in these co-promotion territories as marketing, selling, and administrative expenses. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. All royalties due to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. Generic versions of Effient launched in the U.S. in the third quarter of 2017.
The following table summarizes our revenue recognized with respect to Effient:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Revenue
$
45.3

 
$
55.9

 
$
104.8

 
$
326.6

Tanezumab
We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain, chronic low back pain, and cancer pain. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and certain commercialization expenses. As of September 30, 2018, Pfizer is eligible to receive up to $350.0 million in success-based regulatory milestones and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.

20


Note 5: Asset Impairment, Restructuring, and Other Special Charges
The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below.
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Severance:
 
 
 
 
 
 
 
Human pharmaceutical products
$
—

 
$
165.7

 
$
(24.7
)
 
$
277.1

Animal health products
(5.4
)
 
5.8

 
(0.6
)
 
62.1

Total severance
(5.4
)
 
171.5

 
(25.3
)
 
339.2

Asset impairment and other special charges:
 
 
 
 
 
 
 
Human pharmaceutical products
3.5

 
25.0

 
2.0

 
25.0

Animal health products
85.2

 
210.0

 
259.3

 
306.2

Total asset impairment and other special charges
88.7

 
235.0

 
261.3

 
331.2

Total asset impairment, restructuring, and other special charges
$
83.3

 
$
406.5

 
$
236.0

 
$
670.4

Severance charges recognized during the nine months ended September 30, 2018 primarily relate to severance adjustments recorded in the second quarter of 2018. Our severance charges recognized in the second half of 2017 as part of planned restructuring activities were based upon estimates for the number of employees that either lost or were going to lose their then current roles and would ultimately leave the company. During the second quarter of 2018, we determined that more displaced employees than expected were able to find other roles within the company, resulting in an immaterial reduction in the actual severance costs incurred. We expect the majority of the remaining severance payments to be made in the next 12 months.
Asset impairment and other special charges recognized during the three months ended September 30, 2018 resulted primarily from asset impairment and other restructuring charges related to the sale of the Posilac® (rbST) brand and the associated Augusta, Georgia manufacturing site. We also incurred expenses associated with the IPO and separation of Elanco. These expenses were offset by a gain recognized associated with the pension curtailment (see Note 8 for additional discussion).
In addition to the charges for the three months ended September 30, 2018, additional asset impairment and other special charges for the nine months ended September 30, 2018 included asset impairment, exit costs, and other charges related to the decision to end Posilac (rbST) production at the Augusta, Georgia manufacturing site, and charges related to the decision to suspend commercialization of Imrestor®, an animal health product. We also incurred expenses associated with the review of strategic alternatives for the Elanco animal health business.
Severance costs recognized during the three and nine months ended September 30, 2017 were incurred as a result of actions taken to reduce our cost structure, as well as the integration of Novartis Animal Health (Novartis AH).
Substantially all of the asset impairment and other special charges recognized during the three months ended September 30, 2017 were related to lower projected revenue for Posilac (rbST). The assets associated with Posilac (rbST) were written down to their fair values, which were determined based upon a discounted cash flow valuation. Other asset impairment and other special charges recognized during the three months ended September 30, 2017 related to exit costs associated with site closures. Asset impairment and other special charges recognized during the nine months ended September 30, 2017 resulted primarily from charges associated with the Posilac (rbST) impairment, integration costs of Novartis AH, as well as asset impairments due to site closures.

21


Note 6: Financial Instruments
Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.
Our equity investments are accounted for using three different methods depending on the type of equity investment:
•
Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense.
•
For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense.
•
Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense.
We review equity investments other than public equity investments for indications of impairment on a regular basis.
Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.
For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of gains and losses is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the effective portion of foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change.
We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2018, we had outstanding foreign currency forward commitments to purchase 1.40 billion U.S. dollars and sell 1.19 billion euro, commitments to purchase 1.57 billion euro and sell 1.84 billion U.S. dollars, commitments to purchase 426.9 million U.S. dollars and sell 47.94 billion Japanese yen, commitments to purchase 234.1 million Swiss Francs and sell 243.2 million U.S. dollars, commitments to purchase 512.2 million U.S. dollars and sell 389.4 million British pounds, and commitments to purchase 466.4 million British pounds and sell 613.0 million U.S. dollars, which will all settle within 30 days.

22


Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $3.45 billion and $3.70 billion as of September 30, 2018 and December 31, 2017, respectively, and have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated and Swiss franc-denominated foreign operations. Our cross-currency interest rate swaps that convert a portion of our U.S. dollar-denominated floating rate debt to foreign-denominated floating rate debt have also been designated as, and are effective as, economic hedges of net investments. At September 30, 2018, we had outstanding cross currency swaps with notional amounts of $1.53 billion swapping euro to U.S. dollars and $350.0 million swapping British pounds to U.S. dollars, which will all settle within 12 months.
In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.
Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At September 30, 2018, substantially all of our total long-term debt is at a fixed rate. We have converted 20 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.
We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.
We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt.
Elanco Debt Issuance
In August 2018, our wholly owned subsidiary, Elanco, issued $2.00 billion of senior notes in a private placement. The senior notes are comprised of $500.0 million of 3.91 percent senior notes due in August 2021, $750.0 million of 4.27 percent senior notes due in August 2023, and $750.0 million of 4.90 percent senior notes due in August 2028. Interest is to be paid semi-annually and the interest rate payable on each series of senior notes is subject to adjustment if certain bond rating agencies downgrade, or subsequently upgrade, their ratings on the respective series of senior notes.
The indenture that governs the Elanco senior notes contains covenants, including limitations on the ability of Elanco and certain Elanco subsidiaries to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on Elanco's ability to consolidate, merge or sell substantially all of their assets, in addition to other customary terms. Elanco was in compliance with all such covenants under the indentures governing the senior notes as of September 30, 2018.
Elanco has entered into an agreement that requires them to use commercially reasonable efforts to cause a registration statement to become effective with the SEC by August 28, 2019, relating to an offer to exchange the senior notes for registered senior notes having substantially identical terms, or in certain cases, to register the senior notes for resale. If they do not register or exchange the senior notes pursuant to the terms of the registration rights agreement, they will be required to pay additional interest to the holders of the senior notes under certain circumstances.
In September 2018, Elanco entered into a revolving credit agreement with a syndicate of banks providing for a five-year $750.0 million senior revolving credit facility (Revolving Facility). The Revolving Facility bears interest at a variable rate plus specified margin as defined in the agreement and is payable quarterly. There were no borrowings outstanding under the Revolving Facility at September 30, 2018. The Revolving Facility is payable in full at the end of the term.

23


In September 2018, Elanco also entered into a $500.0 million three-year term loan under a term credit facility with a syndicate of banks (the Term Facility and collectively with the Revolving Facility, the Credit Facilities). The Term Facility bears interest at a variable rate plus margin as defined in the Term Facility and is payable quarterly. The Term Facility is payable in full at the end of the term.
The Credit Facilities are subject to various financial and other covenants including restrictions on Elanco's level of borrowings based on their consolidated leverage ratio and their consolidated interest coverage ratio. Elanco was in compliance with all such covenants as of September 30, 2018.
The aggregate net proceeds of the senior notes and Term Facility was $2.48 billion. See Note 3 for a discussion of the use of the proceeds of the debt offerings as part of the formation of Elanco and their IPO process.
The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations
The following effects of risk-management instruments were recognized in other–net, (income) expense:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Fair value hedges:
 
 
 
 
 
 
 
Effect from hedged fixed-rate debt
$
(19.6
)
 
$
(4.0
)
 
$
(94.1
)
 
$
3.6

Effect from interest rate contracts
19.6

 
4.0

 
94.1

 
(3.6
)
Cash flow hedges:
 
 
 
 
 
 
 
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss
3.7

 
3.7

 
11.1

 
11.1

Net losses on foreign currency exchange contracts not designated as hedging instruments
0.7

 
16.3

 
76.5

 
79.2

During the nine months ended September 30, 2018 and 2017, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.
The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)
The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Net investment hedges:
 
 
 
 
 
 
 
    Foreign currency-denominated notes
$
(47.8
)
 
$
(58.7
)
 
$
53.0

 
$
(332.0
)
    Cross-currency interest rate swaps
14.7

 
(38.2
)
 
52.3

 
(95.8
)
Cash flow hedges:
 
 
 
 
 
 
 
    Forward-starting interest rate swaps
—

 
—

 
—

 
13.0

During the next 12 months, we expect to reclassify $15.0 million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other–net, (income) expense.

24


Fair Value of Financial Instruments
The following tables summarize certain fair value information at September 30, 2018 and December 31, 2017 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: 
 
 
 
 
 
Fair Value Measurements Using
 
 
 
Carrying
Amount
 
Cost (1)
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Fair
Value
September 30, 2018
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
$
6,646.3

 
$
6,646.3

 
$
6,646.3

 
$
—

 
$
—

 
$
6,646.3

 
 
 
 
 
 
 
 
 
 
 
 
Short-term investments:
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
$
10.5

 
$
10.6

 
$
10.5

 
$
—

 
$
—

 
$
10.5

Corporate debt securities
52.7

 
52.7

 
—

 
52.7

 
—

 
52.7

Asset-backed securities
11.5

 
11.6

 
—

 
11.5

 
—

 
11.5

Other securities
1.4

 
1.4

 
—

 
1.4

 
—

 
1.4

Short-term investments
$
76.1

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noncurrent investments:
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
$
152.0

 
$
159.6

 
$
152.0

 
$
—

 
$
—

 
$
152.0

Corporate debt securities
622.0

 
631.5

 
—

 
622.0

 
—

 
622.0

Mortgage-backed securities
109.5

 
114.1

 
—

 
109.5

 
—

 
109.5

Asset-backed securities
27.0

 
27.3

 
—

 
27.0

 
—

 
27.0

Other securities
137.4

 
39.3

 
—

 
—

 
137.4

 
137.4

Marketable equity securities
287.9

 
146.4

 
287.9

 
—

 
—

 
287.9

Equity investments without readily determinable fair values (2)
394.7

 
 
 
 
 
 
 
 
 
 
Equity method investments (2)
275.3

 
 
 
 
 
 
 
 
 
 
Noncurrent investments
$
2,005.8

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2017
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
$
4,763.9

 
$
4,763.9

 
$
4,712.4

 
$
51.5

 
$
—

 
$
4,763.9

 
 
 
 
 
 
 
 
 
 
 
 
Short-term investments:
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
$
217.8

 
$
218.2

 
$
217.8

 
$
—

 
$
—

 
$
217.8

Corporate debt securities
1,182.3

 
1,183.2

 
—

 
1,182.3

 
—

 
1,182.3

Asset-backed securities
94.2

 
94.3

 
—

 
94.2

 
—

 
94.2

Other securities
3.6

 
3.6

 
—

 
3.6

 
—

 
3.6

Short-term investments
$
1,497.9

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noncurrent investments:
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
$
360.0

 
$
365.0

 
$
360.0

 
$
—

 
$
—

 
$
360.0

Corporate debt securities
3,464.3

 
3,473.5

 
—

 
3,464.3

 
—

 
3,464.3

Mortgage-backed securities
202.4

 
204.2

 
—

 
202.4

 
—

 
202.4

Asset-backed securities
653.9

 
656.0

 
—

 
653.9

 
—

 
653.9

Other securities
132.1

 
66.4

 
—

 
—

 
132.1

 
132.1

Marketable equity securities
281.3

 
131.0

 
281.3

 
—

 
—

 
281.3

Cost and equity method investments (2)
584.8

 
 
 
 
 
 
 
 
 
 
Noncurrent investments
$
5,678.8

 
 
 
 
 
 
 
 
 
 
(1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.
(2) Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments that do not have readily determinable fair values.

25


 
 
 
Fair Value Measurements Using
 
 
 
Carrying
Amount
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant
Other Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Fair
Value
Short-term commercial paper borrowings
 
 
 
 
 
 
 
 
 
September 30, 2018
$
(399.7
)
 
$
—

 
$
(398.4
)
 
$
—

 
$
(398.4
)
December 31, 2017
(2,696.8
)
 
—

 
(2,690.6
)
 
—

 
(2,690.6
)
Long-term debt, including current portion
 
 
 
 
 
 
 
 
 
September 30, 2018
$
(12,277.1
)
 
$
—

 
$
(12,542.2
)
 
$
—

 
$
(12,542.2
)
December 31, 2017
(10,950.3
)
 
—

 
(11,529.9
)
 
—

 
(11,529.9
)

26


 
 
 
Fair Value Measurements Using
 
 
 
Carrying
Amount
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant
Other Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Fair
Value
September 30, 2018
 
 
 
 
 
 
 
 
 
Risk-management instruments:
 
 
 
 
 
 
 
 
 
Interest rate contracts designated as fair value hedges:
 
 
 
 
 
 
 
 
 
Other current liabilities
$
(2.7
)
 
$
—

 
$
(2.7
)
 
$
—

 
$
(2.7
)
Other noncurrent liabilities
(66.5
)
 
—

 
(66.5
)
 
—

 
(66.5
)
Cross-currency interest rate contracts designated as net investment hedges:
 
 
 
 
 
 
 
 
 
Other receivables
30.3

 
—

 
30.3

 
—

 
30.3

Sundry
6.9

 
—

 
6.9

 
—

 
6.9

Other current liabilities
(16.6
)
 
—

 
(16.6
)
 
—

 
(16.6
)
Foreign exchange contracts not designated as hedging instruments:
 
 
 
 
 
 
 
 
 
Other receivables
6.3

 
—

 
6.3

 
—

 
6.3

Other current liabilities
(14.0
)
 
—

 
(14.0
)
 
—

 
(14.0
)
Contingent consideration liabilities:
 
 
 
 
 
 
 
 
 
Other current liabilities
(62.0
)
 
—

 
—

 
(62.0
)
 
(62.0
)
Other noncurrent liabilities
(41.4
)
 
—

 
—

 
(41.4
)
 
(41.4
)
 
 
 
 
 
 
 
 
 
 
December 31, 2017
 
 
 
 
 
 
 
 
 
Risk-management instruments:
 
 
 
 
 
 
 
 
 
Interest rate contracts designated as fair value hedges:
 
 
 
 
 
 
 
 
 
Other receivables
$
0.8

 
$
—

 
$
0.8

 
$
—

 
$
0.8

Sundry
35.1

 
—

 
35.1

 
—

 
35.1

Other current liabilities
(0.2
)
 
—

 
(0.2
)
 
—

 
(0.2
)
Other noncurrent liabilities
(10.5
)
 
—

 
(10.5
)
 
—

 
(10.5
)
Cross-currency interest rate contracts designated as net investment hedges:
 
 
 
 
 
 
 
 
 
Other current liabilities
(33.4
)
 
—

 
(33.4
)
 
—

 
(33.4
)
Other noncurrent liabilities
(26.0
)
 
—

 
(26.0
)
 
—

 
(26.0
)
Foreign exchange contracts not designated as hedging instruments:
 
 
 
 
 
 
 
 
 
Other receivables
26.8

 
—

 
26.8

 
—

 
26.8

Other current liabilities
(36.0
)
 
—

 
(36.0
)
 
—

 
(36.0
)
Contingent consideration liabilities (1):
 
 
 
 
 
 
 
 
 
Other current liabilities
(208.0
)
 
—

 
—

 
(208.0
)
 
(208.0
)
Other noncurrent liabilities
(45.2
)
 
—

 
—

 
(45.2
)
 
(45.2
)
(1) Contingent consideration liabilities primarily relate to the Erbitux arrangement with BMS discussed in Note 4.
Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to an enforceable master netting arrangement or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.

27


We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available.
Contingent consideration liabilities at December 31, 2017 primarily include contingent consideration related to Erbitux, for which the fair value was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for net sales in North America through September 2018 and an estimated discount rate. The amount to be paid is calculated as a tiered percentage of net sales (see Note 4) and will, therefore, vary directly with increases and decreases in net sales of Erbitux in North America. There is no cap on the amount that may be paid pursuant to this arrangement. The decrease in the fair value of the contingent consideration liabilities during the nine months ended September 30, 2018 was due primarily to cash payments of $155.4 million related to Erbitux. The change in the fair value of the contingent consideration liabilities recognized in earnings during the three and nine months ended September 30, 2018 and 2017 due to changes in time value of money was not material.
The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September 30, 2018:
 
Maturities by Period
  
Total
 
Less Than
1 Year
 
1-5
Years
 
6-10
Years
 
More Than
10 Years
Fair value of debt securities
$
985.1

 
$
74.7

 
$
620.5

 
$
135.4

 
$
154.5

A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows: 
 
September 30, 2018
 
December 31, 2017
Unrealized gross gains
$
2.1

 
$
184.7

Unrealized gross losses
24.4

 
47.5

Fair value of securities in an unrealized gain position
164.0

 
1,434.2

Fair value of securities in an unrealized loss position
816.7

 
4,692.8

A summary of the unrealized gains and losses (pretax) recognized in our consolidated condensed statements of operations for equity securities held as of September 30, 2018 is as follows:
 
Three Months Ended
September 30,
Nine Months Ended
September 30,
Unrealized gain (loss), net
$
(40.8
)
$
(3.4
)
We periodically assess our investment in available-for-sale securities for other-than-temporary impairment losses. There were no other-than-temporary impairment losses in the three or nine months ended September 30, 2018 or the three or nine months ended September 30, 2017.
We periodically assess our investments in equity securities other than public equity securities for impairment losses. Impairment losses recognized on these equity securities in the three and nine months ended September 30, 2018 were immaterial.
For fixed-income securities, the amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.
For equity securities, factors considered in assessing impairment losses include the financial condition and near term prospects of the issuer and general market conditions and industry specific factors.
As of September 30, 2018, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 60 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of September 30, 2018, we do not intend to sell, and it is not more likely than not that we will be required to sell the

28


securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.
Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities, was as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Proceeds from sales
$
52.0

 
$
951.5

 
$
5,598.4

 
$
3,003.0

Realized gross gains on sales
0.4

 
9.0

 
8.1

 
82.9

Realized gross losses on sales
0.7

 
0.8

 
49.7

 
3.2

Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.
Adjustments recorded to our equity investments without readily determinable fair values are based upon changes in the equity instrument's value resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon the impairment considerations mentioned above. Adjustments recorded during the nine months ended September 30, 2018 were immaterial.
Accounts Receivable Factoring Arrangements
We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $645.1 million and $723.2 million of accounts receivable as of September 30, 2018 and December 31, 2017, respectively, under these factoring arrangements. The cost of factoring such accounts receivable on our consolidated condensed results of operations for the nine months ended September 30, 2018 and 2017 was not material.
Note 7: Income Taxes
The effective tax rates were 18.5 percent and 26.2 percent for the three and nine months ended September 30, 2018, respectively, compared with 6.1 percent and 24.1 percent for the three and nine months ended September 30, 2017. The increase in the effective tax rate for the third quarter of 2018 is primarily due to a higher income tax benefit in the third quarter of 2017 for acquired IPR&D charges and asset impairment, restructuring, and other special charges. The increase in the effective rate for the first nine months of 2018 is primarily due to the $1.56 billion non-deductible acquired IPR&D charge related to the acquisitions of ARMO and AurKa. In December 2017, the President of the U.S. signed into law the Tax Cuts and Jobs Act (2017 Tax Act), which includes significant changes to the U.S. corporate income tax system, including a reduction in the corporate income tax rate, transition to a territorial tax system, and modifications to the international tax provisions. The changes that became effective January 1, 2018 resulted in a reduction to our tax expense for the three and nine months ended September 30, 2018 compared to the three and nine months ended September 30, 2017, respectively.
At September 30, 2018, our accounting for the 2017 Tax Act is incomplete; however, we expect to complete our accounting by December 2018. As discussed in our 2017 Annual Report on Form 10-K, we recorded provisional adjustments for effects that we were able to reasonably estimate. Those effects included the one-time repatriation transition tax (also known as the 'Toll Tax'), re-measurement of deferred tax assets and liabilities, unremitted earnings, executive compensation, and uncertain tax positions. At year-end, we were not able to make reasonable estimates for Global Intangible Low-Taxed Income (GILTI) deferred taxes or valuation allowances; therefore, we did not record provisional amounts. We are still evaluating the effects of the GILTI provisions and assessing our valuation allowances, and we have not yet determined our accounting policy election with respect to GILTI deferred taxes or the application of intra-entity transfers of inventory; therefore, the estimated annual effective tax rate reflects GILTI as a period expense. For the three and nine months ended September 30, 2018, we increased our provisional amount of Toll Tax by an immaterial amount. We have not made any additional measurement-period adjustments related to the other provisional items as we are continuing to collect and analyze additional information as well as evaluate the interpretations and assumptions made. Updates to our calculations may result in material changes to the provisional adjustments recorded at year-end and the estimated annual effective tax rate.

29


The U.S. examination of tax years 2013-2015 began in 2016. While we believe it is reasonably possible that this audit could reach resolution within the next 12 months, the IRS examination of tax years 2013-2015 remains ongoing. Therefore, it is not possible to reasonably estimate the change to unrecognized tax benefits and the related future cash flows.
Note 8: Retirement Benefits
Net pension and retiree health benefit (income) cost included the following components:
 
Defined Benefit Pension Plans
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Components of net periodic benefit cost:
 
 
 
 
 
 
 
Service cost
$
74.2

 
$
86.0

 
$
232.3

 
$
251.6

Interest cost
117.9

 
103.6

 
342.5

 
309.2

Expected return on plan assets
(212.7
)
 
(196.4
)
 
(636.3
)
 
(585.7
)
Amortization of prior service cost
1.1

 
1.4

 
3.6

 
4.3

Recognized actuarial loss
79.2

 
72.5

 
261.2

 
215.6

Curtailment loss
1.3

 
—

 
1.3

 
—

Net periodic benefit cost
$
61.0

 
$
67.1

 
$
204.6

 
$
195.0

 
Retiree Health Benefit Plans
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Components of net periodic benefit income:
 
 
 
 
 
 
 
Service cost
$
10.1

 
$
11.6

 
$
31.7

 
$
34.8

Interest cost
14.9

 
13.2

 
42.3

 
39.6

Expected return on plan assets
(44.8
)
 
(40.2
)
 
(132.7
)
 
(120.6
)
Amortization of prior service benefit
(19.3
)
 
(22.5
)
 
(60.2
)
 
(67.5
)
Recognized actuarial loss
0.8

 
4.6

 
5.4

 
13.8

Curtailment gain
(29.3
)
 
—

 
(29.3
)
 
—

Net periodic benefit income
$
(67.6
)
 
$
(33.3
)
 
$
(142.8
)
 
$
(99.9
)

In July 2018, we announced that we would amend our defined benefit pension and retiree health benefit plans to freeze or reduce benefits for certain Elanco employees effective January 1, 2019. We remeasured the impacted pension and retiree health plans’ benefit obligations as of July 31, 2018, which resulted in a net curtailment gain of $28.0 million during the three and nine months ended September 30, 2018, which was recorded as a component of asset impairment, restructuring, and other special charges.
We contributed approximately $35 million required to satisfy minimum funding requirements to our defined benefit pension and retiree health benefit plans during the nine months ended September 30, 2018. Additional discretionary funding totaled $200.0 million during the nine months ended September 30, 2018. During the remainder of 2018, we expect to make contributions to our defined benefit pension and retiree health benefit plans of approximately $15 million to satisfy minimum funding requirements. No additional discretionary funding for the remainder of 2018 is planned.
As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, pension and retiree health benefit cost components other than service costs are presented in other–net, (income) expense.

30


Note 9: Contingencies
We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as noted below with respect to the Alimta® patent litigation and administrative proceedings, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.
Alimta Patent Litigation and Administrative Proceedings
A number of generic manufacturers are seeking approvals in the U.S., Japan, and a number of countries in Europe to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect that a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenue for the product in the relevant market.
U.S. Patent Litigation and Administrative Proceedings
In the U.S., more than 10 Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Alimta prior to the expiration of our vitamin regimen patent (expiring in 2021 plus pediatric exclusivity expiring in 2022) have been filed by a number of companies, including Teva Parenteral Medicines, Inc. (Teva) and APP Pharmaceuticals, LLC (APP) pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). We have received favorable decisions from the U.S. Court of Appeals for the Federal Circuit (affirming the U.S. District Court for the Southern District of Indiana's decisions finding our U.S. vitamin regimen patent valid and infringed) against Teva, APP, and two other defendants' proposed products, and similar favorable judgments have been entered by the U.S. District Court for the Southern District of Indiana against five other companies. The remaining ANDA applicants have agreed to a preliminary injunction or stay pending the appeal of the inter partes review (IPR) described in the following sentence. In October 2017, the U.S. Patent and Trademark Office issued written decisions in our favor following IPR of our vitamin regimen patent, finding that the generic company petitioners failed to show that the claims in our patent are unpatentable. A number of these challengers have filed an appeal.
We currently have pending lawsuits in the U.S. District Court for the Southern District of Indiana alleging infringement against Actavis LLC (Actavis) and Apotex Inc. in response to their applications to market alternative forms of pemetrexed (the active ingredient in Alimta) products, and we filed a similar lawsuit in the U.S. District Court for Delaware against Eagle Pharmaceuticals, Inc. In June 2018, the U.S. District Court for the Southern District of Indiana ruled in our favor in two similar cases, finding Dr. Reddy's Laboratories' (Dr. Reddy) and Hospira, Inc.'s (Hospira) proposed products would infringe our patent. Dr. Reddy and Hospira have appealed those rulings. The lawsuit against Actavis has been stayed, pending a decision in the Dr. Reddy and Hospira appeals.
European Patent Litigation and Administrative Proceedings
In July 2017, the United Kingdom (U.K.) Supreme Court ruled that commercialization of certain salt forms of pemetrexed by Actavis Group ehf and other Actavis companies directly infringes our vitamin regimen patents in the U.K., Italy, France, and Spain. This litigation in the U.K. is now concluded.
Hexal AG (Hexal) and Stada Arzneimittel AG (Stada) have each challenged the validity of our vitamin regimen patent before the German Federal Patent Court. At a hearing in July 2018, the German Federal Patent Court held that our vitamin regimen patent is invalid. We have appealed this decision. Under German law, the patent remains in force pending appeal. A number of generic competitors have received approval to market generic versions of pemetrexed in Germany and may choose to launch at risk. We will seek to remove any generic pemetrexed products launched at risk in Germany, seek damages in respect of such launches, and defend our patent. Injunctions are in place against four of these companies, including Hexal and ratiopharm GmbH (a subsidiary of Teva). Stada has recently launched at risk in Germany and we are seeking an injunction. Whether further injunctions are granted or the current injunctions are maintained pending the appeal, or whether a generic competitor chooses to launch at risk, makes the timing of possible generic entry and market erosion in Germany unpredictable.

31


Additional legal proceedings are ongoing in various national courts throughout Europe. We are aware that several companies have received approval to market generic versions of pemetrexed in major European markets and that generic competitors may choose to launch at risk (including one generic product currently on the market in France). We will continue to seek to remove any generic pemetrexed products launched at risk in European markets, seek damages in respect of such launches, and defend our patents against validity challenges.
Japanese Administrative Proceedings
Three separate sets of demands for invalidation of our two vitamin regimen patents, involving several companies, have been filed with the Japanese Patent Office (JPO). In February 2017, the Japan Intellectual Property High Court confirmed the decisions of the JPO upholding the validity of both our Japanese vitamin regimen patents in the challenge initiated by Sawai Pharmaceutical Co., Ltd. and joined by three other companies. This decision is now final. In May 2017, the JPO resumed one of the two remaining sets of demands, brought by Nipro Corporation (Nipro) and in July 2018, the JPO issued written decisions dismissing Nipro’s invalidation demands. Nipro filed an appeal and we anticipate decisions by the Japan Intellectual Property High Court in the third quarter of 2019. The other set of demands, brought by Hospira, that were previously suspended resumed in August 2018; we anticipate decisions by the JPO in the second quarter of 2019. If upheld through all challenges, these patents provide intellectual property protection for Alimta until June 2021. Notwithstanding our patents, generic versions of Alimta were approved in Japan starting in February 2016. We do not currently anticipate that generic versions of Alimta will proceed to pricing approval.
Cymbalta® Product Liability Litigation
We were named as a defendant in a purported class-action lawsuit in the U.S. District Court for the Central District of California (now called Strafford et al. v. Eli Lilly and Company) involving Cymbalta. The plaintiffs, purporting to represent a class of all persons within the U.S. who purchased and/or paid for Cymbalta, asserted claims under the consumer protection statutes of four states, California, Massachusetts, Missouri, and New York, and sought declaratory, injunctive, and monetary relief for various alleged economic injuries arising from discontinuing treatment with Cymbalta. The district court denied the plaintiffs' motions for class certification. The district court dismissed the suits and plaintiffs appealed to the U.S. Court of Appeals for the Ninth Circuit. In November 2017, the U.S. Court of Appeals for the Ninth Circuit dismissed the suit. In July 2018, the U.S. District Court for the District of California denied plaintiffs’ motion to reopen the case. Plaintiffs’ appeal of this denial is currently pending before the U.S. Court of Appeals for the Ninth Circuit.
We are named in approximately 140 lawsuits involving approximately 1,470 plaintiffs filed in various federal and state courts alleging injuries arising from discontinuation of treatment with Cymbalta. These include approximately 40 individual and multi-plaintiff cases filed in California state court, centralized in a California Judicial Counsel Coordination Proceeding pending in Los Angeles. The first individual product liability cases were tried in August 2015 and resulted in defense verdicts against four plaintiffs. We believe all these Cymbalta lawsuits and claims are without merit. We have reached a settlement framework that provides for a comprehensive resolution of nearly all of these personal injury claims, filed or unfiled, alleging injuries from discontinuing treatment with Cymbalta.
Brazil–Employee Litigation
Our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. The plaintiffs allege that some employees at the facility were exposed to benzene and heavy metals; however, Lilly Brasil maintains that these alleged contaminants were never used in the facility. In May 2014, the labor court judge ruled against Lilly Brasil. The judge's ruling orders Lilly Brasil to undertake several actions of unspecified financial impact, including paying lifetime medical insurance for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We filed an appeal in May 2014. In July 2018, the appeals court affirmed the lower court's ruling with the total financial impact of the ruling estimated to be approximately 500 million Brazilian real (approximately $125 million as of September 30, 2018). The appeals court restricted the broad health coverage awarded by the lower court to health problems that claimants could show arose from exposure to the alleged contamination. We strongly disagree with the court's decision and plan to appeal. Lilly Brasil has taken an initial step in the appeal process by filing a Motion for Clarification; a decision on that motion is expected late in the fourth quarter of 2018 or in the first quarter of 2019.
We are also named in approximately 30 lawsuits filed in the same court by individual former employees making similar claims.

32


Lilly Brasil and Elanco Quimica Ltda. have been named in a lawsuit involving approximately 305 individuals alleging that the companies failed to provide warnings regarding exposure to heavy metals or proper equipment at the former Cosmopolis facility, and that this alleged failure could result in possible harm to employees, former employees, and their dependents. In June 2017, the court denied the plaintiffs' request for a preliminary injunction. In September 2017, the court dismissed the claims brought by all but the first named plaintiff. The plaintiffs are appealing that decision.
Lilly Brasil and Elanco Quimica Ltda. have also been named in a separate lawsuit involving approximately 105 individuals alleging that the companies failed to provide warnings regarding exposure to heavy metals or proper equipment at the former Cosmopolis facility, and that this alleged failure could result in possible harm to contractors and suppliers, and their dependents. In November 2017, the court dismissed the claims brought by all but the first named plaintiff. The plaintiffs are appealing that decision.
We believe all of these lawsuits are without merit and plan to defend against them vigorously.
Agri Stats, Inc.
During the third quarter, we sold Agri Stats, Inc., one of our subsidiaries. As a result of the sale, we no longer hold the liability for litigation in which Agri Stats is named as a party, including the approximately 25 antitrust suits filed in the U.S. District Court for the Northern District of Illinois and the District of Minnesota alleging that defendants engaged in a conspiracy to limit U.S. chicken and swine production and inflate prices.
Adocia, S.A.
We have been named a respondent in two arbitrations filed by Adocia, S.A. (Adocia), with which we entered into agreements for the co-development of an ultra-rapid insulin product. In the first arbitration, Adocia alleged that we failed to make a $11.7 million milestone payment and, in August 2018, an arbitration panel ruled in favor of Adocia. In the second arbitration, Adocia alleged that we misappropriated and misused Adocia's confidential information and intellectual property and is seeking approximately $1.8 billion in damages and other specific relief. We believe these claims are without merit and are defending against them vigorously. We have asserted several counterclaims relating to fraudulent misrepresentation and are seeking approximately $188 million in damages.
Throughout the arbitrations described above, Adocia has made statements alleging that Adocia employees should be listed as inventors on two of our patents related to our ultra-rapid insulin product currently in development. We strongly contest this allegation. While inventorship of these two patents is not at issue in the arbitrations, in October 2018 we filed a declaratory judgment action against Adocia in the U.S. District Court for the Southern District of Indiana to confirm our inventorship.
Product Liability Insurance
Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products.

33


Note 10:    Other Comprehensive Income (Loss)
The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September 30, 2018 and 2017:
(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)
 
Unrealized Net Gains (Losses) on Securities
 
Defined Benefit Pension and Retiree Health Benefit Plans
 
Effective Portion of Cash Flow Hedges
 
Accumulated Other Comprehensive Loss
Balance at July 1, 2018
$
(1,671.5
)
 
$
(18.1
)
 
$
(4,190.6
)
 
$
(228.5
)
 
$
(6,108.7
)
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
60.6

 
1.1

 
548.6

 
—

 
610.3

Net amount reclassified from accumulated other comprehensive loss
—

 
(0.2
)
 
47.2

 
2.9

 
49.9

Net other comprehensive income (loss)
60.6

 
0.9

 
595.8

 
2.9

 
660.2

 
 
 
 
 
 
 
 
 
 
Balance at September 30, 2018 (4)
$
(1,610.9
)
 
$
(17.2
)
 
$
(3,594.8
)
 
$
(225.6
)
 
$
(5,448.5
)
(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)
 
Unrealized Net Gains (Losses) on Securities
 
Defined Benefit Pension and Retiree Health Benefit Plans
 
Effective Portion of Cash Flow Hedges
 
Accumulated Other Comprehensive Loss
Balance at July 1, 2017
$
(1,349.4
)
 
$
153.2

 
$
(3,348.5
)
 
$
(197.6
)
 
$
(4,742.3
)
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
135.8

 
33.9

 
(28.7
)
 
—

 
141.0

Net amount reclassified from accumulated other comprehensive loss
8.1

 
(23.9
)
 
40.1

 
2.4

 
26.7

Net other comprehensive income (loss)
143.9

 
10.0

 
11.4

 
2.4

 
167.7

 
 
 
 
 
 
 
 
 
 
Balance at September 30, 2017 (1)
$
(1,205.5
)
 
$
163.2

 
$
(3,337.1
)
 
$
(195.2
)
 
$
(4,574.6
)

34


The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September 30, 2018 and 2017:
(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)
 
Unrealized Net Gains (Losses) on Securities
 
Defined Benefit Pension and Retiree Health Benefit Plans
 
Effective Portion of Cash Flow Hedges
 
Accumulated Other Comprehensive Loss
Balance at January 1, 2018 (2)
$
(1,233.4
)
 
$
113.5

 
$
(4,340.7
)
 
$
(234.3
)
 
$
(5,694.9
)
 
 
 
 
 
 
 
 
 
 
Reclassification due to adoption of new accounting standard (3)
—

 
(128.9
)
 
—

 
—

 
(128.9
)
Other comprehensive income (loss) before reclassifications
(377.5
)
 
31.0

 
581.0

 
—

 
234.5

Net amount reclassified from accumulated other comprehensive loss
—

 
(32.8
)
 
164.9

 
8.7

 
140.8

Net other comprehensive income (loss)
(377.5
)
 
(1.8
)
 
745.9

 
8.7

 
375.3

 
 
 
 
 
 
 
 
 
 
Balance at September 30, 2018 (4)
$
(1,610.9
)
 
$
(17.2
)
 
$
(3,594.8
)
 
$
(225.6
)
 
$
(5,448.5
)
(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)
 
Unrealized Net Gains (Losses) on Securities
 
Defined Benefit Pension and Retiree Health Benefit Plans
 
Effective Portion of Cash Flow Hedges
 
Accumulated Other Comprehensive Loss
Balance at January 1, 2017 (2)
$
(1,867.3
)
 
$
224.0

 
$
(3,371.6
)
 
$
(210.9
)
 
$
(5,225.8
)
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
653.7

 
9.6

 
(83.3
)
 
8.4

 
588.4

Net amount reclassified from accumulated other comprehensive loss
8.1

 
(70.4
)
 
117.8

 
7.3

 
62.8

Net other comprehensive income (loss)
661.8

 
(60.8
)
 
34.5

 
15.7

 
651.2

 
 
 
 
 
 
 
 
 
 
Balance at September 30, 2017 (1)
$
(1,205.5
)
 
$
163.2

 
$
(3,337.1
)
 
$
(195.2
)
 
$
(4,574.6
)
(1) Accumulated other comprehensive loss as of September 30, 2017 consists of $4.61 billion of accumulated other comprehensive loss attributable to controlling interest and $34.8 million of accumulated other comprehensive income attributable to noncontrolling interest.
(2) Accumulated other comprehensive loss as of January 1, 2018 consists of $5.72 billion of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive income attributable to noncontrolling interest. Accumulated other comprehensive loss as of January 1, 2017 consists of $5.27 billion of accumulated other comprehensive loss attributable to controlling interest and $48.2 million of accumulated other comprehensive income attributable to noncontrolling interest.
(3) This reclassification consists of $104.8 million of accumulated other comprehensive loss attributable to controlling interest and $24.1 million of accumulated other comprehensive loss attributable to noncontrolling interest. Refer to Note 2 for further details regarding the reclassification due to the adoption of Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.
(4) Accumulated other comprehensive loss as of September 30, 2018 consists of $5.44 billion of accumulated other comprehensive loss attributable to controlling interest and $9.0 million of accumulated other comprehensive loss attributable to noncontrolling interest.

35


The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
Tax benefit (expense)
2018
 
2017
 
2018
 
2017
Foreign currency translation gains/losses
$
7.0

 
$
33.9

 
$
(11.2
)
 
$
149.7

Unrealized net gains/losses on securities
(0.2
)
 
(4.2
)
 
1.1

 
25.4

Defined benefit pension and retiree health benefit plans
(152.4
)
 
(9.4
)
 
(190.3
)
 
(24.0
)
Effective portion of cash flow hedges
(0.8
)
 
(1.3
)
 
(2.3
)
 
(8.4
)
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items
$
(146.4
)

$
19.0


$
(202.7
)

$
142.7

Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.
Reclassifications out of accumulated other comprehensive loss were as follows:
 
Details about Accumulated Other Comprehensive Loss Components
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
Affected Line Item in the Consolidated Condensed Statements of Operations
 
 
 
2018
 
2017
 
2018
 
2017
 
Amortization of retirement benefit items:
 
 
 
 
 
 
 
 
 
 
Prior service benefits, net
 
$
(18.2
)
 
$
(21.1
)
 
$
(56.6
)
 
$
(63.2
)
(1) 
 
Actuarial losses, net
 
80.0

 
77.1

 
266.6

 
229.4

(1) 
 
Total before tax
 
61.8

 
56.0

 
210.0

 
166.2

 
 
Tax benefit
 
(14.6
)
 
(15.9
)
 
(45.1
)
 
(48.4
)
Income taxes
 
Net of tax
 
47.2

 
40.1

 
164.9

 
117.8

 
 
 
 
 
 
 
 
 
 
 
 
 
Unrealized gains/losses on available-for-sale securities:
 
 
 
 
 
 
 
 
 
 
Realized (gains), losses, net
 
(0.3
)
 
(36.7
)
 
(41.6
)
 
(108.2
)
Other–net, (income) expense
 
Tax (benefit) expense
 
0.1

 
12.8

 
8.8

 
37.8

Income taxes
 
Net of tax
 
(0.2
)
 
(23.9
)
 
(32.8
)
 
(70.4
)
 
 
Other, net of tax
 
2.9

 
10.5

 
8.7

 
15.4

Other–net, (income) expense
 
Total reclassifications for the period (net of tax)
 
$
49.9

 
$
26.7

 
$
140.8

 
$
62.8

 
(1) These accumulated other comprehensive loss components are included in the computation of net periodic benefit (income) cost (see Note 8).


36


Note 11: Other–Net, (Income) Expense
Other–net, (income) expense consisted of the following:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Interest expense
$
69.4

 
$
61.9

 
$
193.9

 
$
162.1

Interest income
(32.1
)
 
(45.1
)
 
(118.8
)
 
(114.6
)
Retirement benefit
(62.9
)
 
(63.8
)
 
(174.2
)
 
(191.3
)
Other income
41.0

 
(2.9
)
 
9.0

 
(44.8
)
Other–net, (income) expense
$
15.4


$
(49.9
)

$
(90.1
)

$
(188.6
)
As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Results for the three and nine months ended September 30, 2017 have been reclassified to reflect the adoption of this standard.

37


Note 12: Segment Information
We have two operating segments—human pharmaceutical products and animal health products. Our operating segments are distinguished by the ultimate end user of the product—humans or animals. Performance is evaluated based on profit or loss from operations before income taxes.
 
Three Months Ended
September 30,
 
2018
 
2017
 
U.S. (1)
Outside U.S.
Total
 
U.S. (1)
Outside U.S.
Total
Segment revenue—to unaffiliated customers:
 
 
 
 
 
 
 
Human pharmaceutical products:
 
 
 
 
 
 
 
Endocrinology:
 
 
 
 
 
 
 
Trulicity®
$
645.9

$
170.3

$
816.2

 
$
412.9

$
114.8

$
527.7

Humalog®
365.6

299.0

664.6

 
414.9

281.3

696.2

Forteo®
182.5

208.3

390.8

 
234.1

207.6

441.7

Humulin®
216.9

105.1

322.1

 
203.0

97.5

300.5

Basaglar
157.3

43.9

201.2

 
115.2

30.5

145.7

Jardiance
104.2

62.7

166.9

 
83.8

43.4

127.2

Trajenta
50.3

85.3

135.7

 
68.4

84.9

153.3

Other Endocrinology
73.8

66.8

140.4

 
92.1

76.3

168.4

Total Endocrinology
1,796.5

1,041.4

2,837.9

 
1,624.4

936.3

2,560.7

 
 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
 
Alimta
288.5

232.0

520.5

 
260.3

254.2

514.5

Cyramza®
67.0

131.4

198.4

 
69.5

126.5

196.0

Erbitux
132.6

26.9

159.5

 
136.0

27.4

163.5

Other Oncology
131.7

54.1

185.8

 
43.5

40.2

83.6

Total Oncology
619.8

444.4

1,064.2

 
509.3

448.3

957.6

 
 
 
 
 
 
 
 
Cardiovascular:
 
 
 
 
 
 
 
Cialis®
295.9

171.2

467.1

 
319.6

245.3

564.9

Effient
30.2

15.1

45.3

 
42.7

13.1

55.9

Other Cardiovascular
39.7

31.7

71.4

 
4.9

37.3

42.1

Total Cardiovascular
365.8

218.0

583.8

 
367.2

295.7

662.9

 
 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
 
Cymbalta
14.5

157.5

172.0

 
19.6

163.5

183.2

Zyprexa®
7.0

102.8

109.9

 
12.6

128.0

140.6

Strattera®
10.5

88.2

98.7

 
52.9

84.1

137.1

Other Neuroscience
23.8

23.0

46.6

 
23.3

23.7

46.8

Total Neuroscience
55.8

371.5

427.2

 
108.4

399.3

507.7

 
 
 
 
 
 
 
 
Immunology:
 
 
 
 
 
 
 
Taltz®
210.6

53.3

263.9

 
131.3

20.0

151.3

Other Immunology
0.8

54.8

55.6

 
—

16.3

16.3

Total Immunology
211.4

108.1

319.5

 
131.3

36.3

167.6

 
 
 
 
 
 
 
 
Other pharmaceuticals
13.4

43.2

56.6

 
10.7

50.2

60.9

Total human pharmaceutical products
3,062.7

2,226.5

5,289.2

 
2,751.3

2,166.1

4,917.4

Animal health products
383.9

388.8

772.7

 
353.0

387.6

740.6

Revenue
$
3,446.6

$
2,615.3

$
6,061.9

 
$
3,104.4

$
2,553.6

$
5,658.0


38


 
Nine Months Ended
September 30,
 
2018
 
2017
 
U.S. (1)
Outside U.S.
Total
 
U.S. (1)
Outside U.S.
Total
Segment revenue—to unaffiliated customers:
 
 
 
 
 
 
 
Human pharmaceutical products:
 
 
 
 
 
 
 
Endocrinology:
 
 
 
 
 
 
 
Trulicity
$
1,786.5

$
487.8

$
2,274.3

 
$
1,090.1

$
290.7

$
1,380.8

Humalog
1,334.2

891.8

2,226.1

 
1,254.3

828.6

2,083.0

Forteo
529.7

608.8

1,138.5

 
661.5

574.3

1,235.8

Humulin
677.3

316.7

994.0

 
634.9

337.9

972.8

Basaglar
440.4

128.5

569.0

 
196.7

81.6

278.3

Jardiance
284.8

180.3

465.1

 
198.3

105.9

304.3

Trajenta
161.3

257.2

418.5

 
174.2

234.1

408.2

Other Endocrinology
199.4

206.9

406.1

 
283.4

228.5

511.8

Total Endocrinology
5,413.6

3,078.0

8,491.6

 
4,493.4

2,681.6

7,175.0

 
 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
 
Alimta
815.1

760.9

1,576.0

 
761.9

775.4

1,537.3

Cyramza
210.7

390.1

600.8

 
204.3

349.2

553.5

Erbitux
394.0

81.6

475.5

 
398.2

78.8

477.0

Other Oncology
321.4

157.1

478.6

 
128.4

104.3

232.7

Total Oncology
1,741.2

1,389.7

3,130.9

 
1,492.8

1,307.7

2,800.5

 
 
 
 
 
 
 
 
Cardiovascular:
 
 
 
 
 
 
 
Cialis
954.9

546.2

1,501.2

 
997.3

728.5

1,725.7

Effient
59.4

45.3

104.8

 
290.8

35.8

326.6

Other Cardiovascular
143.7

96.3

239.7

 
20.5

99.6

120.2

Total Cardiovascular
1,158.0

687.8

1,845.7

 
1,308.6

863.9

2,172.5

 
 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
 
Cymbalta
39.3

484.2

523.5

 
100.8

463.6

564.4

Zyprexa
27.6

332.8

360.4

 
49.3

379.6

428.9

Strattera
74.4

269.2

343.5

 
276.9

243.0

519.9

Other Neuroscience
72.2

71.2

143.5

 
88.4

72.2

160.5

Total Neuroscience
213.5

1,157.4

1,370.9

 
515.4

1,158.4

1,673.7

 
 
 
 
 
 
 
 
Immunology:
 
 
 
 
 
 
 
Taltz
495.3

135.1

630.4

 
343.6

43.1

386.7

Other Immunology
2.5

130.0

132.5

 
—

22.9

22.9

Total Immunology
497.8

265.1

762.9

 
343.6

66.0

409.6

 
 
 
 
 
 
 
 
Other pharmaceuticals
49.1

139.8

189.1

 
34.6

149.7

184.5

Total human pharmaceutical products
9,073.2

6,717.8

15,791.1

 
8,188.4

6,227.3

14,415.8

Animal health products
1,137.8

1,188.2

2,326.0

 
1,173.4

1,121.4

2,294.8

Revenue
$
10,211.0

$
7,906.1

$
18,117.1

 
$
9,361.8

$
7,348.7

$
16,710.6

Numbers may not add due to rounding.
(1) U.S. revenue includes revenue in Puerto Rico.

39


 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Segment profits:
 
 
 
 
 
 
 
Human pharmaceutical products
$
1,514.0

 
$
1,242.5

 
$
4,751.0

 
$
3,765.7

Animal health products
162.6

 
121.9

 
461.9

 
422.6

Total segment profits
$
1,676.7

 
$
1,364.4

 
$
5,213.0

 
$
4,188.3

 
 
 
 
 
 
 
 
Reconciliation of total segment profits to consolidated income before taxes:
 
 
 
 
 
 
 
Segment profits
$
1,676.7

 
$
1,364.4

 
$
5,213.0

 
$
4,188.3

Other profits (losses):
 
 
 
 
 
 
 
Acquired in-process research and development (Note 3)
(30.0
)
 
(205.0
)
 
(1,654.5
)
 
(1,062.6
)
Amortization of intangible assets
(153.4
)
 
(155.8
)
 
(458.7
)
 
(510.0
)
Asset impairment, restructuring, and other special charges (Note 5)
(83.3
)
 
(406.5
)
 
(236.0
)
 
(670.4
)
Other, net
1.0

 
(5.5
)
 
(7.0
)
 
(32.0
)
Consolidated income before taxes
$
1,411.0

 
$
591.6

 
$
2,856.8

 
$
1,913.3

Numbers may not add due to rounding.
For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing and global administrative services.
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Geographic Information
 
 
 
 
 
 
 
Revenue—to unaffiliated customers (1):
 
 
 
 
 
 
 
United States
$
3,446.6

 
$
3,104.4

 
$
10,211.0

 
$
9,361.8

Europe
1,017.0

 
1,017.0

 
3,142.9

 
2,877.6

Japan
608.8

 
616.7

 
1,828.9

 
1,767.0

Other foreign countries
989.5

 
920.0

 
2,934.3

 
2,704.2

Revenue
$
6,061.9

 
$
5,658.0

 
$
18,117.1

 
$
16,710.6

Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.
Refer to Note 3 for information regarding the IPO of Elanco.

40


Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition
Results of Operations
(Tables present dollars in millions, except per-share data)
General
Management’s discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated condensed financial statements and accompanying footnotes in Item 1 of Part I of this Quarterly Report on Form 10-Q. Certain statements in this Item 2 of Part I of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2017, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.
Executive Overview
This section provides an overview of our financial results, recent product and late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. Earnings per share (EPS) data are presented on a diluted basis.
Financial Results
The following table summarizes our key operating results:
 
Three Months Ended
September 30,
 
 
 
Nine Months Ended
September 30,
 
 
 
2018
 
2017
 
Percent Change
 
2018
 
2017
 
Percent Change
Revenue
$
6,061.9

 
$
5,658.0

 
7
 
$
18,117.1

 
$
16,710.6

 
8
Gross margin
4,499.6

 
4,071.7

 
11
 
13,280.8

 
12,204.7

 
9
Gross margin as a percent of revenue
74.2
%
 
72.0
%
 

 
73.3
%
 
73.0
%
 

Operating expense (1)
$
2,959.9

 
$
2,918.5

 
1
 
$
8,623.6

 
$
8,747.0

 
(1)
Acquired in-process research and development (IPR&D)
30.0

 
205.0

 
(85)
 
1,654.5

 
1,062.6

 
56
Asset impairment, restructuring, and other special charges
83.3

 
406.5

 
(80)
 
236.0

 
670.4

 
(65)
Net income
1,149.5

 
555.6

 
NM
 
2,107.0

 
1,452.8

 
45
Earnings per share
1.12

 
0.53

 
NM
 
2.03

 
1.37

 
48
(1) Operating expense consists of research and development and marketing, selling, and administrative expenses.
NM - not meaningful
Revenue increased for the three and nine months ended September 30, 2018 primarily driven by increased volume. For the three months ended September 30, 2018, the increase was partially offset by lower realized prices and, to a lesser extent, the unfavorable impact of foreign exchange rates. Operating expense remained relatively flat for the three and nine months ended September 30, 2018, reflecting previously-announced actions taken to reduce our cost structure. The following highlighted items also affect comparisons of our financial results for the three and nine months ended September 30, 2018 and 2017:

41


2018
Acquired IPR&D (Note 3 to the consolidated condensed financial statements)
•
We recognized acquired IPR&D charges of $30.0 million (pretax), or $0.02 per share, and $1.65 billion, or $1.57 per share, for the three and nine months ended September 30, 2018, respectively. The charge for the three months ended September 30, 2018 was related to upfront fees paid in connection with the collaboration agreement with Anima Biotech (Anima). The charges for the nine months ended September 30, 2018 also included charges associated with the acquisitions of ARMO Biosciences, Inc. (ARMO) and AurKa Pharma, Inc. (AurKa), and in connection with the collaborative agreement with Sigilon Therapeutics (Siglion). The charges for ARMO and AurKa totaling $1.56 billion were not tax deductible.
Asset Impairment, Restructuring, and Other Special Charges (Note 5 to the consolidated condensed financial statements)
•
We recognized charges of $83.3 million (pretax), or $0.07 per share, and $236.0 million (pretax), or $0.20 per share, for the three and nine months ended September 30, 2018, respectively. The charges for the three months ended September 30, 2018 resulted primarily from asset impairment and restructuring charges related to the sale of the Posilac® (rbST) brand and the October 2018 sale of the related Augusta, Georgia manufacturing site. We also incurred expenses associated with the initial public offering and separation of the Elanco animal health business. The charges for the nine months ended September 30, 2018 also included charges related to the decision to suspend commercialization of Imrestor®, an animal health product, expenses related to the decision to end Posilac (rbST) production, and expenses associated with the review of strategic alternatives for the Elanco animal health business.
2017
Acquired IPR&D (Note 3 to the consolidated condensed financial statements)
•
We recognized acquired IPR&D charges of $205.0 million (pretax), or $0.13 per share, and $1.06 billion (pretax), or $0.94 per share, for the three and nine months ended September 30, 2017, respectively, related to upfront fees paid in connection with the collaboration agreements with Nektar Therapeutics (Nektar) and KeyBioscience AG (KeyBioscience). The charges for the nine months ended September 30, 2017 also included the charge associated with the acquisition of CoLucid Pharmaceuticals, Inc. (CoLucid) which was not tax-deductible.
Asset Impairment, Restructuring, and Other Special Charges (Note 5 to the consolidated condensed financial statements)
•
We recognized charges of $406.5 million (pretax), or $0.29 per share, and $670.4 million (pretax), or $0.48 per share, for the three and nine months ended September 30, 2017, respectively. The charges for the three months ended September 30, 2017 were partially associated with asset impairments related to lower projected revenue for Posilac (rbST), as well as severance costs incurred as a result of actions taken to reduce the company's cost structure. The charges for the nine months ended September 30, 2017 were primarily due to severance costs incurred as a result of actions taken to reduce our cost structure, charges associated with the Posilac (rbST) impairment, integration costs related to the acquisition of Novartis Animal Health (Novartis AH), asset impairments and other charges related to animal health assets, as well as exit costs due to site closures.
The increases in net income and EPS for the three months ended September 30, 2018 were primarily driven by increased revenue and decreased acquired IPR&D and asset impairment, restructuring, and other special charges, partially offset by increased income tax expense. The increase in net income and EPS for the nine months ended September 30, 2018 were primarily driven by increased revenues and decreased asset impairment, restructuring, and other special charges, partially offset by increased acquired IPR&D charges and income tax expense.

42


Late-Stage Pipeline
Our long-term success depends to a great extent on our ability to continue to discover and develop innovative pharmaceutical products and acquire or collaborate on molecules currently in development by other biotechnology or pharmaceutical companies. We currently have approximately 40 potential new drugs in human testing or under regulatory review and a larger number of projects in preclinical research.
The following new molecular entities (NMEs) have been approved by regulatory authorities in at least one of the major geographies for use in the diseases described. The first quarter in which each NME initially was approved in any major geography for any indication is shown in parentheses:
Abemaciclib (Verzenio®) (Q3 2017)—a small molecule cell-cycle inhibitor, selective for cyclin-dependent kinases 4 and 6 for the treatment of metastatic breast cancer.
Baricitinib (Olumiant®) (Q1 2017)—a Janus tyrosine kinase (JAK) inhibitor for the treatment of moderate-to-severe active rheumatoid arthritis (in collaboration with Incyte Corporation).
Galcanezumab* (EmgalityTM) (Q3 2018)—a once-monthly subcutaneously injected calcitonin gene-related peptide (CGRP) antibody for the treatment of migraine prevention. Refer to Item 1, "Legal Proceedings - Other Patent Matters" of Part II for discussion of the lawsuit filed by Teva Pharmaceuticals International GMBH.
Olaratumab* (Lartruvo®) (Q4 2016)—a human lgG1 monoclonal antibody for the treatment of advanced soft tissue sarcoma.
The following NMEs have been submitted for regulatory review in at least one of the major geographies for potential use in the disease described. The first quarter in which the NME initially was submitted in any major geography for any indication is shown in parentheses:
Nasal glucagon* (Q2 2018)—a glucagon nasal powder formulation for the treatment of severe hypoglycemia in patients with diabetes treated with insulin. In the United States (U.S.), nasal glucagon is protected by a delivery device patent (2034), with data protection (3.5 years) expected upon approval. In Europe, nasal glucagon is protected by a delivery device patent (2034), with data protection (6 years) expected upon approval.
The following NMEs and diagnostic agent are currently in Phase III clinical trial testing for potential use in the diseases described which have not yet been submitted for approval for any indication. The first quarter in which each NME and the diagnostic agent initially entered Phase III for any indication is shown in parentheses:
Flortaucipir** (Q3 2015)—a positron emission tomography (PET) tracer intended to image tau (or neurofibrillary) tangles in the brain, which are an indicator of Alzheimer's disease.
Lasmiditan (Q2 2015)—an oral 5-HT1F agonist for the acute treatment of migraine.
Mirikizumab* (Q2 2018)—a human monoclonal antibody designed for the treatment of autoimmune diseases.
Pegilodecakin* (Q1 2017)—a PEGylated IL-10, which has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types.
Solanezumab* (Q2 2009)—an anti-amyloid beta monoclonal antibody for the treatment of preclinical Alzheimer’s disease.
Tanezumab* (Q3 2008)—an anti-nerve growth factor monoclonal antibody for the treatment of osteoarthritis pain, chronic low back pain, and cancer pain (in collaboration with Pfizer Inc.).
Ultra-rapid Lispro* (Q3 2017)—an ultra-rapid insulin for the treatment of type 1 and type 2 diabetes.
*
Biologic molecule subject to the U.S. Biologics Price Competition and Innovation Act
**
Diagnostic agent

43


The following table reflects the status of the recently approved products, NMEs, and diagnostic agent set forth above, as well as certain other developments to our late-stage pipeline since January 1, 2018:
Compound
Indication
U.S.
Europe
Japan
Developments
Endocrinology
Nasal glucagon
Severe hypoglycemia
Submitted
Phase III
Submitted to U.S. Food and Drug Administration (FDA) in second quarter of 2018. Submitted to European regulatory authorities in third quarter of 2018.
Ultra-rapid Lispro
Type 1 and 2 diabetes
Phase III
In October 2018, announced Phase III trials met primary efficacy endpoint. Submission to regulatory authorities expected in 2019.
Immunology
Mirikizumab
Psoriasis
Phase III
Phase III trials were initiated during the second quarter of 2018.
Ulcerative Colitis
Phase III
Phase III trial was initiated during the second quarter of 2018.
Olumiant
Rheumatoid arthritis
Launched
Granted approval of 2mg dose by FDA and launched in U.S. in second quarter of 2018.
Atopic Dermatitis
Phase III
Phase III trials are ongoing.
Systemic Lupus Erythematosus
Phase III
Phase III trials were initiated during the third quarter of 2018.
Neuroscience
Flortaucipir
Alzheimer's disease
Phase III
In the third quarter of 2018, announced Phase III trial met primary endpoints. In discussion with regulatory authorities to determine next steps.
Emgality
Cluster headache
Phase III
In the second quarter of 2018, announced Phase III trial met primary endpoint for episodic cluster headache. Received Breakthrough Therapy Designation(1) in the third quarter of 2018.  Submission to FDA expected in fourth quarter of 2018. A separate Phase III trial did not meet primary endpoint for chronic cluster headache.
Migraine prevention
Launched
Submitted
Phase III
Approved and launched in the U.S. in the third and fourth quarters of 2018, respectively. Received positive opinion from the Committee for Medicinal Products for Human Use in Europe during the third quarter of 2018.
Lanabecestat
Early and mild Alzheimer's disease
Discontinued
Phase III trials discontinued in second quarter of 2018.
Lasmiditan
Migraine
Submitted
Phase III
In third quarter of 2017, announced Phase III trial met primary endpoint. Submitted to FDA in fourth quarter of 2018. See Note 3 to the consolidated condensed financial statements for information on the CoLucid acquisition.
Solanezumab
Preclinical Alzheimer's disease
Phase III
Phase III trial is ongoing.
Tanezumab
Osteoarthritis pain
Phase III
In third quarter of 2018, announced initial Phase III trial met primary endpoints. We anticipate additional readouts from the program to be available in 2019.
Chronic low back pain
Phase III
Phase III trial is ongoing.
Cancer pain
Phase III
Phase III trial is ongoing.

44


Compound
Indication
U.S.
Europe
Japan
Developments
Oncology
Pegilodecakin
Pancreatic cancer
Phase III
Acquired with ARMO in the second quarter of 2018. Phase III trial is ongoing. See Note 3 to the consolidated condensed financial statements for information on the acquisition.
Verzenio
Adjuvant breast cancer
Phase III
Phase III trial is ongoing.
Metastatic breast cancer
Launched
Approved
In October 2018, approved in Europe and Japan.
Lartruvo
Soft tissue sarcoma
Launched
Phase III
Granted accelerated approval(2) by the FDA in fourth quarter of 2016 based on Phase II data. Launched in the U.S. in the fourth quarter of 2016. Granted conditional approval(3) and launched in Europe in fourth quarter of 2016. Phase III trial is ongoing.
(1) The Breakthrough Therapy Designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint.
(2) Continued approval for this indication may be contingent on verification and description of clinical benefit in a confirmatory Phase III trial.
(3) As part of a conditional marketing authorization, results from an ongoing Phase III study will need to be provided. This study is fully enrolled and ongoing. Until availability of the full data, the Committee for Medicinal Products for Human Use will review the benefits and risks of Lartruvo annually to determine whether the conditional marketing authorization can be maintained.
Other Matters
Elanco Animal Health
On September 24, 2018, Elanco Animal Health Incorporated (Elanco) completed an initial public offering (the IPO) of 72.3 million shares of its common stock, which represents 19.8 percent of Elanco's outstanding shares, at $24 per share. In addition, Elanco completed a debt offering and entered into a term loan facility during the third quarter of 2018. See Notes 3 and 6 to the consolidated condensed financial statements for additional information.
We intend to make a distribution to our shareholders of all or a portion of our remaining equity interest in Elanco, which may include one or more distributions effected as a dividend to all our shareholders, one or more distributions in exchange for our shares or other securities, or any combination thereof. We refer to any such potential distribution as the "Distribution". While we intend to effect the Distribution, we have no obligation to pursue or consummate any further dispositions of our ownership in Elanco, including through the Distribution, by any specified date or at all. If pursued, the Distribution may be subject to various conditions, including receipt of any necessary regulatory or other approvals, the existence of satisfactory market conditions, and the receipt of an opinion of counsel to the effect that the separation, together with such Distribution, would be tax-free to us and our shareholders for U.S. federal income tax purposes. The conditions of the Distribution may not be satisfied; we
may decide not to consummate the Distribution even if the conditions are satisfied; or we may decide to waive one or more of these conditions and consummate the Distribution even if all of the conditions are not satisfied.
Patent Matters
We depend on patents or other forms of intellectual-property protection for most of our revenue, cash flows, and earnings. We lost our patent exclusivity for Strattera® in the U.S. in May 2017, and generic versions of Strattera were approved in the same month. Following a settlement related to the compound patent challenge for Effient®, generic products launched in the U.S. in the third quarter of 2017. The entry of generic competition for these products has caused a rapid and severe decline in revenue, which in the aggregate have had a material adverse effect on our consolidated results of operations and cash flows.
Our compound patent protection for Cialis® (tadalafil) and Adcirca® (tadalafil) expired in major European markets and the U.S. in November 2017; however, in the U.S., we were granted pediatric exclusivity through May 2018. Pursuant to a settlement agreement related to our unit dose patent in the U.S., generic tadalafil entered the U.S. market in September 2018. We expect that the entry of generic competition into these markets following the loss of exclusivity will cause a significant decline in revenue for the affected products, which will, in the aggregate, have a material adverse effect on our consolidated results of operations and cash flows.


45


Our formulation patent and use patent for Forteo® expire in December 2018 and August 2019, respectively, in major European markets and the U.S. Both the formulation patent and the use patent expire in 2019 in Japan. While it is difficult to estimate the severity of the impact of generic and/or biosimilar competition in these markets, we expect a rapid and severe decline in revenue in the U.S. as a result of the U.S. patent expirations. Outside the U.S., we expect a decline in revenue as a result of patent expirations, however the decline may not be rapid and severe. In the aggregate, we expect that the decline in revenue will have a material adverse effect on our consolidated results of operations and cash flows.
Additionally, as described in Note 9 to the consolidated condensed financial statements, the Alimta® vitamin regimen patents, which provide us with patent protection for Alimta through June 2021 in Japan and major European countries, and through May 2022 in the U.S., have been challenged in each of these jurisdictions. Our vitamin regimen patents have also been challenged in other smaller European jurisdictions. Our compound patent for Alimta expired in the U.S. in January 2017, and expired in major European countries and Japan in December 2015. We expect that the entry of generic competition for Alimta following the loss of effective patent protection will cause a rapid and severe decline in revenue for the product, which will, in the aggregate, have a material adverse effect on our consolidated results of operations and cash flows. See Note 9 to the consolidated condensed financial statements for a more detailed account of the legal proceedings currently pending in the U.S., Europe, and Japan regarding our Alimta patent.
The compound patent for Humalog® (insulin lispro) has expired in major markets. Global regulators have different legal pathways to approve similar versions of insulin lispro. A similar version of insulin lispro launched in the U.S in the second quarter of 2018 and in certain European markets in 2017. While it is difficult to estimate the severity of the impact of similar insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue; however, we expect additional pricing pressure and some loss of market share that would continue over time.
Foreign Currency Exchange Rates
As a global company with substantial operations outside the U.S., we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro and Japanese yen. While we manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a substantial impact, either positive or negative, on our revenue, cost of sales, and operating expenses. While there is uncertainty in the future movements in foreign exchange rates, fluctuations in these rates could negatively impact our future consolidated results of operations and cash flows.
Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access
United States
In the U.S., public concern over access to and affordability of pharmaceuticals continues to drive the regulatory and legislative debate. These policy and political issues increase the risk that taxes, fees, rebates, or other cost control measures may be enacted to manage federal and state budgets. Key health policy proposals affecting biopharmaceuticals include a reduction in biologic data exclusivity, modifications to Medicare Parts B and D, language that would allow the Department of Health and Human Services to negotiate prices for biologics and drugs in Medicare, proposals that would require biopharmaceutical manufacturers to disclose proprietary drug pricing information, and state-level proposals related to prescription drug prices and reducing the cost of pharmaceuticals purchased by government health care programs. California and several other states have enacted legislation related to prescription drug pricing transparency and it is unclear the affect this legislation will have on our business. The Bipartisan Budget Act, enacted on February 9, 2018, will require manufacturers of brand-name drugs, biologics, and biosimilars to pay a 70 percent discount in the Medicare Part D Coverage Gap, up from the current 50 percent discount. This increase in Coverage Gap discounts will be effective beginning in 2019. In May 2018, the White House released "American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs" (Blueprint). The Administration’s corresponding request for information included more than 30 policy changes. We believe some proposals would be positive and other proposals would have negative consequences to our business. The effect of these proposals, and those that extend beyond the Blueprint, will depend on the details and timing of the final legislation, regulation, or guidance and could lead to a wide range of outcomes. Some of these outcomes could have a material adverse effect on our consolidated results of operations and cash flows.

46


In the private sector, consolidation and integration among healthcare providers is also a major factor in the competitive marketplace for human pharmaceuticals. Health plans, pharmaceutical benefit managers, wholesalers, and other supply chain stakeholders have been consolidating into fewer, larger entities, increasingly through vertical integration, thus enhancing their purchasing strength and importance. Payers typically maintain formularies which specify coverage (the conditions under which drugs are included on a plan's formulary) and reimbursement (the associated out-of-pocket cost to the consumer). Formulary placement can lead to reduced usage of a drug for the relevant patient population due to coverage restrictions, such as prior authorizations and formulary exclusions, or due to reimbursement limitations that result in higher consumer out-of-pocket cost, such as non-preferred co-pay tiers, increased co-insurance levels and higher deductibles. Consequently, pharmaceutical companies compete for formulary placement not only on the basis of product attributes such as greater efficacy, fewer side effects, or greater patient ease of use, but also by providing rebates. Price is an increasingly important factor in formulary decisions, particularly in treatment areas in which the payer has taken the position that multiple branded products are therapeutically comparable. These downward pricing pressures could negatively affect future consolidated results of operations and cash flows.
The main coverage expansion provisions of the Affordable Care Act (ACA) are currently in effect through both state-based exchanges and the expansion of Medicaid. A trend has been the prevalence of benefit designs containing high out-of-pocket costs for patients, particularly for pharmaceuticals. In addition to the coverage expansions, many employers in the commercial market, driven in part by ACA changes such as the 2022 implementation of the excise tax on employer-sponsored health care coverage for which there is an excess benefit (the so-called "Cadillac tax"), continue to evaluate strategies such as private exchanges and wider use of consumer-driven health plans to reduce their healthcare liabilities over time. Federal legislation or administrative actions to repeal or modify some or all of the provisions of the ACA could have a material adverse effect on our consolidated results of operations and cash flows. At the same time, the broader paradigm shift towards performance-based reimbursement and the launch of several value-based purchasing initiatives have placed demands on the pharmaceutical industry to offer products with proven real-world outcomes data and a favorable economic profile.
International
International operations also are generally subject to extensive price and market regulations. Cost-containment measures exist in a number of countries, including additional price controls and mechanisms to limit reimbursement for our products. Such policies are expected to increase in impact and reach given the pressures on national and regional health care budgets that come from a growing aging population and ongoing economic challenges. As additional reforms are finalized, we will assess their impact on future revenues. In addition, governments in many emerging markets are becoming increasingly active in expanding health care system offerings. Given the budget challenges of increasing health care coverage for citizens, policies may be proposed that promote generics and biosimilars only and reduce current and future access to branded human pharmaceutical products.
Tax Matters
We are subject to income taxes in the U.S. and numerous foreign jurisdictions. Changes in the relevant tax laws, regulations, administrative practices, principles, and interpretations could adversely affect our future effective tax rates. The U.S. recently enacted tax reform legislation significantly revising U.S. tax law, and a number of other countries are actively considering or enacting tax changes. Other organizations, such as the Organisation for Economic Co-operation and Development and the European Commission, are active regarding tax-related matters, which could influence international tax policy in countries in which we operate. While outcomes of these initiatives continue to develop and remain uncertain, modifications to key elements of the U.S. or international tax framework could have a material adverse effect on our consolidated results of operations and cash flows.
Our accounting for the Tax Cuts and Jobs Act (2017 Tax Act), signed into law in December 2017, is incomplete; however, we expect to complete our accounting by December 2018. In the fourth quarter of 2017, we recorded provisional adjustments for effects that we were able to reasonably estimate. Refer to Note 7 to the consolidated condensed financial statements for further information related to the 2017 Tax Act.
Acquisitions
See Note 3 to the consolidated condensed financial statements for discussion regarding our recent acquisitions of businesses and assets, including:
•
Our collaboration with Sigilon, completed in April 2018, for an upfront fee of $62.5 million and an equity investment in Sigilon.
•
Our acquisition of AurKa, completed in June 2018, for a cash purchase price of $81.3 million, net of cash acquired, plus net accrued liabilities assumed of $0.5 million.

47


•
Our acquisition of ARMO, completed in June 2018, for a cash purchase price of $1.40 billion, net of cash acquired, plus net accrued liabilities assumed of $75.8 million.
•
Our collaboration with Anima, completed in July 2018, for an upfront fee of $30.0 million.
Legal Matters
Information regarding contingencies relating to certain legal proceedings can be found in Item 1. Legal Proceedings of Part II to the consolidated condensed financial statements and is incorporated here by reference.
Revenue
The following tables summarize our revenue activity by region:
 
Three Months Ended
September 30,
 
 
Nine Months Ended
September 30,
 
 
 
2018
 
2017
 
Percent Change
2018
 
2017
 
Percent Change
U.S. (1)
$
3,446.6

 
$
3,104.4

 
11
$
10,211.0

 
$
9,361.8

 
9
Outside U.S.
2,615.3

 
2,553.6

 
2
7,906.1

 
7,348.7

 
8
Revenue
$
6,061.9

 
$
5,658.0

 
7
$
18,117.1

 
$
16,710.6

 
8
Numbers may not add due to rounding.
(1) U.S. revenue includes revenue in Puerto Rico.
The following are components of the change in revenue compared with the prior year:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018 vs. 2017
 
2018 vs. 2017
 
U.S.
Outside U.S.
Consolidated
 
U.S.
Outside U.S.
Consolidated
Volume
16
 %
8
 %
12
 %
 
8
%
7
 %
7
 %
Price
(5
)
(3
)
(4
)
 
1

(2
)
—

Foreign exchange rates
—

(2
)
(1
)
 
—

4

2

Percent change
11
 %
2
 %
7
 %
 
9
%
8
 %
8
 %
Numbers may not add due to rounding.
In the U.S., for the three and nine months ended September 30, 2018, the volume increase was primarily driven by increased volume for new pharmaceutical products, including Trulicity®, Basaglar®, Taltz®, and Verzenio, partially offset by decreased volume for products that have lost exclusivity, including Cialis, Strattera, and Effient. The decrease in realized prices for the three months ended September 30, 2018 was primarily driven by Basaglar, Humalog, and Taltz.
Outside the U.S., for the three and nine months ended September 30, 2018, the volume increase was primarily driven by increased volume for new pharmaceutical products, including Trulicity, Olumiant, and Taltz, partially offset by decreased volume for Cialis due to loss of exclusivity in several markets. The decrease in realized prices was due to several pharmaceutical products.

48


The following tables summarize our revenue activity by product:
 
Three Months Ended
September 30,
 
 
 
2018
 
2017
Product
U.S. (1)
 
Outside U.S.
 
Total
 
Total
Percent Change
Trulicity
$
645.9

 
$
170.3

 
$
816.2

 
$
527.7

 
55
Humalog
365.6

 
299.0

 
664.6

 
696.2

 
(5)
Alimta
288.5

 
232.0

 
520.5

 
514.5

 
1
Cialis
295.9

 
171.2

 
467.1

 
564.9

 
(17)
Forteo
182.5

 
208.3

 
390.8

 
441.7

 
(12)
Humulin®
216.9

 
105.1

 
322.1

 
300.5

 
7
Taltz
210.6

 
53.3

 
263.9

 
151.3

 
74
Basaglar
157.3

 
43.9

 
201.2

 
145.7

 
38
Cyramza®
67.0

 
131.4

 
198.4

 
196.0

 
1
Cymbalta®
14.5

 
157.5

 
172.0

 
183.2

 
(6)
Jardiance® (2)
104.2

 
62.7

 
166.9

 
127.2

 
31
Erbitux®
132.6

 
26.9

 
159.5

 
163.5

 
(2)
Trajenta™ (3)
50.3

 
85.3

 
135.7

 
153.3

 
(12)
Zyprexa®
7.0

 
102.8

 
109.9

 
140.6

 
(22)
Strattera
10.5

 
88.2

 
98.7

 
137.1

 
(28)
Other human pharmaceutical products
313.4

 
288.6

 
601.7

 
474.0

 
27
Animal health products
383.9

 
388.8

 
772.7

 
740.6

 
4
Revenue
$
3,446.6

 
$
2,615.3

 
$
6,061.9

 
$
5,658.0

 
7

49


 
Nine Months Ended
September 30,
 
 
 
2018
 
2017
Product
U.S. (1)
 
Outside U.S.
 
Total
 
Total
Percent Change
Trulicity
$
1,786.5

 
$
487.8

 
$
2,274.3

 
$
1,380.8

 
65
Humalog
1,334.2

 
891.8

 
2,226.1

 
2,083.0

 
7
Alimta
815.1

 
760.9

 
1,576.0

 
1,537.3

 
3
Cialis
954.9

 
546.2

 
1,501.2

 
1,725.7

 
(13)
Forteo
529.7

 
608.8

 
1,138.5

 
1,235.8

 
(8)
Humulin
677.3

 
316.7

 
994.0

 
972.8

 
2
Taltz
495.3

 
135.1

 
630.4

 
386.7

 
63
Cyramza
210.7

 
390.1

 
600.8

 
553.5

 
9
Basaglar
440.4

 
128.5

 
569.0

 
278.3

 
NM
Cymbalta
39.3

 
484.2

 
523.5

 
564.4

 
(7)
Erbitux
394.0

 
81.6

 
475.5

 
477.0

 
—
Jardiance (2)
284.8

 
180.3

 
465.1

 
304.3

 
53
Trajenta (3)
161.3

 
257.2

 
418.5

 
408.2

 
3
Zyprexa
27.6

 
332.8

 
360.4

 
428.9

 
(16)
Strattera
74.4

 
269.2

 
343.5

 
519.9

 
(34)
Other human pharmaceutical products
847.7

 
846.7

 
1,694.3

 
1,559.2

 
9
Animal health products
1,137.8

 
1,188.2

 
2,326.0

 
2,294.8

 
1
Revenue
$
10,211.0

 
$
7,906.1

 
$
18,117.1

 
$
16,710.6

 
8
Numbers may not add due to rounding.
NM - not meaningful
(1) U.S. revenue includes revenue in Puerto Rico.
(2) Jardiance revenue includes Glyxambi® and Synjardy®.
(3) Trajenta revenue includes Jentadueto®.
Revenue of Trulicity, a treatment for type 2 diabetes, increased 56 percent and 64 percent in the U.S. during the three and nine months ended September 30, 2018, respectively, primarily driven by increased demand. Revenue outside the U.S. increased 48 percent and 68 percent during the three and nine months ended September 30, 2018, respectively, primarily driven by increased volume. The increase during the nine months ended September 30, 2018 was also, to a lesser extent, driven by the favorable impact of foreign exchange rates, partially offset by lower realized prices.
Revenue of Humalog, our injectable human insulin analog for the treatment of diabetes, decreased 12 percent in the U.S. during the three months ended September 30, 2018 driven by lower realized prices primarily due to changes in segment mix and the impact of patient affordability programs. Revenue increased 6 percent in the U.S. during the nine months ended September 30, 2018 driven by increased volume and higher realized prices due to changes in estimates to rebates and discounts and changes in segment mix. Revenue outside the U.S. increased 6 percent and 8 percent during the three and nine months ended September 30, 2018, respectively. The increase during the three months ended September 30, 2018 was driven by increased volume, partially offset by lower realized prices and the unfavorable impact of foreign exchange rates. The increase during the nine months ended September 30, 2018 was driven by increased volume, and to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices. A similar version of insulin lispro launched in the U.S. in the second quarter of 2018 and in certain European markets in 2017. While it is difficult to estimate the severity of the impact of similar insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue; however, we expect additional pricing pressure and some loss of market share that would continue over time. See "Executive Overview - Other Matters - Patent Matters" for more information.

50


Revenue of Alimta, a treatment for various cancers, increased 11 percent and 7 percent in the U.S. during the three and nine months ended September 30, 2018, respectively, driven by increased demand, and to a lesser extent, higher realized prices. Revenue outside the U.S. decreased 9 percent and 2 percent during the three and nine months ended September 30, 2018, respectively, primarily driven by decreased volume due to competitive pressure and loss of exclusivity in several countries. The decrease during the nine months ended September 30, 2018 was partially offset by the favorable impact of foreign exchange rates. We have faced and remain exposed to generic entry in multiple countries, which has eroded revenue and is likely to continue to erode revenue from current levels.
Revenue of Cialis, a treatment for erectile dysfunction and benign prostatic hyperplasia, decreased 7 percent and 4 percent in the U.S. during the three and nine months ended September 30, 2018, respectively, driven by decreased demand due to the entry of generic products, partially offset by higher realized prices. Revenue outside the U.S. decreased 30 percent and 25 percent during the three and nine months ended September 30, 2018, respectively, primarily driven by the loss of exclusivity in Europe. We lost our compound patent protection for Cialis in major European markets in November 2017 and U.S. exclusivity ended in late September 2018. See "Executive Overview - Other Matters - Patent Matters" for more information. In addition to competition from generic tadalafil, we also currently face competition from generic sildenafil, which has accelerated during 2018. We expect that the entry of generic competition due to the loss of exclusivity will continue to cause a rapid and severe decline in revenue.
Revenue of Forteo, an injectable treatment for osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women, decreased 22 percent and 20 percent in the U.S. during the three and nine months ended September 30, 2018, respectively, primarily due to decreased demand and, to a lesser extent, lower realized prices. Revenue outside the U.S. remained flat during the three months ended September 30, 2018 driven by increased volume, offset by lower realized prices and the unfavorable impact of foreign exchange rates. Revenue increased 6 percent during the nine months ended September 30, 2018 driven by increased volume and the favorable impact of foreign exchange rates, partially offset by lower realized prices. Our formulation patent and use patent for Forteo expire in December 2018 and August 2019, respectively, in major European markets and the U.S. Both the formulation patent and the use patent expire in 2019 in Japan. While it is difficult to estimate the severity of the impact of generic and/or biosimilar competition in these markets, we expect a rapid and severe decline in revenue in the U.S. as a result of the U.S. patent expirations. Outside the U.S., we expect a decline in revenue as a result of patent expirations, however the decline may not be rapid and severe. See "Executive Overview - Other Matters - Patent Matters" for more information.
Revenue of Humulin, an injectable human insulin for the treatment of diabetes, increased 7 percent in the U.S. during the three and nine months ended September 30, 2018, primarily driven by increased volume. Revenue outside the U.S. increased 8 percent during the three months ended September 30, 2018 primarily due to buying patterns in China, partially offset by the unfavorable impact of foreign exchange rates. Revenue decreased 6 percent during the nine months ended September 30, 2018 driven by decreased volume, primarily in China, partially offset by the favorable impact of foreign exchange rates.
Revenue of Taltz, a product for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis, increased 60 percent and 44 percent in the U.S. during the three and nine months ended September 30, 2018, respectively, driven by higher demand, partially offset by lower realized prices. Revenue outside the U.S. increased $33.3 million and $92.0 million during the three and nine months ended September 30, 2018, respectively, driven by increased volume from new launches.
Revenue of Cyramza, a treatment for various cancers, decreased 4 percent in the U.S. during the three months ended September 30, 2018 driven by lower realized prices. Revenue increased 3 percent in the U.S. during the nine months ended September 30, 2018 driven by increased volume. Revenue outside the U.S. increased 4 percent and 12 percent during the three and nine months ended September 30, 2018, respectively, driven by increased volume, partially offset by lower realized prices. The increase during the nine months ended September 30, 2018 was also driven by the favorable impact of foreign exchange rates.
Revenue of Basaglar, a long-acting human insulin analog for the treatment of diabetes, which launched in the U.S. in late 2016, increased $42.1 million and $243.7 million in the U.S. during the three and nine months ended September 30, 2018, primarily driven by increased demand, partially offset by lower realized prices due to increased volume in Medicare Part D and, to a lesser extent, changes to estimates for rebates and discounts. Revenue outside the U.S. increased $13.4 million and $46.9 million during the three and nine months ended September 30, 2018, primarily driven by increased demand. The increase during the nine months ended September 30, 2018 was also partially driven by the favorable impact of foreign exchange rates. See Note 4 to the consolidated condensed financial statements for information regarding our collaboration with Boehringer Ingelheim involving Basaglar.

51


Revenue of Cymbalta, a product for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and for the treatment of chronic musculoskeletal pain and the management of fibromyalgia, decreased 26 percent and 61 percent in the U.S. during the three and nine months ended September 30, 2018, respectively, driven by decreased demand, partially offset by higher realized prices. Revenue decreased 4 percent outside the U.S. during the three months ended September 30, 2018, primarily driven by lower realized prices, and to a lesser extent, the unfavorable impact of foreign exchange rates, partially offset by increased volume in Japan. Revenue increased 4 percent outside the U.S. during the nine months ended September 30, 2018, primarily driven by increased volume in Japan, and to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices.
Worldwide animal health revenue increased 4 percent during the three months ended September 30, 2018 driven by higher realized prices and increased volume, partially offset by the negative impact of foreign exchange rates. The overall increase in revenue included increased revenue in the companion animal prevention, ruminants and swine, and companion animal therapeutics product categories, partially offset by decreased revenue of products that are being exited. Worldwide animal health revenue increased 1 percent during the nine months ended September 30, 2018 driven by higher realized prices, and to a lesser extent, the favorable impact of foreign exchange rates, partially offset by decreased volume. The overall increase in revenue included increased revenue in the companion animal prevention, future protein and health products, companion animal therapeutics, and ruminants and swine product categories, partially offset by decreased revenue of products that are being exited.
Gross Margin, Costs, and Expenses
Gross margin as a percent of revenue increased 2.2 percentage points to 74.2 percent and increased 0.3 percentage points to 73.3 percent for the three and nine months ended September 30, 2018, respectively. The increase in gross margin percent for the three months ended September 30, 2018 was primarily due to manufacturing efficiencies, and to a lesser extent, the effect of foreign exchange rates on international inventories sold and favorable impact of product mix, partially offset by the negative impact of price on revenue. The increase in gross margin percent for the nine months ended September 30, 2018 was primarily due to manufacturing efficiencies largely offset by the effect of foreign exchange rates on international inventories sold.
Research and development expenses remained flat at $1.34 billion and $3.85 billion for the three and nine months ended September 30, 2018, respectively, primarily due to additional late-stage development expenditures, offset by lower development milestone payments compared to the prior year periods.
Marketing, selling, and administrative expenses increased 2 percent to $1.62 billion for the three months ended September 30, 2018 primarily due to increased expenses related to new pharmaceutical product launches, partially offset by reduced expenses on late life-cycle products. Marketing, selling, and administrative expenses decreased 2 percent to $4.77 billion for the nine months ended September 30, 2018 due to decreased expenses related to late life-cycle products, partially offset by increased expenses related to new pharmaceutical products.
Both research and development expenses and marketing, selling, and administrative expenses benefited during the three and nine months ended September 30, 2018 from actions taken in 2017 to reduce our cost structure.
We recognized $30.0 million and $1.65 billion of acquired IPR&D charges for the three and nine months ended September 30, 2018, respectively. The charge for the three months ended September 30, 2018 was related to the collaboration with Anima. The nine months ended September 30, 2018 also included charges related to the acquisitions of ARMO and AurKa, as well as the collaboration with Sigilon. We recognized $205.0 million and $1.06 billion of acquired IPR&D charges for the three and nine months ended September 30, 2017, respectively. The charges for the three months ended September 30, 2017 related to the upfront payments associated with our collaborations with Nektar and KeyBioscience. The charges for the nine months ended September 30, 2017 also included the acquired IPR&D charges associated with the acquisition of CoLucid. See Note 3 to the consolidated condensed financial statements for additional information.

52


We recognized asset impairment, restructuring, and other special charges of $83.3 million and $236.0 million for the three and nine months ended September 30, 2018, respectively, compared with charges of $406.5 million and $670.4 million for the three and nine months ended September 30, 2017, respectively. The charges for the third quarter of 2018 were primarily associated with asset impairment and restructuring charges related to the sale of the Posilac (rbST) brand and the October 2018 sale of the Augusta, Georgia manufacturing site. The charges also include expenses associated with the IPO and separation of the Elanco animal health business. In addition to these charges, the charges for the first nine months of 2018 also included charges for contractual commitments related to the suspension of commercial activities for Imrestor, as well as expenses associated with the review of strategic alternatives for the Elanco animal health business. The charges for the third quarter of 2017 were primarily associated with asset impairments related to lower projected revenue for Posilac (rbST), severance costs incurred as a result of actions taken to reduce our cost structure, as well as exit costs due to site closures. The charges for the first nine months of 2017 also include integration costs related to the acquisition of Novartis AH. See Note 5 to the consolidated condensed financial statements for additional information.
Other–net, (income) expense was expense of $15.4 million and income of $90.1 million for the three and nine months ended September 30, 2018, respectively, compared with income of $49.9 million and $188.6 million for the three and nine months ended September 30, 2017. See Note 11 to the consolidated condensed financial statements for additional information.
The effective tax rate was 18.5 percent for the three months ended September 30, 2018, compared with 6.1 percent for the three months ended September 30, 2017, primarily due to a higher income tax benefit in the third quarter of 2017 for acquired IPR&D charges, asset impairment, restructuring, and other special charges. The effective tax rate for the nine months ended September 30, 2018 was 26.2 percent as it reflects non-deductible acquired IPR&D charges totaling $1.56 billion from the acquisitions of ARMO and AurKa. The effective tax rate for the nine months ended September 30, 2017 was 24.1 percent as it reflected the non-deductible acquired IPR&D charge of $857.6 million related to the acquisition of CoLucid, in addition to the items discussed for the third quarter. See Note 7 to the consolidated condensed financial statements for additional information.
Financial Condition
Cash and cash equivalents increased to $8.96 billion as of September 30, 2018, compared with $6.54 billion as of December 31, 2017. Refer to the consolidated condensed statements of cash flows for additional details on the significant sources and uses of cash for the nine months ended September 30, 2018 and 2017. Approximately $4.2 billion of the cash and cash equivalents as of September 30, 2018 is intended to be used for debt repayment, dividends, and/or share repurchases. See Note 3 to the consolidated condensed financial statements for additional details.
In addition to our cash and cash equivalents, we held total investments of $2.08 billion and $7.18 billion as of September 30, 2018 and December 31, 2017, respectively. See Note 6 to the consolidated condensed financial statements for additional details.
Total debt decreased to $12.68 billion as of September 30, 2018, compared with $13.65 billion as of December 31, 2017. The decrease was primarily due to the net decrease in the balance of commercial paper outstanding of $2.30 billion and the repayment of $1.00 billion of long term debt, partially offset by an increase due to the debt offering and credit facilities entered into by Elanco totaling $2.48 billion. See Note 6 to the consolidated condensed financial statements for additional details.
Excluding Elanco, as of September 30, 2018, we had a total of $5.57 billion of committed bank credit facilities, $5.00 billion of which is available to support our commercial paper program. $3.80 billion of the committed bank credit facilities will expire before the end of 2018. We believe that amounts accessible through existing commercial paper markets should be adequate to fund short-term borrowing needs.
In September 2018, Elanco entered into a revolving credit agreement providing for a five-year $750.0 million senior unsecured revolving credit facility, which expires September 2023. See Note 6 to the consolidated condensed financial statements for additional details.
During the nine months ended September 30, 2018, we repurchased $3.05 billion of shares. We completed the $5.00 billion share repurchase program announced in October 2013, and the board authorized a new $8.00 billion share repurchase program. There were $1.00 billion of shares repurchased under the $8.00 billion program during the nine months ended September 30, 2018.
We believe that cash generated from operations, along with available cash and cash equivalents, will be sufficient to fund our normal operating needs, including dividends, share repurchases, and capital expenditures.

53


See "Executive Overview - Other Matters - Patent Matters" for information regarding recent and upcoming losses of patent protection.
Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of health care legislation; various international government funding levels; and changes in foreign currency exchange rates (see "Executive Overview - Other Matters - Foreign Currency Exchange Rates").
Financial Expectations
Full-year 2018 EPS is now anticipated to be in the range of $3.04 to $3.09. We now expect 2018 revenue of between $24.3 billion and $24.5 billion, with the increase in the low end of the revenue range from prior guidance due to strong performance across the pharmaceutical portfolio, particularly in diabetes. We still expect revenue growth to be driven by new pharmaceutical products including Trulicity, Taltz, Basaglar, Jardiance, Verzenio, Cyramza, Olumiant, and Lartruvo.
Gross margin as a percent of revenue is still expected to be approximately 73.5 percent. Research and development expenses are still expected to be in the range of $5.2 billion to $5.4 billion. Marketing, selling, and administrative expenses are now expected to be in the range of $6.3 billion to $6.5 billion. Other—net, (income) expense is still expected to be income between $75 million and $200 million.
The 2018 tax rate is still expected to be approximately 22.5 percent. The 2018 effective tax rate benefits from a lower corporate income tax rate, partially offset by the changes to certain business exclusions, deductions, credits, and international tax provisions as a result of the 2017 Tax Act. The 2018 effective tax rate is subject to change based upon changes in our interpretations of the tax laws, along with subsequent regulations, interpretations, guidance, and accounting policy elections that we continue to evaluate.
Capital expenditures are still expected to be approximately $1.2 billion.
Available Information on our Website
We make available through our company website, free of charge, our company filings with the Securities and Exchange Commission (SEC) as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. The reports we make available include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents.
The website link to our SEC filings is http://investor.lilly.com/sec.cfm.
Item 4. Controls and Procedures
(a)
Evaluation of Disclosure Controls and Procedures. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-Q) is recorded, processed, summarized, and reported on a timely basis.
Our management, with the participation of David A. Ricks, chairman, president, and chief executive officer, and Joshua L. Smiley, senior vice president and chief financial officer, evaluated our disclosure controls and procedures as of September 30, 2018, and concluded that they are effective.
(b)
Changes in Internal Controls. During the third quarter of 2018, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

54


PART II. Other Information
Item 1. Legal Proceedings
See "Notes to Consolidated Condensed Financial Statements - Note 9, Contingencies" for information on various legal proceedings, including but not limited to:
•The patent litigation and administrative proceedings involving Alimta.
•The product liability litigation involving Cymbalta.
•The employee litigation in Brazil.
•Antitrust litigation involving Agri Stats, Inc.
•The arbitration filed by Adocia, S.A.
That information is incorporated into this Item by reference.
This Item should be read in conjunction with the Legal Proceedings disclosures in our Annual Report on Form 10-K for the year ended December 31, 2017 (Part I, Item 3) and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2018 and June 30, 2018 (Part II, Item 1).
Other Product Liability Litigation
We are named as a defendant in approximately 550 Axiron product liability lawsuits in the U.S. involving approximately 550 plaintiffs. In about one-third of the cases, other manufacturers of testosterone are named as co-defendants. Nearly all of these lawsuits have been consolidated in a federal multidistrict litigation (MDL) in the U.S. District Court for the Northern District of Illinois. A small number of lawsuits have been filed in state courts. The cases generally allege cardiovascular and related injuries. We have reached agreement on a settlement framework that provides for a comprehensive resolution of nearly all of these personal injury claims alleging cardiovascular and related injuries from Axiron treatment. There can be no assurances, however, that a final settlement will be reached. Medical Mutual of Ohio (“MMO”) has filed a class action complaint against multiple manufacturers of testosterone products, including us, in the Northern District of Illinois, on behalf of third-party payers who paid for those products. MMO’s motion for class certification was denied, but MMO continues to pursue its individual claims and seek damages under the federal Racketeer Influenced and Corrupt Organizations Act (the federal RICO Act). We believe all of these lawsuits and claims are without merit and plan to defend against them vigorously.
We are named as a defendant in approximately 270 Cialis product liability lawsuits in the U.S. These cases, originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have the filed cases and an unspecified number of future cases coordinated into a federal MDL in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra® . The JPML ordered the transfer of the existing cases to the now-renamed MDL In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation. We believe these lawsuits and claims are without merit and plan to defend against them vigorously.
Other Patent Matters
Boehringer Ingelheim, our partner in marketing and development of Jardiance, is engaged in various U.S. patent litigation in the U.S. District Court for the District of Delaware involving Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Several companies submitted Abbreviated New Drug Applications (ANDA) seeking approval to market generic versions of Jardiance prior to the expiration of the relevant patents, alleging certain patents, including in some allegations the compound patent, are invalid or would not be infringed.
Boehringer Ingelheim, our partner in marketing and development of Trajenta, is engaged in various U.S. patent litigation matters in the U.S. District Court for the District of New Jersey involving Trajenta and Jentadueto in accordance with the procedures set out in the Hatch-Waxman Act. Eleven groups of companies submitted ANDAs seeking approval to market generic versions of Trajenta prior to the expiration of the relevant patents, alleging certain patents, including in some allegations the compound patent, are invalid or would not be infringed. In October 2018, the District Court held that some of the secondary patents were invalid; however, the challenge to the compound patent, which runs through 2025, was withdrawn.


55


We are named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, trade secret misappropriation, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. A trial date has not been set. We believe this lawsuit is without merit, and are vigorously defending ourselves against these claims.
In October 2017, Teva Pharmaceuticals International GMBH filed a lawsuit against us in the U.S. District Court for the District of Massachusetts seeking a ruling that various patents would be infringed if we launched Emgality for the prevention of migraine in adults. Teva Pharmaceuticals USA, Inc. (collectively with Teva Pharmaceuticals International GMBH, Teva) was added as a plaintiff in January 2018. In February 2018, Teva filed another lawsuit in the same court seeking a ruling that two recently granted Teva patents would also be infringed if we launched Emgality for the prevention of migraine in adults. While those lawsuits were dismissed without prejudice in September 2018, Teva subsequently refiled their complaint, alleging infringement of the same patents asserted in the previous suits. We believe this newly filed lawsuit is without merit and we plan to defend against it vigorously.
In Canada, several generic companies previously challenged the validity of our Zyprexa compound patent. In September 2012, the Canadian Federal Court of Appeals affirmed the lower court's decision that the patent was invalid for lack of utility. In 2013, our petition for leave to appeal the decision to the Supreme Court of Canada was denied. Two of the generic companies, Apotex, Inc. (Apotex) and Teva Canada Limited (Teva Canada), pursued claims for damages arising from our enforcement of the patent under Canadian regulations. In April 2014, the Supreme Court of Canada dismissed Apotex's damages suit. Teva Canada's claim for damages remains, and in January 2017, the court issued a ruling that Teva Canada is entitled to damages. We appealed the ruling, and in February 2018 the Canadian Federal Court of Appeal affirmed the lower court ruling. In April 2018, we filed a petition for leave to appeal the decision to the Supreme Court of Canada and expect a decision on the petition in the fourth quarter of 2018.
Other Matters
We, along with Sanofi and Novo Nordisk, were named as defendants in a consolidated purported class action lawsuit, In re. Insulin Pricing Litigation, in the U.S. District Court of New Jersey relating to insulin pricing Plantiffs seek damages under various state consumer protection laws and the federal RICO Act. Separately, we, along with Sanofi and Novo Nordisk, were named as defendants in a purported class action lawsuit, MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al., in the the same court seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. Finally, the Minnesota Attorney General’s Office filed a complaint against us, Sanofi and Novo Nordisk, State of Minnesota v. Sanofi-Aventis U.S. LLC et al., in the U.S. District Court of New Jersey, alleging unjust enrichment, and violations of various Minnesota state consumer protection laws and the federal RICO Act. We believe these claims are without merit and plan to defend against them vigorously.
We are also a defendant in other litigation and investigations, including product liability, patent, employment, and premises liability litigation, of a character we regard as normal to our business.
Item 1A. Risk Factors
Our material risk factors are disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017. There have been no material changes from the risk factors previously disclosed in our Annual Report.

56


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table summarizes the activity related to repurchases of our equity securities during the three months ended September 30, 2018:
Period
Total Number of
Shares Purchased
(in thousands)
 
Average Price Paid 
per Share
 
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
(in thousands)
 
Approximate Dollar Value 
of Shares that May Yet Be
Purchased Under the 
Plans or Programs
(in millions)
July 2018
8,471

 
$
96.93

 
8,471

 
$
7,178.8

August 2018
1,719

 
103.96

 
1,719

 
7,000.0

September 2018
—

 
—

 
—

 
7,000.0

Total
10,191

 
98.12

 
10,191

 
 
Numbers may not add due to rounding.

During the three months ended September 30, 2018, we repurchased $1.00 billion of shares under the $8.00 billion share repurchase program authorized in June 2018.
Item 6. Exhibits
The following documents are filed as exhibits to this Report:
EXHIBIT 3.1
 
Amended Articles of Incorporation
 
 
 
EXHIBIT 3.2
 
By-laws, as amended
 
 
 
EXHIBIT 10.1
 
Master Separation Agreement
 
 
 
EXHIBIT 31.1
  
Rule 13a-14(a) Certification of David A. Ricks, Chairman, President, and Chief Executive Officer
 
 
EXHIBIT 31.2
  
Rule 13a-14(a) Certification of Joshua L. Smiley, Senior Vice President and Chief Financial Officer
 
 
EXHIBIT 32.
  
Section 1350 Certification
 
 
EXHIBIT 101.
  
Interactive Data Files

57


Index to Exhibits
The following documents are filed as a part of this Report:
Exhibit
  
 
EXHIBIT 3.1
 
 
 
 
EXHIBIT 3.2
 
 
 
 
EXHIBIT 10.1
 
 
 
 
EXHIBIT 31.1
  
 
 
 
EXHIBIT 31.2
  
 
 
EXHIBIT 32.
  
 
 
 
EXHIBIT 101.
  
Interactive Data Files
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
ELI LILLY AND COMPANY
 
 
(Registrant)
 
 
 
Date:
11/6/2018
/s/Bronwen L. Mantlo
 
 
Bronwen L. Mantlo
 
 
Corporate Secretary
 
 
Date:
11/6/2018
/s/Donald A. Zakrowski
 
 
Donald A. Zakrowski
 
 
Vice President, Finance and Chief Accounting Officer

58
 EX-31.1 2 lly-9302018x10qxexhibit311.htm RULE 13A-14(A) CERTIFICATION OF DAVID A. RICKS, CHAIRMAN, PRESIDENT, AND CEO Exhibit


EXHIBIT 31.1 Rule 13a-14(a) Certification of David A. Ricks, Chairman, President, and Chief Executive Officer
CERTIFICATIONS
I, David A. Ricks, certify that:
1.
I have reviewed this report on Form 10-Q of Eli Lilly and Company;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
November 6, 2018
 
 
 
By:
 
/s/David A. Ricks
 
 
David A. Ricks
 
 
Chairman, President, and Chief Executive Officer


 EX-31.2 3 lly-9302018x10qxexhibit312.htm RULE 13A-14(A) CERTIFICATION OF JOSHUA L. SMILEY, SENIOR VICE PRESIDENT AND CFO Exhibit


EXHIBIT 31.2 Rule 13a-14(a) Certification of Joshua L. Smiley, Senior Vice President and Chief Financial Officer
CERTIFICATIONS
I, Joshua L. Smiley, certify that:
1.
I have reviewed this report on Form 10-Q of Eli Lilly and Company;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
November 6, 2018
 
 
 
By:
 
/s/Joshua L. Smiley
 
 
Joshua L. Smiley
 
 
Senior Vice President and Chief Financial Officer


 EX-32 4 lly-9302018x10qxexhibit32.htm SECTION 1350 CERTIFICATION Exhibit


EXHIBIT 32. Section 1350 Certification
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Eli Lilly and Company, an Indiana corporation (the “Company”), does hereby certify that, to the best of their knowledge:
The Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
November 6, 2018
 
/s/David A. Ricks
 
 
 
David A. Ricks
 
 
 
Chairman, President, and Chief Executive Officer
 
 
 
 
 
 
 
 
 
 
 
 
Date:
November 6, 2018
 
/s/Joshua L. Smiley
 
 
 
Joshua L. Smiley
 
 
 
Senior Vice President and Chief Financial Officer


 EX-101.INS 5 lly-20180930.xml XBRL INSTANCE DOCUMENT 0000059478 2018-01-01 2018-09-30 0000059478 lly:BoehringerIngelheimVetmedicaInc.sU.S.VaccinePortfolioMember 2018-01-01 2018-09-30 0000059478 lly:BiCompoundsMember 2018-01-01 2018-09-30 0000059478 lly:EffientMember 2018-01-01 2018-09-30 0000059478 lly:ErbituxMember 2018-01-01 2018-09-30 0000059478 lly:DiabetesCollaborationMember 2018-01-01 2018-09-30 0000059478 2018-11-02 0000059478 2017-01-01 2017-09-30 0000059478 2017-07-01 2017-09-30 0000059478 2018-07-01 2018-09-30 0000059478 2017-12-31 0000059478 2018-09-30 0000059478 us-gaap:NoncontrollingInterestMember 2018-09-30 0000059478 us-gaap:NoncontrollingInterestMember 2018-07-01 2018-09-30 0000059478 us-gaap:TreasuryStockMember 2018-09-30 0000059478 us-gaap:RetainedEarningsMember 2017-09-30 0000059478 us-gaap:AdditionalPaidInCapitalMember 2017-07-01 2017-09-30 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-07-01 2017-09-30 0000059478 us-gaap:TreasuryStockMember 2017-06-30 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2017-09-30 0000059478 us-gaap:RetainedEarningsMember 2017-06-30 0000059478 us-gaap:NoncontrollingInterestMember 2017-07-01 2017-09-30 0000059478 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000059478 us-gaap:CommonStockMember 2017-09-30 0000059478 us-gaap:NoncontrollingInterestMember 2018-06-30 0000059478 us-gaap:TreasuryStockMember 2018-07-01 2018-09-30 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000059478 us-gaap:CommonStockMember 2017-07-01 2017-09-30 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2018-06-30 0000059478 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0000059478 us-gaap:RetainedEarningsMember 2017-07-01 2017-09-30 0000059478 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0000059478 us-gaap:TreasuryStockMember 2017-09-30 0000059478 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000059478 us-gaap:RetainedEarningsMember 2018-09-30 0000059478 us-gaap:CommonStockMember 2017-06-30 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000059478 us-gaap:TreasuryStockMember 2018-06-30 0000059478 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2018-09-30 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000059478 us-gaap:NoncontrollingInterestMember 2017-06-30 0000059478 us-gaap:NoncontrollingInterestMember 2017-09-30 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2017-06-30 0000059478 us-gaap:CommonStockMember 2018-09-30 0000059478 us-gaap:CommonStockMember 2018-06-30 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000059478 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000059478 us-gaap:RetainedEarningsMember 2018-06-30 0000059478 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000059478 us-gaap:TreasuryStockMember 2017-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0000059478 us-gaap:TreasuryStockMember 2018-01-01 2018-09-30 0000059478 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0000059478 us-gaap:RetainedEarningsMember 2017-12-31 0000059478 us-gaap:TreasuryStockMember 2017-01-01 2017-09-30 0000059478 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-09-30 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2016-12-31 0000059478 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0000059478 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000059478 us-gaap:CommonStockMember 2017-12-31 0000059478 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0000059478 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0000059478 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-09-30 0000059478 us-gaap:TreasuryStockMember 2016-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-09-30 0000059478 us-gaap:CommonStockMember 2016-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2016-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0000059478 us-gaap:RetainedEarningsMember 2016-12-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2017-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2017-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000059478 2018-06-30 0000059478 2016-12-31 0000059478 2017-09-30 0000059478 us-gaap:RoyaltyMember 2018-07-01 2018-09-30 0000059478 us-gaap:RoyaltyMember 2018-01-01 2018-09-30 0000059478 us-gaap:RoyaltyMember 2017-07-01 2017-09-30 0000059478 us-gaap:RoyaltyMember 2017-01-01 2017-09-30 0000059478 us-gaap:ProductMember 2018-01-01 2018-09-30 0000059478 lly:CollaborationandOtherRevenueMember 2017-01-01 2017-09-30 0000059478 lly:CollaborationandOtherRevenueMember 2018-01-01 2018-09-30 0000059478 us-gaap:ProductMember 2017-07-01 2017-09-30 0000059478 lly:CollaborationandOtherRevenueMember 2017-07-01 2017-09-30 0000059478 lly:CollaborationandOtherRevenueMember 2018-07-01 2018-09-30 0000059478 us-gaap:ProductMember 2018-07-01 2018-09-30 0000059478 us-gaap:ProductMember 2017-01-01 2017-09-30 0000059478 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 0000059478 us-gaap:AccountingStandardsUpdate201707Member 2017-01-01 2017-09-30 0000059478 us-gaap:AccountingStandardsUpdate201707Member 2017-07-01 2017-09-30 0000059478 us-gaap:AccountingStandardsUpdate201601Member 2018-01-01 0000059478 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 0000059478 lly:SigilonTherapeuticsMember 2018-04-01 2018-04-30 0000059478 lly:KeyBiosciencesDualAmylinCalcitoninReceptorAgonistsMember 2017-07-01 2017-07-31 0000059478 lly:ARMOBiosciencesInc.Member 2018-06-01 2018-06-30 0000059478 lly:NektarsPhaseIImmunologicalTherapyMember 2017-08-01 2017-08-31 0000059478 lly:CoLucidPharmaceuticalsMember 2017-03-01 2017-03-31 0000059478 lly:AnimaBiotechMember 2018-07-01 2018-07-31 0000059478 lly:AurkaPharmaMember 2018-06-01 2018-06-30 0000059478 lly:PriorityReviewMember us-gaap:ScenarioForecastMember 2018-10-01 2018-12-31 0000059478 lly:DicernaPharmaceuticalsMember us-gaap:SubsequentEventMember 2018-10-01 2018-10-31 0000059478 lly:BoehringerIngelheimVetmedicaInc.sU.S.VaccinePortfolioMember 2017-01-03 2017-01-31 0000059478 us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsSpinoffMember lly:ElancoAnimalHealthIncorporatedMember 2018-09-24 2018-09-24 0000059478 lly:ChugaiPharmaceuticalCompanyMember us-gaap:ScenarioForecastMember 2018-10-01 2018-12-31 0000059478 lly:ElancoAnimalHealthIncorporatedMember us-gaap:IPOMember 2018-09-24 2018-09-24 0000059478 lly:ElancoAnimalHealthIncorporatedMember 2018-09-30 0000059478 lly:ElancoAnimalHealthIncorporatedMember 2018-09-24 2018-09-24 0000059478 lly:NextCureInc.Member us-gaap:ScenarioForecastMember 2018-10-01 2018-12-31 0000059478 lly:ElancoAnimalHealthIncorporatedMember us-gaap:IPOMember 2018-09-24 0000059478 lly:NextCureInc.Member us-gaap:ScenarioForecastMember 2018-11-01 2018-11-30 0000059478 lly:PriorityReviewMember us-gaap:ScenarioForecastMember 2018-11-01 2018-11-30 0000059478 lly:BoehringerIngelheimVetmedicaInc.sU.S.VaccinePortfolioMember 2017-01-03 0000059478 lly:EffientMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:EffientMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:EffientMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:EffientMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OlumiantMember lly:MilestonePaymentsDevelopmentandRegulatoryExpensedMember 2016-01-01 2016-12-31 0000059478 lly:OlumiantMember country:JP lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember 2017-01-01 2017-12-31 0000059478 lly:OlumiantMember lly:MilestonePaymentsDevelopmentandRegulatoryExpensedMember 2018-01-01 2018-09-30 0000059478 lly:OlumiantMember srt:EuropeMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember 2017-01-01 2017-12-31 0000059478 lly:OlumiantMember lly:MilestonePaymentsDevelopmentandRegulatoryExpensedMember 2017-01-01 2017-12-31 0000059478 lly:OlumiantMember country:US lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember 2018-01-01 2018-09-30 0000059478 lly:ErbituxMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:ErbituxCollaborationandOtherRevenueMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ErbituxCollaborationandOtherRevenueMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ErbituxMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ErbituxMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ErbituxMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ErbituxCollaborationandOtherRevenueMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ErbituxProductMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ErbituxProductMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ErbituxProductMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ErbituxCollaborationandOtherRevenueMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:ErbituxProductMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:JardianceBIMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember 2014-01-01 2016-12-31 0000059478 lly:TrajentaBIMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember 2011-01-01 2016-12-31 0000059478 lly:BasaglarMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember 2015-01-01 2016-12-31 0000059478 lly:EffientMember lly:ProfitAndDevelopmentAndMarketingShareMember 2018-01-01 2018-09-30 0000059478 lly:TanezumabMember lly:MilestonePaymentsSalesBasedMember 2018-01-01 2018-09-30 0000059478 lly:OlumiantMember us-gaap:RoyaltyAgreementTermsMember 2018-01-01 2018-09-30 0000059478 lly:OlumiantMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0000059478 lly:OlumiantMember lly:MilestonePaymentsDevelopmentAndRegulatoryMember 2018-01-01 2018-09-30 0000059478 lly:ErbituxMember lly:AcquisitionTermsContingentConsiderationMember 2018-01-01 2018-09-30 0000059478 lly:OlumiantMember lly:MilestonePaymentsSalesBasedMember 2018-01-01 2018-09-30 0000059478 lly:TanezumabMember lly:MilestonePaymentsDevelopmentAndRegulatoryMember 2018-01-01 2018-09-30 0000059478 lly:TrajentaBIMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:BasaglarMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:JardianceBIMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:JardianceBIMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:TrajentaBIMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:BasaglarMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:BasaglarMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:BasaglarMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:TrajentaBIMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:JardianceBIMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:TrajentaBIMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:JardianceBIMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:AnimalHealthMember 2018-01-01 2018-09-30 0000059478 lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:AnimalHealthMember 2018-07-01 2018-09-30 0000059478 lly:AnimalHealthMember 2017-01-01 2017-09-30 0000059478 lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:AnimalHealthMember 2017-07-01 2017-09-30 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2017-07-01 2017-09-30 0000059478 us-gaap:NetInvestmentHedgingMember 2018-01-01 2018-09-30 0000059478 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2018-07-01 2018-09-30 0000059478 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2017-01-01 2017-09-30 0000059478 us-gaap:NetInvestmentHedgingMember 2017-01-01 2017-09-30 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2018-01-01 2018-09-30 0000059478 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2017-07-01 2017-09-30 0000059478 us-gaap:NetInvestmentHedgingMember 2018-07-01 2018-09-30 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2018-07-01 2018-09-30 0000059478 us-gaap:NetInvestmentHedgingMember 2017-07-01 2017-09-30 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2017-01-01 2017-09-30 0000059478 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2018-01-01 2018-09-30 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2018-09-30 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-09-30 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2018-09-30 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2018-09-30 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-09-30 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2018-09-30 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-09-30 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:EquityMethodAndOtherInvestmentsMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2018-09-30 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2018-09-30 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2018-09-30 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:EquityMethodAndOtherInvestmentsMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2018-09-30 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:MarketableSecuritiesMember 2018-09-30 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2018-09-30 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2018-09-30 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2018-09-30 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2018-09-30 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-09-30 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2018-09-30 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2018-09-30 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2018-09-30 0000059478 us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2018-09-30 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2017-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:NondesignatedMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000059478 us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2017-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:NondesignatedMember 2018-09-30 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2018-09-30 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000059478 us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000059478 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2018-09-30 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-09-30 0000059478 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-09-30 0000059478 us-gaap:EquitySecuritiesMember 2018-01-01 2018-09-30 0000059478 us-gaap:EquitySecuritiesMember 2018-07-01 2018-09-30 0000059478 lly:BuyBritishPoundandSellUSDollarsMember 2018-09-30 0000059478 lly:SeniorNotesDueAugustTwentySevenTwentyTwentyOneMember us-gaap:SeniorNotesMember 2018-08-14 0000059478 lly:BuyEuroSellUsDollarMember 2018-09-30 0000059478 lly:BuyUSdollarSellBritishpoundMember 2018-09-30 0000059478 lly:SeniorNotesDueAugustTwentyEightTwentyTwentyEightMember us-gaap:SeniorNotesMember 2018-08-14 0000059478 us-gaap:InterestRateSwapMember 2018-09-30 0000059478 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-05 0000059478 lly:TermFacilityMember us-gaap:SecuredDebtMember 2018-09-30 0000059478 lly:BuyUSdollarSellJapaneseYenMember 2018-09-30 0000059478 lly:TermFacilityMember us-gaap:SecuredDebtMember 2018-09-01 2018-09-30 0000059478 lly:ForeignCurrencyDenominatedDebtMember 2018-09-30 0000059478 lly:BuyUsDollarSellEuroMember 2018-09-30 0000059478 lly:BuySwissfrancsSellUSdollarMember 2018-09-30 0000059478 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-05 2018-09-05 0000059478 lly:ForeignCurrencyDenominatedDebtMember 2017-12-31 0000059478 lly:SeniorNotesDueAugustTwentyEightTwentyTwentyThreeMember us-gaap:SeniorNotesMember 2018-08-14 0000059478 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-09-30 0000059478 us-gaap:SeniorNotesMember 2018-08-14 0000059478 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-07-01 2018-09-30 0000059478 lly:HedgedFixedRateDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-01-01 2017-09-30 0000059478 lly:HedgedFixedRateDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-07-01 2018-09-30 0000059478 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-01-01 2017-09-30 0000059478 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-07-01 2017-09-30 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-01-01 2018-09-30 0000059478 lly:HedgedFixedRateDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-09-30 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2017-01-01 2017-09-30 0000059478 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-09-30 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2017-07-01 2017-09-30 0000059478 lly:HedgedFixedRateDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-07-01 2017-09-30 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-07-01 2018-09-30 0000059478 lly:ARMOandAurKaMember 2018-01-01 2018-09-30 0000059478 us-gaap:TaxYear2015Member 2018-01-01 2018-09-30 0000059478 us-gaap:TaxYear2013Member 2018-01-01 2018-09-30 0000059478 us-gaap:TaxYear2014Member 2018-01-01 2018-09-30 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2017-01-01 2017-09-30 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2017-07-01 2017-09-30 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2018-07-01 2018-09-30 0000059478 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-07-01 2018-09-30 0000059478 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2017-01-01 2017-09-30 0000059478 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2017-07-01 2017-09-30 0000059478 lly:ProductLiabilityLitigationMember lly:CymbaltaMember 2018-01-01 2018-09-30 0000059478 lly:EmployeeLitigationMember country:BR 2018-01-01 2018-09-30 0000059478 lly:EmployeeLitigationMember country:BR lly:PlaintiffAppealingDecisionofCourtMember 2018-01-01 2018-09-30 0000059478 lly:JapaneseAdministrativeProceedingsMember 2017-02-28 0000059478 lly:AdociaS.AMember 2018-08-01 2018-08-31 0000059478 lly:AlimtaMember country:US 2018-09-30 0000059478 lly:AdociaS.AMember 2018-08-31 0000059478 lly:DrReddysLabMember 2018-06-01 2018-06-30 0000059478 lly:AlimtaMember country:US 2018-01-01 2018-09-30 0000059478 lly:JapaneseAdministrativeProceedingsMember 2018-09-30 0000059478 lly:ProductLiabilityLitigationMember lly:CymbaltaMember stpr:CA 2018-01-01 2018-09-30 0000059478 lly:ProductLiabilityLitigationMember lly:CymbaltaMember 2015-08-01 2015-08-31 0000059478 lly:AgriStatsInc.Member 2018-08-29 2018-08-29 0000059478 2018-07-01 2018-07-31 0000059478 lly:AdociaS.AMember 2018-01-01 2018-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-07-01 2018-09-30 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-07-01 2018-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-07-01 2018-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-07-01 2017-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-07-01 2017-09-30 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-07-01 2017-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-09-30 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-09-30 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember 2017-07-01 2017-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember 2018-07-01 2018-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember 2018-01-01 2018-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember 2017-01-01 2017-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember 2017-07-01 2017-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2017-07-01 2017-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember 2018-07-01 2018-09-30 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2017-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-09-30 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2017-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-09-30 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-09-30 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-09-30 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-09-30 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-09-30 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2018-09-30 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-09-30 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-07-01 2018-09-30 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-07-01 2018-09-30 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2018-07-01 2018-09-30 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-06-30 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-06-30 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2018-06-30 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-06-30 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-06-30 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2017-07-01 2017-09-30 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-06-30 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-07-01 2017-09-30 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2017-09-30 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-09-30 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2017-06-30 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-07-01 2017-09-30 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2017-06-30 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2017-09-30 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-09-30 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-06-30 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-09-30 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-06-30 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-09-30 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2016-12-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-09-30 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-09-30 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2016-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2016-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-12-31 0000059478 us-gaap:AociAttributableToNoncontrollingInterestMember 2017-12-31 0000059478 us-gaap:AociAttributableToNoncontrollingInterestMember 2017-09-30 0000059478 us-gaap:AociAttributableToNoncontrollingInterestMember 2016-12-31 0000059478 us-gaap:AociAttributableToNoncontrollingInterestMember 2018-09-30 0000059478 srt:EuropeMember 2018-07-01 2018-09-30 0000059478 srt:EuropeMember 2017-07-01 2017-09-30 0000059478 country:JP 2018-07-01 2018-09-30 0000059478 country:US 2018-07-01 2018-09-30 0000059478 country:US 2017-01-01 2017-09-30 0000059478 country:JP 2018-01-01 2018-09-30 0000059478 country:JP 2017-01-01 2017-09-30 0000059478 country:JP 2017-07-01 2017-09-30 0000059478 lly:OtherForeignCountriesMember 2017-01-01 2017-09-30 0000059478 lly:OtherForeignCountriesMember 2018-07-01 2018-09-30 0000059478 lly:OtherForeignCountriesMember 2017-07-01 2017-09-30 0000059478 country:US 2018-01-01 2018-09-30 0000059478 country:US 2017-07-01 2017-09-30 0000059478 srt:EuropeMember 2017-01-01 2017-09-30 0000059478 lly:OtherForeignCountriesMember 2018-01-01 2018-09-30 0000059478 srt:EuropeMember 2018-01-01 2018-09-30 0000059478 lly:TrajentaBIMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:TaltzMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:StratteraMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:JardianceBIMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OncologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherImmunologyMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherCardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherOncologyMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:CyramzaMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:InternationalMember 2017-01-01 2017-09-30 0000059478 lly:ImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherOncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:HumulinMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:TrulicityMemberMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherEndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherCardiovascularMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:InternationalMember lly:AnimalHealthProductsMember 2018-01-01 2018-09-30 0000059478 lly:HumulinMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:AlimtaMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:NeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ImmunologyMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:CardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:ForteoMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ZyprexaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:AlimtaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:CymbaltaMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:AnimalHealthProductsMember 2018-01-01 2018-09-30 0000059478 lly:CyramzaMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:CialisMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherCardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:AlimtaMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:TrajentaBIMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:BasaglarMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:HumalogMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ErbituxMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherEndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:TaltzMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:EffientMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:TrajentaBIMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:EndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherOncologyMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:CymbaltaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:CyramzaMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherNeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:CymbaltaMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:EndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:ZyprexaMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:EndocrinologyMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherNeuroscienceMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:AlimtaMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:CialisMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:CardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:CardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:NeuroscienceMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:NeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:HumulinMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:StratteraMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:CymbaltaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:JardianceBIMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:TaltzMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:HumulinMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherCardiovascularMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:ZyprexaMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:TrulicityMemberMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:NeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ErbituxMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:StratteraMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherNeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:EndocrinologyMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherPharmaceuticalsMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:AlimtaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:CyramzaMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:ForteoMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:TrajentaBIMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:InternationalMember 2018-01-01 2018-09-30 0000059478 lly:OncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ZyprexaMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:ErbituxMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:StratteraMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:StratteraMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OncologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:CardiovascularMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:EndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ForteoMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherEndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:InternationalMember lly:AnimalHealthProductsMember 2017-01-01 2017-09-30 0000059478 lly:AlimtaMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:TaltzMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherOncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:HumulinMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ForteoMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OncologyMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherPharmaceuticalsMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:TrulicityMemberMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherOncologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:HumulinMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:BasaglarMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherNeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:ForteoMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:CyramzaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:HumalogMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:CymbaltaMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherImmunologyMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:EffientMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:CialisMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 country:US lly:AnimalHealthProductsMember 2018-01-01 2018-09-30 0000059478 lly:BasaglarMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:AnimalHealthProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherNeuroscienceMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherEndocrinologyMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherPharmaceuticalsMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:CyramzaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OncologyMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherNeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:HumalogMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:CialisMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:NeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherOncologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:CialisMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 country:US lly:AnimalHealthProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherEndocrinologyMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:ImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:HumalogMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:TrulicityMemberMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:ForteoMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:ErbituxMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ZyprexaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:TrulicityMemberMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherCardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:TaltzMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:EndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherPharmaceuticalsMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:ZyprexaMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:ImmunologyMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:JardianceBIMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherCardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:EffientMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:HumalogMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:StratteraMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:OtherPharmaceuticalsMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:CardiovascularMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:CialisMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherPharmaceuticalsMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:BasaglarMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:TaltzMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:CardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:EffientMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:TrulicityMemberMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:OtherEndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:CymbaltaMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 lly:HumalogMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:NeuroscienceMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 lly:JardianceBIMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 us-gaap:OperatingSegmentsMember lly:AnimalHealthProductsMember 2017-01-01 2017-09-30 0000059478 us-gaap:OperatingSegmentsMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 us-gaap:CorporateNonSegmentMember 2017-07-01 2017-09-30 0000059478 us-gaap:CorporateNonSegmentMember 2018-07-01 2018-09-30 0000059478 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-09-30 0000059478 us-gaap:OperatingSegmentsMember 2017-07-01 2017-09-30 0000059478 us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0000059478 us-gaap:OperatingSegmentsMember lly:AnimalHealthProductsMember 2017-07-01 2017-09-30 0000059478 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-09-30 0000059478 us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0000059478 us-gaap:OperatingSegmentsMember lly:AnimalHealthProductsMember 2018-01-01 2018-09-30 0000059478 us-gaap:OperatingSegmentsMember lly:AnimalHealthProductsMember 2018-07-01 2018-09-30 0000059478 us-gaap:OperatingSegmentsMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-09-30 0000059478 us-gaap:OperatingSegmentsMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-09-30 0000059478 us-gaap:OperatingSegmentsMember 2017-01-01 2017-09-30 0000059478 us-gaap:OperatingSegmentsMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:NeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CyramzaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:HumulinMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:HumulinMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherEndocrinologyMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:TrulicityMemberMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:EffientMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:EndocrinologyMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:CymbaltaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:HumalogMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ErbituxMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ZyprexaMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:TaltzMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:HumalogMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:EndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:NeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:TrajentaBIMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:TrajentaBIMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:TrulicityMemberMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:EndocrinologyMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CyramzaMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherPharmaceuticalsMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherImmunologyMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherNeuroscienceMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:CialisMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ErbituxMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:EndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherPharmaceuticalsMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OncologyMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:StratteraMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherCardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OncologyMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:InternationalMember lly:AnimalHealthProductsMember 2018-07-01 2018-09-30 0000059478 lly:InternationalMember lly:AnimalHealthProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ErbituxMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:NeuroscienceMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:CyramzaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:StratteraMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CialisMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:InternationalMember 2018-07-01 2018-09-30 0000059478 lly:OtherImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 country:US lly:AnimalHealthProductsMember 2017-07-01 2017-09-30 0000059478 lly:TaltzMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherPharmaceuticalsMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherNeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ForteoMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:CymbaltaMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:CymbaltaMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherNeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CialisMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:TrulicityMemberMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ForteoMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ZyprexaMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:JardianceBIMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:AlimtaMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CialisMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherCardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:AlimtaMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CialisMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ZyprexaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:JardianceBIMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:HumalogMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherOncologyMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:CardiovascularMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:CyramzaMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:TaltzMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ZyprexaMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:CyramzaMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:JardianceBIMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:JardianceBIMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:CymbaltaMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherOncologyMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherOncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OncologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherPharmaceuticalsMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:BasaglarMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:AlimtaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherImmunologyMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:AlimtaMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherPharmaceuticalsMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherNeuroscienceMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ForteoMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:EndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherCardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ForteoMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:BasaglarMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:HumalogMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:NeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:EffientMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:HumulinMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:AnimalHealthProductsMember 2018-07-01 2018-09-30 0000059478 lly:BasaglarMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:AlimtaMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:StratteraMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ErbituxMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:InternationalMember 2017-07-01 2017-09-30 0000059478 lly:EffientMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:NeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:EffientMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:HumulinMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:BasaglarMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ImmunologyMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:StratteraMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherOncologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OncologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ZyprexaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:ForteoMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CymbaltaMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherOncologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:CyramzaMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherPharmaceuticalsMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:HumulinMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:TrajentaBIMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:AnimalHealthProductsMember 2017-07-01 2017-09-30 0000059478 lly:TaltzMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherCardiovascularMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ZyprexaMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 country:US lly:AnimalHealthProductsMember 2018-07-01 2018-09-30 0000059478 lly:EndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ForteoMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherEndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherCardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CardiovascularMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:TrulicityMemberMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:TrulicityMemberMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:HumalogMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherEndocrinologyMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherNeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:TrajentaBIMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherEndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:TaltzMember country:US lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:TaltzMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherOncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:StratteraMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:NeuroscienceMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:StratteraMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:ImmunologyMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherCardiovascularMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:HumulinMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:TrulicityMemberMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:HumalogMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:OtherNeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherEndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CymbaltaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:OtherEndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 0000059478 lly:AlimtaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-07-01 2017-09-30 0000059478 lly:CialisMember country:US lly:HumanPharmaceuticalProductsMember 2018-07-01 2018-09-30 iso4217:USD xbrli:shares xbrli:pure xbrli:shares iso4217:USD iso4217:EUR lly:lawsuit lly:claim iso4217:BRL iso4217:CHF iso4217:GBP lly:case lly:company lly:patent lly:individual lly:plaintiff lly:demand iso4217:JPY lly:defendant lly:product lly:application lly:segment false --12-31 Q3 2018 2018-09-30 10-Q 0000059478 1059322255 Yes false Large Accelerated Filer Lilly Eli & Co false 857600000 150000000 55000000 66900000 1475800000 81800000 30000000 135000000 205000000 205000000 1062600000 1062600000 30000000 30000000 1654500000 1654500000 1560000000 50000000 30000000 80000000 400000 8100000 700000 49700000 8200000 4200000000 0.50 0.38 0.30 0.20 -250000000 446400000 299500000 15000000 65000000 100000000 130000000 150000000 350000000 1230000000 5066400000 14797300000 4650900000 15260300000 1434200000 164000000 0.20 629200000 9000000 629200000 1017200000 9000000 629200000 1017200000 1800000000 25 30 140 40 4 3 1 5 3 2 1 105 305 10 2 2 200000000 0 1659700000 52000000 5598400000 831800000 62500000 1400000000 81300000 25000000 100000000 1036800000 1578200000 50000000 P75D P30D 0.198 4465100000 5129400000 1410700000 1281200000 4546300000 4859400000 3776500000 3740500000 9264600000 9671700000 -5718600000 -5439500000 -105000000 P10Y 5817800000 6522900000 38700000 34000000 155800000 510000000 153400000 458700000 235000000 210000000 25000000 331200000 306200000 25000000 88700000 85200000 3500000 261300000 259300000 2000000 44981000000 44625100000 19202100000 20685900000 16952400000 15125100000 184700000 2100000 47500000 24400000 135400000 620500000 154500000 74700000 985100000 0 0 0 217800000 94200000 1182300000 3600000 0 0 0 0 0 1497900000 94200000 1182300000 3600000 217800000 94200000 1182300000 3600000 217800000 94300000 1183200000 3600000 218200000 0 0 0 10500000 11500000 52700000 1400000 0 0 0 0 0 76100000 11500000 52700000 1400000 10500000 11500000 52700000 1400000 10500000 11600000 52700000 1400000 10600000 0 0 0 360000000 653900000 3464300000 202400000 0 0 0 0 0 653900000 3464300000 202400000 360000000 653900000 3464300000 202400000 360000000 656000000 3473500000 204200000 365000000 0 0 0 152000000 27000000 622000000 109500000 0 0 0 0 0 27000000 622000000 109500000 152000000 27000000 622000000 109500000 152000000 27300000 631500000 114100000 159600000 281300000 0 0 281300000 281300000 131000000 9000000 82900000 800000 3200000 0.60 882100000 80000000 -155400000 0 0 208000000 208000000 208000000 0 0 62000000 62000000 62000000 0 0 45200000 45200000 45200000 0 0 41400000 41400000 41400000 297000000 108600000 562000000 148200000 882100000 4582100000 3724300000 6536200000 8960000000 300000000 4712400000 51500000 0 4763900000 4763900000 4763900000 6646300000 0 0 6646300000 6646300000 6646300000 -857800000 2423800000 -4000000 3600000 -19600000 -94100000 4000000 -3600000 19600000 94100000 0 2690600000 0 2696800000 2690600000 0 398400000 0 399700000 398400000 1.04 1.13 3013200000 3013200000 687900000 667100000 723300000 2104000000 1809700000 2482300000 165500000 2200000 664600000 -13400000 660200000 375300000 335200000 308600000 1586300000 20200000 4505900000 60500000 1562300000 4836300000 0 0 0 -128900000 -104800000 -24100000 -128900000 -105200000 2584400000 3706600000 1002200000 500000000 750000000 750000000 500000000 2000000000 0.049 0.04272 0.03912 P5Y P3Y 4692800000 816700000 1166400000 3132300000 2500000000 -4600000 -72500000 -13800000 -215600000 -800000 -79200000 -5400000 -261200000 -22500000 1400000 -67500000 4300000 -19300000 1100000 -60200000 3600000 15000000 40200000 196400000 120600000 585700000 44800000 212700000 132700000 636300000 13200000 103600000 39600000 309200000 14900000 117900000 42300000 342500000 -33300000 67100000 -99900000 195000000 -67600000 61000000 -142800000 204600000 0 0 0 0 28000000 29300000 -1300000 28000000 29300000 -1300000 11600000 86000000 34800000 251600000 10100000 74200000 31700000 232300000 1155400000 1263500000 613000000 1840000000 243200000 389400000 47940000000 1190000000 350000000 0 26800000 0 26800000 26800000 0 800000 0 800000 800000 0 30300000 0 30300000 30300000 0 6300000 0 6300000 6300000 0 35100000 0 35100000 35100000 0 6900000 0 6900000 6900000 3700000 11100000 3700000 11100000 0 33400000 0 33400000 33400000 0 36000000 0 36000000 36000000 0 200000 0 200000 200000 0 16600000 0 16600000 16600000 0 14000000 0 14000000 14000000 0 2700000 0 2700000 2700000 0 26000000 0 26000000 26000000 0 10500000 0 10500000 10500000 0 66500000 0 66500000 66500000 466400000 1570000000 234100000 512200000 426900000 1400000000 1530000000 1095700000 1148600000 590600000 0 0.53 1.38 1.13 2.04 0.53 1.37 1.12 2.03 21700000 48200000 0.061 0.241 0.185 0.262 997900000 858500000 287900000 0 0 0 0 137400000 287900000 137400000 287900000 137400000 146400000 39300000 394700000 188000000 -16300000 -79200000 -700000 -76500000 4370100000 4358400000 320100000 0 0 0 0 591600000 1364400000 121900000 1242500000 1913300000 4188300000 422600000 3765700000 1411000000 1676700000 162600000 1514000000 2856800000 5213000000 461900000 4751000000 23900000 70400000 200000 32800000 2013 2014 2015 36000000 12800000 460500000 37800000 261500000 100000 749800000 8800000 -151700000 -161600000 525200000 1638200000 4029200000 3619400000 61900000 162100000 69400000 193900000 -15000000 4458300000 4118000000 45100000 114600000 32100000 118800000 44981000000 44625100000 14535900000 10826700000 18777200000 19647500000 0 750000000 11700000 0 11529900000 0 10950300000 11529900000 3700000000 0 12542200000 0 12277100000 12542200000 3450000000 9940500000 11674700000 5678800000 5678800000 2005800000 2005800000 2 125000000 500000000 2 2 4 1470 P30D 75700000 1074300000 1020000000 684900000 -4265200000 -5436500000 2565000000 3872100000 4075800000 555600000 1452800000 1149500000 2107000000 26700000 62800000 49900000 140800000 -63800000 -191300000 -62900000 -174200000 25800000 75800000 500000 49900000 -5500000 63800000 -10500000 36700000 188600000 -32000000 191300000 -15400000 108200000 -15400000 1000000 -2900000 300000 90100000 -7000000 -8700000 41600000 2 1707900000 2009200000 141000000 -28700000 135800000 0 33900000 588400000 -83300000 653700000 8400000 9600000 610300000 548600000 60600000 0 1100000 234500000 581000000 -377500000 0 31000000 167700000 11400000 143900000 2400000 10000000 651200000 34500000 661800000 15700000 -60800000 660200000 595800000 60600000 2900000 900000 375300000 745900000 -377500000 8700000 -1800000 2200000 -13400000 165500000 664600000 -19000000 9400000 -33900000 1300000 4200000 -142700000 24000000 -149700000 8400000 -25400000 146400000 152400000 -7000000 800000 200000 202700000 190300000 11200000 2300000 -1100000 -38200000 0 -58700000 -95800000 13000000 -332000000 14700000 0 -47800000 52300000 0 53000000 2832100000 2146200000 1546300000 1547800000 0 0 132100000 584800000 132100000 132100000 66400000 275300000 2900000 44800000 -41000000 -9000000 365700000 320700000 715900000 793200000 178000000 188800000 633300000 816300000 199900000 3050700000 1643800000 1739200000 882100000 0 3739600000 719700000 2973800000 112200000 3513900000 2684500000 35000000 1447500000 1879200000 2480000000 2232000000 2477700000 -299600000 -314100000 1226800000 -2297100000 951500000 3003000000 1686900000 3444700000 2320200000 2535500000 300000 555600000 14300000 1452800000 -5200000 1149500000 -600000 2107000000 8826500000 8814100000 -77100000 21100000 -56000000 -229400000 63200000 -166200000 -80000000 18200000 -61800000 -266600000 56600000 -210000000 -26700000 -40100000 -8100000 -2400000 23900000 -62800000 -117800000 -8100000 -7300000 70400000 -49900000 -47200000 0 -2900000 200000 -140800000 -164900000 0 -8700000 32800000 -15900000 -48400000 -14600000 -45100000 630600000 1001500000 55000000 1340000000 20600000 3870400000 61800000 30000000 1343300000 3853300000 20000000 406500000 406500000 670400000 670400000 83300000 83300000 236000000 236000000 13894100000 14408700000 5000000 105000000 2500000000 5658000000 260300000 254200000 514500000 115200000 30500000 145700000 367200000 295700000 662900000 319600000 245300000 564900000 334200000 19600000 163500000 183200000 69500000 126500000 196000000 42700000 13100000 55900000 1624400000 936300000 2560700000 25900000 136000000 27400000 163500000 137600000 234100000 207600000 441700000 414900000 281300000 696200000 203000000 97500000 300500000 131300000 36300000 167600000 83800000 43400000 127200000 108400000 399300000 507700000 509300000 448300000 957600000 4900000 37300000 42100000 92100000 76300000 168400000 0 16300000 16300000 23300000 23700000 46800000 43500000 40200000 83600000 10700000 50200000 60900000 52900000 84100000 137100000 131300000 20000000 151300000 68400000 84900000 153300000 412900000 114800000 527700000 12600000 128000000 140600000 5323800000 36700000 616700000 3104400000 353000000 2751300000 2553600000 387600000 2166100000 920000000 1017000000 740600000 4917400000 16710600000 761900000 775400000 1537300000 196700000 81600000 278300000 1308600000 863900000 2172500000 997300000 728500000 1725700000 869100000 100800000 463600000 564400000 204300000 349200000 553500000 290800000 35800000 326600000 4493400000 2681600000 7175000000 73700000 398200000 78800000 477000000 403300000 661500000 574300000 1235800000 1254300000 828600000 2083000000 634900000 337900000 972800000 343600000 66000000 409600000 198300000 105900000 304300000 515400000 1158400000 1673700000 1492800000 1307700000 2800500000 20500000 99600000 120200000 283400000 228500000 511800000 0 22900000 22900000 88400000 72200000 160500000 128400000 104300000 232700000 34600000 149700000 184500000 276900000 243000000 519900000 343600000 43100000 386700000 174200000 234100000 408200000 1090100000 290700000 1380800000 49300000 379600000 428900000 15841500000 105500000 1767000000 9361800000 1173400000 8188400000 7348700000 1121400000 6227300000 2704200000 2877600000 2294800000 14415800000 6061900000 288500000 232000000 520500000 157300000 43900000 201200000 365800000 218000000 583800000 295900000 171200000 467100000 397400000 14500000 157500000 172000000 67000000 131400000 198400000 30200000 15100000 45300000 1796500000 1041400000 2837900000 25800000 132600000 26900000 159500000 133700000 182500000 208300000 390800000 365600000 299000000 664600000 216900000 105100000 322100000 211400000 108100000 319500000 104200000 62700000 166900000 55800000 371500000 427200000 619800000 444400000 1064200000 39700000 31700000 71400000 73800000 66800000 140400000 800000 54800000 55600000 23800000 23000000 46600000 131700000 54100000 185800000 13400000 43200000 56600000 10500000 88200000 98700000 210600000 53300000 263900000 50300000 85300000 135700000 645900000 170300000 816200000 7000000 102800000 109900000 5664500000 76200000 608800000 3446600000 383900000 3062700000 2615300000 388800000 2226500000 989500000 1017000000 772700000 5289200000 18117100000 815100000 760900000 1576000000 440400000 128500000 569000000 1158000000 687800000 1845700000 954900000 546200000 1501200000 1211500000 39300000 484200000 523500000 210700000 390100000 600800000 59400000 45300000 104800000 5413600000 3078000000 8491600000 78500000 394000000 81600000 475500000 397000000 529700000 608800000 1138500000 1334200000 891800000 2226100000 677300000 316700000 994000000 497800000 265100000 762900000 284800000 180300000 465100000 213500000 1157400000 1370900000 1741200000 1389700000 3130900000 143700000 96300000 239700000 199400000 206900000 406100000 2500000 130000000 132500000 72200000 71200000 143500000 321400000 157100000 478600000 49100000 139800000 189100000 74400000 269200000 343500000 495300000 135100000 630400000 161300000 257200000 418500000 1786500000 487800000 2274300000 27600000 332800000 360400000 16905600000 258400000 1828900000 10211000000 1137800000 9073200000 7906100000 1188200000 6717800000 2934300000 3142900000 2326000000 15791100000 72300000 24 1578500000 23000000 4876600000 69000000 1616600000 4770300000 171500000 5800000 165700000 339200000 62100000 277100000 -5400000 -5400000 0 -25300000 -600000 -24700000 209100000 206700000 1101586000 711000 1101646000 664000 1101672000 664000 1100672000 664000 1077548000 604000 1067374000 604000 1497900000 76100000 26000 3277000 -47000 17000 2716000 -60000 -1200000 -155000000 2000000 4700000 -500000 -130800000 1700000 6400000 69800000 209100000 68500000 206700000 8000000000 7000000000 11592200000 13076600000 -3371600000 -1867300000 -210900000 224000000 -5274000000 -5270000000 5640600000 48200000 -5225800000 688500000 72800000 16046300000 -80500000 -3013200000 -3348500000 -1349400000 -197600000 153200000 -4774900000 5686100000 -4742300000 688500000 68900000 15590100000 -75800000 -3013200000 -3337100000 -1205500000 -195200000 163200000 -4609400000 -4610000000 5754700000 34800000 -4574600000 688500000 70300000 16145500000 -75800000 -3013200000 11667900000 -4340700000 -1233400000 -234300000 113500000 -5718600000 -5720000000 5817800000 23700000 -5694900000 687900000 75700000 13894100000 -75800000 -3013200000 -4190600000 -1671500000 -228500000 -18100000 -6108700000 5825700000 -6108700000 673500000 65600000 14247300000 -69400000 -3013200000 14150900000 -3594800000 -1610900000 -225600000 -17200000 -5440000000 -5439500000 6522900000 -9000000 -5448500000 667100000 1074300000 14408700000 -69400000 -3013200000 -1100000 -200000 -3400000 -3300000 5600000 -18000000 532900000 409200000 723200000 645100000 2000000 257900000 -259900000 6400000 993700000 -1000000000 22500000 3028200000 -3050700000 -3191000 -10191000 -36014000 3191000 3191000 10191000 10191000 36014000 36014000 75800000 69400000 -60000000 259900000 1000000000 3050700000 -40800000 -3400000 1056000000 1057000000 1026300000 1037800000 1053400000 1054800000 1020400000 1033200000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We and Daiichi Sankyo each have exclusive marketing rights in certain other territories.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:48%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Territory</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Marketing Rights</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Selling Party</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Co-promotion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lilly</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Major European markets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Co-promotion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Daiichi Sankyo</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Japan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exclusive</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Daiichi Sankyo</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon acquisition, the acquired in-process research and development (IPR&amp;D) charges related to these products were immediately expensed because the products had no alternative future use.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition have been included in our consolidated condensed financial statements from the date of acquisition.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Collaborations and Other Arrangements</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the collaboration partner. See Note 1 for amounts of collaboration and other revenue recognized from these types of arrangements. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Boehringer Ingelheim Diabetes Collaboration</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim&#8217;s oral diabetes products: Trajenta, Jentadueto</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, Jardiance, Glyxambi</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, and Synjardy</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, as well as our basal insulin: Basaglar</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes significant regulatory and commercialization events and milestones (deferred) capitalized for the compounds included in this collaboration: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Launched</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Milestones </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Deferred) Capitalized </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Product Family</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Japan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Trajenta </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cumulative </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4) </sup></font><font style="font-family:Arial;font-size:10pt;">- all prior to 2017</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">446.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jardiance </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cumulative </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4) </sup></font><font style="font-family:Arial;font-size:10pt;">- all prior to 2017</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">299.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Basaglar</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cumulative </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font><font style="font-family:Arial;font-size:10pt;">&#160;- all prior to 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(250.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></font><font style="font-family:Arial;font-size:8pt;">Jentadueto is included in the Trajenta product family. The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></font><font style="font-family:Arial;font-size:8pt;">Glyxambi and Synjardy</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></font><font style="font-family:Arial;font-size:8pt;">are included in the Jardiance product family. The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4) </sup></font><font style="font-family:Arial;font-size:8pt;">The cumulative amount represents the total initial amounts that were (deferred) or capitalized from the start of this collaboration through the end of the reporting period.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the most significant markets, we and Boehringer Ingelheim share equally the ongoing development costs, commercialization costs, and agreed upon gross margin for any product resulting from the collaboration. We record our portion of the gross margin associated with Boehringer Ingelheim's compounds as collaboration and other revenue. We record our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company is entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments result in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may be reduced by any performance payments we make related to these products. Similarly, performance payments we may receive related to Basaglar effectively reduce Boehringer Ingelheim's share of the gross margin, which reduces our cost of sales.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Basaglar</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">201.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">145.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">569.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">278.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jardiance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">166.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">127.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">465.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">304.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Trajenta</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">135.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">153.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">418.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">408.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Erbitux</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup>&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have several collaborations with respect to Erbitux. The most significant collaborations are or, where applicable, were in Japan, and prior to the transfer of commercialization rights in the fourth quarter of 2015, the U.S. and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). Certain rights to Erbitux outside the U.S. and Canada (collectively, North America) will remain with Merck KGaA (Merck) upon expiration of that agreement.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized with respect to Erbitux:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net product revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">133.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">137.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">397.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">403.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Collaboration and other revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">25.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">78.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">73.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">159.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">163.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">475.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">477.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Bristol-Myers Squibb Company</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to commercial agreements with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), we had been co-developing Erbitux in North America exclusively with BMS. On October 1, 2015, BMS transferred their commercialization rights to us with respect to Erbitux in North America pursuant to a modification of our existing arrangement, and we began selling Erbitux at that time. This modification did not affect our rights with respect to Erbitux in other jurisdictions. In connection with the modification of terms, we provided consideration to BMS based upon a tiered percentage of net sales of Erbitux in North America estimated to average </font><font style="font-family:Arial;font-size:10pt;">38 percent</font><font style="font-family:Arial;font-size:10pt;"> through September 2018. The transfer of the commercialization rights was accounted for as an acquisition of a business. The consideration to be paid to BMS was accounted for as contingent consideration liability. See Note 6 for discussion regarding the estimation of this liability.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Merck KGaA</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A development and license agreement grants Merck exclusive rights to market Erbitux outside of North America until December 2018. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. This agreement was amended in 2015 to grant Merck exclusive commercialization rights in Japan but did not result in any changes to our rights.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Merck manufactures Erbitux for supply in its territory as well as for Japan. We receive a royalty on the sales of Erbitux outside of North America, which is included in collaboration and other revenue as the underlying sales occur. Royalties due to third parties are recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Olumiant</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup>&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte) which provides us the development and commercialization rights to its Janus tyrosine kinase inhibitor compound, now known as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to </font><font style="font-family:Arial;font-size:10pt;">20 percent</font><font style="font-family:Arial;font-size:10pt;"> if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding </font><font style="font-family:Arial;font-size:10pt;">30 percent</font><font style="font-family:Arial;font-size:10pt;"> of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. Incyte exercised its option to co-develop Olumiant in rheumatoid arthritis in 2010 and psoriatic arthritis, atopic dermatitis, alopecia areata, and systemic lupus erythematosus (SLE) in 2017. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our milestones achieved:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Event</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Classification</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Regulatory submissions in the U.S. and Europe</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">R&amp;D expense</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Regulatory approval in Europe</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Regulatory approval in Japan</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Began Phase III testing for atopic dermatitis</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">R&amp;D expense</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Regulatory approval in the U.S.</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Began Phase III testing for SLE</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">R&amp;D Expense</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, Incyte is eligible to receive up to </font><font style="font-family:Arial;font-size:10pt;">$130.0 million</font><font style="font-family:Arial;font-size:10pt;"> of additional payments from us contingent upon certain development and success-based regulatory milestones. Incyte is also eligible to receive up to </font><font style="font-family:Arial;font-size:10pt;">$150.0 million</font><font style="font-family:Arial;font-size:10pt;"> of potential sales-based milestones.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Effient</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup>&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. Marketing rights for major territories are shown below. We and Daiichi Sankyo each have exclusive marketing rights in certain other territories.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:48%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Territory</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Marketing Rights</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Selling Party</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Co-promotion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lilly</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Major European markets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Co-promotion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Daiichi Sankyo</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Japan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exclusive</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Daiichi Sankyo</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">While major European markets are a co-promotion territory under the terms of our arrangement, Daiichi Sankyo exclusively promotes Effient in these markets. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The parties share approximately </font><font style="font-family:Arial;font-size:10pt;">50</font><font style="font-family:Arial;font-size:10pt;">/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories, including the major European markets. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We record net product revenue in our exclusive and co-promotion territories where we are the selling party. Profit-share payments due to Daiichi Sankyo for co-promotion countries where we are the selling party are recorded as marketing, selling, and administrative expenses. Any profit-share payments due to us from Daiichi Sankyo for the major European markets are recorded as collaboration and other revenue. We also record our share of the expenses in these co-promotion territories as marketing, selling, and administrative expenses. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. All royalties due to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. Generic versions of Effient launched in the U.S. in the third quarter of 2017.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized with respect to Effient:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">45.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">104.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">326.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Tanezumab</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain, chronic low back pain, and cancer pain. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and certain commercialization expenses. As of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, Pfizer is eligible to receive up to </font><font style="font-family:Arial;font-size:10pt;">$350.0 million</font><font style="font-family:Arial;font-size:10pt;"> in success-based regulatory milestones and up to </font><font style="font-family:Arial;font-size:10pt;">$1.23 billion</font><font style="font-family:Arial;font-size:10pt;"> in a series of sales-based milestones, contingent upon the commercial success of tanezumab.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as noted below with respect to the Alimta</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> patent litigation and administrative proceedings, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Alimta Patent Litigation and Administrative Proceedings </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A number of generic manufacturers are seeking approvals in the U.S., Japan, and a number of countries in Europe to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers.&#160;However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail.&#160;An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position.&#160;We expect that a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenue for the product in the relevant market.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">U.S. Patent Litigation and Administrative Proceedings</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the U.S., more than </font><font style="font-family:Arial;font-size:10pt;">10</font><font style="font-family:Arial;font-size:10pt;"> Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Alimta prior to the expiration of our vitamin regimen patent (expiring in 2021 plus pediatric exclusivity expiring in 2022) have been filed by a number of companies, including Teva Parenteral Medicines, Inc. (Teva) and APP Pharmaceuticals, LLC (APP) pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). We have received favorable decisions from the U.S. Court of Appeals for the Federal Circuit (affirming the U.S. District Court for the Southern District of Indiana's decisions finding our U.S. vitamin regimen patent valid and infringed) against Teva, APP, and </font><font style="font-family:Arial;font-size:10pt;">two</font><font style="font-family:Arial;font-size:10pt;"> other defendants' proposed products, and similar favorable judgments have been entered by the U.S. District Court for the Southern District of Indiana against </font><font style="font-family:Arial;font-size:10pt;">five</font><font style="font-family:Arial;font-size:10pt;"> other companies. The remaining ANDA applicants have agreed to a preliminary injunction or stay pending the appeal of the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Arial;font-size:10pt;"> review (IPR) described in the following sentence. In October 2017, the U.S. Patent and Trademark Office issued written decisions in our favor following IPR of our vitamin regimen patent, finding that the generic company petitioners failed to show that the claims in our patent are unpatentable. A number of these challengers have filed an appeal</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We currently have pending lawsuits in the U.S. District Court for the Southern District of Indiana alleging infringement against Actavis LLC (Actavis) and Apotex Inc. in response to their applications to market alternative forms of pemetrexed (the active ingredient in Alimta) products, and we filed a similar lawsuit in the U.S. District Court for Delaware against Eagle Pharmaceuticals, Inc. In June 2018, the U.S. District Court for the Southern District of Indiana ruled in our favor in </font><font style="font-family:Arial;font-size:10pt;">two</font><font style="font-family:Arial;font-size:10pt;"> similar cases, finding Dr. Reddy's Laboratories' (Dr. Reddy) and Hospira, Inc.'s (Hospira) proposed products would infringe our patent. Dr. Reddy and Hospira have appealed those rulings. The lawsuit against Actavis has been stayed, pending a decision in the Dr. Reddy and Hospira appeals.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">European Patent Litigation and Administrative Proceedings</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2017, the United Kingdom (U.K.) Supreme Court ruled that commercialization of certain salt forms of pemetrexed by Actavis Group ehf and other Actavis companies directly infringes our vitamin regimen patents in the U.K., Italy, France, and Spain. This litigation in the U.K. is now concluded. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hexal AG (Hexal) and Stada Arzneimittel AG (Stada) have each challenged the validity of our vitamin regimen patent before the German Federal Patent Court. At a hearing in July 2018, the German Federal Patent Court held that our vitamin regimen patent is invalid. We have appealed this decision. Under German law, the patent remains in force pending appeal. A number of generic competitors have received approval to market generic versions of pemetrexed in Germany and may choose to launch at risk. We will seek to remove any generic pemetrexed products launched at risk in Germany, seek damages in respect of such launches, and defend our patent.&#160;Injunctions are in place against </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> of these companies, including Hexal and ratiopharm GmbH (a subsidiary of Teva). Stada has recently launched at risk in Germany and we are seeking an injunction. Whether further injunctions are granted or the current injunctions are maintained pending the appeal, or whether a generic competitor chooses to launch at risk, makes the timing of possible generic entry and market erosion in Germany unpredictable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additional legal proceedings are ongoing in various national courts throughout Europe.&#160;We are aware that several companies have received approval to market generic versions of pemetrexed in major European markets and that generic competitors may choose to launch at risk (including </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;"> generic product currently on the market in France). We will continue to seek to remove any generic pemetrexed products launched at risk in European markets, seek damages in respect of such launches, and defend our patents against validity challenges.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Japanese Administrative Proceedings</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Three</font><font style="font-family:Arial;font-size:10pt;"> separate sets of demands for invalidation of our </font><font style="font-family:Arial;font-size:10pt;">two</font><font style="font-family:Arial;font-size:10pt;"> vitamin regimen patents, involving several companies, have been filed with the Japanese Patent Office (JPO). In February 2017, the Japan Intellectual Property High Court confirmed the decisions of the JPO upholding the validity of both our Japanese vitamin regimen patents in the challenge initiated by Sawai Pharmaceutical Co., Ltd. and joined by </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> other companies. This decision is now final. In May 2017, the JPO resumed </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;"> of the </font><font style="font-family:Arial;font-size:10pt;">two</font><font style="font-family:Arial;font-size:10pt;"> remaining sets of demands, brought by Nipro Corporation (Nipro) and in July 2018, the JPO issued written decisions dismissing Nipro&#8217;s invalidation demands. Nipro filed an appeal and we anticipate decisions by the Japan Intellectual Property High Court in the third quarter of 2019. The other set of demands, brought by Hospira, that were previously suspended resumed in August 2018; we anticipate decisions by the JPO in the second quarter of 2019. If upheld through all challenges, these patents provide intellectual property protection for Alimta until June 2021. Notwithstanding our patents, generic versions of Alimta were approved in Japan starting in February 2016. We do not currently anticipate that generic versions of Alimta will proceed to pricing approval.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cymbalta</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> Product Liability Litigation</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We were named as a defendant in a purported class-action lawsuit in the U.S. District Court for the Central District of California (now called </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Strafford et al. v. Eli Lilly and Company</font><font style="font-family:Arial;font-size:10pt;">) involving Cymbalta. The plaintiffs, purporting to represent a class of all persons within the U.S. who purchased and/or paid for Cymbalta, asserted claims under the consumer protection statutes of four states, California, Massachusetts, Missouri, and New York, and sought declaratory, injunctive, and monetary relief for various alleged economic injuries arising from discontinuing treatment with Cymbalta. The district court denied the plaintiffs' motions for class certification.&#160;The district court dismissed the suits and plaintiffs appealed to the U.S. Court of Appeals for the Ninth Circuit. In November 2017, the U.S. Court of Appeals for the Ninth Circuit dismissed the suit. In July 2018, the U.S. District Court for the District of California denied plaintiffs&#8217; motion to reopen the case. Plaintiffs&#8217; appeal of this denial is currently pending before the U.S. Court of Appeals for the Ninth Circuit.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are</font><font style="font-family:Arial;font-size:10pt;color:#1f497d;"> </font><font style="font-family:Arial;font-size:10pt;">named in approximately </font><font style="font-family:Arial;font-size:10pt;">140</font><font style="font-family:Arial;font-size:10pt;"> lawsuits involving approximately </font><font style="font-family:Arial;font-size:10pt;">1,470</font><font style="font-family:Arial;font-size:10pt;"> plaintiffs filed in various federal and state courts alleging injuries arising from discontinuation of treatment with Cymbalta. These include approximately </font><font style="font-family:Arial;font-size:10pt;">40</font><font style="font-family:Arial;font-size:10pt;"> individual and multi-plaintiff cases filed in California state court, centralized in a California Judicial Counsel Coordination Proceeding pending in Los Angeles. The first individual product liability cases were tried in August 2015 and resulted in defense verdicts against </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">plaintiffs. We believe all these Cymbalta lawsuits and claims are without merit. We have reached a settlement framework that provides for a comprehensive resolution of nearly all of these personal injury claims, filed or unfiled, alleging injuries from discontinuing treatment with Cymbalta.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Brazil&#8211;Employee Litigation</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. The plaintiffs allege that some employees at the facility were exposed to benzene and heavy metals; however, Lilly Brasil maintains that these alleged contaminants were never used in the facility. In May 2014, the labor court judge ruled against Lilly Brasil. The judge's ruling orders Lilly Brasil to undertake several actions of unspecified financial impact, including paying lifetime medical insurance for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We filed an appeal in May 2014. In July 2018, the appeals court affirmed the lower court's ruling with the total financial impact of the ruling estimated to be approximately </font><font style="font-family:Arial;font-size:10pt;">500 million</font><font style="font-family:Arial;font-size:10pt;"> Brazilian real (approximately </font><font style="font-family:Arial;font-size:10pt;">$125 million</font><font style="font-family:Arial;font-size:10pt;"> as of September 30, 2018). The appeals court restricted the broad health coverage awarded by the lower court to health problems that claimants could show arose from exposure to the alleged contamination. We strongly disagree with the court's decision and plan to appeal. Lilly Brasil has taken an initial step in the appeal process by filing a Motion for Clarification; a decision on that motion is expected late in the fourth quarter of 2018 or in the first quarter of 2019.</font><font style="font-family:Arial;font-size:10pt;color:#1f497d;"> </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are also named in approximately </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;"> lawsuits filed in the same court by individual former employees making similar claims. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lilly Brasil and Elanco Quimica Ltda. have been named in a lawsuit involving approximately </font><font style="font-family:Arial;font-size:10pt;">305</font><font style="font-family:Arial;font-size:10pt;"> individuals alleging that the companies failed to provide warnings regarding exposure to heavy metals or proper equipment at the former Cosmopolis facility, and that this alleged failure could result in possible harm to employees, former employees, and their dependents.&#160;In June 2017, the court denied the plaintiffs' request for a preliminary injunction. In September 2017, the court dismissed the claims brought by all but the first named plaintiff. The plaintiffs are appealing that decision.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lilly Brasil and Elanco Quimica Ltda. have also been named in a separate lawsuit involving approximately</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">105</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">individuals alleging that the companies failed to provide warnings regarding exposure to heavy metals or proper equipment at the former Cosmopolis facility, and that this alleged failure could result in possible harm to contractors and suppliers, and their dependents.&#160;In November 2017, the court dismissed the claims brought by all but the first named plaintiff. The plaintiffs are appealing that decision.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We believe all of these lawsuits are without merit and plan to defend against them vigorously. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Agri Stats, Inc.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the third quarter, we sold Agri Stats, Inc., one of our subsidiaries. As a result of the sale, we no longer hold the liability for litigation in which Agri Stats is named as a party, including the approximately </font><font style="font-family:Arial;font-size:10pt;">25</font><font style="font-family:Arial;font-size:10pt;"> antitrust suits filed in the U.S. District Court for the Northern District of Illinois and the District of Minnesota alleging that defendants engaged in a conspiracy to limit U.S. chicken and swine production and inflate prices.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Adocia, S.A.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have been named a respondent in </font><font style="font-family:Arial;font-size:10pt;">two</font><font style="font-family:Arial;font-size:10pt;"> arbitrations filed by Adocia, S.A. (Adocia), with which we entered into agreements for the co-development of an ultra-rapid insulin product. In the first arbitration, Adocia alleged that we failed to make a </font><font style="font-family:Arial;font-size:10pt;">$11.7 million</font><font style="font-family:Arial;font-size:10pt;"> milestone payment and, in August 2018, an arbitration panel ruled in favor of Adocia. In the second arbitration, Adocia alleged that we misappropriated and misused Adocia's confidential information and intellectual property and is seeking approximately </font><font style="font-family:Arial;font-size:10pt;">$1.8 billion</font><font style="font-family:Arial;font-size:10pt;"> in damages and other specific relief. We believe these claims are without merit and are defending against them vigorously. We have asserted several counterclaims relating to fraudulent misrepresentation and are seeking approximately </font><font style="font-family:Arial;font-size:10pt;">$188 million</font><font style="font-family:Arial;font-size:10pt;"> in damages. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Throughout the arbitrations described above, Adocia has made statements alleging that Adocia employees should be listed as inventors on </font><font style="font-family:Arial;font-size:10pt;">two</font><font style="font-family:Arial;font-size:10pt;"> of our patents related to our ultra-rapid insulin product currently in development. We strongly contest this allegation. While inventorship of these </font><font style="font-family:Arial;font-size:10pt;">two</font><font style="font-family:Arial;font-size:10pt;"> patents is not at issue in the arbitrations, in October 2018 we filed a declaratory judgment action against Adocia in the U.S. District Court for the Southern District of Indiana to confirm our inventorship.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Product Liability Insurance</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables summarize the activity related to each component of other comprehensive income (loss) during the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Amounts presented net of taxes)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Foreign Currency Translation Gains&#160;(Losses)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Unrealized Net Gains (Losses) on&#160;Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Portion of Cash&#160;Flow Hedges</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Accumulated Other Comprehensive Loss</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at July 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(1,671.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(18.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(4,190.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(228.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(6,108.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">60.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">548.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">610.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">47.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">49.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">60.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">595.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">660.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at September 30, 2018 </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(1,610.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(17.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(3,594.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(225.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(5,448.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Amounts presented net of taxes)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Foreign Currency Translation Gains&#160;(Losses)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Unrealized Net Gains (Losses) on&#160;Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Portion of Cash&#160;Flow Hedges</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Accumulated Other Comprehensive Loss</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at July 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,349.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">153.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,348.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(197.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,742.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">135.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">33.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(28.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(23.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">143.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">167.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at September 30, 2017 </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,205.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">163.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,337.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(195.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,574.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables summarize the activity related to each component of other comprehensive income (loss) during the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Amounts presented net of taxes)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Foreign Currency Translation Gains&#160;(Losses)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Unrealized Net Gains (Losses) on&#160;Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Portion of Cash&#160;Flow Hedges</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Accumulated Other Comprehensive Loss</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at January 1, 2018 </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(1,233.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">113.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(4,340.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(234.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(5,694.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Reclassification due to adoption of new accounting standard </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(128.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(128.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(377.5</font></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">31.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">581.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">234.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(32.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">164.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">140.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(377.5</font></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">745.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">375.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at September 30, 2018 </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(1,610.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(17.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(3,594.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(225.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(5,448.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Amounts presented net of taxes)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Foreign Currency Translation Gains&#160;(Losses)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Unrealized Net Gains (Losses) on&#160;Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Portion of Cash&#160;Flow Hedges</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Accumulated Other Comprehensive Loss</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at January 1, 2017 </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,867.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">224.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,371.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(210.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5,225.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">653.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(83.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">588.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(70.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">117.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">62.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">661.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(60.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">651.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at September 30, 2017 </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,205.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">163.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,337.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(195.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,574.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></font><font style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss as of </font><font style="font-family:Arial;font-size:8pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:8pt;"> consists of </font><font style="font-family:Arial;font-size:8pt;">$4.61 billion</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </font><font style="font-family:Arial;font-size:8pt;">$34.8 million</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive income attributable to noncontrolling interest.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2) </sup></font><font style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss as of January 1, 2018 consists of </font><font style="font-family:Arial;font-size:8pt;">$5.72 billion</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </font><font style="font-family:Arial;font-size:8pt;">$23.7 million</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive income attributable to noncontrolling interest. Accumulated other comprehensive loss as of January 1, 2017 consists of </font><font style="font-family:Arial;font-size:8pt;">$5.27 billion</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </font><font style="font-family:Arial;font-size:8pt;">$48.2 million</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive income attributable to noncontrolling interest. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></font><font style="font-family:Arial;font-size:8pt;">This reclassification consists of </font><font style="font-family:Arial;font-size:8pt;">$104.8 million</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </font><font style="font-family:Arial;font-size:8pt;">$24.1 million</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to noncontrolling interest. Refer to Note 2 for further details regarding the reclassification due to the adoption of Accounting Standards Update 2016-01, </font><font style="font-family:Arial;font-size:8pt;font-style:italic;">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font><font style="font-family:Arial;font-size:8pt;font-style:italic;"> </font><font style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss as of </font><font style="font-family:Arial;font-size:8pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:8pt;"> consists of </font><font style="font-family:Arial;font-size:8pt;">$5.44 billion</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </font><font style="font-family:Arial;font-size:8pt;">$9.0 million</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to noncontrolling interest.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Tax benefit (expense) </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation gains/losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">33.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(11.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">149.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized net gains/losses on securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4.2</font></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Defined benefit pension and retiree health benefit plans</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(152.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(9.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(190.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(24.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective portion of cash flow hedges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(146.4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(202.7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">142.7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Reclassifications out of accumulated other comprehensive loss were as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Details about Accumulated Other Comprehensive Loss Components</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Affected Line Item in the Consolidated Condensed Statements of Operations</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amortization of retirement benefit items:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior service benefits, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(18.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(21.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(56.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(63.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup>&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Actuarial losses, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">80.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">77.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">266.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">229.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup>&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total before tax</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">61.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">56.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">210.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">166.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(45.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(48.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Income taxes</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net of tax</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">47.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">164.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">117.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized gains/losses on available-for-sale securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Realized (gains), losses, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(36.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(41.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(108.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other&#8211;net, (income) expense</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tax (benefit) expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Income taxes</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(23.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(32.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(70.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other, net of tax</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other&#8211;net, (income) expense</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total reclassifications for the period (net of tax)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">49.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">140.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">62.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">These accumulated other comprehensive loss components are included in the computation of net periodic benefit (income) cost (see Note 8).</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have the following amounts recorded for contract liabilities:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Contract liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">308.6</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">335.2</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized gross gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">184.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized gross losses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">24.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">47.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair value of securities in an unrealized gain position</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">164.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,434.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair value of securities in an unrealized loss position</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">816.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,692.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Maturities by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Less&#160;Than</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">1 Year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">1-5</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">6-10</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">More&#160;Than</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">10 Years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair value of debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">985.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">74.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">620.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">135.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">154.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of gains and losses is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the effective portion of foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net product revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,664.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,323.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">16,905.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,841.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Collaboration and other revenue </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">397.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">334.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,211.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">869.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6,061.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,658.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">18,117.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16,710.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">Collaboration and other revenue associated with prior year transfers of intellectual property was </font><font style="font-family:Arial;font-size:8pt;">$76.2 million</font><font style="font-family:Arial;font-size:8pt;"> and </font><font style="font-family:Arial;font-size:8pt;">$258.4 million</font><font style="font-family:Arial;font-size:8pt;"> during the </font><font style="font-family:Arial;font-size:8pt;">three</font><font style="font-family:Arial;font-size:8pt;"> and </font><font style="font-family:Arial;font-size:8pt;">nine</font><font style="font-family:Arial;font-size:8pt;"> months ended </font><font style="font-family:Arial;font-size:8pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:8pt;">, respectively, and </font><font style="font-family:Arial;font-size:8pt;">$36.7 million</font><font style="font-family:Arial;font-size:8pt;"> and </font><font style="font-family:Arial;font-size:8pt;">$105.5 million</font><font style="font-family:Arial;font-size:8pt;"> during the </font><font style="font-family:Arial;font-size:8pt;">three</font><font style="font-family:Arial;font-size:8pt;"> and </font><font style="font-family:Arial;font-size:8pt;">nine</font><font style="font-family:Arial;font-size:8pt;"> months ended </font><font style="font-family:Arial;font-size:8pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:8pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables summarize certain fair value information at </font><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;"> for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Cost </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Observable Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,646.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,646.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,646.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,646.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">U.S. government and agency securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">10.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">52.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">52.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">52.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">52.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">11.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">76.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Noncurrent investments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">U.S. government and agency securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">152.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">159.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">152.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">152.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">622.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">631.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">622.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">622.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mortgage-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">109.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">114.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">109.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">109.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">27.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">27.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">27.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">27.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">137.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">39.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">137.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">137.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">287.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">146.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">287.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">287.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity investments without readily determinable fair values </font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">394.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity method investments </font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">275.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Noncurrent investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2,005.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,763.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,763.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,712.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">51.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,763.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">U.S. government and agency securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">217.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">218.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">217.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">217.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,182.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,183.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,182.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,182.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">94.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">94.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">94.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">94.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,497.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Noncurrent investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">U.S. government and agency securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">360.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">365.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">360.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">360.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,464.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,473.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,464.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,464.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mortgage-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">202.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">204.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">202.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">202.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">653.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">656.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">653.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">653.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">132.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">66.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">132.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">132.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">281.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">131.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">281.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">281.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cost and equity method investments </font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">584.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Noncurrent investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,678.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</font></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></font><font style="font-family:Arial;font-size:8pt;">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments that do not have readily determinable fair values.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Other Observable Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-management instruments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest rate contracts designated as fair value hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(66.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(66.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(66.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cross-currency interest rate contracts designated as net investment hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">30.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">30.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">30.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sundry</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(16.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(16.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(16.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign exchange contracts not designated as hedging instruments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(14.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(14.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(14.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Contingent consideration liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(62.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(62.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(62.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-management instruments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest rate contracts designated as fair value hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sundry</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cross-currency interest rate contracts designated as net investment hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(33.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(33.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(33.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(26.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(26.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(26.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign exchange contracts not designated as hedging instruments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(36.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(36.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(36.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Contingent consideration liabilities </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font><font style="font-family:Arial;font-size:10pt;">:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(208.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(208.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(208.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">Contingent consideration liabilities primarily relate to the Erbitux arrangement with BMS discussed in Note 4.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our equity investments are accounted for using three different methods depending on the type of equity investment:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We review equity investments other than public equity investments for indications of impairment on a regular basis.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of gains and losses is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the effective portion of foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, we had outstanding foreign currency forward commitments to purchase </font><font style="font-family:Arial;font-size:10pt;">1.40 billion</font><font style="font-family:Arial;font-size:10pt;"> U.S. dollars and sell </font><font style="font-family:Arial;font-size:10pt;">1.19 billion</font><font style="font-family:Arial;font-size:10pt;"> euro, commitments to purchase </font><font style="font-family:Arial;font-size:10pt;">1.57 billion</font><font style="font-family:Arial;font-size:10pt;"> euro and sell </font><font style="font-family:Arial;font-size:10pt;">1.84 billion</font><font style="font-family:Arial;font-size:10pt;"> U.S. dollars, commitments to purchase </font><font style="font-family:Arial;font-size:10pt;">426.9 million</font><font style="font-family:Arial;font-size:10pt;"> U.S. dollars and sell </font><font style="font-family:Arial;font-size:10pt;">47.94 billion</font><font style="font-family:Arial;font-size:10pt;"> Japanese yen, commitments to purchase </font><font style="font-family:Arial;font-size:10pt;">234.1 million</font><font style="font-family:Arial;font-size:10pt;"> Swiss Francs and sell </font><font style="font-family:Arial;font-size:10pt;">243.2 million</font><font style="font-family:Arial;font-size:10pt;"> U.S. dollars, commitments to purchase </font><font style="font-family:Arial;font-size:10pt;">512.2 million</font><font style="font-family:Arial;font-size:10pt;"> U.S. dollars and sell </font><font style="font-family:Arial;font-size:10pt;">389.4 million</font><font style="font-family:Arial;font-size:10pt;"> British pounds, and commitments to purchase </font><font style="font-family:Arial;font-size:10pt;">466.4 million</font><font style="font-family:Arial;font-size:10pt;"> British pounds and sell </font><font style="font-family:Arial;font-size:10pt;">613.0 million</font><font style="font-family:Arial;font-size:10pt;"> U.S. dollars, which will all settle within </font><font style="font-family:Arial;font-size:10pt;">30 days</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of </font><font style="font-family:Arial;font-size:10pt;">$3.45 billion</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$3.70 billion</font><font style="font-family:Arial;font-size:10pt;"> as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, and have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated and Swiss franc-denominated foreign operations. Our cross-currency interest rate swaps that convert a portion of our U.S. dollar-denominated floating rate debt to foreign-denominated floating rate debt have also been designated as, and are effective as, economic hedges of net investments. At </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, we had outstanding cross currency swaps with notional amounts of </font><font style="font-family:Arial;font-size:10pt;">$1.53 billion</font><font style="font-family:Arial;font-size:10pt;"> swapping euro to U.S. dollars and </font><font style="font-family:Arial;font-size:10pt;">$350.0 million</font><font style="font-family:Arial;font-size:10pt;"> swapping British pounds to U.S. dollars, which will all settle within 12 months. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, substantially all of our total long-term debt is at a fixed rate. We have converted </font><font style="font-family:Arial;font-size:10pt;">20 percent</font><font style="font-family:Arial;font-size:10pt;"> of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Elanco Debt Issuance</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, our wholly owned subsidiary, Elanco, issued </font><font style="font-family:Arial;font-size:10pt;">$2.00 billion</font><font style="font-family:Arial;font-size:10pt;"> of senior notes in a private placement. The senior notes are comprised of </font><font style="font-family:Arial;font-size:10pt;">$500.0 million</font><font style="font-family:Arial;font-size:10pt;"> of </font><font style="font-family:Arial;font-size:10pt;">3.91 percent</font><font style="font-family:Arial;font-size:10pt;"> senior notes due in August&#160;2021, </font><font style="font-family:Arial;font-size:10pt;">$750.0 million</font><font style="font-family:Arial;font-size:10pt;"> of </font><font style="font-family:Arial;font-size:10pt;">4.27 percent</font><font style="font-family:Arial;font-size:10pt;"> senior notes due in August&#160;2023, and </font><font style="font-family:Arial;font-size:10pt;">$750.0 million</font><font style="font-family:Arial;font-size:10pt;"> of </font><font style="font-family:Arial;font-size:10pt;">4.90 percent</font><font style="font-family:Arial;font-size:10pt;"> senior notes due in August&#160;2028. Interest is to be paid semi-annually and the interest rate payable on each series of senior notes is subject to adjustment if certain bond rating agencies downgrade, or subsequently upgrade, their ratings on the respective series of senior notes. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The indenture that governs the Elanco senior notes contains covenants, including limitations on the ability of Elanco and certain Elanco subsidiaries to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on Elanco's ability to consolidate, merge or sell substantially all of their assets, in addition to other customary terms. Elanco was in compliance with all such covenants under the indentures governing the senior notes as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Elanco has entered into an agreement that requires them to use commercially reasonable efforts to cause a registration statement to become effective with the SEC by August 28, 2019, relating to an offer to exchange the senior notes for registered senior notes having substantially identical terms, or in certain cases, to register the senior notes for resale. If they do not register or exchange the senior notes pursuant to the terms of the registration rights agreement, they will be required to pay additional interest to the holders of the senior notes under certain circumstances. </font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In September 2018, Elanco entered into a revolving credit agreement with a syndicate of banks providing for a </font><font style="font-family:Arial;font-size:10pt;">five</font><font style="font-family:Arial;font-size:10pt;">-year </font><font style="font-family:Arial;font-size:10pt;">$750.0 million</font><font style="font-family:Arial;font-size:10pt;"> senior revolving credit facility (Revolving Facility). The Revolving Facility bears interest at a variable rate plus specified margin as defined in the agreement and is payable quarterly. There were </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> borrowings outstanding under the Revolving Facility at September&#160;30, 2018. The Revolving Facility is payable in full at the end of the term.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In September&#160;2018, Elanco also entered into a </font><font style="font-family:Arial;font-size:10pt;">$500.0 million</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;">-year term loan under a term credit facility with a syndicate of banks (the Term Facility and collectively with the Revolving Facility, the Credit Facilities). The Term Facility bears interest at a variable rate plus margin as defined in the Term Facility and is payable quarterly. The Term Facility is payable in full at the end of the term.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Credit Facilities are subject to various financial and other covenants including restrictions on Elanco's level of borrowings based on their consolidated leverage ratio and their consolidated interest coverage ratio. Elanco was in compliance with all such covenants as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The aggregate net proceeds of the senior notes and Term Facility was $</font><font style="font-family:Arial;font-size:10pt;">2.48 billion</font><font style="font-family:Arial;font-size:10pt;">. See Note 3 for a discussion of the use of the proceeds of the debt offerings as part of the formation of Elanco and their IPO process. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair value hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effect from hedged fixed-rate debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(19.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(94.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effect from interest rate contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">19.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">94.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash flow hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">11.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net losses on foreign currency exchange contracts not designated as hedging instruments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">76.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">79.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net investment hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(47.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(58.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">53.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(332.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(38.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">52.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(95.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash flow hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the next 12&#160;months, we expect to reclassify </font><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">$15.0&#160;million</font><font style="font-family:Arial;font-size:10pt;"> of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables summarize certain fair value information at </font><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;"> for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Cost </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Observable Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,646.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,646.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,646.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,646.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">U.S. government and agency securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">10.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">52.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">52.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">52.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">52.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">11.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">76.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Noncurrent investments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">U.S. government and agency securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">152.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">159.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">152.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">152.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">622.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">631.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">622.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">622.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mortgage-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">109.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">114.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">109.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">109.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">27.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">27.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">27.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">27.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">137.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">39.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">137.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">137.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">287.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">146.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">287.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">287.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity investments without readily determinable fair values </font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">394.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity method investments </font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">275.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Noncurrent investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2,005.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,763.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,763.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,712.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">51.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,763.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">U.S. government and agency securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">217.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">218.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">217.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">217.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,182.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,183.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,182.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,182.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">94.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">94.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">94.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">94.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,497.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Noncurrent investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">U.S. government and agency securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">360.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">365.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">360.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">360.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,464.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,473.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,464.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,464.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Mortgage-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">202.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">204.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">202.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">202.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">653.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">656.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">653.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">653.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">132.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">66.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">132.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">132.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">281.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">131.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">281.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">281.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cost and equity method investments </font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">584.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Noncurrent investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,678.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</font></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></font><font style="font-family:Arial;font-size:8pt;">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments that do not have readily determinable fair values.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Other Observable Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Short-term commercial paper borrowings</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(399.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(398.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(398.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,696.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,690.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,690.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Long-term debt, including current portion</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(12,277.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(12,542.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(12,542.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10,950.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,529.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,529.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Other Observable Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-management instruments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest rate contracts designated as fair value hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(66.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(66.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(66.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cross-currency interest rate contracts designated as net investment hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">30.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">30.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">30.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sundry</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(16.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(16.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(16.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign exchange contracts not designated as hedging instruments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(14.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(14.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(14.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Contingent consideration liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(62.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(62.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(62.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-management instruments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest rate contracts designated as fair value hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sundry</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cross-currency interest rate contracts designated as net investment hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(33.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(33.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(33.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(26.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(26.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(26.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign exchange contracts not designated as hedging instruments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(36.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(36.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(36.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Contingent consideration liabilities </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font><font style="font-family:Arial;font-size:10pt;">:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(208.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(208.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(208.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">Contingent consideration liabilities primarily relate to the Erbitux arrangement with BMS discussed in Note 4.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to an enforceable master netting arrangement or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Contingent consideration liabilities at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;"> primarily include contingent consideration related to Erbitux, for which the fair value was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for net sales in North America through September 2018 and an estimated discount rate. The amount to be paid is calculated as a tiered percentage of net sales (see Note 4) and will, therefore, vary directly with increases and decreases in net sales of Erbitux in North America. There is no cap on the amount that may be paid pursuant to this arrangement. The decrease in the fair value of the contingent consideration liabilities during the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> was due primarily to cash payments of </font><font style="font-family:Arial;font-size:10pt;">$155.4 million</font><font style="font-family:Arial;font-size:10pt;"> related to Erbitux. The change in the fair value of the contingent consideration liabilities recognized in earnings during the three and </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;"> due to changes in time value of money was not material.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Maturities by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Less&#160;Than</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">1 Year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">1-5</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">6-10</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">More&#160;Than</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">10 Years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair value of debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">985.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">74.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">620.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">135.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">154.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized gross gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">184.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized gross losses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">24.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">47.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair value of securities in an unrealized gain position</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">164.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,434.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair value of securities in an unrealized loss position</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">816.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,692.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A summary of the unrealized gains and losses (pretax) recognized in our consolidated condensed statements of operations for equity securities held as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized gain (loss), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(40.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(3.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We periodically assess our investment in available-for-sale securities for other-than-temporary impairment losses. There were </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> other-than-temporary impairment losses in the three or </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> or the three or </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We periodically assess our investments in equity securities other than public equity securities for impairment losses. Impairment losses recognized on these equity securities in the three and </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> were immaterial. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For fixed-income securities, the amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For equity securities, factors considered in assessing impairment losses include the financial condition and near term prospects of the issuer and general market conditions and industry specific factors.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately </font><font style="font-family:Arial;font-size:10pt;">60 percent</font><font style="font-family:Arial;font-size:10pt;">&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, we do not intend to sell, and it is not more likely than not that we will be required to sell the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities, was as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Proceeds from sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">52.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">951.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,598.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,003.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Realized gross gains on sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">82.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Realized gross losses on sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">49.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Adjustments recorded to our equity investments without readily determinable fair values are based upon changes in the equity instrument's value resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon the impairment considerations mentioned above. Adjustments recorded during the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> were immaterial.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Accounts Receivable Factoring Arrangements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized </font><font style="font-family:Arial;font-size:10pt;">$645.1 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$723.2 million</font><font style="font-family:Arial;font-size:10pt;">&#160;of accounts receivable as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and December 31, </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, under these factoring arrangements. The cost of factoring such accounts receivable on our consolidated condensed results of operations for the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">&#160;was&#160;not material.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Other Observable Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Short-term commercial paper borrowings</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(399.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(398.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(398.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,696.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,690.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,690.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Long-term debt, including current portion</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(12,277.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(12,542.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(12,542.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10,950.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,529.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,529.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities, was as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Proceeds from sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">52.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">951.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,598.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,003.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Realized gross gains on sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">82.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Realized gross losses on sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">49.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The effective tax rates were </font><font style="font-family:Arial;font-size:10pt;">18.5 percent</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">26.2 percent</font><font style="font-family:Arial;font-size:10pt;"> for the three and </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, respectively, compared with </font><font style="font-family:Arial;font-size:10pt;">6.1 percent</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">24.1 percent</font><font style="font-family:Arial;font-size:10pt;"> for the three and </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">. The increase in the effective tax rate for the </font><font style="font-family:Arial;font-size:10pt;">third</font><font style="font-family:Arial;font-size:10pt;"> quarter of </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;"> is primarily due to a higher income tax benefit in the third quarter of 2017 for acquired IPR&amp;D charges and asset impairment, restructuring, and other special charges. The increase in the effective rate for the first </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months of </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;"> is primarily due to the </font><font style="font-family:Arial;font-size:10pt;">$1.56 billion</font><font style="font-family:Arial;font-size:10pt;"> non-deductible acquired IPR&amp;D charge related to the acquisitions of ARMO and AurKa. In December 2017, the President of the U.S. signed into law the Tax Cuts and Jobs Act (2017 Tax Act), which includes significant changes to the U.S. corporate income tax system, including a reduction in the corporate income tax rate, transition to a territorial tax system, and modifications to the international tax provisions. The changes that became effective January 1, 2018 resulted in a reduction to our tax expense for the three and </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> compared to the three and </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At September 30, 2018, our accounting for the 2017 Tax Act is incomplete; however, we expect to complete our accounting by December 2018. As discussed in our 2017 Annual Report on Form 10-K, we recorded provisional adjustments for effects that we were able to reasonably estimate. Those effects included the one-time repatriation transition tax (also known as the 'Toll Tax'), re-measurement of deferred tax assets and liabilities, unremitted earnings, executive compensation, and uncertain tax positions.&#160;At year-end, we were not able to make reasonable estimates for Global Intangible Low-Taxed Income (GILTI) deferred taxes or valuation allowances; therefore, we did not record provisional amounts. We are still evaluating the effects of the GILTI provisions and assessing our valuation allowances, and we have not yet determined our accounting policy election with respect to GILTI deferred taxes or the application of intra-entity transfers of inventory; therefore, the estimated annual effective tax rate reflects GILTI as a period expense. For the three and </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, we increased our provisional amount of Toll Tax by an immaterial amount. We have not made any additional measurement-period adjustments related to the other provisional items as we are continuing to collect and analyze additional information as well as evaluate the interpretations and assumptions made. Updates to our calculations may result in material changes to the provisional adjustments recorded at year-end and the estimated annual effective tax rate.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The U.S. examination of tax years </font><font style="font-family:Arial;font-size:10pt;">2013</font><font style="font-family:Arial;font-size:10pt;">-</font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> began in 2016. While we believe it is reasonably possible that this audit could reach resolution within the next 12 months, the IRS examination of tax years 2013-2015 remains ongoing. Therefore, it is not possible to reasonably estimate the change to unrecognized tax benefits and the related future cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Divestiture and Acquisitions</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Divestiture</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Formation of Elanco and Initial Public Offering</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On September 24, 2018, Elanco Animal Health Incorporated (Elanco) completed an initial public offering (the IPO) resulting in the issuance of </font><font style="font-family:Arial;font-size:10pt;">72.3 million</font><font style="font-family:Arial;font-size:10pt;"> shares of its common stock, which represents </font><font style="font-family:Arial;font-size:10pt;">19.8 percent</font><font style="font-family:Arial;font-size:10pt;"> of Elanco's outstanding shares, at </font><font style="font-family:Arial;font-size:10pt;">$24</font><font style="font-family:Arial;font-size:10pt;"> per share.&#160;Elanco shares began trading on the New York Stock Exchange under the symbol "ELAN" in September 2018. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the completion of the IPO, through a series of equity and other transactions, we transferred to Elanco the animal health businesses that form its business going forward.&#160;In exchange, Elanco transferred to us, or will transfer to us, consideration of approximately </font><font style="font-family:Arial;font-size:10pt;">$4.2 billion</font><font style="font-family:Arial;font-size:10pt;">, which consists primarily of the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco in August 2018, and the term loan facility entered into by Elanco during the period (see Note 6). The consideration that we receive is intended to be used for debt repayment, dividends, and/or share repurchases. The excess of the net proceeds from the IPO over the net book value of our divested interest was </font><font style="font-family:Arial;font-size:10pt;">$629.2 million</font><font style="font-family:Arial;font-size:10pt;"> and was recorded in additional paid-in capital. Of our consolidated cash and cash equivalents as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, approximately </font><font style="font-family:Arial;font-size:10pt;">$300 million</font><font style="font-family:Arial;font-size:10pt;"> is retained by Elanco for working capital purposes.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We continue to consolidate Elanco, as we retain control over Elanco. The earnings attributable to the divested, noncontrolling interest for the period from IPO until September 30, 2018 were not material for the three and </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">. As of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, the noncontrolling interest of </font><font style="font-family:Arial;font-size:10pt;">$1.02 billion</font><font style="font-family:Arial;font-size:10pt;"> associated with Elanco is reflected in noncontrolling interests in the consolidated condensed balance sheet. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On January 3, 2017, we completed the acquisition of Boehringer Ingelheim Vetmedica, Inc.'s United States (U.S.) feline, canine, and rabies vaccine portfolio and other related assets (BIVIVP). This transaction, as further discussed in this note below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition have been included in our consolidated condensed financial statements from the date of acquisition.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to the acquisition of BIVIVP, we acquired assets in development in the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, which are further discussed in this note below in Asset Acquisitions. Upon acquisition, the acquired in-process research and development (IPR&amp;D) charges related to these products were immediately expensed because the products had no alternative future use. We incurred acquired IPR&amp;D charges of </font><font style="font-family:Arial;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">and </font><font style="font-family:Arial;font-size:10pt;">$1.65 billion</font><font style="font-family:Arial;font-size:10pt;"> for the three and </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, respectively, and </font><font style="font-family:Arial;font-size:10pt;">$205.0 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$1.06 billion</font><font style="font-family:Arial;font-size:10pt;"> for the three and </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Acquisition of a Business</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">Boehringer Ingelheim Vetmedica, Inc. Vaccine Portfolio Acquisition</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Overview of Transaction</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In 2017, we acquired BIVIVP in an all-cash transaction for </font><font style="font-family:Arial;font-size:10pt;">$882.1 million</font><font style="font-family:Arial;font-size:10pt;">. Under the terms of the agreement, we acquired a manufacturing and research and development site and a U.S. vaccine portfolio, including vaccines used for the treatment of bordetella, Lyme disease, rabies, and parvovirus, among others. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Assets Acquired and Liabilities Assumed</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated Fair Value at January 3, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inventories</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">108.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Marketed products </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">297.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">148.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other assets and liabilities - net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total identifiable net assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">562.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Goodwill </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">320.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total consideration transferred - net of cash acquired</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">882.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">These intangible assets, which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of </font><font style="font-family:Arial;font-size:8pt;">10 years</font><font style="font-family:Arial;font-size:8pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></font><font style="font-family:Arial;font-size:8pt;">The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy animal health business, future unidentified projects and products, and the assembled workforce of BIVIVP. The goodwill associated with this acquisition is deductible for tax purposes.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Asset Acquisitions</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table and narrative summarize our asset acquisitions during the </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Counterparty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Compound(s) or Therapy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Acquisition Month</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Phase of Development </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Acquired IPR&amp;D Expense</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sigilon Therapeutics (Sigilon)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Encapsulated cell therapies for the potential treatment of type 1 diabetes</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">April 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pre-clinical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">66.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AurKa Pharma, Inc. (AurKa)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AK-01, an Aurora kinase A inhibitor</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">June 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARMO Biosciences, Inc. (ARMO)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cancer therapy - pegilodecakin</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">June 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase III</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,475.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Anima Biotech (Anima)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Translation inhibitors for selected neuroscience targets</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">July 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pre-clinical</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">CoLucid Pharmaceuticals, Inc. (CoLucid)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Oral therapy for the acute treatment of migraine - lasmiditan</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">857.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">KeyBioscience AG (KeyBioscience)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Multiple molecules for treatment of metabolic disorders</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">July 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase II</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nektar Therapeutics (Nektar)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Immunological therapy - NKTR-358</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">August 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">150.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> </sup></font><font style="font-family:Arial;font-size:8pt;">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the arrangements described herein, our partners may be entitled to future royalties and/or commercial milestones based on sales should these products be approved for commercialization and/or milestones based on the successful progress of the compounds through the development process.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We entered into a collaboration agreement with Sigilon to develop encapsulated cell therapies for the potential treatment of type 1 diabetes. Sigilon will create proprietary products comprised of induced pluripotent stem cells engineered into differentiated insulin-producing pancreatic beta cells and encapsulated using Sigilon's Afibromer technology. We will receive an exclusive worldwide license to Sigilon's Afibromer technology for islet cell encapsulation. Under the terms of the agreement, we paid an upfront fee of </font><font style="font-family:Arial;font-size:10pt;">$62.5 million</font><font style="font-family:Arial;font-size:10pt;"> and made an equity investment in Sigilon.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We acquired AK-01 through the acquisition of AurKa. Under the terms of the agreement, we acquired all shares of AurKa for a cash purchase price of </font><font style="font-family:Arial;font-size:10pt;">$81.3 million</font><font style="font-family:Arial;font-size:10pt;">, net of cash acquired, plus net accrued liabilities assumed of </font><font style="font-family:Arial;font-size:10pt;">$0.5 million</font><font style="font-family:Arial;font-size:10pt;">. Substantially all the value of AurKa was related to AK-01, its only significant asset. The acquired IPR&amp;D expense was not tax deductible.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We acquired pegilodecakin through the acquisition of ARMO. Under the terms of the agreement, we acquired all shares of ARMO for a cash purchase price of </font><font style="font-family:Arial;font-size:10pt;">$1.40 billion</font><font style="font-family:Arial;font-size:10pt;">, net of cash acquired, plus net accrued liabilities assumed of </font><font style="font-family:Arial;font-size:10pt;">$75.8 million</font><font style="font-family:Arial;font-size:10pt;">. Substantially all of the value of ARMO was related to pegilodecakin, its only significant asset. The acquired IPR&amp;D expense was not tax deductible.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We entered into a collaboration agreement with Anima for the discovery and development of translation inhibitors for several target proteins by using Anima's translation control therapeutics platform. Under the terms of the agreement, we paid an upfront fee of </font><font style="font-family:Arial;font-size:10pt;">$30.0 million</font><font style="font-family:Arial;font-size:10pt;">. Anima will use its technology platform to discover lead candidates that are translation inhibitors of our selected neuroscience targets. We will be responsible for all clinical development and commercialization activities and costs related to the collaboration.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We acquired lasmiditan through the acquisition of CoLucid. Under the terms of the agreement, we acquired all shares of CoLucid for a cash purchase price of </font><font style="font-family:Arial;font-size:10pt;">$831.8 million</font><font style="font-family:Arial;font-size:10pt;">, net of cash acquired, plus net accrued liabilities assumed of </font><font style="font-family:Arial;font-size:10pt;">$25.8 million</font><font style="font-family:Arial;font-size:10pt;">. Substantially all of the value of CoLucid was related to lasmiditan, its only significant asset. The acquired IPR&amp;D expense was not tax deductible.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our collaboration agreement with KeyBioscience provides us with access to KeyBioscience's Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of treatments for metabolic disorders such as type 2 diabetes, along with multiple molecules. Prior to entering into the agreement, KeyBioscience had initiated Phase II development of the lead molecule. The other assets included in the collaboration range from pre-clinical to Phase I development. Under the terms of the agreement, we receive worldwide rights to develop and commercialize these molecules. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our collaboration with Nektar is to co-develop Nektar's compound which has the potential to treat a number of autoimmune and other chronic inflammatory conditions. Under the terms of the agreement, we are responsible for all costs of global commercialization. Nektar will have an option to co-promote in the U.S. under certain conditions.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In September 2018, we announced a license agreement with Chugai Pharmaceutical Company for OWL833, an oral non-peptidic GLP-1 receptor agonist. OWL833 is a preclinical asset that is being studied for the treatment of type 2 diabetes. Under the terms of the agreement, we will acquire worldwide development and commercialization rights to OWL833 for a cash purchase price of </font><font style="font-family:Arial;font-size:10pt;">$50.0 million</font><font style="font-family:Arial;font-size:10pt;"> and success-based milestones and royalties. The transaction is expected to close in the fourth quarter of 2018, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. We expect an acquired IPR&amp;D charge of </font><font style="font-family:Arial;font-size:10pt;">$50.0 million</font><font style="font-family:Arial;font-size:10pt;"> in the fourth quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In October 2018, we announced a global license and research agreement with Dicerna Pharmaceuticals (Dicerna) for the discovery, development, and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration, and pain. Under terms of the agreement, we will pay an upfront fee of </font><font style="font-family:Arial;font-size:10pt;">$100.0 million</font><font style="font-family:Arial;font-size:10pt;"> and make an equity investment in Dicerna. The transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Upon closing, we will record an acquired IPR&amp;D expense of approximately </font><font style="font-family:Arial;font-size:10pt;">$135 million</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In October 2018, we acquired a Priority Review Voucher from SIGA Technologies, Inc. for a cash purchase price of </font><font style="font-family:Arial;font-size:10pt;">$80.0 million</font><font style="font-family:Arial;font-size:10pt;">. We intend to utilize the voucher to fast track a product application for an existing R&amp;D project, although the specific project has not yet been determined. As a result of this transaction, we will record an acquired IPR&amp;D expense of </font><font style="font-family:Arial;font-size:10pt;">$80.0 million</font><font style="font-family:Arial;font-size:10pt;"> in the fourth quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In November 2018, we entered into a collaboration agreement with NextCure, Inc. (NextCure) for the discovery and development of immuno-oncology cancer therapies. NextCure will apply its discovery platform technology to identify novel, functional immune-related targets and we will develop antibodies to these targets. The parties will be able to exclusively license antibodies resulting from the collaboration. Under terms of the agreement, we will pay an upfront fee of </font><font style="font-family:Arial;font-size:10pt;">$25.0 million</font><font style="font-family:Arial;font-size:10pt;"> and make an equity investment in NextCure. As a result of this transaction, we will record an acquired IPR&amp;D expense of approximately </font><font style="font-family:Arial;font-size:10pt;">$30 million</font><font style="font-family:Arial;font-size:10pt;"> in the fourth quarter of 2018.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Implementation of New Financial Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2014-09 and various other related updates, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 12.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-16, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified<br clear="none"/>retrospective approach to adoption.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption, the cumulative effect of applying the standard resulted in an increase to deferred tax assets and retained earnings of approximately $2.5 billion. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2017-07, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other&#8211;net, (income) expense. The application of the new standard resulted in reclassification to other income of $63.8 million for the three months ended September 30, 2017, while increasing cost of sales by $20.2 million, marketing, selling, and administrative expenses by $23.0 million, and research and development expenses by $20.6 million for the same period. The application of the new standard resulted in reclassification to other income of $191.3 million for the nine months ended September 30, 2017, while increasing cost of sales by $60.5 million, marketing, selling, and administrative expenses by $69.0 million, and research and development expenses by $61.8 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on our financial statements:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-02, Leases</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt on that date.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2014-09 and various other related updates, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 12.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-16, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified<br clear="none"/>retrospective approach to adoption.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption, the cumulative effect of applying the standard resulted in an increase to deferred tax assets and retained earnings of approximately $2.5 billion. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2017-07, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other&#8211;net, (income) expense. The application of the new standard resulted in reclassification to other income of $63.8 million for the three months ended September 30, 2017, while increasing cost of sales by $20.2 million, marketing, selling, and administrative expenses by $23.0 million, and research and development expenses by $20.6 million for the same period. The application of the new standard resulted in reclassification to other income of $191.3 million for the nine months ended September 30, 2017, while increasing cost of sales by $60.5 million, marketing, selling, and administrative expenses by $69.0 million, and research and development expenses by $61.8 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on our financial statements:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-02, Leases</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt on that date.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Basis of Presentation and Revenue</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">. We issue our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of incremental shares from our stock-based compensation programs.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Adoption of Revenue Accounting Standard</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;"> and other related updates (see Note 2 for additional discussion). The new standard has been applied to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don&#8217;t believe the effect of applying this practical expedient resulted in material differences. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for the three and </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> do not differ materially from amounts that would have resulted from application of the previous standards.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net product revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,664.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,323.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">16,905.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,841.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Collaboration and other revenue </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">397.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">334.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,211.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">869.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6,061.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,658.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">18,117.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16,710.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">Collaboration and other revenue associated with prior year transfers of intellectual property was </font><font style="font-family:Arial;font-size:8pt;">$76.2 million</font><font style="font-family:Arial;font-size:8pt;"> and </font><font style="font-family:Arial;font-size:8pt;">$258.4 million</font><font style="font-family:Arial;font-size:8pt;"> during the </font><font style="font-family:Arial;font-size:8pt;">three</font><font style="font-family:Arial;font-size:8pt;"> and </font><font style="font-family:Arial;font-size:8pt;">nine</font><font style="font-family:Arial;font-size:8pt;"> months ended </font><font style="font-family:Arial;font-size:8pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:8pt;">, respectively, and </font><font style="font-family:Arial;font-size:8pt;">$36.7 million</font><font style="font-family:Arial;font-size:8pt;"> and </font><font style="font-family:Arial;font-size:8pt;">$105.5 million</font><font style="font-family:Arial;font-size:8pt;"> during the </font><font style="font-family:Arial;font-size:8pt;">three</font><font style="font-family:Arial;font-size:8pt;"> and </font><font style="font-family:Arial;font-size:8pt;">nine</font><font style="font-family:Arial;font-size:8pt;"> months ended </font><font style="font-family:Arial;font-size:8pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:8pt;">, respectively.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#8482;</sup></font><font style="font-family:Arial;font-size:10pt;"> and Jardiance</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Net Product Revenue</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;"> to </font><font style="font-family:Arial;font-size:10pt;">75</font><font style="font-family:Arial;font-size:10pt;"> days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates and discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received;</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates and discounts and returns. The following describe the most significant of these judgments:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Sales Rebates and Discounts - Background and Uncertainties</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Most of our pharmaceutical products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. Most of our animal health products are sold to wholesale distributors. We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback contracts in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Sales Returns - Background and Uncertainties</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuances, or a changing competitive environment. We maintain a returns policy that allows U.S. pharmaceutical customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products sold to major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Actual product returns have been less than 2 percent of our net revenue over each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. </font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Adjustments to Revenue</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, for product shipped in previous years were not material.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Disaggregation of Revenue</font><font style="font-family:Arial;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our disaggregated revenue is disclosed in Note 12.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Collaborations and Other Arrangements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Royalty revenue from licensees, which is based on sales to third parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have entered into arrangements whereby we transferred rights to products and committed to supply for a period of time. For those arrangements for which we concluded that the obligations were not distinct, any amounts received upfront are being amortized to revenue as net product revenue over the period of the supply arrangement as the performance obligation is satisfied.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Contract Liabilities</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales rebates, discounts, and returns. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have the following amounts recorded for contract liabilities:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Contract liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">308.6</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">335.2</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The contract liabilities amount disclosed above as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, is primarily related to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The remaining license period of symbolic intellectual property, and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Obligations to supply product for a defined period of time.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue recognized from contract liabilities as of January 1, </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;">, during the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Other&#8211;Net, (Income) Expense</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other&#8211;net, (income) expense consisted of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">69.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">61.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">193.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">162.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(32.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(118.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(114.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Retirement benefit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(62.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(63.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(174.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(191.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">41.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">9.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(44.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other&#8211;net, (income) expense</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">15.4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(49.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(90.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(188.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, </font><font style="font-family:Arial;font-size:10pt;">pension and postretirement benefit cost components other than service costs are presented in other&#8211;net, (income) expense. Results for the three and nine months ended September 30, 2017 have been reclassified to reflect the adoption of this standard.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Retirement Benefits</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net pension and retiree health benefit (income) cost included the following components:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Defined Benefit Pension Plans</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Components of net periodic benefit cost:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Service cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">74.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">86.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">232.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">251.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">117.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">103.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">342.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">309.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected return on plan assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(212.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(196.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(636.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(585.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amortization of prior service cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Recognized actuarial loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">79.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">72.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">261.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">215.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Curtailment loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net periodic benefit cost</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">61.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">67.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">204.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">195.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Retiree Health Benefit Plans</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Components of net periodic benefit income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Service cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">10.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">31.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">14.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">42.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">39.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected return on plan assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(44.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(40.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(132.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(120.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amortization of prior service benefit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(19.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(22.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(60.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(67.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Recognized actuarial loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Curtailment gain</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(29.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(29.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net periodic benefit income</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(67.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(33.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(142.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(99.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2018, we announced that we would amend our defined benefit pension and retiree health benefit plans to freeze or reduce benefits for certain Elanco employees effective January 1, 2019. We remeasured the impacted pension and retiree health plans&#8217; benefit obligations as of July 31, 2018, which resulted in a net curtailment gain of </font><font style="font-family:Arial;font-size:10pt;">$28.0 million</font><font style="font-family:Arial;font-size:10pt;"> during the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, which was recorded as a component of asset impairment, restructuring, and other special charges.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We contributed approximately </font><font style="font-family:Arial;font-size:10pt;">$35 million</font><font style="font-family:Arial;font-size:10pt;"> required to satisfy minimum funding requirements to our defined benefit pension and retiree health benefit plans during the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">. Additional discretionary funding totaled </font><font style="font-family:Arial;font-size:10pt;">$200.0 million</font><font style="font-family:Arial;font-size:10pt;"> during the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">. During the remainder of </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;">, we expect to make contributions to our defined benefit pension and retiree health benefit plans of approximately </font><font style="font-family:Arial;font-size:10pt;">$15 million</font><font style="font-family:Arial;font-size:10pt;"> to satisfy minimum funding requirements. No additional discretionary funding for the remainder of </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;"> is planned.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, </font><font style="font-family:Arial;font-size:10pt;">pension and retiree health benefit cost components other than service costs are presented in other&#8211;net, (income) expense.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Reclassifications out of accumulated other comprehensive loss were as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Details about Accumulated Other Comprehensive Loss Components</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Affected Line Item in the Consolidated Condensed Statements of Operations</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amortization of retirement benefit items:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior service benefits, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(18.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(21.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(56.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(63.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup>&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Actuarial losses, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">80.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">77.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">266.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">229.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup>&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total before tax</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">61.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">56.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">210.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">166.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(15.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(45.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(48.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Income taxes</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net of tax</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">47.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">164.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">117.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized gains/losses on available-for-sale securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Realized (gains), losses, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(36.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(41.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(108.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other&#8211;net, (income) expense</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tax (benefit) expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Income taxes</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(23.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(32.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(70.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other, net of tax</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other&#8211;net, (income) expense</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total reclassifications for the period (net of tax)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">49.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">140.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">62.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">These accumulated other comprehensive loss components are included in the computation of net periodic benefit (income) cost (see Note 8).</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Asset Impairment, Restructuring, and Other Special Charges</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Severance:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Human pharmaceutical products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">165.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(24.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">277.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Animal health products</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">62.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total severance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(5.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">171.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(25.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">339.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset impairment and other special charges: </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Human pharmaceutical products</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Animal health products</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">85.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">210.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">259.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">306.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total asset impairment and other special charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">88.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">235.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">261.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">331.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total asset impairment, restructuring, and other special charges</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">83.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">406.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">236.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">670.4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Severance charges recognized during the </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> primarily relate to severance adjustments recorded in the second quarter of 2018. Our severance charges recognized in the second half of 2017 as part of planned restructuring activities were based upon estimates for the number of employees that either lost or were going to lose their then current roles and would ultimately leave the company. During the second quarter of 2018, we determined that more displaced employees than expected were able to find other roles within the company, resulting in an immaterial reduction in the actual severance costs incurred. We expect the majority of the remaining severance payments to be made in the next 12 months. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset impairment and other special charges recognized during the three months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> resulted primarily from asset impairment and other restructuring charges related to the sale of the Posilac</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> (rbST) brand and the associated Augusta, Georgia manufacturing site. We also incurred expenses associated with the IPO and separation of Elanco. These expenses were offset by a gain recognized associated with the pension curtailment (see Note 8 for additional discussion).</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to the charges for the three months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, additional asset impairment and other special charges for the </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> included asset impairment, exit costs, and other charges related to the decision to end Posilac</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> </sup></font><font style="font-family:Arial;font-size:10pt;">(rbST) production at the Augusta, Georgia manufacturing site, and charges related to the decision to suspend commercialization of Imrestor</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, an animal health product. We also incurred expenses associated with the review of strategic alternatives for the Elanco animal health business.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Severance costs recognized during the three and </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> were incurred as a result of actions taken to reduce our cost structure, as well as the integration of Novartis Animal Health (Novartis AH). </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Substantially all of the asset impairment and other special charges recognized during the three months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> were related to lower projected revenue for Posilac (rbST). The assets associated with Posilac (rbST) were written down to their fair values, which were determined based upon a discounted cash flow valuation. Other asset impairment and other special charges recognized during the three months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> related to exit costs associated with site closures. Asset impairment and other special charges recognized during the </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;"> resulted primarily from charges associated with the Posilac (rbST) impairment, integration costs of Novartis AH, as well as asset impairments due to site closures.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables summarize the activity related to each component of other comprehensive income (loss) during the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Amounts presented net of taxes)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Foreign Currency Translation Gains&#160;(Losses)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Unrealized Net Gains (Losses) on&#160;Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Portion of Cash&#160;Flow Hedges</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Accumulated Other Comprehensive Loss</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at July 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(1,671.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(18.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(4,190.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(228.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(6,108.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">60.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">548.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">610.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">47.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">49.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">60.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">595.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">660.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at September 30, 2018 </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(1,610.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(17.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(3,594.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(225.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(5,448.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Amounts presented net of taxes)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Foreign Currency Translation Gains&#160;(Losses)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Unrealized Net Gains (Losses) on&#160;Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Portion of Cash&#160;Flow Hedges</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Accumulated Other Comprehensive Loss</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at July 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,349.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">153.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,348.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(197.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,742.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">135.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">33.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(28.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">141.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(23.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">143.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">167.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at September 30, 2017 </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,205.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">163.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,337.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(195.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,574.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables summarize the activity related to each component of other comprehensive income (loss) during the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Amounts presented net of taxes)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Foreign Currency Translation Gains&#160;(Losses)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Unrealized Net Gains (Losses) on&#160;Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Portion of Cash&#160;Flow Hedges</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Accumulated Other Comprehensive Loss</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at January 1, 2018 </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(1,233.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">113.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(4,340.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(234.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(5,694.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Reclassification due to adoption of new accounting standard </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(128.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(128.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(377.5</font></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">31.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">581.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">234.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(32.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">164.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">140.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(377.5</font></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">745.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">375.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at September 30, 2018 </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(1,610.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(17.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(3,594.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(225.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(5,448.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Amounts presented net of taxes)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Foreign Currency Translation Gains&#160;(Losses)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Unrealized Net Gains (Losses) on&#160;Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Portion of Cash&#160;Flow Hedges</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Accumulated Other Comprehensive Loss</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at January 1, 2017 </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,867.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">224.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,371.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(210.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5,225.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">653.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(83.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">588.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(70.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">117.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">62.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">661.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(60.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">651.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Balance at September 30, 2017 </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,205.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">163.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,337.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(195.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,574.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></font><font style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss as of </font><font style="font-family:Arial;font-size:8pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:8pt;"> consists of </font><font style="font-family:Arial;font-size:8pt;">$4.61 billion</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </font><font style="font-family:Arial;font-size:8pt;">$34.8 million</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive income attributable to noncontrolling interest.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2) </sup></font><font style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss as of January 1, 2018 consists of </font><font style="font-family:Arial;font-size:8pt;">$5.72 billion</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </font><font style="font-family:Arial;font-size:8pt;">$23.7 million</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive income attributable to noncontrolling interest. Accumulated other comprehensive loss as of January 1, 2017 consists of </font><font style="font-family:Arial;font-size:8pt;">$5.27 billion</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </font><font style="font-family:Arial;font-size:8pt;">$48.2 million</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive income attributable to noncontrolling interest. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></font><font style="font-family:Arial;font-size:8pt;">This reclassification consists of </font><font style="font-family:Arial;font-size:8pt;">$104.8 million</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </font><font style="font-family:Arial;font-size:8pt;">$24.1 million</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to noncontrolling interest. Refer to Note 2 for further details regarding the reclassification due to the adoption of Accounting Standards Update 2016-01, </font><font style="font-family:Arial;font-size:8pt;font-style:italic;">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font><font style="font-family:Arial;font-size:8pt;font-style:italic;"> </font><font style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss as of </font><font style="font-family:Arial;font-size:8pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:8pt;"> consists of </font><font style="font-family:Arial;font-size:8pt;">$5.44 billion</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </font><font style="font-family:Arial;font-size:8pt;">$9.0 million</font><font style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to noncontrolling interest.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Tax benefit (expense) </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation gains/losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">33.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(11.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">149.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized net gains/losses on securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4.2</font></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Defined benefit pension and retiree health benefit plans</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(152.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(9.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(190.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(24.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective portion of cash flow hedges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(146.4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(202.7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">142.7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized with respect to Erbitux:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net product revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">133.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">137.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">397.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">403.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Collaboration and other revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">25.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">78.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">73.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">159.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">163.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">475.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">477.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes significant regulatory and commercialization events and milestones (deferred) capitalized for the compounds included in this collaboration: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Launched</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Milestones </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Deferred) Capitalized </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Product Family</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Japan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Trajenta </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cumulative </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4) </sup></font><font style="font-family:Arial;font-size:10pt;">- all prior to 2017</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">446.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jardiance </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cumulative </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4) </sup></font><font style="font-family:Arial;font-size:10pt;">- all prior to 2017</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">299.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Basaglar</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cumulative </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font><font style="font-family:Arial;font-size:10pt;">&#160;- all prior to 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(250.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></font><font style="font-family:Arial;font-size:8pt;">Jentadueto is included in the Trajenta product family. The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></font><font style="font-family:Arial;font-size:8pt;">Glyxambi and Synjardy</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></font><font style="font-family:Arial;font-size:8pt;">are included in the Jardiance product family. The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4) </sup></font><font style="font-family:Arial;font-size:8pt;">The cumulative amount represents the total initial amounts that were (deferred) or capitalized from the start of this collaboration through the end of the reporting period.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized with respect to Effient:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">45.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">104.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">326.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">tones. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our milestones achieved:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Event</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Classification</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Regulatory submissions in the U.S. and Europe</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">R&amp;D expense</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Regulatory approval in Europe</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Regulatory approval in Japan</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Began Phase III testing for atopic dermatitis</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">R&amp;D expense</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Regulatory approval in the U.S.</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Began Phase III testing for SLE</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">R&amp;D Expense</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Basaglar</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">201.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">145.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">569.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">278.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jardiance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">166.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">127.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">465.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">304.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Trajenta</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">135.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">153.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">418.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">408.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net investment hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(47.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(58.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">53.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(332.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(38.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">52.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(95.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash flow hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair value hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effect from hedged fixed-rate debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(19.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(94.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effect from interest rate contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">19.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">94.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash flow hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">11.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net losses on foreign currency exchange contracts not designated as hedging instruments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">76.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">79.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Retiree Health Benefit Plans</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Components of net periodic benefit income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Service cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">10.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">31.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">14.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">42.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">39.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected return on plan assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(44.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(40.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(132.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(120.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amortization of prior service benefit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(19.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(22.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(60.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(67.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Recognized actuarial loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Curtailment gain</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(29.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(29.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net periodic benefit income</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(67.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(33.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(142.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(99.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net pension and retiree health benefit (income) cost included the following components:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Defined Benefit Pension Plans</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Components of net periodic benefit cost:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Service cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">74.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">86.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">232.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">251.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">117.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">103.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">342.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">309.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected return on plan assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(212.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(196.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(636.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(585.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amortization of prior service cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Recognized actuarial loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">79.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">72.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">261.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">215.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Curtailment loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net periodic benefit cost</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">61.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">67.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">204.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">195.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2014-09 and various other related updates, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 12.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-16, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified<br clear="none"/>retrospective approach to adoption.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption, the cumulative effect of applying the standard resulted in an increase to deferred tax assets and retained earnings of approximately $2.5 billion. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2017-07, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other&#8211;net, (income) expense. The application of the new standard resulted in reclassification to other income of $63.8 million for the three months ended September 30, 2017, while increasing cost of sales by $20.2 million, marketing, selling, and administrative expenses by $23.0 million, and research and development expenses by $20.6 million for the same period. The application of the new standard resulted in reclassification to other income of $191.3 million for the nine months ended September 30, 2017, while increasing cost of sales by $60.5 million, marketing, selling, and administrative expenses by $69.0 million, and research and development expenses by $61.8 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on our financial statements:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-02, Leases</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt on that date.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other&#8211;net, (income) expense consisted of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">69.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">61.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">193.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">162.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(32.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(45.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(118.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(114.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Retirement benefit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(62.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(63.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(174.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(191.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">41.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">9.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(44.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other&#8211;net, (income) expense</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">15.4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(49.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(90.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(188.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Estimated Fair Value at January 3, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inventories</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">108.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Marketed products </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">297.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">148.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other assets and liabilities - net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total identifiable net assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">562.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Goodwill </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">320.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total consideration transferred - net of cash acquired</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">882.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">These intangible assets, which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of </font><font style="font-family:Arial;font-size:8pt;">10 years</font><font style="font-family:Arial;font-size:8pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></font><font style="font-family:Arial;font-size:8pt;">The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy animal health business, future unidentified projects and products, and the assembled workforce of BIVIVP. The goodwill associated with this acquisition is deductible for tax purposes.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table and narrative summarize our asset acquisitions during the </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Arial;font-size:10pt;">.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Counterparty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Compound(s) or Therapy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Acquisition Month</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Phase of Development </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Acquired IPR&amp;D Expense</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sigilon Therapeutics (Sigilon)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Encapsulated cell therapies for the potential treatment of type 1 diabetes</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">April 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pre-clinical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">66.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AurKa Pharma, Inc. (AurKa)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AK-01, an Aurora kinase A inhibitor</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">June 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARMO Biosciences, Inc. (ARMO)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cancer therapy - pegilodecakin</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">June 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase III</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,475.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Anima Biotech (Anima)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Translation inhibitors for selected neuroscience targets</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">July 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pre-clinical</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">CoLucid Pharmaceuticals, Inc. (CoLucid)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Oral therapy for the acute treatment of migraine - lasmiditan</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">857.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">KeyBioscience AG (KeyBioscience)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Multiple molecules for treatment of metabolic disorders</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">July 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase II</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nektar Therapeutics (Nektar)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Immunological therapy - NKTR-358</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">August 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">150.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> </sup></font><font style="font-family:Arial;font-size:8pt;">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Severance:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Human pharmaceutical products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">165.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(24.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">277.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Animal health products</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">62.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total severance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(5.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">171.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(25.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">339.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset impairment and other special charges: </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Human pharmaceutical products</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Animal health products</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">85.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">210.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">259.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">306.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total asset impairment and other special charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">88.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">235.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">261.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">331.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total asset impairment, restructuring, and other special charges</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">83.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">406.5</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">236.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">670.4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;padding-top:8px;padding-left:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Geographic Information</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue&#8212;to unaffiliated customers </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font><font style="font-family:Arial;font-size:10pt;">:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,446.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,104.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">10,211.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,361.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,017.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,017.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,142.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,877.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Japan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">608.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">616.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,828.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,767.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other foreign countries</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">989.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">920.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,934.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,704.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6,061.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,658.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">18,117.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16,710.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Numbers may not add due to rounding.</font></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">Revenue is attributed to the countries based on the location of the customer.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outside U.S.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outside U.S.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Segment revenue&#8212;to unaffiliated customers:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Human pharmaceutical products:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Endocrinology:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Trulicity</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">645.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">170.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">816.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">412.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">114.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">527.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Humalog</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">365.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">299.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">664.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">414.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">281.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">696.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Forteo</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">182.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">208.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">390.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">234.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">207.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">441.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Humulin</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">216.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">105.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">322.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">203.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">97.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">300.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Basaglar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">157.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">43.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">201.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">115.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">145.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Jardiance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">104.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">62.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">166.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">83.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">127.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Trajenta</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">50.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">85.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">135.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">68.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">84.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">153.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Endocrinology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">73.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">66.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">140.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">92.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">76.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">168.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Endocrinology</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,796.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,041.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,837.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,624.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">936.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,560.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Oncology:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Alimta</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">288.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">232.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">520.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">260.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">254.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">514.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cyramza</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">67.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">131.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">198.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">69.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">126.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">196.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Erbitux</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">132.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">26.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">159.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">136.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">163.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Oncology</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">131.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">54.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">185.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">40.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">83.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Oncology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">619.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">444.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,064.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">509.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">448.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">957.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cardiovascular:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cialis</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">295.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">171.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">467.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">319.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">245.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">564.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Effient</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">30.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">15.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">45.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Cardiovascular</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">39.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">31.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">71.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Cardiovascular</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">365.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">218.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">583.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">367.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">295.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">662.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Neuroscience:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cymbalta</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">14.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">157.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">172.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">163.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">183.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Zyprexa</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">102.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">109.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">128.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">140.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Strattera</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">88.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">98.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">52.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">84.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">137.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Neuroscience</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">23.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">23.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">46.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">46.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Neuroscience</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">55.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">371.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">427.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">108.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">399.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">507.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Immunology:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Taltz</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">210.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">53.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">263.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">131.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">151.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Immunology</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">54.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">55.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Immunology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">211.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">108.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">319.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">131.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">36.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">167.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other pharmaceuticals</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">13.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">43.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">56.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">50.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">60.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total human pharmaceutical products</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,062.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,226.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,289.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,751.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,166.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,917.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Animal health products</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">383.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">388.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">772.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">353.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">387.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">740.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,446.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,615.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6,061.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,104.4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,553.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,658.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outside U.S.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outside U.S.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Segment revenue&#8212;to unaffiliated customers:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Human pharmaceutical products:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Endocrinology:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Trulicity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,786.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">487.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,274.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,090.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">290.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,380.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Humalog</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,334.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">891.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,226.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,254.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">828.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,083.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Forteo</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">529.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">608.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,138.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">661.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">574.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,235.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Humulin</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">677.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">316.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">994.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">634.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">337.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">972.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Basaglar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">440.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">128.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">569.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">196.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">278.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Jardiance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">284.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">180.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">465.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">105.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">304.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Trajenta</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">161.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">257.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">418.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">174.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">234.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">408.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Endocrinology</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">199.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">206.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">406.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">283.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">228.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">511.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Endocrinology</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,413.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,078.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8,491.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,493.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,681.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,175.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Oncology:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Alimta</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">815.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">760.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,576.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">761.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">775.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,537.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cyramza</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">210.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">390.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">600.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">204.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">349.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">553.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Erbitux</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">394.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">81.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">475.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">398.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">78.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">477.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Oncology</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">321.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">157.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">478.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">128.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">104.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">232.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Oncology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,741.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,389.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,130.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,492.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,307.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,800.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cardiovascular:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cialis</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">954.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">546.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,501.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">997.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">728.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,725.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Effient</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">59.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">45.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">104.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">290.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">326.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Cardiovascular</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">143.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">96.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">239.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">99.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Cardiovascular</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,158.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">687.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,845.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,308.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">863.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Neuroscience:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cymbalta </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">39.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">484.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">523.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">463.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">564.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Zyprexa</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">27.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">332.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">360.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">49.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">379.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">428.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Strattera</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">74.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">269.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">343.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">276.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">243.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">519.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Neuroscience</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">72.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">71.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">143.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">88.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">72.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">160.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Neuroscience</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">213.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,157.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,370.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">515.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,158.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,673.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Immunology:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Taltz</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">495.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">135.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">630.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">343.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">386.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Immunology</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">130.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">132.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Immunology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">497.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">265.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">762.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">343.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">66.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">409.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other pharmaceuticals</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">49.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">139.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">189.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">149.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">184.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total human pharmaceutical products</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">9,073.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6,717.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">15,791.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8,188.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,227.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14,415.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Animal health products</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,137.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,188.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,326.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,173.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,121.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,294.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">10,211.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7,906.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">18,117.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,361.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,348.7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16,710.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Numbers may not add due to rounding.</font></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">U.S. revenue includes revenue in Puerto Rico.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Segment profits:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Human pharmaceutical products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,514.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,242.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4,751.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,765.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Animal health products</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">162.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">121.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">461.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">422.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total segment profits</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,676.7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,364.4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,213.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,188.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Reconciliation of total segment profits to consolidated income before taxes:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Segment profits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,676.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,364.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,213.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,188.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other profits (losses):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Acquired in-process research and development (Note&#160;3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(30.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(205.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(1,654.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,062.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amortization of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(153.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(155.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(458.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(510.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset impairment, restructuring, and other special charges (Note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(83.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(406.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(236.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(670.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(7.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(32.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Consolidated income before taxes</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,411.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">591.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,856.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,913.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Numbers may not add due to rounding.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have </font><font style="font-family:Arial;font-size:10pt;">two</font><font style="font-family:Arial;font-size:10pt;"> operating segments&#8212;human pharmaceutical products and animal health products. Our operating segments are distinguished by the ultimate end user of the product&#8212;humans or animals. Performance is evaluated based on profit or loss from operations before income taxes.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outside U.S.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outside U.S.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Segment revenue&#8212;to unaffiliated customers:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Human pharmaceutical products:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Endocrinology:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Trulicity</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">645.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">170.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">816.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">412.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">114.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">527.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Humalog</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">365.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">299.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">664.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">414.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">281.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">696.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Forteo</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">182.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">208.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">390.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">234.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">207.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">441.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Humulin</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">216.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">105.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">322.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">203.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">97.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">300.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Basaglar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">157.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">43.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">201.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">115.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">145.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Jardiance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">104.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">62.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">166.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">83.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">127.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Trajenta</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">50.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">85.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">135.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">68.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">84.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">153.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Endocrinology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">73.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">66.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">140.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">92.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">76.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">168.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Endocrinology</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,796.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,041.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,837.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,624.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">936.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,560.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Oncology:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Alimta</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">288.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">232.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">520.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">260.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">254.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">514.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cyramza</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">67.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">131.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">198.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">69.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">126.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">196.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Erbitux</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">132.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">26.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">159.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">136.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">163.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Oncology</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">131.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">54.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">185.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">40.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">83.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Oncology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">619.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">444.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,064.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">509.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">448.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">957.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cardiovascular:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cialis</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">295.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">171.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">467.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">319.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">245.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">564.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Effient</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">30.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">15.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">45.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Cardiovascular</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">39.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">31.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">71.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Cardiovascular</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">365.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">218.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">583.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">367.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">295.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">662.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Neuroscience:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cymbalta</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">14.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">157.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">172.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">163.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">183.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Zyprexa</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">102.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">109.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">128.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">140.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Strattera</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">88.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">98.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">52.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">84.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">137.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Neuroscience</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">23.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">23.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">46.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">46.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Neuroscience</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">55.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">371.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">427.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">108.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">399.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">507.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Immunology:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Taltz</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">210.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">53.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">263.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">131.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">151.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Immunology</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">54.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">55.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Immunology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">211.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">108.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">319.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">131.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">36.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">167.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other pharmaceuticals</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">13.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">43.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">56.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">50.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">60.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total human pharmaceutical products</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,062.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,226.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,289.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,751.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,166.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,917.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Animal health products</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">383.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">388.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">772.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">353.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">387.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">740.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,446.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,615.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6,061.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,104.4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,553.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,658.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outside U.S.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S. </font><font style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outside U.S.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Segment revenue&#8212;to unaffiliated customers:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Human pharmaceutical products:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Endocrinology:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Trulicity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,786.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">487.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,274.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,090.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">290.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,380.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Humalog</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,334.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">891.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,226.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,254.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">828.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,083.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Forteo</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">529.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">608.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,138.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">661.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">574.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,235.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Humulin</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">677.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">316.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">994.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">634.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">337.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">972.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Basaglar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">440.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">128.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">569.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">196.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">278.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Jardiance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">284.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">180.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">465.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">105.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">304.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Trajenta</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">161.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">257.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">418.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">174.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">234.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">408.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Endocrinology</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">199.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">206.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">406.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">283.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">228.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">511.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Endocrinology</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,413.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,078.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8,491.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,493.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,681.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,175.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Oncology:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Alimta</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">815.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">760.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,576.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">761.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">775.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,537.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cyramza</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">210.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">390.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">600.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">204.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">349.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">553.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Erbitux</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">394.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">81.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">475.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">398.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">78.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">477.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Oncology</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">321.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">157.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">478.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">128.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">104.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">232.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Oncology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,741.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,389.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,130.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,492.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,307.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,800.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cardiovascular:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cialis</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">954.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">546.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,501.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">997.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">728.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,725.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Effient</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">59.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">45.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">104.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">290.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">326.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Cardiovascular</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">143.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">96.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">239.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">99.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Cardiovascular</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,158.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">687.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,845.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,308.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">863.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Neuroscience:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cymbalta </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">39.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">484.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">523.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">463.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">564.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Zyprexa</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">27.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">332.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">360.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">49.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">379.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">428.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Strattera</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">74.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">269.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">343.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">276.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">243.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">519.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Neuroscience</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">72.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">71.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">143.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">88.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">72.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">160.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Neuroscience</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">213.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,157.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,370.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">515.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,158.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,673.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Immunology:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Taltz</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">495.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">135.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">630.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">343.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">386.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Immunology</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">130.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">132.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Immunology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">497.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">265.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">762.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">343.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">66.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">409.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other pharmaceuticals</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">49.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">139.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">189.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">149.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">184.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total human pharmaceutical products</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">9,073.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6,717.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">15,791.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8,188.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,227.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14,415.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Animal health products</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,137.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,188.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,326.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,173.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,121.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,294.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">10,211.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7,906.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">18,117.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,361.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,348.7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16,710.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Numbers may not add due to rounding.</font></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">U.S. revenue includes revenue in Puerto Rico.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Segment profits:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Human pharmaceutical products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,514.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,242.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4,751.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,765.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Animal health products</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">162.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">121.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">461.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">422.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total segment profits</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,676.7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,364.4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,213.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,188.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Reconciliation of total segment profits to consolidated income before taxes:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Segment profits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,676.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,364.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,213.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,188.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other profits (losses):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Acquired in-process research and development (Note&#160;3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(30.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(205.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(1,654.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,062.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amortization of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(153.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(155.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(458.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(510.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset impairment, restructuring, and other special charges (Note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(83.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(406.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(236.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(670.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(7.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(32.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Consolidated income before taxes</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,411.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">591.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,856.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,913.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Numbers may not add due to rounding.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:8px;padding-left:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing and global administrative services.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Geographic Information</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue&#8212;to unaffiliated customers </font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font><font style="font-family:Arial;font-size:10pt;">:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,446.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,104.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">10,211.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,361.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,017.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,017.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,142.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,877.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Japan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">608.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">616.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,828.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,767.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other foreign countries</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">989.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">920.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2,934.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,704.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6,061.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,658.0</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">18,117.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16,710.6</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Numbers may not add due to rounding.</font></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">Revenue is attributed to the countries based on the location of the customer.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Refer to Note 3 for information regarding the IPO of Elanco.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A summary of the unrealized gains and losses (pretax) recognized in our consolidated condensed statements of operations for equity securities held as of </font><font style="font-family:Arial;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;"> is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unrealized gain (loss), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(40.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(3.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div></div> As of September 30, 2018, there was $7.00 billion remaining under our $8.00 billion share repurchase program authorized in June 2018. Other comprehensive income for the three and nine months ended September 30, 2018 was all attributable to controlling interest. Other comprehensive income for the three and nine months ended September 30, 2017 consisted of $165.5 million and $664.6 million, respectively, of other comprehensive income attributable to controlling interest and $2.2 million and $(13.4) million of other comprehensive income (loss) attributable to noncontrolling interest during the same periods. EX-101.SCH 6 lly-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2105100 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation and Revenue link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation and Revenue Basis of Presentation and Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2301301 - Disclosure - Basis of Presentation and Revenue Basis of Presentation and Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Collaborations and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Collaborations and Other Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Collaborations and Other Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Consolidated Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002001 - Statement - Consolidated Condensed Statements of Comprehensive Income (Loss) (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Condensed Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003001 - Statement - Consolidated Condensed Statements of Shareholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Divestiture and Acquisitions (Acquisitions) (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Divestiture and Acquisitions (Formation of Elanco and IPO) (Details) link:presentationLink link:calculationLink link:definitionLink 2203201 - Disclosure - Divestiture and Acquisitions (Policies) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Divestiture and Acquisitions (Purchased Price) (Details) link:presentationLink link:calculationLink link:definitionLink 2303302 - Disclosure - Divestiture and Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Divestures and Acquisitions link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2406408 - Disclosure - Financial Instruments (Contractual Maturities) (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Financial Instruments (Effect of Risk-Management Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Financial Instruments (Elanco Debt Issuance) (Details) link:presentationLink link:calculationLink link:definitionLink 2406406 - Disclosure - Financial Instruments (Fair Value of Financial Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Financial Instruments (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2206201 - Disclosure - Financial Instruments (Policies) link:presentationLink link:calculationLink link:definitionLink 2406410 - Disclosure - Financial Instruments (Realized gain and losses) (Details) link:presentationLink link:calculationLink link:definitionLink 2406407 - Disclosure - Financial Instruments (Risk Management Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 2306302 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2406409 - Disclosure - Financial Instruments (Unrealized gain and losses) (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Implementation of New Accounting Pronouncements (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Implementation of New Financial Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Implementation of New Financial Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Implementation of New Financial Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Other Comprehensive Income (Loss) (Tax effect) (Details) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Other-Net, (Income) Expense link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Other - Net, (Income) Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Other - Net, (Income) Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Retirement Benefits link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Retirement Benefits (Components of Net Periodic Benefit Cost) (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Retirement Benefits (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Retirement Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Segment Information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Segment Information (Revenue by Product) (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Segment Information (Segment profit) (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 lly-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 lly-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 lly-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Combinations [Abstract] Business Combinations Policy Business Combinations Policy [Policy Text Block] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Concentration Risk [Table] Concentration Risk [Table] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Difference between Revenue Guidance in Effect before and after Topic 606 Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2016-01 Accounting Standards Update 2016-01 [Member] Accounting Standards Update 2016-16 Accounting Standards Update 2016-16 [Member] Accounting Standards Update 2017-07 Accounting Standards Update 2017-07 [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Retained earnings Retained Earnings (Accumulated Deficit) Increase to deferred tax assets upon adoption Deferred Tax Assets, Net Other, net Nonoperating Income (Expense) Cost of sales Cost of Goods and Services Sold Marketing, selling, and administrative Selling, General and Administrative Expense Research and development Research and Development Expense Equity [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Prior service benefits, net Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member] Amortization of retirement benefit items Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Defined Benefit Pension and Retiree Health Benefit Plans Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Unrealized net gains/losses on securities Accumulated Net Investment Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Other, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Amortization of retirement benefit items: Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Tax benefit Reclassification from AOCI, Current Period, Tax Total reclassifications for the period (net of tax) Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other, net Tax (benefit) expense Income Tax Expense (Benefit) Net of tax Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Total reclassifications for the period (net of tax) Net Income (Loss) Available to Common Stockholders, Basic Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] U.S. UNITED STATES Outside U.S. International [Member] International [Member] Europe Europe [Member] Japan JAPAN Other foreign countries Other Foreign Countries [Member] Other Foreign Countries [Member] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Endocrinology Endocrinology [Member] Revenue to unaffiliated customers, Endocrinology Trulicity Trulicity [Member] [Member] Trulicity [Member] [Member] Humalog Humalog [Member] Humalog [Member] Forteo Forteo [Member] Forteo [Member] Humulin® Humulin [Member] Humulin [Member] Basaglar Basaglar [Member] Basaglar [Member] Jardiance Jardiance (BI) [Member] Jardiance (BI) [Member] Trajenta Trajenta (BI) [Member] Trajenta (BI) [Member] Other Endocrinology Other Endocrinology [Member] Other Endocrinology [Member] Oncology Oncology [Member] Revenue to unaffiliated customers, Oncology Alimta Alimta [Member] Alimta [Member] Cyramza Cyramza [Member] Cyramza [Member] Erbitux Erbitux [Member] Erbitux [Member] Other Oncology Other Oncology [Member] Other Oncology [Member] Cardiovascular Cardiovascular [Member] Revenue to unaffiliated customers, Cardiovascular Cialis Cialis [Member] Cialis [Member] Effient Effient [Member] Effient [Member] Other Cardiovascular Other Cardiovascular [Member] Other Cardiovascular [Member] Neuroscience Neuroscience [Member] Revenue to unaffiliated customers, Neuroscience Cymbalta Cymbalta [Member] Cymbalta [Member] Zyprexa Zyprexa [Member] Zyprexa [Member] Strattera® Strattera [Member] Strattera [Member] Other Neuroscience Other Neuroscience [Member] Other Neuroscience [Member] Immunology Immunology [Member] Immunology [Member] Taltz® Taltz [Member] Taltz [Member] Other Immunology Other Immunology [Member] Other Immunology [Member] Other pharmaceuticals Other Pharmaceuticals [Member] Revenue to unaffiliated customers, Other pharmaceuticals Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Human pharmaceutical products Human Pharmaceutical Products [Member] Human Pharmaceutical Products [Member] Animal health products Animal Health Products [Member] Animal Health Products [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Revenues Revenues Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Milestone Payments, Development and Regulatory, Capitalized, Cumulative Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member] Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] Sales Acquisition Terms - Contingent Consideration [Member] Acquisition Terms - Contingent Consideration [Member] Royalty Agreement Terms Royalty Agreement Terms [Member] Research and Development Exp Research and Development Expense [Member] Milestone Payments, Development and Regulatory, Expensed Milestone Payments, Development and Regulatory, Expensed [Member] Milestone Payments, Development and Regulatory, Expensed [Member] Milestone Payments, Development and Regulatory, Capitalized (Deferred) Milestone Payments, Development and Regulatory, Capitalized (Deferred) [Member] Milestone Payments, Development and Regulatory, Capitalized [Member] Milestone Payments, Development and Regulatory Milestone Payments, Development and Regulatory [Member] Milestone Payments, Development and Regulatory [Member] Milestone Payments, Sales-based Milestone Payments, Sales-based [Member] Milestone Payments, Sales-based [Member] Profit and Development and Marketing Share Profit And Development And Marketing Share [Member] Share of profits, research and development expenses, and marketing expenses pursuant to the terms of a collaborative arrangement. Basaglar Product Erbitux, Product [Member] Erbitux, Product [Member] Collaboration and Other Revenue Erbitux, Collaboration and Other Revenue [Member] Erbitux, Collaboration and Other Revenue [Member] Olumiant Olumiant [Member] Olumiant [Member] Tanezumab Tanezumab [Member] Tanezumab [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Milestones (deferred) capitalized Collaborative Arrangement, Rights and Obligations, Terms Terms or rights and obligations under collaborative arrangements. Revenue Collaborative arrangement, rights and obligations (percentage) Collaborative Arrangement, Rights and Obligations Percent Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes. Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Income Statement [Abstract] Revenue Costs, expenses, and other: Costs and Expenses [Abstract] Acquired in-process research and development (Note 3) Acquired in-process research and development The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT) Asset impairment, restructuring, and other special charges (Note 5) Restructuring, Settlement and Impairment Provisions Other–net, (income) expense (Note 11) Cost of sales, operating expenses, and other-net Cost of sales, operating expenses, and other-net Cost of sales, operating expenses, and other-net Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income taxes (Note 7) Net income Net Income (Loss) Attributable to Parent Earnings per share: Earnings Per Share [Abstract] Basic (usd per share) Earnings Per Share, Basic Diluted (usd per share) Earnings Per Share, Diluted Shares used in calculation of earnings per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Statement of Stockholders' Equity [Abstract] Dividend declared (usd per share) Common Stock, Dividends, Per Share, Declared Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Restructuring and Related Activities [Abstract] The components of the charges included in asset impairment, restructuring, and other special charges Restructuring and Related Costs [Table Text Block] Segment Information Segment Reporting Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Schedule of components of other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of reclassifications out of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Accounting Changes and Error Corrections [Abstract] Schedule of New Accounting Pronouncements and Changes in Accounting Principles Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Retirement Benefits Pension and Other Postretirement Benefits Disclosure [Text Block] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments Operating Segments [Member] Corporate, Non-Segment Corporate, Non-Segment [Member] Consolidated income before taxes Acquired in-process research and development (Note 3) Amortization of intangible assets Amortization of Intangible Assets Asset impairment, restructuring, and other special charges (Note 5) Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Net investment hedges Net Investment Hedging [Member] Cash Flow Hedging Cash Flow Hedging [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Effect from hedged fixed-rate debt Hedged Fixed Rate Debt [Member] Hedged Fixed-Rate Debt [Member] Effect from interest rate contracts Interest Rate Contract [Member] Foreign currency exchange contracts Foreign Exchange Contract [Member] Cross-currency interest rate swaps Cross Currency Interest Rate Contract [Member] Interest Rate Swap Interest Rate Swap [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Effect from hedged fixed-rate debt Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Effect from interest rate contracts Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion Net losses on foreign currency exchange contracts not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying Amount Reported Value Measurement [Member] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Other receivables Derivative Asset, Current Sundry Derivative Asset, Noncurrent Other current liabilities Derivative Liability, Current Other noncurrent liabilities Derivative Liability, Noncurrent Other current liabilities Business Combination, Contingent Consideration, Liability, Current Other noncurrent liabilities Business Combination, Contingent Consideration, Liability, Noncurrent Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Foreign currency translation gains/losses Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Defined benefit pension and retiree health benefit plans Effective portion of cash flow hedges Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items Other Comprehensive Income (Loss), Tax Description of Derivative Risk Management Policy Derivatives, Policy [Policy Text Block] Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Plaintiff Appealing Decision of Court Plaintiff Appealing Decision of Court [Member] Plaintiff Appealing Decision of Court [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Product Liability Litigation Product Liability Litigation [Member] Matters related to product liability litigation Litigation Case [Axis] Litigation Case [Axis] Litigation Case Type [Domain] Litigation Case [Domain] Dr Reddy's Lab Dr Reddy's Lab [Member] Dr Reddy's Lab [Member] Japanese Administrative Proceedings Japanese Administrative Proceedings [Member] Japanese Administrative Proceedings [Member] Employee Litigation Employee Litigation [Member] Employee Litigation [Member] Agri Stats, Inc. Agri Stats, Inc. [Member] Agri Stats, Inc. [Member] Adocia S.A Adocia S.A [Member] Adocia S.A [Member] California CALIFORNIA Brazil BRAZIL Loss Contingency [Line Items] Loss Contingencies [Line Items] Number of new application Number of New Application Number of New Application Number of defendants Loss Contingency, Number of Defendants Number of companies Number of Companies Number of Companies Number of cases ruled in favor Loss Contingency, Claims Settled and Dismissed, Number Number of companies Loss Contingency, Number of Companies Loss Contingency, Number of Companies Number of generic products Loss Contingency, Number of Generic Products Loss Contingency, Number of Generic Products Number of demands Loss Contingency, Number of Demands Loss Contingency, Number of Demands Number of patents Number of Patents Number of Patents Number of demands resumed Number of Demands Resumed Number of Demands Resumed Number of demands remaining Number of Demands Remaining Number of Demands Remaining Number of lawsuits Loss Contingency, Number of Lawsuits Number of lawsuits in a particular litigation or loss contingency. Number of plaintiffs Loss Contingency, Number of Plaintiffs Damages awarded, value Loss Contingency, Damages Awarded, Value Number of Individuals Number of Individuals Number of Individuals New claims filed Loss Contingency, New Claims Filed, Number Amount awarded to other party Litigation Settlement, Amount Awarded to Other Party Estimated possible loss Loss Contingency, Amount of Claim Loss Contingency, Amount of Claim Gain Contingency, Unrecorded Amount Gain Contingency, Unrecorded Amount New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Proceeds from sales Proceeds from Sale of Available-for-sale Securities, Equity Realized gross gains on sales Available-for-sale Securities, Gross Realized Gains Realized gross losses on sales Available-for-sale Securities, Gross Realized Losses Adoption of ASU [Abstract] Adoption of ASU [Abstract] Adoption of ASU [Abstract] Proceeds from sales Proceeds from Sale of Equity and Available for Sale Securities Proceeds from Sale of Equity and Available for Sale Securities Realized gross gains on sales Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Realized gross losses on sales Available for sale Securities and Equity Securities, FV-NI, Realized Loss Available for sale Securities and Equity Securities, FV-NI, Realized Loss Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Boehringer Ingelheim Vetmedica, Inc.'s U.S. Vaccine Portfolio Boehringer Ingelheim Vetmedica, Inc.'s U.S. Vaccine Portfolio [Member] Boehringer Ingelheim Vetmedica, Inc.'s U.S. Feline, Canine, and Rabies Vaccine Portfolio Business Acquisition [Line Items] Business Acquisition [Line Items] Schedule of the amounts recognized for assets acquired and liabilities assumed as of the acquisition date Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of asset acquisition Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block] Net income Other comprehensive income, net of tax (Note 10) Other Comprehensive Income (Loss), Net of Tax Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Basis of Presentation and Revenue Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Unrealized gross gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Unrealized gross losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Fair value of securities in an unrealized gain position Debt Securities, Available-for-sale, Unrealized Gain Position Debt Securities, Available-for-sale, Unrealized Gain Position Fair value of securities in an unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position Asset Impairment, Restructuring, and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Number of operating segments Number of Operating Segments Divestiture and Acquisitions Mergers, Acquisitions and Dispositions Disclosures [Text Block] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Animal health products Animal Health [Member] Revenue to unaffiliated customers, Animal health Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Severance Severance Costs Total asset impairment and other special charges Asset Impairment Charges Asset impairment and other special charges Diabetes Collaboration Diabetes Collaboration [Member] Diabetes Collaboration [Member] Bi Compounds Bi Compounds [Member] describes BI's compounds contributed to the diabetes collaboration -- linagliptin and BI10773. Schedule of revenue recognized Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block] Schedule of exclusive marketing rights in certain other territories. Schedule of Marketing Rights [Table Text Block] Schedule of Marketing Rights [Table Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Nonoperating Income (Expense) [Abstract] Schedule of other–net, (income) expense Schedule of Other Nonoperating Income (Expense) [Table Text Block] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Elanco Animal Health Incorporated Elanco Animal Health Incorporated [Member] Elanco Animal Health Incorporated [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] IPO IPO [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Spin-off Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Spinoff [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Number of shares sold (shares) Sale of Stock, Number of Shares Issued in Transaction Price per share sold (usd per share) Sale of Stock, Price Per Share Percentage of ownership sold (percentage) Sale Of Stock, Percentage Of Stock Sold Sale Of Stock, Percentage Of Stock Sold Cash Transfered From Subsidiary to Parent Cash Transfered From Subsidiary to Parent Cash Transfered From Subsidiary to Parent Sale of Elanco stock (Note 3) Impact on Equity of Sale of Noncontrolling Interest in Subsidiary Impact on Equity of Sale of Noncontrolling Interest in Subsidiary Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Document & Entity Information [Abstract] Document & Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Statement [Table] Statement [Table] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Retained Earnings Retained Earnings [Member] Employee Benefit Trust Trust for Benefit of Employees [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Common Stock in Treasury Treasury Stock [Member] Noncontrolling Interest Noncontrolling Interest [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning Balance, shares Shares, Issued Beginning balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other comprehensive income, net of tax Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Cash dividends declared Dividends Retirement of treasury shares, shares Treasury Stock, Shares, Retired Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount Purchase of treasury shares, shares Treasury Stock, Shares, Acquired Purchase of treasury shares Treasury Stock, Value, Acquired, Cost Method Issuance of stock under employee stock plans, net, shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of stock under employee stock plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Stock-based compensation Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Adoption of new accounting standards (Note 2) Cumulative Effect of New Accounting Principle in Period of Adoption Other Stockholders' Equity, Other Ending balance Ending Balance, shares Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Notes Senior Notes [Member] Secured Debt Secured Debt [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Senior Notes Due August 27, 2021 Senior Notes Due August Twenty Seven, Twenty Twenty One [Member] Senior Notes Due August Twenty Seven, Twenty Twenty One [Member] Senior Notes Due August 28, 2023 Senior Notes Due August Twenty Eight, Twenty Twenty Three [Member] Senior Notes Due August Twenty Eight, Twenty Twenty Three [Member] Senior Notes Due August 28, 2028 Senior Notes Due August Twenty Eight , Twenty Twenty Eight [Member] Senior Notes Due August Twenty Eight , Twenty Twenty Eight [Member] Line of Credit Line of Credit [Member] Term Facility Term Facility [Member] Term Facility [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Debt instrument, face amount Debt Instrument, Face Amount Stated interest rate (percentage) Debt Instrument, Interest Rate, Stated Percentage Debt instrument, term Debt Instrument, Term Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Line of credit, outstanding balance Long-term Line of Credit Proceeds from issuance of notes Proceeds from Issuance of Debt Curtailment gain Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Pension contributions Payment for Pension Benefits Payment for additional discretionary funding Payment for Pension Benefits, Additional Discretionary Funding Payment for Pension Benefits, Additional Discretionary Funding Estimated future employer contributions in current fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Effective Portion of Cash Flow Hedges AOCI Attributable to Parent AOCI Attributable to Noncontrolling Interest AOCI Attributable to Noncontrolling Interest [Member] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Reclassification due to adoption of new accounting standard Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Net amount reclassified from accumulated other comprehensive loss Net other comprehensive income (loss) Other - Net, (Income) Expense Other Income and Other Expense Disclosure [Text Block] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Tax Period [Axis] Tax Period [Axis] Tax Period [Domain] Tax Period [Domain] Tax Year 2013 Tax Year 2013 [Member] Tax Year 2014 Tax Year 2014 [Member] Tax Year 2015 Tax Year 2015 [Member] ARMO and AurKa ARMO and AurKa [Member] ARMO and AurKa [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Effective income tax rate, percentage Effective Income Tax Rate Reconciliation, Percent Acquired in-process research and development Tax year under examination Income Tax Examination, Year under Examination Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product Product [Member] Collaboration and Other Revenue Collaboration and Other Revenue [Member] Collaboration and Other Revenue [Member] Royalty Royalty [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Payment term, minimum (in days) Revenue from Contract, Payment Term, Minimum Revenue from Contract, Payment Term Payment term, maximum (in days) Revenue from Contract, Payment Term, Maximum Revenue from Contract, Payment Term, Maximum Contract liabilities Contract with Customer, Liability Receivables, Net, Current [Abstract] Allowances for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Property and equipment, accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Financial Instruments Fair Value Disclosures [Text Block] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Defined Benefit Pension Plans Pension Plan [Member] Retiree Health Benefit Plans Other Postretirement Benefits Plan [Member] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Schedule of net pension and retiree health benefit (income) cost Schedule of Net Benefit Costs [Table Text Block] Implementation of New Financial Accounting Pronouncements New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Schedule of segment reporting information, by segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of revenue from external customers and long-lived assets, by geographical areas Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Equity Securities Equity Securities [Member] Foreign Currency Denominated Debt Foreign Currency Denominated Debt [Member] Foreign Currency Denominated Debt [Member] Buy Us Dollar Sell Euro Buy Us Dollar Sell Euro [Member] Foreign Currency Forward commitment to Buy US dollar Sell euro Buy Euro Sell Us Dollar Buy Euro Sell Us Dollar [Member] Foreign Currency Forward Commitment to Buy euro Sell US dollar Buy US dollar Sell Japanese Yen Buy US dollar Sell Japanese Yen [Member] Buy US dollar Sell Japanese Yen [Member] Buy GBP Sell USD Buy Swiss francs Sell US dollar [Member] Buy Swiss francs Sell US dollar [Member] Buy US dollar Sell British pound Buy US dollar Sell British pound [Member] Buy US dollar Sell British pound [Member] Buy British Pound and Sell US Dollars Buy British Pound and Sell US Dollars [Member] Buy British Pound and Sell US Dollars [Member] Derivative liability, notional amount Derivative Liability, Notional Amount Derivative asset, notional amount Derivative Asset, Notional Amount Maximum remaining maturity of foreign currency derivatives Maximum Remaining Maturity of Foreign Currency Derivatives Long-term debt, including current portion Long-term Debt Description of derivative activity volume (percentage) Description of Derivative Activity Volume Percent Label: Description of Derivative Activity Volume Element ID: us-gaap_DescriptionOfDerivativeActivityVolume Balance Type: na Data Type: PERCENT Period Type: duration --------------------------------------------------------------------- Definition: Information that would enable users to understand the volume of the entity's derivative activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 44 -Subparagraph 2 Interest rate cash flow hedge gain (loss) to be reclassified during next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Cash payment Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Unrealized gain (loss), net Unrealized Gain (Loss) on Securities OTTI recognized Other than Temporary Impairment Losses, Investments Available-for-sale, percentage of nonperforming assets (percentage) Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets Amount of receivable derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Schedule of revenue recognized in our consolidated condensed statements of operations Disaggregation of Revenue [Table Text Block] Schedule of amounts recorded for contract liabilities Contract with Customer, Asset and Liability [Table Text Block] Debt Securities Contractual Maturities Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract] Total Debt Securities, Available-for-sale Less Than 1 Year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value 1-5 Years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value 6-10 Years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value More Than 10 Years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value Interest expense Interest Expense Interest income Investment Income, Interest Retirement benefit Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Other income Other Nonoperating Income (Expense) Other–net, (income) expense Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Stock-based compensation expense Share-based Compensation Other changes in operating assets and liabilities, net of acquisitions Increase (Decrease) in Other Operating Assets and Liabilities, Net Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Net purchases of property and equipment Payments for (Proceeds from) Productive Assets Proceeds from sales and maturities of short-term investments Proceeds from Sale of Short-term Investments Purchases of short-term investments Payments to Acquire Short-term Investments Proceeds from sales of noncurrent investments Proceeds from Sale of Long-term Investments Purchases of noncurrent investments Payments to Acquire Long-term Investments Cash paid for acquisitions, net of cash acquired (Note 3) Payments to Acquire Businesses, Net of Cash Acquired Purchase of in-process research and development (Note 3) Purchased in-process research and development The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS). Other investing activities, net Payments for (Proceeds from) Other Investing Activities Net Cash Provided by (Used for) Investing Activities Net Cash Provided by (Used in) Investing Activities Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Dividends paid Payments of Dividends Net change in short-term borrowings Proceeds from (Repayments of) Short-term Debt Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Repayments of long-term debt Repayments of Long-term Debt Purchases of common stock Payments for Repurchase of Common Stock Net proceeds from Elanco initial public offering (Note 3) Proceeds from Issuance or Sale of Equity from Subsidiary Proceeds from Issuance or Sale of Equity from Subsidiary Other financing activities, net Proceeds from (Payments for) Other Financing Activities Net Cash Provided by (Used for) Financing Activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at January 1 Cash and Cash Equivalents at September 30 Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Marketed products Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Other assets and liabilities - net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets and Liabilities, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets and Liabilities, Net Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Goodwill Goodwill Total consideration transferred - net of cash acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Other comprehensive income attributable to controlling interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive income (loss) attributable to noncontrolling interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest U.S. government and agency securities US Government Agencies Debt Securities [Member] Corporate debt securities Corporate Debt Securities [Member] Mortgage-backed securities Collateralized Mortgage Backed Securities [Member] Asset-backed securities Asset-backed Securities [Member] Other securities Other Equity Securities [Member] Other Equity Securities [Member] Marketable equity securities Marketable Securities [Member] Marketable Securities [Member] Marketable equity securities Other securities Other Debt Obligations [Member] Cost and equity method investments Equity Method And Other Investments [Member] Equity Method and Other Investments [Member] Cost Portion at Other than Fair Value Measurement [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Short-term investments, debt securities Debt Securities, Available-for-sale, Current Noncurrent investments, debt securities Debt Securities, Available-for-sale, Noncurrent Equity securities Equity Securities, FV-NI Equity Securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Cost and equity method investments Other Long-term Investments Marketable equity securities Available-for-sale Securities, Equity Securities, Noncurrent Noncurrent investments Long-term Investments Short-term commercial paper borrowings Commercial Paper Long-term debt, including current portion Schedule of effects of risk-management instruments were recognized in other–net, (income) expense Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Summary certain fair value information Fair Value, Assets Measured on Recurring Basis [Table Text Block] Summary certain fair value information, liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Fair value, by balance sheet grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Summary the contractual maturities of our investments in debt securities measured at fair value Debt Securities, Available-for-sale [Table Text Block] Summary of the amount of unrealized gains and losses (pretax) recognized in our statement of operations for equity securities Unrealized Gain (Loss) on Investments [Table Text Block] Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities Gain (Loss) on Securities [Table Text Block] Retirement Benefits [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Service cost Defined Benefit Plan, Service Cost Interest cost Defined Benefit Plan, Interest Cost Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Recognized actuarial loss Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit Curtailment (gain) loss Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Forecast Scenario, Forecast [Member] Sigilon Therapeutics (Sigilon) Sigilon Therapeutics [Member] Sigilon Therapeutics [Member] AurKa Pharma, Inc. (AurKa) Aurka Pharma [Member] Aurka Pharma [Member] ARMO Biosciences, Inc. (ARMO) ARMO Biosciences, Inc. [Member] ARMO Biosciences, Inc. [Member] Anima Biotech (Anima) Anima Biotech [Member] Anima Biotech [Member] CoLucid Pharmaceuticals, Inc. (CoLucid) CoLucid Pharmaceuticals [Member] CoLucid Pharmaceuticals [Member] KeyBioscience AG (KeyBioscience) KeyBioscience's Dual Amylin Calcitonin Receptor Agonists [Member] KeyBioscience's Dual Amylin Calcitonin Receptor Agonists [Member] Nektar Therapeutics (Nektar) Nektar's Phase I Immunological Therapy [Member] Nektar's Phase I Immunological Therapy [Member] Chugai Pharmaceutical Company Chugai Pharmaceutical Company [Member] Chugai Pharmaceutical Company [Member] Dicerna Pharmaceuticals Dicerna Pharmaceuticals [Member] Dicerna Pharmaceuticals [Member] Priority Review Voucher Priority Review [Member] Priority Review [Member] NextCure, Inc. NextCure, Inc. [Member] NextCure, Inc. [Member] All cash transaction Business Combination, Consideration Transferred Useful life (years) Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Purchase of in-process research and development Value of liabilities assumed Noncash or Part Noncash Acquisition, Value of Liabilities Assumed Statement of Financial Position [Abstract] Assets Assets [Abstract] Current Assets Assets, Current [Abstract] Cash and cash equivalents (Note 6) Short-term investments (Note 6) Short-term Investments Accounts receivable, net of allowances of $34.0 (2018) and $38.7 (2017) Accounts Receivable, Net, Current Other receivables Other Receivables, Net, Current Inventories Inventory, Net Prepaid expenses and other Prepaid Expense, Current Total current assets Assets, Current Other Assets Assets, Noncurrent [Abstract] Investments (Note 6) Other intangibles Intangible Assets, Net (Excluding Goodwill) Deferred tax assets Sundry Other Assets, Noncurrent Total other assets Assets, Noncurrent Property and equipment, net of accumulated depreciation of $9,671.7 (2018) and $9,264.6 (2017) Property, Plant and Equipment, Net Total assets Assets Liabilities and Equity Liabilities and Equity [Abstract] Current Liabilities Liabilities, Current [Abstract] Short-term borrowings and current maturities of long-term debt Debt, Current Accounts payable Accounts Payable, Current Employee compensation Employee-related Liabilities, Current Sales rebates and discounts Sales rebates and discounts Sales rebates and discounts Dividends payable Dividends Payable, Current Income taxes payable Taxes Payable, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Other Liabilities Liabilities, Noncurrent [Abstract] Long-term debt Long-term Debt, Excluding Current Maturities Accrued retirement benefits (Note 8) Liability, Defined Benefit Plan, Noncurrent Long-term income taxes payable Accrued Income Taxes, Noncurrent Other noncurrent liabilities Other Liabilities, Noncurrent Total other liabilities Liabilities, Noncurrent Eli Lilly and Company Shareholders’ Equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Common stock Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Employee benefit trust Common Stock, Shares Held in Employee Trust Accumulated other comprehensive loss (Note 10) Cost of common stock in treasury Treasury Stock, Value Total Eli Lilly and Company shareholders’ equity Stockholders' Equity Attributable to Parent Noncontrolling interests (Note 3) Total equity Total liabilities and equity Liabilities and Equity Contingencies Commitments and Contingencies Disclosure [Text Block] EX-101.PRE 10 lly-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Nov. 02, 2018
Document & Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Entity Registrant Name Lilly Eli & Co  
Entity Central Index Key 0000059478  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Large Accelerated Filer  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Common Stock, Shares Outstanding   1,059,322,255
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Condensed Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
Revenue $ 6,061.9 $ 5,658.0 $ 18,117.1 $ 16,710.6
Costs, expenses, and other:        
Cost of sales 1,562.3 1,586.3 4,836.3 4,505.9
Research and development 1,343.3 1,340.0 3,853.3 3,870.4
Marketing, selling, and administrative 1,616.6 1,578.5 4,770.3 4,876.6
Acquired in-process research and development (Note 3) 30.0 205.0 1,654.5 1,062.6
Asset impairment, restructuring, and other special charges (Note 5) 83.3 406.5 236.0 670.4
Other–net, (income) expense (Note 11) 15.4 (49.9) (90.1) (188.6)
Cost of sales, operating expenses, and other-net 4,650.9 5,066.4 15,260.3 14,797.3
Income before income taxes 1,411.0 591.6 2,856.8 1,913.3
Income taxes (Note 7) 261.5 36.0 749.8 460.5
Net income $ 1,149.5 $ 555.6 $ 2,107.0 $ 1,452.8
Earnings per share:        
Basic (usd per share) $ 1.13 $ 0.53 $ 2.04 $ 1.38
Diluted (usd per share) $ 1.12 $ 0.53 $ 2.03 $ 1.37
Shares used in calculation of earnings per share:        
Basic (shares) 1,020.4 1,053.4 1,033.2 1,054.8
Diluted (shares) 1,026.3 1,056.0 1,037.8 1,057.0
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Condensed Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Statement of Comprehensive Income [Abstract]        
Net income $ 1,149.5 $ 555.6 $ 2,107.0 $ 1,452.8
Other comprehensive income, net of tax (Note 10) [1] 660.2 167.7 375.3 651.2
Comprehensive income $ 1,809.7 $ 723.3 $ 2,482.3 $ 2,104.0
[1] Other comprehensive income for the three and nine months ended September 30, 2018 was all attributable to controlling interest. Other comprehensive income for the three and nine months ended September 30, 2017 consisted of $165.5 million and $664.6 million, respectively, of other comprehensive income attributable to controlling interest and $2.2 million and $(13.4) million of other comprehensive income (loss) attributable to noncontrolling interest during the same periods.
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Condensed Statements of Comprehensive Income (Loss) (Unaudited) (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2017
Statement of Comprehensive Income [Abstract]    
Other comprehensive income attributable to controlling interest $ 165.5 $ 664.6
Other comprehensive income (loss) attributable to noncontrolling interest $ 2.2 $ (13.4)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Condensed Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents (Note 6) $ 8,960.0 $ 6,536.2
Short-term investments (Note 6) 76.1 1,497.9
Accounts receivable, net of allowances of $34.0 (2018) and $38.7 (2017) 4,859.4 4,546.3
Other receivables 793.2 715.9
Inventories 4,118.0 4,458.3
Prepaid expenses and other 1,879.2 1,447.5
Total current assets 20,685.9 19,202.1
Other Assets    
Investments (Note 6) 2,005.8 5,678.8
Goodwill 4,358.4 4,370.1
Other intangibles 3,619.4 4,029.2
Deferred tax assets 3,132.3 1,166.4
Sundry 2,009.2 1,707.9
Total other assets 15,125.1 16,952.4
Property and equipment, net of accumulated depreciation of $9,671.7 (2018) and $9,264.6 (2017) 8,814.1 8,826.5
Total assets 44,625.1 44,981.0
Current Liabilities    
Short-term borrowings and current maturities of long-term debt 1,002.2 3,706.6
Accounts payable 1,281.2 1,410.7
Employee compensation 858.5 997.9
Sales rebates and discounts 5,129.4 4,465.1
Dividends payable 0.0 590.6
Income taxes payable 409.2 532.9
Other current liabilities 2,146.2 2,832.1
Total current liabilities 10,826.7 14,535.9
Other Liabilities    
Long-term debt 11,674.7 9,940.5
Accrued retirement benefits (Note 8) 2,684.5 3,513.9
Long-term income taxes payable 3,740.5 3,776.5
Other noncurrent liabilities 1,547.8 1,546.3
Total other liabilities 19,647.5 18,777.2
Eli Lilly and Company Shareholders’ Equity    
Common stock 667.1 687.9
Additional paid-in capital 6,522.9 5,817.8
Retained earnings 14,408.7 13,894.1
Employee benefit trust (3,013.2) (3,013.2)
Accumulated other comprehensive loss (Note 10) (5,439.5) (5,718.6)
Cost of common stock in treasury (69.4) (75.8)
Total Eli Lilly and Company shareholders’ equity 13,076.6 11,592.2
Noncontrolling interests (Note 3) 1,074.3 75.7
Total equity 14,150.9 11,667.9
Total liabilities and equity $ 44,625.1 $ 44,981.0
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Millions
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Employee Benefit Trust
Accumulated Other Comprehensive Loss
Common Stock in Treasury
Noncontrolling Interest
Beginning Balance, shares at Dec. 31, 2016   1,101,586         711  
Beginning balance at Dec. 31, 2016   $ 688.5 $ 5,640.6 $ 16,046.3 $ (3,013.2) $ (5,274.0) $ (80.5) $ 72.8
Increase (Decrease) in Shareholders' Equity [Roll Forward]                
Net income (loss)       1,452.8       14.3
Other comprehensive income, net of tax           664.6   (13.4)
Cash dividends declared       (1,095.7)        
Retirement of treasury shares, shares   (3,191)         (3,191)  
Retirement of treasury shares   $ (2.0)   (257.9)     $ 259.9  
Purchase of treasury shares, shares             3,191  
Purchase of treasury shares     60.0       $ (259.9)  
Issuance of stock under employee stock plans, net, shares   3,277         (47)  
Issuance of stock under employee stock plans, net   $ (2.0) 155.0       $ (4.7)  
Stock-based compensation     209.1          
Other               (3.4)
Ending balance at Sep. 30, 2017   $ 688.5 5,754.7 16,145.5 (3,013.2) (4,609.4) $ (75.8) 70.3
Ending Balance, shares at Sep. 30, 2017   1,101,672         664  
Beginning Balance, shares at Jun. 30, 2017   1,101,646         664  
Beginning balance at Jun. 30, 2017   $ 688.5 5,686.1 15,590.1 (3,013.2) (4,774.9) $ (75.8) 68.9
Increase (Decrease) in Shareholders' Equity [Roll Forward]                
Net income (loss)       555.6       0.3
Other comprehensive income, net of tax           165.5   2.2
Issuance of stock under employee stock plans, net, shares   26            
Issuance of stock under employee stock plans, net     1.2          
Stock-based compensation     69.8          
Other       (0.2)       (1.1)
Ending balance at Sep. 30, 2017   $ 688.5 5,754.7 16,145.5 (3,013.2) (4,609.4) $ (75.8) 70.3
Ending Balance, shares at Sep. 30, 2017   1,101,672         664  
Increase (Decrease) in Shareholders' Equity [Roll Forward]                
Adoption of new accounting standards (Note 2)           (104.8)    
Beginning Balance, shares at Dec. 31, 2017   1,100,672         664  
Beginning balance at Dec. 31, 2017 $ 11,667.9 $ 687.9 5,817.8 13,894.1 (3,013.2) (5,718.6) $ (75.8) 75.7
Increase (Decrease) in Shareholders' Equity [Roll Forward]                
Net income (loss)       2,107.0       (0.6)
Other comprehensive income, net of tax           375.3    
Cash dividends declared       (1,148.6)        
Retirement of treasury shares, shares   (36,014)         (36,014)  
Retirement of treasury shares   $ (22.5)   (3,028.2)     $ 3,050.7  
Purchase of treasury shares, shares [1]             36,014  
Purchase of treasury shares [1]             $ (3,050.7)  
Issuance of stock under employee stock plans, net, shares   2,716         (60)  
Issuance of stock under employee stock plans, net   $ (1.7) 130.8       $ (6.4)  
Stock-based compensation     206.7          
Sale of Elanco stock (Note 3)     629.2     9.0   1,017.2
Other               (18.0)
Ending balance at Sep. 30, 2018 14,150.9 $ 667.1 6,522.9 14,408.7 (3,013.2) (5,439.5) $ (69.4) 1,074.3
Ending Balance, shares at Sep. 30, 2018   1,067,374         604  
Beginning Balance, shares at Jun. 30, 2018   1,077,548         604  
Beginning balance at Jun. 30, 2018   $ 673.5 5,825.7 14,247.3 (3,013.2) (6,108.7) $ (69.4) 65.6
Increase (Decrease) in Shareholders' Equity [Roll Forward]                
Net income (loss)       1,149.5       (5.2)
Other comprehensive income, net of tax           660.2    
Retirement of treasury shares, shares   (10,191)         (10,191)  
Retirement of treasury shares   $ (6.4)   (993.7)     $ 1,000.0  
Purchase of treasury shares, shares [1]             10,191  
Purchase of treasury shares [1]             $ (1,000.0)  
Issuance of stock under employee stock plans, net, shares   17            
Issuance of stock under employee stock plans, net     0.5          
Stock-based compensation     68.5          
Sale of Elanco stock (Note 3)     629.2     9.0   1,017.2
Other       5.6       (3.3)
Ending balance at Sep. 30, 2018 $ 14,150.9 $ 667.1 $ 6,522.9 14,408.7 $ (3,013.2) (5,439.5) $ (69.4) 1,074.3
Ending Balance, shares at Sep. 30, 2018   1,067,374         604  
Increase (Decrease) in Shareholders' Equity [Roll Forward]                
Adoption of new accounting standards (Note 2)       $ 2,584.4   $ (105.2)  
[1] As of September 30, 2018, there was $7.00 billion remaining under our $8.00 billion share repurchase program authorized in June 2018.
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Condensed Statements of Shareholders' Equity (Unaudited) (Parenthetical) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Jun. 30, 2018
Statement of Stockholders' Equity [Abstract]      
Dividend declared (usd per share) $ 1.13 $ 1.04  
Remaining authorized repurchase amount $ 7,000    
Stock repurchase program, authorized amount     $ 8,000
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Condensed Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Receivables, Net, Current [Abstract]    
Allowances for doubtful accounts $ 34.0 $ 38.7
Property and equipment, accumulated depreciation $ 9,671.7 $ 9,264.6
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Condensed Statements of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash Flows from Operating Activities    
Net income $ 2,107.0 $ 1,452.8
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:    
Depreciation and amortization 1,263.5 1,155.4
Change in deferred income taxes 161.6 151.7
Stock-based compensation expense 206.7 209.1
Acquired in-process research and development 1,654.5 1,062.6
Other changes in operating assets and liabilities, net of acquisitions (1,638.2) (525.2)
Other non-cash operating activities, net 320.7 365.7
Net Cash Provided by Operating Activities 4,075.8 3,872.1
Cash Flows from Investing Activities    
Net purchases of property and equipment (816.3) (633.3)
Proceeds from sales and maturities of short-term investments 2,535.5 2,320.2
Purchases of short-term investments (112.2) (2,973.8)
Proceeds from sales of noncurrent investments 3,444.7 1,686.9
Purchases of noncurrent investments (719.7) (3,739.6)
Cash paid for acquisitions, net of cash acquired (Note 3) 0.0 (882.1)
Purchase of in-process research and development (Note 3) (1,578.2) (1,036.8)
Other investing activities, net (188.8) (178.0)
Net Cash Provided by (Used for) Investing Activities 2,565.0 (5,436.5)
Cash Flows from Financing Activities    
Dividends paid (1,739.2) (1,643.8)
Net change in short-term borrowings (2,297.1) 1,226.8
Proceeds from issuance of long-term debt 2,477.7 2,232.0
Repayments of long-term debt (1,001.5) (630.6)
Purchases of common stock (3,050.7) (199.9)
Net proceeds from Elanco initial public offering (Note 3) 1,659.7 0.0
Other financing activities, net (314.1) (299.6)
Net Cash Provided by (Used for) Financing Activities (4,265.2) 684.9
Effect of exchange rate changes on cash and cash equivalents 48.2 21.7
Net increase (decrease) in cash and cash equivalents 2,423.8 (857.8)
Cash and cash equivalents at January 1 6,536.2 4,582.1
Cash and Cash Equivalents at September 30 $ 8,960.0 $ 3,724.3
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Revenue
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Revenue
Basis of Presentation and Revenue
We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2017. We issue our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing.
All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of incremental shares from our stock-based compensation programs.
Adoption of Revenue Accounting Standard
Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers and other related updates (see Note 2 for additional discussion). The new standard has been applied to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don’t believe the effect of applying this practical expedient resulted in material differences. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for the three and nine months ended September 30, 2018 do not differ materially from amounts that would have resulted from application of the previous standards.
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Net product revenue
$
5,664.5

 
$
5,323.8

 
$
16,905.6

 
$
15,841.5

Collaboration and other revenue (1)
397.4

 
334.2

 
1,211.5

 
869.1

Revenue
$
6,061.9

 
$
5,658.0

 
$
18,117.1

 
$
16,710.6


(1) Collaboration and other revenue associated with prior year transfers of intellectual property was $76.2 million and $258.4 million during the three and nine months ended September 30, 2018, respectively, and $36.7 million and $105.5 million during the three and nine months ended September 30, 2017, respectively.
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta™ and Jardiance® families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Net Product Revenue
Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 75 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates and discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.
Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates and discounts and returns. The following describe the most significant of these judgments:
Sales Rebates and Discounts - Background and Uncertainties
•
Most of our pharmaceutical products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. Most of our animal health products are sold to wholesale distributors. We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.
•
The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.
•
The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback contracts in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.
•
Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.
Sales Returns - Background and Uncertainties
•
When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuances, or a changing competitive environment. We maintain a returns policy that allows U.S. pharmaceutical customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.
•
As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products sold to major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.
•
Actual product returns have been less than 2 percent of our net revenue over each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market.
Adjustments to Revenue
Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended September 30, 2018, for product shipped in previous years were not material.
Disaggregation of Revenue
Our disaggregated revenue is disclosed in Note 12.
Collaborations and Other Arrangements
We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers.
•
Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.
•
Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date.
•
Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.
•
Royalty revenue from licensees, which is based on sales to third parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.
•
For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.
•
Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval.
•
We have entered into arrangements whereby we transferred rights to products and committed to supply for a period of time. For those arrangements for which we concluded that the obligations were not distinct, any amounts received upfront are being amortized to revenue as net product revenue over the period of the supply arrangement as the performance obligation is satisfied.
Contract Liabilities
Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales rebates, discounts, and returns. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.
We have the following amounts recorded for contract liabilities:
 
September 30, 2018
 
December 31, 2017
Contract liabilities
$
308.6

 
$
335.2


The contract liabilities amount disclosed above as of September 30, 2018, is primarily related to:
•
The remaining license period of symbolic intellectual property, and
•
Obligations to supply product for a defined period of time.
Revenue recognized from contract liabilities as of January 1, 2018, during the three and nine months ended September 30, 2018, was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Implementation of New Financial Accounting Pronouncements
 9 Months Ended
Sep. 30, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
Implementation of New Financial Accounting Pronouncements
Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:
Standard
 
Description
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers
 
This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.
 
Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 12.
Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities
 
This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.
 
Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.
Standard
 
Description
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory
 
This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified
retrospective approach to adoption.
 
Upon adoption, the cumulative effect of applying the standard resulted in an increase to deferred tax assets and retained earnings of approximately $2.5 billion. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.
Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost
 
This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component.
 
Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. The application of the new standard resulted in reclassification to other income of $63.8 million for the three months ended September 30, 2017, while increasing cost of sales by $20.2 million, marketing, selling, and administrative expenses by $23.0 million, and research and development expenses by $20.6 million for the same period. The application of the new standard resulted in reclassification to other income of $191.3 million for the nine months ended September 30, 2017, while increasing cost of sales by $60.5 million, marketing, selling, and administrative expenses by $69.0 million, and research and development expenses by $61.8 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.


The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on our financial statements:
Standard
 
Description
 
Effective Date
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases
 
This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.
 
This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt on that date.
 
We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Divestures and Acquisitions
 9 Months Ended
Sep. 30, 2018
Business Combinations [Abstract]  
Divestiture and Acquisitions
Divestiture and Acquisitions
Divestiture
Formation of Elanco and Initial Public Offering
On September 24, 2018, Elanco Animal Health Incorporated (Elanco) completed an initial public offering (the IPO) resulting in the issuance of 72.3 million shares of its common stock, which represents 19.8 percent of Elanco's outstanding shares, at $24 per share. Elanco shares began trading on the New York Stock Exchange under the symbol "ELAN" in September 2018.
In connection with the completion of the IPO, through a series of equity and other transactions, we transferred to Elanco the animal health businesses that form its business going forward. In exchange, Elanco transferred to us, or will transfer to us, consideration of approximately $4.2 billion, which consists primarily of the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco in August 2018, and the term loan facility entered into by Elanco during the period (see Note 6). The consideration that we receive is intended to be used for debt repayment, dividends, and/or share repurchases. The excess of the net proceeds from the IPO over the net book value of our divested interest was $629.2 million and was recorded in additional paid-in capital. Of our consolidated cash and cash equivalents as of September 30, 2018, approximately $300 million is retained by Elanco for working capital purposes.
We continue to consolidate Elanco, as we retain control over Elanco. The earnings attributable to the divested, noncontrolling interest for the period from IPO until September 30, 2018 were not material for the three and nine months ended September 30, 2018. As of September 30, 2018, the noncontrolling interest of $1.02 billion associated with Elanco is reflected in noncontrolling interests in the consolidated condensed balance sheet.
Acquisitions
On January 3, 2017, we completed the acquisition of Boehringer Ingelheim Vetmedica, Inc.'s United States (U.S.) feline, canine, and rabies vaccine portfolio and other related assets (BIVIVP). This transaction, as further discussed in this note below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition have been included in our consolidated condensed financial statements from the date of acquisition.
In addition to the acquisition of BIVIVP, we acquired assets in development in the nine months ended September 30, 2018, which are further discussed in this note below in Asset Acquisitions. Upon acquisition, the acquired in-process research and development (IPR&D) charges related to these products were immediately expensed because the products had no alternative future use. We incurred acquired IPR&D charges of $30.0 million and $1.65 billion for the three and nine months ended September 30, 2018, respectively, and $205.0 million and $1.06 billion for the three and nine months ended September 30, 2017, respectively.
Acquisition of a Business
Boehringer Ingelheim Vetmedica, Inc. Vaccine Portfolio Acquisition
Overview of Transaction
In 2017, we acquired BIVIVP in an all-cash transaction for $882.1 million. Under the terms of the agreement, we acquired a manufacturing and research and development site and a U.S. vaccine portfolio, including vaccines used for the treatment of bordetella, Lyme disease, rabies, and parvovirus, among others.
Assets Acquired and Liabilities Assumed
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at January 3, 2017
Inventories
$
108.6

Marketed products (1)
297.0

Property and equipment
148.2

Other assets and liabilities - net
8.2

Total identifiable net assets
562.0

Goodwill (2)
320.1

Total consideration transferred - net of cash acquired
$
882.1


(1) These intangible assets, which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 10 years.
(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy animal health business, future unidentified projects and products, and the assembled workforce of BIVIVP. The goodwill associated with this acquisition is deductible for tax purposes.
Asset Acquisitions
The following table and narrative summarize our asset acquisitions during the nine months ended September 30, 2018 and September 30, 2017.
Counterparty
Compound(s) or Therapy
Acquisition Month
 
Phase of Development (1)
 
Acquired IPR&D Expense
Sigilon Therapeutics (Sigilon)
Encapsulated cell therapies for the potential treatment of type 1 diabetes
April 2018
 
Pre-clinical
 
$
66.9

AurKa Pharma, Inc. (AurKa)
AK-01, an Aurora kinase A inhibitor
June 2018
 
Phase I
 
81.8

ARMO Biosciences, Inc. (ARMO)
Cancer therapy - pegilodecakin
June 2018
 
Phase III
 
1,475.8

Anima Biotech (Anima)
Translation inhibitors for selected neuroscience targets
July 2018
 
Pre-clinical
 
30.0

 
 
 
 
 
 
 
CoLucid Pharmaceuticals, Inc. (CoLucid)
Oral therapy for the acute treatment of migraine - lasmiditan
March 2017
 
Phase III
 
857.6

KeyBioscience AG (KeyBioscience)
Multiple molecules for treatment of metabolic disorders
July 2017
 
Phase II
 
55.0

Nektar Therapeutics (Nektar)
Immunological therapy - NKTR-358
August 2017
 
Phase I
 
150.0


(1) The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.
In connection with the arrangements described herein, our partners may be entitled to future royalties and/or commercial milestones based on sales should these products be approved for commercialization and/or milestones based on the successful progress of the compounds through the development process.
We entered into a collaboration agreement with Sigilon to develop encapsulated cell therapies for the potential treatment of type 1 diabetes. Sigilon will create proprietary products comprised of induced pluripotent stem cells engineered into differentiated insulin-producing pancreatic beta cells and encapsulated using Sigilon's Afibromer technology. We will receive an exclusive worldwide license to Sigilon's Afibromer technology for islet cell encapsulation. Under the terms of the agreement, we paid an upfront fee of $62.5 million and made an equity investment in Sigilon.
We acquired AK-01 through the acquisition of AurKa. Under the terms of the agreement, we acquired all shares of AurKa for a cash purchase price of $81.3 million, net of cash acquired, plus net accrued liabilities assumed of $0.5 million. Substantially all the value of AurKa was related to AK-01, its only significant asset. The acquired IPR&D expense was not tax deductible.
We acquired pegilodecakin through the acquisition of ARMO. Under the terms of the agreement, we acquired all shares of ARMO for a cash purchase price of $1.40 billion, net of cash acquired, plus net accrued liabilities assumed of $75.8 million. Substantially all of the value of ARMO was related to pegilodecakin, its only significant asset. The acquired IPR&D expense was not tax deductible.
We entered into a collaboration agreement with Anima for the discovery and development of translation inhibitors for several target proteins by using Anima's translation control therapeutics platform. Under the terms of the agreement, we paid an upfront fee of $30.0 million. Anima will use its technology platform to discover lead candidates that are translation inhibitors of our selected neuroscience targets. We will be responsible for all clinical development and commercialization activities and costs related to the collaboration.
We acquired lasmiditan through the acquisition of CoLucid. Under the terms of the agreement, we acquired all shares of CoLucid for a cash purchase price of $831.8 million, net of cash acquired, plus net accrued liabilities assumed of $25.8 million. Substantially all of the value of CoLucid was related to lasmiditan, its only significant asset. The acquired IPR&D expense was not tax deductible.
Our collaboration agreement with KeyBioscience provides us with access to KeyBioscience's Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of treatments for metabolic disorders such as type 2 diabetes, along with multiple molecules. Prior to entering into the agreement, KeyBioscience had initiated Phase II development of the lead molecule. The other assets included in the collaboration range from pre-clinical to Phase I development. Under the terms of the agreement, we receive worldwide rights to develop and commercialize these molecules.
Our collaboration with Nektar is to co-develop Nektar's compound which has the potential to treat a number of autoimmune and other chronic inflammatory conditions. Under the terms of the agreement, we are responsible for all costs of global commercialization. Nektar will have an option to co-promote in the U.S. under certain conditions.
In September 2018, we announced a license agreement with Chugai Pharmaceutical Company for OWL833, an oral non-peptidic GLP-1 receptor agonist. OWL833 is a preclinical asset that is being studied for the treatment of type 2 diabetes. Under the terms of the agreement, we will acquire worldwide development and commercialization rights to OWL833 for a cash purchase price of $50.0 million and success-based milestones and royalties. The transaction is expected to close in the fourth quarter of 2018, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. We expect an acquired IPR&D charge of $50.0 million in the fourth quarter of 2018.
In October 2018, we announced a global license and research agreement with Dicerna Pharmaceuticals (Dicerna) for the discovery, development, and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration, and pain. Under terms of the agreement, we will pay an upfront fee of $100.0 million and make an equity investment in Dicerna. The transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Upon closing, we will record an acquired IPR&D expense of approximately $135 million.
In October 2018, we acquired a Priority Review Voucher from SIGA Technologies, Inc. for a cash purchase price of $80.0 million. We intend to utilize the voucher to fast track a product application for an existing R&D project, although the specific project has not yet been determined. As a result of this transaction, we will record an acquired IPR&D expense of $80.0 million in the fourth quarter of 2018.
In November 2018, we entered into a collaboration agreement with NextCure, Inc. (NextCure) for the discovery and development of immuno-oncology cancer therapies. NextCure will apply its discovery platform technology to identify novel, functional immune-related targets and we will develop antibodies to these targets. The parties will be able to exclusively license antibodies resulting from the collaboration. Under terms of the agreement, we will pay an upfront fee of $25.0 million and make an equity investment in NextCure. As a result of this transaction, we will record an acquired IPR&D expense of approximately $30 million in the fourth quarter of 2018.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborations and Other Arrangements
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaborations and Other Arrangements
Collaborations and Other Arrangements
We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the collaboration partner. See Note 1 for amounts of collaboration and other revenue recognized from these types of arrangements.
Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.
Boehringer Ingelheim Diabetes Collaboration
We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim’s oral diabetes products: Trajenta, Jentadueto®, Jardiance, Glyxambi®, and Synjardy®, as well as our basal insulin: Basaglar®.
The table below summarizes significant regulatory and commercialization events and milestones (deferred) capitalized for the compounds included in this collaboration:
 
 
Year Launched
 
Milestones
(Deferred) Capitalized (1)
Product Family
 
U.S.
 
Europe
 
Japan
 
Year
Amount
Trajenta (2)
 
2011
 
2011
 
2011
 
Cumulative (4) - all prior to 2017
$
446.4

Jardiance (3)
 
2014
 
2014
 
2015
 
Cumulative (4) - all prior to 2017
299.5

Basaglar
 
2016
 
2015
 
2015
 
Cumulative (4) - all prior to 2017
(250.0
)

(1) In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration.
(2) Jentadueto is included in the Trajenta product family. The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
(3) Glyxambi and Synjardy are included in the Jardiance product family. The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
(4) The cumulative amount represents the total initial amounts that were (deferred) or capitalized from the start of this collaboration through the end of the reporting period.
In the most significant markets, we and Boehringer Ingelheim share equally the ongoing development costs, commercialization costs, and agreed upon gross margin for any product resulting from the collaboration. We record our portion of the gross margin associated with Boehringer Ingelheim's compounds as collaboration and other revenue. We record our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company is entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments result in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may be reduced by any performance payments we make related to these products. Similarly, performance payments we may receive related to Basaglar effectively reduce Boehringer Ingelheim's share of the gross margin, which reduces our cost of sales.
The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Basaglar
$
201.2

 
$
145.7

 
$
569.0

 
$
278.3

Jardiance
166.9

 
127.2

 
465.1

 
304.3

Trajenta
135.7

 
153.3

 
418.5

 
408.2


Erbitux® 
We have several collaborations with respect to Erbitux. The most significant collaborations are or, where applicable, were in Japan, and prior to the transfer of commercialization rights in the fourth quarter of 2015, the U.S. and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). Certain rights to Erbitux outside the U.S. and Canada (collectively, North America) will remain with Merck KGaA (Merck) upon expiration of that agreement.
The following table summarizes our revenue recognized with respect to Erbitux:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Net product revenue
$
133.7

 
$
137.6

 
$
397.0

 
$
403.3

Collaboration and other revenue
25.8

 
25.9

 
78.5

 
73.7

Revenue
$
159.5


$
163.5


$
475.5


$
477.0


Bristol-Myers Squibb Company
Pursuant to commercial agreements with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), we had been co-developing Erbitux in North America exclusively with BMS. On October 1, 2015, BMS transferred their commercialization rights to us with respect to Erbitux in North America pursuant to a modification of our existing arrangement, and we began selling Erbitux at that time. This modification did not affect our rights with respect to Erbitux in other jurisdictions. In connection with the modification of terms, we provided consideration to BMS based upon a tiered percentage of net sales of Erbitux in North America estimated to average 38 percent through September 2018. The transfer of the commercialization rights was accounted for as an acquisition of a business. The consideration to be paid to BMS was accounted for as contingent consideration liability. See Note 6 for discussion regarding the estimation of this liability.
Merck KGaA
A development and license agreement grants Merck exclusive rights to market Erbitux outside of North America until December 2018. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. This agreement was amended in 2015 to grant Merck exclusive commercialization rights in Japan but did not result in any changes to our rights.
Merck manufactures Erbitux for supply in its territory as well as for Japan. We receive a royalty on the sales of Erbitux outside of North America, which is included in collaboration and other revenue as the underlying sales occur. Royalties due to third parties are recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties.
Olumiant® 
We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte) which provides us the development and commercialization rights to its Janus tyrosine kinase inhibitor compound, now known as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. Incyte exercised its option to co-develop Olumiant in rheumatoid arthritis in 2010 and psoriatic arthritis, atopic dermatitis, alopecia areata, and systemic lupus erythematosus (SLE) in 2017. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones.
The following table summarizes our milestones achieved:
Year
Event
Classification
Amount
2016
Regulatory submissions in the U.S. and Europe
R&D expense
$
55.0

2017
Regulatory approval in Europe
Intangible asset
65.0

Regulatory approval in Japan
Intangible asset
15.0

Began Phase III testing for atopic dermatitis
R&D expense
30.0

2018
Regulatory approval in the U.S.
Intangible asset
100.0

Began Phase III testing for SLE
R&D Expense
20.0


As of September 30, 2018, Incyte is eligible to receive up to $130.0 million of additional payments from us contingent upon certain development and success-based regulatory milestones. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones.
Effient® 
We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. Marketing rights for major territories are shown below. We and Daiichi Sankyo each have exclusive marketing rights in certain other territories.
Territory
 
Marketing Rights
 
Selling Party
U.S.
 
Co-promotion
 
Lilly
Major European markets
 
Co-promotion
 
Daiichi Sankyo
Japan
 
Exclusive
 
Daiichi Sankyo

While major European markets are a co-promotion territory under the terms of our arrangement, Daiichi Sankyo exclusively promotes Effient in these markets.
The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories, including the major European markets.
We record net product revenue in our exclusive and co-promotion territories where we are the selling party. Profit-share payments due to Daiichi Sankyo for co-promotion countries where we are the selling party are recorded as marketing, selling, and administrative expenses. Any profit-share payments due to us from Daiichi Sankyo for the major European markets are recorded as collaboration and other revenue. We also record our share of the expenses in these co-promotion territories as marketing, selling, and administrative expenses. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. All royalties due to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. Generic versions of Effient launched in the U.S. in the third quarter of 2017.
The following table summarizes our revenue recognized with respect to Effient:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Revenue
$
45.3

 
$
55.9

 
$
104.8

 
$
326.6


Tanezumab
We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain, chronic low back pain, and cancer pain. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and certain commercialization expenses. As of September 30, 2018, Pfizer is eligible to receive up to $350.0 million in success-based regulatory milestones and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Impairment, Restructuring, and Other Special Charges
 9 Months Ended
Sep. 30, 2018
Restructuring and Related Activities [Abstract]  
Asset Impairment, Restructuring, and Other Special Charges
Asset Impairment, Restructuring, and Other Special Charges
The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below.
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Severance:
 
 
 
 
 
 
 
Human pharmaceutical products
$
—

 
$
165.7

 
$
(24.7
)
 
$
277.1

Animal health products
(5.4
)
 
5.8

 
(0.6
)
 
62.1

Total severance
(5.4
)
 
171.5

 
(25.3
)
 
339.2

Asset impairment and other special charges:
 
 
 
 
 
 
 
Human pharmaceutical products
3.5

 
25.0

 
2.0

 
25.0

Animal health products
85.2

 
210.0

 
259.3

 
306.2

Total asset impairment and other special charges
88.7

 
235.0

 
261.3

 
331.2

Total asset impairment, restructuring, and other special charges
$
83.3

 
$
406.5

 
$
236.0

 
$
670.4


Severance charges recognized during the nine months ended September 30, 2018 primarily relate to severance adjustments recorded in the second quarter of 2018. Our severance charges recognized in the second half of 2017 as part of planned restructuring activities were based upon estimates for the number of employees that either lost or were going to lose their then current roles and would ultimately leave the company. During the second quarter of 2018, we determined that more displaced employees than expected were able to find other roles within the company, resulting in an immaterial reduction in the actual severance costs incurred. We expect the majority of the remaining severance payments to be made in the next 12 months.
Asset impairment and other special charges recognized during the three months ended September 30, 2018 resulted primarily from asset impairment and other restructuring charges related to the sale of the Posilac® (rbST) brand and the associated Augusta, Georgia manufacturing site. We also incurred expenses associated with the IPO and separation of Elanco. These expenses were offset by a gain recognized associated with the pension curtailment (see Note 8 for additional discussion).
In addition to the charges for the three months ended September 30, 2018, additional asset impairment and other special charges for the nine months ended September 30, 2018 included asset impairment, exit costs, and other charges related to the decision to end Posilac (rbST) production at the Augusta, Georgia manufacturing site, and charges related to the decision to suspend commercialization of Imrestor®, an animal health product. We also incurred expenses associated with the review of strategic alternatives for the Elanco animal health business.
Severance costs recognized during the three and nine months ended September 30, 2017 were incurred as a result of actions taken to reduce our cost structure, as well as the integration of Novartis Animal Health (Novartis AH).
Substantially all of the asset impairment and other special charges recognized during the three months ended September 30, 2017 were related to lower projected revenue for Posilac (rbST). The assets associated with Posilac (rbST) were written down to their fair values, which were determined based upon a discounted cash flow valuation. Other asset impairment and other special charges recognized during the three months ended September 30, 2017 related to exit costs associated with site closures. Asset impairment and other special charges recognized during the nine months ended September 30, 2017 resulted primarily from charges associated with the Posilac (rbST) impairment, integration costs of Novartis AH, as well as asset impairments due to site closures.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments
 9 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Financial Instruments
Financial Instruments
Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.
Our equity investments are accounted for using three different methods depending on the type of equity investment:
•
Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense.
•
For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense.
•
Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense.
We review equity investments other than public equity investments for indications of impairment on a regular basis.
Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.
For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of gains and losses is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the effective portion of foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change.
We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2018, we had outstanding foreign currency forward commitments to purchase 1.40 billion U.S. dollars and sell 1.19 billion euro, commitments to purchase 1.57 billion euro and sell 1.84 billion U.S. dollars, commitments to purchase 426.9 million U.S. dollars and sell 47.94 billion Japanese yen, commitments to purchase 234.1 million Swiss Francs and sell 243.2 million U.S. dollars, commitments to purchase 512.2 million U.S. dollars and sell 389.4 million British pounds, and commitments to purchase 466.4 million British pounds and sell 613.0 million U.S. dollars, which will all settle within 30 days.
Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $3.45 billion and $3.70 billion as of September 30, 2018 and December 31, 2017, respectively, and have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated and Swiss franc-denominated foreign operations. Our cross-currency interest rate swaps that convert a portion of our U.S. dollar-denominated floating rate debt to foreign-denominated floating rate debt have also been designated as, and are effective as, economic hedges of net investments. At September 30, 2018, we had outstanding cross currency swaps with notional amounts of $1.53 billion swapping euro to U.S. dollars and $350.0 million swapping British pounds to U.S. dollars, which will all settle within 12 months.
In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.
Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At September 30, 2018, substantially all of our total long-term debt is at a fixed rate. We have converted 20 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.
We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.
We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt.
Elanco Debt Issuance
In August 2018, our wholly owned subsidiary, Elanco, issued $2.00 billion of senior notes in a private placement. The senior notes are comprised of $500.0 million of 3.91 percent senior notes due in August 2021, $750.0 million of 4.27 percent senior notes due in August 2023, and $750.0 million of 4.90 percent senior notes due in August 2028. Interest is to be paid semi-annually and the interest rate payable on each series of senior notes is subject to adjustment if certain bond rating agencies downgrade, or subsequently upgrade, their ratings on the respective series of senior notes.
The indenture that governs the Elanco senior notes contains covenants, including limitations on the ability of Elanco and certain Elanco subsidiaries to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on Elanco's ability to consolidate, merge or sell substantially all of their assets, in addition to other customary terms. Elanco was in compliance with all such covenants under the indentures governing the senior notes as of September 30, 2018.
Elanco has entered into an agreement that requires them to use commercially reasonable efforts to cause a registration statement to become effective with the SEC by August 28, 2019, relating to an offer to exchange the senior notes for registered senior notes having substantially identical terms, or in certain cases, to register the senior notes for resale. If they do not register or exchange the senior notes pursuant to the terms of the registration rights agreement, they will be required to pay additional interest to the holders of the senior notes under certain circumstances.
In September 2018, Elanco entered into a revolving credit agreement with a syndicate of banks providing for a five-year $750.0 million senior revolving credit facility (Revolving Facility). The Revolving Facility bears interest at a variable rate plus specified margin as defined in the agreement and is payable quarterly. There were no borrowings outstanding under the Revolving Facility at September 30, 2018. The Revolving Facility is payable in full at the end of the term.
In September 2018, Elanco also entered into a $500.0 million three-year term loan under a term credit facility with a syndicate of banks (the Term Facility and collectively with the Revolving Facility, the Credit Facilities). The Term Facility bears interest at a variable rate plus margin as defined in the Term Facility and is payable quarterly. The Term Facility is payable in full at the end of the term.
The Credit Facilities are subject to various financial and other covenants including restrictions on Elanco's level of borrowings based on their consolidated leverage ratio and their consolidated interest coverage ratio. Elanco was in compliance with all such covenants as of September 30, 2018.
The aggregate net proceeds of the senior notes and Term Facility was $2.48 billion. See Note 3 for a discussion of the use of the proceeds of the debt offerings as part of the formation of Elanco and their IPO process.
The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations
The following effects of risk-management instruments were recognized in other–net, (income) expense:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Fair value hedges:
 
 
 
 
 
 
 
Effect from hedged fixed-rate debt
$
(19.6
)
 
$
(4.0
)
 
$
(94.1
)
 
$
3.6

Effect from interest rate contracts
19.6

 
4.0

 
94.1

 
(3.6
)
Cash flow hedges:
 
 
 
 
 
 
 
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss
3.7

 
3.7

 
11.1

 
11.1

Net losses on foreign currency exchange contracts not designated as hedging instruments
0.7

 
16.3

 
76.5

 
79.2


During the nine months ended September 30, 2018 and 2017, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.
The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)
The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Net investment hedges:
 
 
 
 
 
 
 
    Foreign currency-denominated notes
$
(47.8
)
 
$
(58.7
)
 
$
53.0

 
$
(332.0
)
    Cross-currency interest rate swaps
14.7

 
(38.2
)
 
52.3

 
(95.8
)
Cash flow hedges:
 
 
 
 
 
 
 
    Forward-starting interest rate swaps
—

 
—

 
—

 
13.0


During the next 12 months, we expect to reclassify $15.0 million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other–net, (income) expense.
Fair Value of Financial Instruments
The following tables summarize certain fair value information at September 30, 2018 and December 31, 2017 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: 
 
 
 
 
 
Fair Value Measurements Using
 
 
 
Carrying
Amount
 
Cost (1)
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Fair
Value
September 30, 2018
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
$
6,646.3

 
$
6,646.3

 
$
6,646.3

 
$
—

 
$
—

 
$
6,646.3

 
 
 
 
 
 
 
 
 
 
 
 
Short-term investments:
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
$
10.5

 
$
10.6

 
$
10.5

 
$
—

 
$
—

 
$
10.5

Corporate debt securities
52.7

 
52.7

 
—

 
52.7

 
—

 
52.7

Asset-backed securities
11.5

 
11.6

 
—

 
11.5

 
—

 
11.5

Other securities
1.4

 
1.4

 
—

 
1.4

 
—

 
1.4

Short-term investments
$
76.1

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noncurrent investments:
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
$
152.0

 
$
159.6

 
$
152.0

 
$
—

 
$
—

 
$
152.0

Corporate debt securities
622.0

 
631.5

 
—

 
622.0

 
—

 
622.0

Mortgage-backed securities
109.5

 
114.1

 
—

 
109.5

 
—

 
109.5

Asset-backed securities
27.0

 
27.3

 
—

 
27.0

 
—

 
27.0

Other securities
137.4

 
39.3

 
—

 
—

 
137.4

 
137.4

Marketable equity securities
287.9

 
146.4

 
287.9

 
—

 
—

 
287.9

Equity investments without readily determinable fair values (2)
394.7

 
 
 
 
 
 
 
 
 
 
Equity method investments (2)
275.3

 
 
 
 
 
 
 
 
 
 
Noncurrent investments
$
2,005.8

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2017
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
$
4,763.9

 
$
4,763.9

 
$
4,712.4

 
$
51.5

 
$
—

 
$
4,763.9

 
 
 
 
 
 
 
 
 
 
 
 
Short-term investments:
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
$
217.8

 
$
218.2

 
$
217.8

 
$
—

 
$
—

 
$
217.8

Corporate debt securities
1,182.3

 
1,183.2

 
—

 
1,182.3

 
—

 
1,182.3

Asset-backed securities
94.2

 
94.3

 
—

 
94.2

 
—

 
94.2

Other securities
3.6

 
3.6

 
—

 
3.6

 
—

 
3.6

Short-term investments
$
1,497.9

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noncurrent investments:
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
$
360.0

 
$
365.0

 
$
360.0

 
$
—

 
$
—

 
$
360.0

Corporate debt securities
3,464.3

 
3,473.5

 
—

 
3,464.3

 
—

 
3,464.3

Mortgage-backed securities
202.4

 
204.2

 
—

 
202.4

 
—

 
202.4

Asset-backed securities
653.9

 
656.0

 
—

 
653.9

 
—

 
653.9

Other securities
132.1

 
66.4

 
—

 
—

 
132.1

 
132.1

Marketable equity securities
281.3

 
131.0

 
281.3

 
—

 
—

 
281.3

Cost and equity method investments (2)
584.8

 
 
 
 
 
 
 
 
 
 
Noncurrent investments
$
5,678.8

 
 
 
 
 
 
 
 
 
 

(1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.
(2) Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments that do not have readily determinable fair values.
 
 
 
Fair Value Measurements Using
 
 
 
Carrying
Amount
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant
Other Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Fair
Value
Short-term commercial paper borrowings
 
 
 
 
 
 
 
 
 
September 30, 2018
$
(399.7
)
 
$
—

 
$
(398.4
)
 
$
—

 
$
(398.4
)
December 31, 2017
(2,696.8
)
 
—

 
(2,690.6
)
 
—

 
(2,690.6
)
Long-term debt, including current portion
 
 
 
 
 
 
 
 
 
September 30, 2018
$
(12,277.1
)
 
$
—

 
$
(12,542.2
)
 
$
—

 
$
(12,542.2
)
December 31, 2017
(10,950.3
)
 
—

 
(11,529.9
)
 
—

 
(11,529.9
)

 
 
 
Fair Value Measurements Using
 
 
 
Carrying
Amount
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant
Other Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Fair
Value
September 30, 2018
 
 
 
 
 
 
 
 
 
Risk-management instruments:
 
 
 
 
 
 
 
 
 
Interest rate contracts designated as fair value hedges:
 
 
 
 
 
 
 
 
 
Other current liabilities
$
(2.7
)
 
$
—

 
$
(2.7
)
 
$
—

 
$
(2.7
)
Other noncurrent liabilities
(66.5
)
 
—

 
(66.5
)
 
—

 
(66.5
)
Cross-currency interest rate contracts designated as net investment hedges:
 
 
 
 
 
 
 
 
 
Other receivables
30.3

 
—

 
30.3

 
—

 
30.3

Sundry
6.9

 
—

 
6.9

 
—

 
6.9

Other current liabilities
(16.6
)
 
—

 
(16.6
)
 
—

 
(16.6
)
Foreign exchange contracts not designated as hedging instruments:
 
 
 
 
 
 
 
 
 
Other receivables
6.3

 
—

 
6.3

 
—

 
6.3

Other current liabilities
(14.0
)
 
—

 
(14.0
)
 
—

 
(14.0
)
Contingent consideration liabilities:
 
 
 
 
 
 
 
 
 
Other current liabilities
(62.0
)
 
—

 
—

 
(62.0
)
 
(62.0
)
Other noncurrent liabilities
(41.4
)
 
—

 
—

 
(41.4
)
 
(41.4
)
 
 
 
 
 
 
 
 
 
 
December 31, 2017
 
 
 
 
 
 
 
 
 
Risk-management instruments:
 
 
 
 
 
 
 
 
 
Interest rate contracts designated as fair value hedges:
 
 
 
 
 
 
 
 
 
Other receivables
$
0.8

 
$
—

 
$
0.8

 
$
—

 
$
0.8

Sundry
35.1

 
—

 
35.1

 
—

 
35.1

Other current liabilities
(0.2
)
 
—

 
(0.2
)
 
—

 
(0.2
)
Other noncurrent liabilities
(10.5
)
 
—

 
(10.5
)
 
—

 
(10.5
)
Cross-currency interest rate contracts designated as net investment hedges:
 
 
 
 
 
 
 
 
 
Other current liabilities
(33.4
)
 
—

 
(33.4
)
 
—

 
(33.4
)
Other noncurrent liabilities
(26.0
)
 
—

 
(26.0
)
 
—

 
(26.0
)
Foreign exchange contracts not designated as hedging instruments:
 
 
 
 
 
 
 
 
 
Other receivables
26.8

 
—

 
26.8

 
—

 
26.8

Other current liabilities
(36.0
)
 
—

 
(36.0
)
 
—

 
(36.0
)
Contingent consideration liabilities (1):
 
 
 
 
 
 
 
 
 
Other current liabilities
(208.0
)
 
—

 
—

 
(208.0
)
 
(208.0
)
Other noncurrent liabilities
(45.2
)
 
—

 
—

 
(45.2
)
 
(45.2
)
(1) Contingent consideration liabilities primarily relate to the Erbitux arrangement with BMS discussed in Note 4.
Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to an enforceable master netting arrangement or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.
We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available.
Contingent consideration liabilities at December 31, 2017 primarily include contingent consideration related to Erbitux, for which the fair value was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for net sales in North America through September 2018 and an estimated discount rate. The amount to be paid is calculated as a tiered percentage of net sales (see Note 4) and will, therefore, vary directly with increases and decreases in net sales of Erbitux in North America. There is no cap on the amount that may be paid pursuant to this arrangement. The decrease in the fair value of the contingent consideration liabilities during the nine months ended September 30, 2018 was due primarily to cash payments of $155.4 million related to Erbitux. The change in the fair value of the contingent consideration liabilities recognized in earnings during the three and nine months ended September 30, 2018 and 2017 due to changes in time value of money was not material.
The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September 30, 2018:
 
Maturities by Period
  
Total
 
Less Than
1 Year
 
1-5
Years
 
6-10
Years
 
More Than
10 Years
Fair value of debt securities
$
985.1

 
$
74.7

 
$
620.5

 
$
135.4

 
$
154.5


A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows: 
 
September 30, 2018
 
December 31, 2017
Unrealized gross gains
$
2.1

 
$
184.7

Unrealized gross losses
24.4

 
47.5

Fair value of securities in an unrealized gain position
164.0

 
1,434.2

Fair value of securities in an unrealized loss position
816.7

 
4,692.8


A summary of the unrealized gains and losses (pretax) recognized in our consolidated condensed statements of operations for equity securities held as of September 30, 2018 is as follows:
 
Three Months Ended
September 30,
Nine Months Ended
September 30,
Unrealized gain (loss), net
$
(40.8
)
$
(3.4
)

We periodically assess our investment in available-for-sale securities for other-than-temporary impairment losses. There were no other-than-temporary impairment losses in the three or nine months ended September 30, 2018 or the three or nine months ended September 30, 2017.
We periodically assess our investments in equity securities other than public equity securities for impairment losses. Impairment losses recognized on these equity securities in the three and nine months ended September 30, 2018 were immaterial.
For fixed-income securities, the amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.
For equity securities, factors considered in assessing impairment losses include the financial condition and near term prospects of the issuer and general market conditions and industry specific factors.
As of September 30, 2018, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 60 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of September 30, 2018, we do not intend to sell, and it is not more likely than not that we will be required to sell the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.
Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities, was as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Proceeds from sales
$
52.0

 
$
951.5

 
$
5,598.4

 
$
3,003.0

Realized gross gains on sales
0.4

 
9.0

 
8.1

 
82.9

Realized gross losses on sales
0.7

 
0.8

 
49.7

 
3.2


Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.
Adjustments recorded to our equity investments without readily determinable fair values are based upon changes in the equity instrument's value resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon the impairment considerations mentioned above. Adjustments recorded during the nine months ended September 30, 2018 were immaterial.
Accounts Receivable Factoring Arrangements
We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $645.1 million and $723.2 million of accounts receivable as of September 30, 2018 and December 31, 2017, respectively, under these factoring arrangements. The cost of factoring such accounts receivable on our consolidated condensed results of operations for the nine months ended September 30, 2018 and 2017 was not material.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes
 9 Months Ended
Sep. 30, 2018
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
The effective tax rates were 18.5 percent and 26.2 percent for the three and nine months ended September 30, 2018, respectively, compared with 6.1 percent and 24.1 percent for the three and nine months ended September 30, 2017. The increase in the effective tax rate for the third quarter of 2018 is primarily due to a higher income tax benefit in the third quarter of 2017 for acquired IPR&D charges and asset impairment, restructuring, and other special charges. The increase in the effective rate for the first nine months of 2018 is primarily due to the $1.56 billion non-deductible acquired IPR&D charge related to the acquisitions of ARMO and AurKa. In December 2017, the President of the U.S. signed into law the Tax Cuts and Jobs Act (2017 Tax Act), which includes significant changes to the U.S. corporate income tax system, including a reduction in the corporate income tax rate, transition to a territorial tax system, and modifications to the international tax provisions. The changes that became effective January 1, 2018 resulted in a reduction to our tax expense for the three and nine months ended September 30, 2018 compared to the three and nine months ended September 30, 2017, respectively.
At September 30, 2018, our accounting for the 2017 Tax Act is incomplete; however, we expect to complete our accounting by December 2018. As discussed in our 2017 Annual Report on Form 10-K, we recorded provisional adjustments for effects that we were able to reasonably estimate. Those effects included the one-time repatriation transition tax (also known as the 'Toll Tax'), re-measurement of deferred tax assets and liabilities, unremitted earnings, executive compensation, and uncertain tax positions. At year-end, we were not able to make reasonable estimates for Global Intangible Low-Taxed Income (GILTI) deferred taxes or valuation allowances; therefore, we did not record provisional amounts. We are still evaluating the effects of the GILTI provisions and assessing our valuation allowances, and we have not yet determined our accounting policy election with respect to GILTI deferred taxes or the application of intra-entity transfers of inventory; therefore, the estimated annual effective tax rate reflects GILTI as a period expense. For the three and nine months ended September 30, 2018, we increased our provisional amount of Toll Tax by an immaterial amount. We have not made any additional measurement-period adjustments related to the other provisional items as we are continuing to collect and analyze additional information as well as evaluate the interpretations and assumptions made. Updates to our calculations may result in material changes to the provisional adjustments recorded at year-end and the estimated annual effective tax rate.
The U.S. examination of tax years 2013-2015 began in 2016. While we believe it is reasonably possible that this audit could reach resolution within the next 12 months, the IRS examination of tax years 2013-2015 remains ongoing. Therefore, it is not possible to reasonably estimate the change to unrecognized tax benefits and the related future cash flows.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Retirement Benefits
 9 Months Ended
Sep. 30, 2018
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
Retirement Benefits
Retirement Benefits
Net pension and retiree health benefit (income) cost included the following components:
 
Defined Benefit Pension Plans
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Components of net periodic benefit cost:
 
 
 
 
 
 
 
Service cost
$
74.2

 
$
86.0

 
$
232.3

 
$
251.6

Interest cost
117.9

 
103.6

 
342.5

 
309.2

Expected return on plan assets
(212.7
)
 
(196.4
)
 
(636.3
)
 
(585.7
)
Amortization of prior service cost
1.1

 
1.4

 
3.6

 
4.3

Recognized actuarial loss
79.2

 
72.5

 
261.2

 
215.6

Curtailment loss
1.3

 
—

 
1.3

 
—

Net periodic benefit cost
$
61.0

 
$
67.1

 
$
204.6

 
$
195.0


 
Retiree Health Benefit Plans
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Components of net periodic benefit income:
 
 
 
 
 
 
 
Service cost
$
10.1

 
$
11.6

 
$
31.7

 
$
34.8

Interest cost
14.9

 
13.2

 
42.3

 
39.6

Expected return on plan assets
(44.8
)
 
(40.2
)
 
(132.7
)
 
(120.6
)
Amortization of prior service benefit
(19.3
)
 
(22.5
)
 
(60.2
)
 
(67.5
)
Recognized actuarial loss
0.8

 
4.6

 
5.4

 
13.8

Curtailment gain
(29.3
)
 
—

 
(29.3
)
 
—

Net periodic benefit income
$
(67.6
)
 
$
(33.3
)
 
$
(142.8
)
 
$
(99.9
)


In July 2018, we announced that we would amend our defined benefit pension and retiree health benefit plans to freeze or reduce benefits for certain Elanco employees effective January 1, 2019. We remeasured the impacted pension and retiree health plans’ benefit obligations as of July 31, 2018, which resulted in a net curtailment gain of $28.0 million during the three and nine months ended September 30, 2018, which was recorded as a component of asset impairment, restructuring, and other special charges.
We contributed approximately $35 million required to satisfy minimum funding requirements to our defined benefit pension and retiree health benefit plans during the nine months ended September 30, 2018. Additional discretionary funding totaled $200.0 million during the nine months ended September 30, 2018. During the remainder of 2018, we expect to make contributions to our defined benefit pension and retiree health benefit plans of approximately $15 million to satisfy minimum funding requirements. No additional discretionary funding for the remainder of 2018 is planned.
As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, pension and retiree health benefit cost components other than service costs are presented in other–net, (income) expense.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Contingencies
 9 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Contingencies
Contingencies
We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as noted below with respect to the Alimta® patent litigation and administrative proceedings, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.
Alimta Patent Litigation and Administrative Proceedings
A number of generic manufacturers are seeking approvals in the U.S., Japan, and a number of countries in Europe to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect that a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenue for the product in the relevant market.
U.S. Patent Litigation and Administrative Proceedings
In the U.S., more than 10 Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Alimta prior to the expiration of our vitamin regimen patent (expiring in 2021 plus pediatric exclusivity expiring in 2022) have been filed by a number of companies, including Teva Parenteral Medicines, Inc. (Teva) and APP Pharmaceuticals, LLC (APP) pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). We have received favorable decisions from the U.S. Court of Appeals for the Federal Circuit (affirming the U.S. District Court for the Southern District of Indiana's decisions finding our U.S. vitamin regimen patent valid and infringed) against Teva, APP, and two other defendants' proposed products, and similar favorable judgments have been entered by the U.S. District Court for the Southern District of Indiana against five other companies. The remaining ANDA applicants have agreed to a preliminary injunction or stay pending the appeal of the inter partes review (IPR) described in the following sentence. In October 2017, the U.S. Patent and Trademark Office issued written decisions in our favor following IPR of our vitamin regimen patent, finding that the generic company petitioners failed to show that the claims in our patent are unpatentable. A number of these challengers have filed an appeal.
We currently have pending lawsuits in the U.S. District Court for the Southern District of Indiana alleging infringement against Actavis LLC (Actavis) and Apotex Inc. in response to their applications to market alternative forms of pemetrexed (the active ingredient in Alimta) products, and we filed a similar lawsuit in the U.S. District Court for Delaware against Eagle Pharmaceuticals, Inc. In June 2018, the U.S. District Court for the Southern District of Indiana ruled in our favor in two similar cases, finding Dr. Reddy's Laboratories' (Dr. Reddy) and Hospira, Inc.'s (Hospira) proposed products would infringe our patent. Dr. Reddy and Hospira have appealed those rulings. The lawsuit against Actavis has been stayed, pending a decision in the Dr. Reddy and Hospira appeals.
European Patent Litigation and Administrative Proceedings
In July 2017, the United Kingdom (U.K.) Supreme Court ruled that commercialization of certain salt forms of pemetrexed by Actavis Group ehf and other Actavis companies directly infringes our vitamin regimen patents in the U.K., Italy, France, and Spain. This litigation in the U.K. is now concluded.
Hexal AG (Hexal) and Stada Arzneimittel AG (Stada) have each challenged the validity of our vitamin regimen patent before the German Federal Patent Court. At a hearing in July 2018, the German Federal Patent Court held that our vitamin regimen patent is invalid. We have appealed this decision. Under German law, the patent remains in force pending appeal. A number of generic competitors have received approval to market generic versions of pemetrexed in Germany and may choose to launch at risk. We will seek to remove any generic pemetrexed products launched at risk in Germany, seek damages in respect of such launches, and defend our patent. Injunctions are in place against four of these companies, including Hexal and ratiopharm GmbH (a subsidiary of Teva). Stada has recently launched at risk in Germany and we are seeking an injunction. Whether further injunctions are granted or the current injunctions are maintained pending the appeal, or whether a generic competitor chooses to launch at risk, makes the timing of possible generic entry and market erosion in Germany unpredictable.
Additional legal proceedings are ongoing in various national courts throughout Europe. We are aware that several companies have received approval to market generic versions of pemetrexed in major European markets and that generic competitors may choose to launch at risk (including one generic product currently on the market in France). We will continue to seek to remove any generic pemetrexed products launched at risk in European markets, seek damages in respect of such launches, and defend our patents against validity challenges.
Japanese Administrative Proceedings
Three separate sets of demands for invalidation of our two vitamin regimen patents, involving several companies, have been filed with the Japanese Patent Office (JPO). In February 2017, the Japan Intellectual Property High Court confirmed the decisions of the JPO upholding the validity of both our Japanese vitamin regimen patents in the challenge initiated by Sawai Pharmaceutical Co., Ltd. and joined by three other companies. This decision is now final. In May 2017, the JPO resumed one of the two remaining sets of demands, brought by Nipro Corporation (Nipro) and in July 2018, the JPO issued written decisions dismissing Nipro’s invalidation demands. Nipro filed an appeal and we anticipate decisions by the Japan Intellectual Property High Court in the third quarter of 2019. The other set of demands, brought by Hospira, that were previously suspended resumed in August 2018; we anticipate decisions by the JPO in the second quarter of 2019. If upheld through all challenges, these patents provide intellectual property protection for Alimta until June 2021. Notwithstanding our patents, generic versions of Alimta were approved in Japan starting in February 2016. We do not currently anticipate that generic versions of Alimta will proceed to pricing approval.
Cymbalta® Product Liability Litigation
We were named as a defendant in a purported class-action lawsuit in the U.S. District Court for the Central District of California (now called Strafford et al. v. Eli Lilly and Company) involving Cymbalta. The plaintiffs, purporting to represent a class of all persons within the U.S. who purchased and/or paid for Cymbalta, asserted claims under the consumer protection statutes of four states, California, Massachusetts, Missouri, and New York, and sought declaratory, injunctive, and monetary relief for various alleged economic injuries arising from discontinuing treatment with Cymbalta. The district court denied the plaintiffs' motions for class certification. The district court dismissed the suits and plaintiffs appealed to the U.S. Court of Appeals for the Ninth Circuit. In November 2017, the U.S. Court of Appeals for the Ninth Circuit dismissed the suit. In July 2018, the U.S. District Court for the District of California denied plaintiffs’ motion to reopen the case. Plaintiffs’ appeal of this denial is currently pending before the U.S. Court of Appeals for the Ninth Circuit.
We are named in approximately 140 lawsuits involving approximately 1,470 plaintiffs filed in various federal and state courts alleging injuries arising from discontinuation of treatment with Cymbalta. These include approximately 40 individual and multi-plaintiff cases filed in California state court, centralized in a California Judicial Counsel Coordination Proceeding pending in Los Angeles. The first individual product liability cases were tried in August 2015 and resulted in defense verdicts against four plaintiffs. We believe all these Cymbalta lawsuits and claims are without merit. We have reached a settlement framework that provides for a comprehensive resolution of nearly all of these personal injury claims, filed or unfiled, alleging injuries from discontinuing treatment with Cymbalta.
Brazil–Employee Litigation
Our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. The plaintiffs allege that some employees at the facility were exposed to benzene and heavy metals; however, Lilly Brasil maintains that these alleged contaminants were never used in the facility. In May 2014, the labor court judge ruled against Lilly Brasil. The judge's ruling orders Lilly Brasil to undertake several actions of unspecified financial impact, including paying lifetime medical insurance for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We filed an appeal in May 2014. In July 2018, the appeals court affirmed the lower court's ruling with the total financial impact of the ruling estimated to be approximately 500 million Brazilian real (approximately $125 million as of September 30, 2018). The appeals court restricted the broad health coverage awarded by the lower court to health problems that claimants could show arose from exposure to the alleged contamination. We strongly disagree with the court's decision and plan to appeal. Lilly Brasil has taken an initial step in the appeal process by filing a Motion for Clarification; a decision on that motion is expected late in the fourth quarter of 2018 or in the first quarter of 2019.
We are also named in approximately 30 lawsuits filed in the same court by individual former employees making similar claims.
Lilly Brasil and Elanco Quimica Ltda. have been named in a lawsuit involving approximately 305 individuals alleging that the companies failed to provide warnings regarding exposure to heavy metals or proper equipment at the former Cosmopolis facility, and that this alleged failure could result in possible harm to employees, former employees, and their dependents. In June 2017, the court denied the plaintiffs' request for a preliminary injunction. In September 2017, the court dismissed the claims brought by all but the first named plaintiff. The plaintiffs are appealing that decision.
Lilly Brasil and Elanco Quimica Ltda. have also been named in a separate lawsuit involving approximately 105 individuals alleging that the companies failed to provide warnings regarding exposure to heavy metals or proper equipment at the former Cosmopolis facility, and that this alleged failure could result in possible harm to contractors and suppliers, and their dependents. In November 2017, the court dismissed the claims brought by all but the first named plaintiff. The plaintiffs are appealing that decision.
We believe all of these lawsuits are without merit and plan to defend against them vigorously.
Agri Stats, Inc.
During the third quarter, we sold Agri Stats, Inc., one of our subsidiaries. As a result of the sale, we no longer hold the liability for litigation in which Agri Stats is named as a party, including the approximately 25 antitrust suits filed in the U.S. District Court for the Northern District of Illinois and the District of Minnesota alleging that defendants engaged in a conspiracy to limit U.S. chicken and swine production and inflate prices.
Adocia, S.A.
We have been named a respondent in two arbitrations filed by Adocia, S.A. (Adocia), with which we entered into agreements for the co-development of an ultra-rapid insulin product. In the first arbitration, Adocia alleged that we failed to make a $11.7 million milestone payment and, in August 2018, an arbitration panel ruled in favor of Adocia. In the second arbitration, Adocia alleged that we misappropriated and misused Adocia's confidential information and intellectual property and is seeking approximately $1.8 billion in damages and other specific relief. We believe these claims are without merit and are defending against them vigorously. We have asserted several counterclaims relating to fraudulent misrepresentation and are seeking approximately $188 million in damages.
Throughout the arbitrations described above, Adocia has made statements alleging that Adocia employees should be listed as inventors on two of our patents related to our ultra-rapid insulin product currently in development. We strongly contest this allegation. While inventorship of these two patents is not at issue in the arbitrations, in October 2018 we filed a declaratory judgment action against Adocia in the U.S. District Court for the Southern District of Indiana to confirm our inventorship.
Product Liability Insurance
Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2018
Statement of Comprehensive Income [Abstract]  
Other Comprehensive Income (Loss)
Other Comprehensive Income (Loss)
The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September 30, 2018 and 2017:
(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)
 
Unrealized Net Gains (Losses) on Securities
 
Defined Benefit Pension and Retiree Health Benefit Plans
 
Effective Portion of Cash Flow Hedges
 
Accumulated Other Comprehensive Loss
Balance at July 1, 2018
$
(1,671.5
)
 
$
(18.1
)
 
$
(4,190.6
)
 
$
(228.5
)
 
$
(6,108.7
)
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
60.6

 
1.1

 
548.6

 
—

 
610.3

Net amount reclassified from accumulated other comprehensive loss
—

 
(0.2
)
 
47.2

 
2.9

 
49.9

Net other comprehensive income (loss)
60.6

 
0.9

 
595.8

 
2.9

 
660.2

 
 
 
 
 
 
 
 
 
 
Balance at September 30, 2018 (4)
$
(1,610.9
)
 
$
(17.2
)
 
$
(3,594.8
)
 
$
(225.6
)
 
$
(5,448.5
)
(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)
 
Unrealized Net Gains (Losses) on Securities
 
Defined Benefit Pension and Retiree Health Benefit Plans
 
Effective Portion of Cash Flow Hedges
 
Accumulated Other Comprehensive Loss
Balance at July 1, 2017
$
(1,349.4
)
 
$
153.2

 
$
(3,348.5
)
 
$
(197.6
)
 
$
(4,742.3
)
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
135.8

 
33.9

 
(28.7
)
 
—

 
141.0

Net amount reclassified from accumulated other comprehensive loss
8.1

 
(23.9
)
 
40.1

 
2.4

 
26.7

Net other comprehensive income (loss)
143.9

 
10.0

 
11.4

 
2.4

 
167.7

 
 
 
 
 
 
 
 
 
 
Balance at September 30, 2017 (1)
$
(1,205.5
)
 
$
163.2

 
$
(3,337.1
)
 
$
(195.2
)
 
$
(4,574.6
)
The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September 30, 2018 and 2017:
(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)
 
Unrealized Net Gains (Losses) on Securities
 
Defined Benefit Pension and Retiree Health Benefit Plans
 
Effective Portion of Cash Flow Hedges
 
Accumulated Other Comprehensive Loss
Balance at January 1, 2018 (2)
$
(1,233.4
)
 
$
113.5

 
$
(4,340.7
)
 
$
(234.3
)
 
$
(5,694.9
)
 
 
 
 
 
 
 
 
 
 
Reclassification due to adoption of new accounting standard (3)
—

 
(128.9
)
 
—

 
—

 
(128.9
)
Other comprehensive income (loss) before reclassifications
(377.5
)
 
31.0

 
581.0

 
—

 
234.5

Net amount reclassified from accumulated other comprehensive loss
—

 
(32.8
)
 
164.9

 
8.7

 
140.8

Net other comprehensive income (loss)
(377.5
)
 
(1.8
)
 
745.9

 
8.7

 
375.3

 
 
 
 
 
 
 
 
 
 
Balance at September 30, 2018 (4)
$
(1,610.9
)
 
$
(17.2
)
 
$
(3,594.8
)
 
$
(225.6
)
 
$
(5,448.5
)

(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)
 
Unrealized Net Gains (Losses) on Securities
 
Defined Benefit Pension and Retiree Health Benefit Plans
 
Effective Portion of Cash Flow Hedges
 
Accumulated Other Comprehensive Loss
Balance at January 1, 2017 (2)
$
(1,867.3
)
 
$
224.0

 
$
(3,371.6
)
 
$
(210.9
)
 
$
(5,225.8
)
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
653.7

 
9.6

 
(83.3
)
 
8.4

 
588.4

Net amount reclassified from accumulated other comprehensive loss
8.1

 
(70.4
)
 
117.8

 
7.3

 
62.8

Net other comprehensive income (loss)
661.8

 
(60.8
)
 
34.5

 
15.7

 
651.2

 
 
 
 
 
 
 
 
 
 
Balance at September 30, 2017 (1)
$
(1,205.5
)
 
$
163.2

 
$
(3,337.1
)
 
$
(195.2
)
 
$
(4,574.6
)
(1) Accumulated other comprehensive loss as of September 30, 2017 consists of $4.61 billion of accumulated other comprehensive loss attributable to controlling interest and $34.8 million of accumulated other comprehensive income attributable to noncontrolling interest.
(2) Accumulated other comprehensive loss as of January 1, 2018 consists of $5.72 billion of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive income attributable to noncontrolling interest. Accumulated other comprehensive loss as of January 1, 2017 consists of $5.27 billion of accumulated other comprehensive loss attributable to controlling interest and $48.2 million of accumulated other comprehensive income attributable to noncontrolling interest.
(3) This reclassification consists of $104.8 million of accumulated other comprehensive loss attributable to controlling interest and $24.1 million of accumulated other comprehensive loss attributable to noncontrolling interest. Refer to Note 2 for further details regarding the reclassification due to the adoption of Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.
(4) Accumulated other comprehensive loss as of September 30, 2018 consists of $5.44 billion of accumulated other comprehensive loss attributable to controlling interest and $9.0 million of accumulated other comprehensive loss attributable to noncontrolling interest.
The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
Tax benefit (expense)
2018
 
2017
 
2018
 
2017
Foreign currency translation gains/losses
$
7.0

 
$
33.9

 
$
(11.2
)
 
$
149.7

Unrealized net gains/losses on securities
(0.2
)
 
(4.2
)
 
1.1

 
25.4

Defined benefit pension and retiree health benefit plans
(152.4
)
 
(9.4
)
 
(190.3
)
 
(24.0
)
Effective portion of cash flow hedges
(0.8
)
 
(1.3
)
 
(2.3
)
 
(8.4
)
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items
$
(146.4
)

$
19.0


$
(202.7
)

$
142.7


Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.
Reclassifications out of accumulated other comprehensive loss were as follows:
 
Details about Accumulated Other Comprehensive Loss Components
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
Affected Line Item in the Consolidated Condensed Statements of Operations
 
 
 
2018
 
2017
 
2018
 
2017
 
Amortization of retirement benefit items:
 
 
 
 
 
 
 
 
 
 
Prior service benefits, net
 
$
(18.2
)
 
$
(21.1
)
 
$
(56.6
)
 
$
(63.2
)
(1) 
 
Actuarial losses, net
 
80.0

 
77.1

 
266.6

 
229.4

(1) 
 
Total before tax
 
61.8

 
56.0

 
210.0

 
166.2

 
 
Tax benefit
 
(14.6
)
 
(15.9
)
 
(45.1
)
 
(48.4
)
Income taxes
 
Net of tax
 
47.2

 
40.1

 
164.9

 
117.8

 
 
 
 
 
 
 
 
 
 
 
 
 
Unrealized gains/losses on available-for-sale securities:
 
 
 
 
 
 
 
 
 
 
Realized (gains), losses, net
 
(0.3
)
 
(36.7
)
 
(41.6
)
 
(108.2
)
Other–net, (income) expense
 
Tax (benefit) expense
 
0.1

 
12.8

 
8.8

 
37.8

Income taxes
 
Net of tax
 
(0.2
)
 
(23.9
)
 
(32.8
)
 
(70.4
)
 
 
Other, net of tax
 
2.9

 
10.5

 
8.7

 
15.4

Other–net, (income) expense
 
Total reclassifications for the period (net of tax)
 
$
49.9

 
$
26.7

 
$
140.8

 
$
62.8

 
(1) These accumulated other comprehensive loss components are included in the computation of net periodic benefit (income) cost (see Note 8).
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other-Net, (Income) Expense
 9 Months Ended
Sep. 30, 2018
Nonoperating Income (Expense) [Abstract]  
Other - Net, (Income) Expense
Other–Net, (Income) Expense
Other–net, (income) expense consisted of the following:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Interest expense
$
69.4

 
$
61.9

 
$
193.9

 
$
162.1

Interest income
(32.1
)
 
(45.1
)
 
(118.8
)
 
(114.6
)
Retirement benefit
(62.9
)
 
(63.8
)
 
(174.2
)
 
(191.3
)
Other income
41.0

 
(2.9
)
 
9.0

 
(44.8
)
Other–net, (income) expense
$
15.4


$
(49.9
)

$
(90.1
)

$
(188.6
)

As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Results for the three and nine months ended September 30, 2017 have been reclassified to reflect the adoption of this standard.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Segment Information
Segment Information
We have two operating segments—human pharmaceutical products and animal health products. Our operating segments are distinguished by the ultimate end user of the product—humans or animals. Performance is evaluated based on profit or loss from operations before income taxes.
 
Three Months Ended
September 30,
 
2018
 
2017
 
U.S. (1)
Outside U.S.
Total
 
U.S. (1)
Outside U.S.
Total
Segment revenue—to unaffiliated customers:
 
 
 
 
 
 
 
Human pharmaceutical products:
 
 
 
 
 
 
 
Endocrinology:
 
 
 
 
 
 
 
Trulicity®
$
645.9

$
170.3

$
816.2

 
$
412.9

$
114.8

$
527.7

Humalog®
365.6

299.0

664.6

 
414.9

281.3

696.2

Forteo®
182.5

208.3

390.8

 
234.1

207.6

441.7

Humulin®
216.9

105.1

322.1

 
203.0

97.5

300.5

Basaglar
157.3

43.9

201.2

 
115.2

30.5

145.7

Jardiance
104.2

62.7

166.9

 
83.8

43.4

127.2

Trajenta
50.3

85.3

135.7

 
68.4

84.9

153.3

Other Endocrinology
73.8

66.8

140.4

 
92.1

76.3

168.4

Total Endocrinology
1,796.5

1,041.4

2,837.9

 
1,624.4

936.3

2,560.7

 
 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
 
Alimta
288.5

232.0

520.5

 
260.3

254.2

514.5

Cyramza®
67.0

131.4

198.4

 
69.5

126.5

196.0

Erbitux
132.6

26.9

159.5

 
136.0

27.4

163.5

Other Oncology
131.7

54.1

185.8

 
43.5

40.2

83.6

Total Oncology
619.8

444.4

1,064.2

 
509.3

448.3

957.6

 
 
 
 
 
 
 
 
Cardiovascular:
 
 
 
 
 
 
 
Cialis®
295.9

171.2

467.1

 
319.6

245.3

564.9

Effient
30.2

15.1

45.3

 
42.7

13.1

55.9

Other Cardiovascular
39.7

31.7

71.4

 
4.9

37.3

42.1

Total Cardiovascular
365.8

218.0

583.8

 
367.2

295.7

662.9

 
 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
 
Cymbalta
14.5

157.5

172.0

 
19.6

163.5

183.2

Zyprexa®
7.0

102.8

109.9

 
12.6

128.0

140.6

Strattera®
10.5

88.2

98.7

 
52.9

84.1

137.1

Other Neuroscience
23.8

23.0

46.6

 
23.3

23.7

46.8

Total Neuroscience
55.8

371.5

427.2

 
108.4

399.3

507.7

 
 
 
 
 
 
 
 
Immunology:
 
 
 
 
 
 
 
Taltz®
210.6

53.3

263.9

 
131.3

20.0

151.3

Other Immunology
0.8

54.8

55.6

 
—

16.3

16.3

Total Immunology
211.4

108.1

319.5

 
131.3

36.3

167.6

 
 
 
 
 
 
 
 
Other pharmaceuticals
13.4

43.2

56.6

 
10.7

50.2

60.9

Total human pharmaceutical products
3,062.7

2,226.5

5,289.2

 
2,751.3

2,166.1

4,917.4

Animal health products
383.9

388.8

772.7

 
353.0

387.6

740.6

Revenue
$
3,446.6

$
2,615.3

$
6,061.9

 
$
3,104.4

$
2,553.6

$
5,658.0

 
Nine Months Ended
September 30,
 
2018
 
2017
 
U.S. (1)
Outside U.S.
Total
 
U.S. (1)
Outside U.S.
Total
Segment revenue—to unaffiliated customers:
 
 
 
 
 
 
 
Human pharmaceutical products:
 
 
 
 
 
 
 
Endocrinology:
 
 
 
 
 
 
 
Trulicity
$
1,786.5

$
487.8

$
2,274.3

 
$
1,090.1

$
290.7

$
1,380.8

Humalog
1,334.2

891.8

2,226.1

 
1,254.3

828.6

2,083.0

Forteo
529.7

608.8

1,138.5

 
661.5

574.3

1,235.8

Humulin
677.3

316.7

994.0

 
634.9

337.9

972.8

Basaglar
440.4

128.5

569.0

 
196.7

81.6

278.3

Jardiance
284.8

180.3

465.1

 
198.3

105.9

304.3

Trajenta
161.3

257.2

418.5

 
174.2

234.1

408.2

Other Endocrinology
199.4

206.9

406.1

 
283.4

228.5

511.8

Total Endocrinology
5,413.6

3,078.0

8,491.6

 
4,493.4

2,681.6

7,175.0

 
 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
 
Alimta
815.1

760.9

1,576.0

 
761.9

775.4

1,537.3

Cyramza
210.7

390.1

600.8

 
204.3

349.2

553.5

Erbitux
394.0

81.6

475.5

 
398.2

78.8

477.0

Other Oncology
321.4

157.1

478.6

 
128.4

104.3

232.7

Total Oncology
1,741.2

1,389.7

3,130.9

 
1,492.8

1,307.7

2,800.5

 
 
 
 
 
 
 
 
Cardiovascular:
 
 
 
 
 
 
 
Cialis
954.9

546.2

1,501.2

 
997.3

728.5

1,725.7

Effient
59.4

45.3

104.8

 
290.8

35.8

326.6

Other Cardiovascular
143.7

96.3

239.7

 
20.5

99.6

120.2

Total Cardiovascular
1,158.0

687.8

1,845.7

 
1,308.6

863.9

2,172.5

 
 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
 
Cymbalta
39.3

484.2

523.5

 
100.8

463.6

564.4

Zyprexa
27.6

332.8

360.4

 
49.3

379.6

428.9

Strattera
74.4

269.2

343.5

 
276.9

243.0

519.9

Other Neuroscience
72.2

71.2

143.5

 
88.4

72.2

160.5

Total Neuroscience
213.5

1,157.4

1,370.9

 
515.4

1,158.4

1,673.7

 
 
 
 
 
 
 
 
Immunology:
 
 
 
 
 
 
 
Taltz
495.3

135.1

630.4

 
343.6

43.1

386.7

Other Immunology
2.5

130.0

132.5

 
—

22.9

22.9

Total Immunology
497.8

265.1

762.9

 
343.6

66.0

409.6

 
 
 
 
 
 
 
 
Other pharmaceuticals
49.1

139.8

189.1

 
34.6

149.7

184.5

Total human pharmaceutical products
9,073.2

6,717.8

15,791.1

 
8,188.4

6,227.3

14,415.8

Animal health products
1,137.8

1,188.2

2,326.0

 
1,173.4

1,121.4

2,294.8

Revenue
$
10,211.0

$
7,906.1

$
18,117.1

 
$
9,361.8

$
7,348.7

$
16,710.6


Numbers may not add due to rounding.
(1) U.S. revenue includes revenue in Puerto Rico.
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Segment profits:
 
 
 
 
 
 
 
Human pharmaceutical products
$
1,514.0

 
$
1,242.5

 
$
4,751.0

 
$
3,765.7

Animal health products
162.6

 
121.9

 
461.9

 
422.6

Total segment profits
$
1,676.7

 
$
1,364.4

 
$
5,213.0

 
$
4,188.3

 
 
 
 
 
 
 
 
Reconciliation of total segment profits to consolidated income before taxes:
 
 
 
 
 
 
 
Segment profits
$
1,676.7

 
$
1,364.4

 
$
5,213.0

 
$
4,188.3

Other profits (losses):
 
 
 
 
 
 
 
Acquired in-process research and development (Note 3)
(30.0
)
 
(205.0
)
 
(1,654.5
)
 
(1,062.6
)
Amortization of intangible assets
(153.4
)
 
(155.8
)
 
(458.7
)
 
(510.0
)
Asset impairment, restructuring, and other special charges (Note 5)
(83.3
)
 
(406.5
)
 
(236.0
)
 
(670.4
)
Other, net
1.0

 
(5.5
)
 
(7.0
)
 
(32.0
)
Consolidated income before taxes
$
1,411.0

 
$
591.6

 
$
2,856.8

 
$
1,913.3

Numbers may not add due to rounding.
For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing and global administrative services.
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Geographic Information
 
 
 
 
 
 
 
Revenue—to unaffiliated customers (1):
 
 
 
 
 
 
 
United States
$
3,446.6

 
$
3,104.4

 
$
10,211.0

 
$
9,361.8

Europe
1,017.0

 
1,017.0

 
3,142.9

 
2,877.6

Japan
608.8

 
616.7

 
1,828.9

 
1,767.0

Other foreign countries
989.5

 
920.0

 
2,934.3

 
2,704.2

Revenue
$
6,061.9

 
$
5,658.0

 
$
18,117.1

 
$
16,710.6

Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.
Refer to Note 3 for information regarding the IPO of Elanco.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Implementation of New Financial Accounting Pronouncements (Policies)
 9 Months Ended
Sep. 30, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
New Accounting Pronouncements
Standard
 
Description
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers
 
This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.
 
Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 12.
Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities
 
This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.
 
Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.
Standard
 
Description
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory
 
This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified
retrospective approach to adoption.
 
Upon adoption, the cumulative effect of applying the standard resulted in an increase to deferred tax assets and retained earnings of approximately $2.5 billion. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.
Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost
 
This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component.
 
Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. The application of the new standard resulted in reclassification to other income of $63.8 million for the three months ended September 30, 2017, while increasing cost of sales by $20.2 million, marketing, selling, and administrative expenses by $23.0 million, and research and development expenses by $20.6 million for the same period. The application of the new standard resulted in reclassification to other income of $191.3 million for the nine months ended September 30, 2017, while increasing cost of sales by $60.5 million, marketing, selling, and administrative expenses by $69.0 million, and research and development expenses by $61.8 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.


The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on our financial statements:
Standard
 
Description
 
Effective Date
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases
 
This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.
 
This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt on that date.
 
We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Divestiture and Acquisitions (Policies)
 9 Months Ended
Sep. 30, 2018
Business Combinations [Abstract]  
Business Combinations Policy
Upon acquisition, the acquired in-process research and development (IPR&D) charges related to these products were immediately expensed because the products had no alternative future use.
Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition have been included in our consolidated condensed financial statements from the date of acquisition.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments (Policies)
 9 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Description of Derivative Risk Management Policy
Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.
For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of gains and losses is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the effective portion of foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change.
We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Revenue Basis of Presentation and Revenue (Tables)
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of revenue recognized in our consolidated condensed statements of operations
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Net product revenue
$
5,664.5

 
$
5,323.8

 
$
16,905.6

 
$
15,841.5

Collaboration and other revenue (1)
397.4

 
334.2

 
1,211.5

 
869.1

Revenue
$
6,061.9

 
$
5,658.0

 
$
18,117.1

 
$
16,710.6


(1) Collaboration and other revenue associated with prior year transfers of intellectual property was $76.2 million and $258.4 million during the three and nine months ended September 30, 2018, respectively, and $36.7 million and $105.5 million during the three and nine months ended September 30, 2017, respectively.
Schedule of amounts recorded for contract liabilities
We have the following amounts recorded for contract liabilities:
 
September 30, 2018
 
December 31, 2017
Contract liabilities
$
308.6

 
$
335.2
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Implementation of New Accounting Pronouncements (Tables)
 9 Months Ended
Sep. 30, 2018
Accounting Changes and Error Corrections [Abstract]  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles
The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:
Standard
 
Description
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers
 
This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.
 
Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 12.
Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities
 
This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.
 
Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.
Standard
 
Description
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory
 
This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified
retrospective approach to adoption.
 
Upon adoption, the cumulative effect of applying the standard resulted in an increase to deferred tax assets and retained earnings of approximately $2.5 billion. Adoption of this standard did not result in a material change in net income for the three and nine months ended September 30, 2018.
Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost
 
This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component.
 
Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. The application of the new standard resulted in reclassification to other income of $63.8 million for the three months ended September 30, 2017, while increasing cost of sales by $20.2 million, marketing, selling, and administrative expenses by $23.0 million, and research and development expenses by $20.6 million for the same period. The application of the new standard resulted in reclassification to other income of $191.3 million for the nine months ended September 30, 2017, while increasing cost of sales by $60.5 million, marketing, selling, and administrative expenses by $69.0 million, and research and development expenses by $61.8 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.


The following table provides a brief description of the accounting standard that has not yet been adopted and could have a material effect on our financial statements:
Standard
 
Description
 
Effective Date
 
Effect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases
 
This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.
 
This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt on that date.
 
We are in the process of determining the impact on our consolidated financial statements. We have selected a software solution to be compatible with our enterprise software system. Development of our selected solution is ongoing, as it is not yet fully compliant with the requirements of the standard. The timely readiness of the lease software system is critical to ensure an efficient and effective adoption of the standard.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Divestiture and Acquisitions (Tables)
 9 Months Ended
Sep. 30, 2018
Business Acquisition [Line Items]  
Schedule of asset acquisition
The following table and narrative summarize our asset acquisitions during the nine months ended September 30, 2018 and September 30, 2017.
Counterparty
Compound(s) or Therapy
Acquisition Month
 
Phase of Development (1)
 
Acquired IPR&D Expense
Sigilon Therapeutics (Sigilon)
Encapsulated cell therapies for the potential treatment of type 1 diabetes
April 2018
 
Pre-clinical
 
$
66.9

AurKa Pharma, Inc. (AurKa)
AK-01, an Aurora kinase A inhibitor
June 2018
 
Phase I
 
81.8

ARMO Biosciences, Inc. (ARMO)
Cancer therapy - pegilodecakin
June 2018
 
Phase III
 
1,475.8

Anima Biotech (Anima)
Translation inhibitors for selected neuroscience targets
July 2018
 
Pre-clinical
 
30.0

 
 
 
 
 
 
 
CoLucid Pharmaceuticals, Inc. (CoLucid)
Oral therapy for the acute treatment of migraine - lasmiditan
March 2017
 
Phase III
 
857.6

KeyBioscience AG (KeyBioscience)
Multiple molecules for treatment of metabolic disorders
July 2017
 
Phase II
 
55.0

Nektar Therapeutics (Nektar)
Immunological therapy - NKTR-358
August 2017
 
Phase I
 
150.0


(1) The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.
Boehringer Ingelheim Vetmedica, Inc.'s U.S. Vaccine Portfolio  
Business Acquisition [Line Items]  
Schedule of the amounts recognized for assets acquired and liabilities assumed as of the acquisition date
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at January 3, 2017
Inventories
$
108.6

Marketed products (1)
297.0

Property and equipment
148.2

Other assets and liabilities - net
8.2

Total identifiable net assets
562.0

Goodwill (2)
320.1

Total consideration transferred - net of cash acquired
$
882.1


(1) These intangible assets, which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 10 years.
(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy animal health business, future unidentified projects and products, and the assembled workforce of BIVIVP. The goodwill associated with this acquisition is deductible for tax purposes.
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborations and Other Arrangements (Tables)
 9 Months Ended
Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of revenue recognized
tones.
The following table summarizes our milestones achieved:
Year
Event
Classification
Amount
2016
Regulatory submissions in the U.S. and Europe
R&D expense
$
55.0

2017
Regulatory approval in Europe
Intangible asset
65.0

Regulatory approval in Japan
Intangible asset
15.0

Began Phase III testing for atopic dermatitis
R&D expense
30.0

2018
Regulatory approval in the U.S.
Intangible asset
100.0

Began Phase III testing for SLE
R&D Expense
20.0
Schedule of exclusive marketing rights in certain other territories.
We and Daiichi Sankyo each have exclusive marketing rights in certain other territories.
Territory
 
Marketing Rights
 
Selling Party
U.S.
 
Co-promotion
 
Lilly
Major European markets
 
Co-promotion
 
Daiichi Sankyo
Japan
 
Exclusive
 
Daiichi Sankyo
Diabetes Collaboration  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of revenue recognized
The table below summarizes significant regulatory and commercialization events and milestones (deferred) capitalized for the compounds included in this collaboration:
 
 
Year Launched
 
Milestones
(Deferred) Capitalized (1)
Product Family
 
U.S.
 
Europe
 
Japan
 
Year
Amount
Trajenta (2)
 
2011
 
2011
 
2011
 
Cumulative (4) - all prior to 2017
$
446.4

Jardiance (3)
 
2014
 
2014
 
2015
 
Cumulative (4) - all prior to 2017
299.5

Basaglar
 
2016
 
2015
 
2015
 
Cumulative (4) - all prior to 2017
(250.0
)

(1) In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration.
(2) Jentadueto is included in the Trajenta product family. The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
(3) Glyxambi and Synjardy are included in the Jardiance product family. The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
(4) The cumulative amount represents the total initial amounts that were (deferred) or capitalized from the start of this collaboration through the end of the reporting period.
Bi Compounds  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of revenue recognized
The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Basaglar
$
201.2

 
$
145.7

 
$
569.0

 
$
278.3

Jardiance
166.9

 
127.2

 
465.1

 
304.3

Trajenta
135.7

 
153.3

 
418.5

 
408.2
Erbitux  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of revenue recognized
The following table summarizes our revenue recognized with respect to Erbitux:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Net product revenue
$
133.7

 
$
137.6

 
$
397.0

 
$
403.3

Collaboration and other revenue
25.8

 
25.9

 
78.5

 
73.7

Revenue
$
159.5


$
163.5


$
475.5


$
477.0
Effient  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of revenue recognized
The following table summarizes our revenue recognized with respect to Effient:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Revenue
$
45.3

 
$
55.9

 
$
104.8

 
$
326.6
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Impairment, Restructuring, and Other Special Charges (Tables)
 9 Months Ended
Sep. 30, 2018
Restructuring and Related Activities [Abstract]  
The components of the charges included in asset impairment, restructuring, and other special charges
The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below.
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Severance:
 
 
 
 
 
 
 
Human pharmaceutical products
$
—

 
$
165.7

 
$
(24.7
)
 
$
277.1

Animal health products
(5.4
)
 
5.8

 
(0.6
)
 
62.1

Total severance
(5.4
)
 
171.5

 
(25.3
)
 
339.2

Asset impairment and other special charges:
 
 
 
 
 
 
 
Human pharmaceutical products
3.5

 
25.0

 
2.0

 
25.0

Animal health products
85.2

 
210.0

 
259.3

 
306.2

Total asset impairment and other special charges
88.7

 
235.0

 
261.3

 
331.2

Total asset impairment, restructuring, and other special charges
$
83.3

 
$
406.5

 
$
236.0

 
$
670.4
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Schedule of effects of risk-management instruments were recognized in other–net, (income) expense
The following effects of risk-management instruments were recognized in other–net, (income) expense:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Fair value hedges:
 
 
 
 
 
 
 
Effect from hedged fixed-rate debt
$
(19.6
)
 
$
(4.0
)
 
$
(94.1
)
 
$
3.6

Effect from interest rate contracts
19.6

 
4.0

 
94.1

 
(3.6
)
Cash flow hedges:
 
 
 
 
 
 
 
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss
3.7

 
3.7

 
11.1

 
11.1

Net losses on foreign currency exchange contracts not designated as hedging instruments
0.7

 
16.3

 
76.5

 
79.2
Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss)
The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Net investment hedges:
 
 
 
 
 
 
 
    Foreign currency-denominated notes
$
(47.8
)
 
$
(58.7
)
 
$
53.0

 
$
(332.0
)
    Cross-currency interest rate swaps
14.7

 
(38.2
)
 
52.3

 
(95.8
)
Cash flow hedges:
 
 
 
 
 
 
 
    Forward-starting interest rate swaps
—

 
—

 
—

 
13.0
Summary certain fair value information
The following tables summarize certain fair value information at September 30, 2018 and December 31, 2017 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: 
 
 
 
 
 
Fair Value Measurements Using
 
 
 
Carrying
Amount
 
Cost (1)
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Fair
Value
September 30, 2018
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
$
6,646.3

 
$
6,646.3

 
$
6,646.3

 
$
—

 
$
—

 
$
6,646.3

 
 
 
 
 
 
 
 
 
 
 
 
Short-term investments:
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
$
10.5

 
$
10.6

 
$
10.5

 
$
—

 
$
—

 
$
10.5

Corporate debt securities
52.7

 
52.7

 
—

 
52.7

 
—

 
52.7

Asset-backed securities
11.5

 
11.6

 
—

 
11.5

 
—

 
11.5

Other securities
1.4

 
1.4

 
—

 
1.4

 
—

 
1.4

Short-term investments
$
76.1

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noncurrent investments:
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
$
152.0

 
$
159.6

 
$
152.0

 
$
—

 
$
—

 
$
152.0

Corporate debt securities
622.0

 
631.5

 
—

 
622.0

 
—

 
622.0

Mortgage-backed securities
109.5

 
114.1

 
—

 
109.5

 
—

 
109.5

Asset-backed securities
27.0

 
27.3

 
—

 
27.0

 
—

 
27.0

Other securities
137.4

 
39.3

 
—

 
—

 
137.4

 
137.4

Marketable equity securities
287.9

 
146.4

 
287.9

 
—

 
—

 
287.9

Equity investments without readily determinable fair values (2)
394.7

 
 
 
 
 
 
 
 
 
 
Equity method investments (2)
275.3

 
 
 
 
 
 
 
 
 
 
Noncurrent investments
$
2,005.8

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2017
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
$
4,763.9

 
$
4,763.9

 
$
4,712.4

 
$
51.5

 
$
—

 
$
4,763.9

 
 
 
 
 
 
 
 
 
 
 
 
Short-term investments:
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
$
217.8

 
$
218.2

 
$
217.8

 
$
—

 
$
—

 
$
217.8

Corporate debt securities
1,182.3

 
1,183.2

 
—

 
1,182.3

 
—

 
1,182.3

Asset-backed securities
94.2

 
94.3

 
—

 
94.2

 
—

 
94.2

Other securities
3.6

 
3.6

 
—

 
3.6

 
—

 
3.6

Short-term investments
$
1,497.9

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noncurrent investments:
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
$
360.0

 
$
365.0

 
$
360.0

 
$
—

 
$
—

 
$
360.0

Corporate debt securities
3,464.3

 
3,473.5

 
—

 
3,464.3

 
—

 
3,464.3

Mortgage-backed securities
202.4

 
204.2

 
—

 
202.4

 
—

 
202.4

Asset-backed securities
653.9

 
656.0

 
—

 
653.9

 
—

 
653.9

Other securities
132.1

 
66.4

 
—

 
—

 
132.1

 
132.1

Marketable equity securities
281.3

 
131.0

 
281.3

 
—

 
—

 
281.3

Cost and equity method investments (2)
584.8

 
 
 
 
 
 
 
 
 
 
Noncurrent investments
$
5,678.8

 
 
 
 
 
 
 
 
 
 

(1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.
(2) Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments that do not have readily determinable fair values.
Summary certain fair value information, liabilities
 
 
 
Fair Value Measurements Using
 
 
 
Carrying
Amount
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant
Other Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Fair
Value
Short-term commercial paper borrowings
 
 
 
 
 
 
 
 
 
September 30, 2018
$
(399.7
)
 
$
—

 
$
(398.4
)
 
$
—

 
$
(398.4
)
December 31, 2017
(2,696.8
)
 
—

 
(2,690.6
)
 
—

 
(2,690.6
)
Long-term debt, including current portion
 
 
 
 
 
 
 
 
 
September 30, 2018
$
(12,277.1
)
 
$
—

 
$
(12,542.2
)
 
$
—

 
$
(12,542.2
)
December 31, 2017
(10,950.3
)
 
—

 
(11,529.9
)
 
—

 
(11,529.9
)
Fair value, by balance sheet grouping
 
 
 
Fair Value Measurements Using
 
 
 
Carrying
Amount
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant
Other Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Fair
Value
September 30, 2018
 
 
 
 
 
 
 
 
 
Risk-management instruments:
 
 
 
 
 
 
 
 
 
Interest rate contracts designated as fair value hedges:
 
 
 
 
 
 
 
 
 
Other current liabilities
$
(2.7
)
 
$
—

 
$
(2.7
)
 
$
—

 
$
(2.7
)
Other noncurrent liabilities
(66.5
)
 
—

 
(66.5
)
 
—

 
(66.5
)
Cross-currency interest rate contracts designated as net investment hedges:
 
 
 
 
 
 
 
 
 
Other receivables
30.3

 
—

 
30.3

 
—

 
30.3

Sundry
6.9

 
—

 
6.9

 
—

 
6.9

Other current liabilities
(16.6
)
 
—

 
(16.6
)
 
—

 
(16.6
)
Foreign exchange contracts not designated as hedging instruments:
 
 
 
 
 
 
 
 
 
Other receivables
6.3

 
—

 
6.3

 
—

 
6.3

Other current liabilities
(14.0
)
 
—

 
(14.0
)
 
—

 
(14.0
)
Contingent consideration liabilities:
 
 
 
 
 
 
 
 
 
Other current liabilities
(62.0
)
 
—

 
—

 
(62.0
)
 
(62.0
)
Other noncurrent liabilities
(41.4
)
 
—

 
—

 
(41.4
)
 
(41.4
)
 
 
 
 
 
 
 
 
 
 
December 31, 2017
 
 
 
 
 
 
 
 
 
Risk-management instruments:
 
 
 
 
 
 
 
 
 
Interest rate contracts designated as fair value hedges:
 
 
 
 
 
 
 
 
 
Other receivables
$
0.8

 
$
—

 
$
0.8

 
$
—

 
$
0.8

Sundry
35.1

 
—

 
35.1

 
—

 
35.1

Other current liabilities
(0.2
)
 
—

 
(0.2
)
 
—

 
(0.2
)
Other noncurrent liabilities
(10.5
)
 
—

 
(10.5
)
 
—

 
(10.5
)
Cross-currency interest rate contracts designated as net investment hedges:
 
 
 
 
 
 
 
 
 
Other current liabilities
(33.4
)
 
—

 
(33.4
)
 
—

 
(33.4
)
Other noncurrent liabilities
(26.0
)
 
—

 
(26.0
)
 
—

 
(26.0
)
Foreign exchange contracts not designated as hedging instruments:
 
 
 
 
 
 
 
 
 
Other receivables
26.8

 
—

 
26.8

 
—

 
26.8

Other current liabilities
(36.0
)
 
—

 
(36.0
)
 
—

 
(36.0
)
Contingent consideration liabilities (1):
 
 
 
 
 
 
 
 
 
Other current liabilities
(208.0
)
 
—

 
—

 
(208.0
)
 
(208.0
)
Other noncurrent liabilities
(45.2
)
 
—

 
—

 
(45.2
)
 
(45.2
)
(1) Contingent consideration liabilities primarily relate to the Erbitux arrangement with BMS discussed in Note 4.
Summary the contractual maturities of our investments in debt securities measured at fair value
A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows: 
 
September 30, 2018
 
December 31, 2017
Unrealized gross gains
$
2.1

 
$
184.7

Unrealized gross losses
24.4

 
47.5

Fair value of securities in an unrealized gain position
164.0

 
1,434.2

Fair value of securities in an unrealized loss position
816.7

 
4,692.8

The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September 30, 2018:
 
Maturities by Period
  
Total
 
Less Than
1 Year
 
1-5
Years
 
6-10
Years
 
More Than
10 Years
Fair value of debt securities
$
985.1

 
$
74.7

 
$
620.5

 
$
135.4

 
$
154.5
Summary of the amount of unrealized gains and losses (pretax) recognized in our statement of operations for equity securities
A summary of the unrealized gains and losses (pretax) recognized in our consolidated condensed statements of operations for equity securities held as of September 30, 2018 is as follows:
 
Three Months Ended
September 30,
Nine Months Ended
September 30,
Unrealized gain (loss), net
$
(40.8
)
$
(3.4
)
Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities
Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities, was as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Proceeds from sales
$
52.0

 
$
951.5

 
$
5,598.4

 
$
3,003.0

Realized gross gains on sales
0.4

 
9.0

 
8.1

 
82.9

Realized gross losses on sales
0.7

 
0.8

 
49.7

 
3.2
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Retirement Benefits (Tables)
 9 Months Ended
Sep. 30, 2018
Defined Benefit Pension Plans  
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]  
Schedule of net pension and retiree health benefit (income) cost
Net pension and retiree health benefit (income) cost included the following components:
 
Defined Benefit Pension Plans
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Components of net periodic benefit cost:
 
 
 
 
 
 
 
Service cost
$
74.2

 
$
86.0

 
$
232.3

 
$
251.6

Interest cost
117.9

 
103.6

 
342.5

 
309.2

Expected return on plan assets
(212.7
)
 
(196.4
)
 
(636.3
)
 
(585.7
)
Amortization of prior service cost
1.1

 
1.4

 
3.6

 
4.3

Recognized actuarial loss
79.2

 
72.5

 
261.2

 
215.6

Curtailment loss
1.3

 
—

 
1.3

 
—

Net periodic benefit cost
$
61.0

 
$
67.1

 
$
204.6

 
$
195.0
Retiree Health Benefit Plans  
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]  
Schedule of net pension and retiree health benefit (income) cost
 
Retiree Health Benefit Plans
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Components of net periodic benefit income:
 
 
 
 
 
 
 
Service cost
$
10.1

 
$
11.6

 
$
31.7

 
$
34.8

Interest cost
14.9

 
13.2

 
42.3

 
39.6

Expected return on plan assets
(44.8
)
 
(40.2
)
 
(132.7
)
 
(120.6
)
Amortization of prior service benefit
(19.3
)
 
(22.5
)
 
(60.2
)
 
(67.5
)
Recognized actuarial loss
0.8

 
4.6

 
5.4

 
13.8

Curtailment gain
(29.3
)
 
—

 
(29.3
)
 
—

Net periodic benefit income
$
(67.6
)
 
$
(33.3
)
 
$
(142.8
)
 
$
(99.9
)
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2018
Statement of Comprehensive Income [Abstract]  
Schedule of components of other comprehensive income (loss)
The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September 30, 2018 and 2017:
(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)
 
Unrealized Net Gains (Losses) on Securities
 
Defined Benefit Pension and Retiree Health Benefit Plans
 
Effective Portion of Cash Flow Hedges
 
Accumulated Other Comprehensive Loss
Balance at July 1, 2018
$
(1,671.5
)
 
$
(18.1
)
 
$
(4,190.6
)
 
$
(228.5
)
 
$
(6,108.7
)
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
60.6

 
1.1

 
548.6

 
—

 
610.3

Net amount reclassified from accumulated other comprehensive loss
—

 
(0.2
)
 
47.2

 
2.9

 
49.9

Net other comprehensive income (loss)
60.6

 
0.9

 
595.8

 
2.9

 
660.2

 
 
 
 
 
 
 
 
 
 
Balance at September 30, 2018 (4)
$
(1,610.9
)
 
$
(17.2
)
 
$
(3,594.8
)
 
$
(225.6
)
 
$
(5,448.5
)
(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)
 
Unrealized Net Gains (Losses) on Securities
 
Defined Benefit Pension and Retiree Health Benefit Plans
 
Effective Portion of Cash Flow Hedges
 
Accumulated Other Comprehensive Loss
Balance at July 1, 2017
$
(1,349.4
)
 
$
153.2

 
$
(3,348.5
)
 
$
(197.6
)
 
$
(4,742.3
)
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
135.8

 
33.9

 
(28.7
)
 
—

 
141.0

Net amount reclassified from accumulated other comprehensive loss
8.1

 
(23.9
)
 
40.1

 
2.4

 
26.7

Net other comprehensive income (loss)
143.9

 
10.0

 
11.4

 
2.4

 
167.7

 
 
 
 
 
 
 
 
 
 
Balance at September 30, 2017 (1)
$
(1,205.5
)
 
$
163.2

 
$
(3,337.1
)
 
$
(195.2
)
 
$
(4,574.6
)
The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September 30, 2018 and 2017:
(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)
 
Unrealized Net Gains (Losses) on Securities
 
Defined Benefit Pension and Retiree Health Benefit Plans
 
Effective Portion of Cash Flow Hedges
 
Accumulated Other Comprehensive Loss
Balance at January 1, 2018 (2)
$
(1,233.4
)
 
$
113.5

 
$
(4,340.7
)
 
$
(234.3
)
 
$
(5,694.9
)
 
 
 
 
 
 
 
 
 
 
Reclassification due to adoption of new accounting standard (3)
—

 
(128.9
)
 
—

 
—

 
(128.9
)
Other comprehensive income (loss) before reclassifications
(377.5
)
 
31.0

 
581.0

 
—

 
234.5

Net amount reclassified from accumulated other comprehensive loss
—

 
(32.8
)
 
164.9

 
8.7

 
140.8

Net other comprehensive income (loss)
(377.5
)
 
(1.8
)
 
745.9

 
8.7

 
375.3

 
 
 
 
 
 
 
 
 
 
Balance at September 30, 2018 (4)
$
(1,610.9
)
 
$
(17.2
)
 
$
(3,594.8
)
 
$
(225.6
)
 
$
(5,448.5
)

(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)
 
Unrealized Net Gains (Losses) on Securities
 
Defined Benefit Pension and Retiree Health Benefit Plans
 
Effective Portion of Cash Flow Hedges
 
Accumulated Other Comprehensive Loss
Balance at January 1, 2017 (2)
$
(1,867.3
)
 
$
224.0

 
$
(3,371.6
)
 
$
(210.9
)
 
$
(5,225.8
)
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
653.7

 
9.6

 
(83.3
)
 
8.4

 
588.4

Net amount reclassified from accumulated other comprehensive loss
8.1

 
(70.4
)
 
117.8

 
7.3

 
62.8

Net other comprehensive income (loss)
661.8

 
(60.8
)
 
34.5

 
15.7

 
651.2

 
 
 
 
 
 
 
 
 
 
Balance at September 30, 2017 (1)
$
(1,205.5
)
 
$
163.2

 
$
(3,337.1
)
 
$
(195.2
)
 
$
(4,574.6
)
(1) Accumulated other comprehensive loss as of September 30, 2017 consists of $4.61 billion of accumulated other comprehensive loss attributable to controlling interest and $34.8 million of accumulated other comprehensive income attributable to noncontrolling interest.
(2) Accumulated other comprehensive loss as of January 1, 2018 consists of $5.72 billion of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive income attributable to noncontrolling interest. Accumulated other comprehensive loss as of January 1, 2017 consists of $5.27 billion of accumulated other comprehensive loss attributable to controlling interest and $48.2 million of accumulated other comprehensive income attributable to noncontrolling interest.
(3) This reclassification consists of $104.8 million of accumulated other comprehensive loss attributable to controlling interest and $24.1 million of accumulated other comprehensive loss attributable to noncontrolling interest. Refer to Note 2 for further details regarding the reclassification due to the adoption of Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.
(4) Accumulated other comprehensive loss as of September 30, 2018 consists of $5.44 billion of accumulated other comprehensive loss attributable to controlling interest and $9.0 million of accumulated other comprehensive loss attributable to noncontrolling interest.
The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
Tax benefit (expense)
2018
 
2017
 
2018
 
2017
Foreign currency translation gains/losses
$
7.0

 
$
33.9

 
$
(11.2
)
 
$
149.7

Unrealized net gains/losses on securities
(0.2
)
 
(4.2
)
 
1.1

 
25.4

Defined benefit pension and retiree health benefit plans
(152.4
)
 
(9.4
)
 
(190.3
)
 
(24.0
)
Effective portion of cash flow hedges
(0.8
)
 
(1.3
)
 
(2.3
)
 
(8.4
)
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items
$
(146.4
)

$
19.0


$
(202.7
)

$
142.7
Schedule of reclassifications out of accumulated other comprehensive loss
Reclassifications out of accumulated other comprehensive loss were as follows:
 
Details about Accumulated Other Comprehensive Loss Components
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
Affected Line Item in the Consolidated Condensed Statements of Operations
 
 
 
2018
 
2017
 
2018
 
2017
 
Amortization of retirement benefit items:
 
 
 
 
 
 
 
 
 
 
Prior service benefits, net
 
$
(18.2
)
 
$
(21.1
)
 
$
(56.6
)
 
$
(63.2
)
(1) 
 
Actuarial losses, net
 
80.0

 
77.1

 
266.6

 
229.4

(1) 
 
Total before tax
 
61.8

 
56.0

 
210.0

 
166.2

 
 
Tax benefit
 
(14.6
)
 
(15.9
)
 
(45.1
)
 
(48.4
)
Income taxes
 
Net of tax
 
47.2

 
40.1

 
164.9

 
117.8

 
 
 
 
 
 
 
 
 
 
 
 
 
Unrealized gains/losses on available-for-sale securities:
 
 
 
 
 
 
 
 
 
 
Realized (gains), losses, net
 
(0.3
)
 
(36.7
)
 
(41.6
)
 
(108.2
)
Other–net, (income) expense
 
Tax (benefit) expense
 
0.1

 
12.8

 
8.8

 
37.8

Income taxes
 
Net of tax
 
(0.2
)
 
(23.9
)
 
(32.8
)
 
(70.4
)
 
 
Other, net of tax
 
2.9

 
10.5

 
8.7

 
15.4

Other–net, (income) expense
 
Total reclassifications for the period (net of tax)
 
$
49.9

 
$
26.7

 
$
140.8

 
$
62.8

 
(1) These accumulated other comprehensive loss components are included in the computation of net periodic benefit (income) cost (see Note 8).
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other - Net, (Income) Expense (Tables)
 9 Months Ended
Sep. 30, 2018
Nonoperating Income (Expense) [Abstract]  
Schedule of other–net, (income) expense
Other–net, (income) expense consisted of the following:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Interest expense
$
69.4

 
$
61.9

 
$
193.9

 
$
162.1

Interest income
(32.1
)
 
(45.1
)
 
(118.8
)
 
(114.6
)
Retirement benefit
(62.9
)
 
(63.8
)
 
(174.2
)
 
(191.3
)
Other income
41.0

 
(2.9
)
 
9.0

 
(44.8
)
Other–net, (income) expense
$
15.4


$
(49.9
)

$
(90.1
)

$
(188.6
)
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Schedule of segment reporting information, by segment
 
Three Months Ended
September 30,
 
2018
 
2017
 
U.S. (1)
Outside U.S.
Total
 
U.S. (1)
Outside U.S.
Total
Segment revenue—to unaffiliated customers:
 
 
 
 
 
 
 
Human pharmaceutical products:
 
 
 
 
 
 
 
Endocrinology:
 
 
 
 
 
 
 
Trulicity®
$
645.9

$
170.3

$
816.2

 
$
412.9

$
114.8

$
527.7

Humalog®
365.6

299.0

664.6

 
414.9

281.3

696.2

Forteo®
182.5

208.3

390.8

 
234.1

207.6

441.7

Humulin®
216.9

105.1

322.1

 
203.0

97.5

300.5

Basaglar
157.3

43.9

201.2

 
115.2

30.5

145.7

Jardiance
104.2

62.7

166.9

 
83.8

43.4

127.2

Trajenta
50.3

85.3

135.7

 
68.4

84.9

153.3

Other Endocrinology
73.8

66.8

140.4

 
92.1

76.3

168.4

Total Endocrinology
1,796.5

1,041.4

2,837.9

 
1,624.4

936.3

2,560.7

 
 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
 
Alimta
288.5

232.0

520.5

 
260.3

254.2

514.5

Cyramza®
67.0

131.4

198.4

 
69.5

126.5

196.0

Erbitux
132.6

26.9

159.5

 
136.0

27.4

163.5

Other Oncology
131.7

54.1

185.8

 
43.5

40.2

83.6

Total Oncology
619.8

444.4

1,064.2

 
509.3

448.3

957.6

 
 
 
 
 
 
 
 
Cardiovascular:
 
 
 
 
 
 
 
Cialis®
295.9

171.2

467.1

 
319.6

245.3

564.9

Effient
30.2

15.1

45.3

 
42.7

13.1

55.9

Other Cardiovascular
39.7

31.7

71.4

 
4.9

37.3

42.1

Total Cardiovascular
365.8

218.0

583.8

 
367.2

295.7

662.9

 
 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
 
Cymbalta
14.5

157.5

172.0

 
19.6

163.5

183.2

Zyprexa®
7.0

102.8

109.9

 
12.6

128.0

140.6

Strattera®
10.5

88.2

98.7

 
52.9

84.1

137.1

Other Neuroscience
23.8

23.0

46.6

 
23.3

23.7

46.8

Total Neuroscience
55.8

371.5

427.2

 
108.4

399.3

507.7

 
 
 
 
 
 
 
 
Immunology:
 
 
 
 
 
 
 
Taltz®
210.6

53.3

263.9

 
131.3

20.0

151.3

Other Immunology
0.8

54.8

55.6

 
—

16.3

16.3

Total Immunology
211.4

108.1

319.5

 
131.3

36.3

167.6

 
 
 
 
 
 
 
 
Other pharmaceuticals
13.4

43.2

56.6

 
10.7

50.2

60.9

Total human pharmaceutical products
3,062.7

2,226.5

5,289.2

 
2,751.3

2,166.1

4,917.4

Animal health products
383.9

388.8

772.7

 
353.0

387.6

740.6

Revenue
$
3,446.6

$
2,615.3

$
6,061.9

 
$
3,104.4

$
2,553.6

$
5,658.0

 
Nine Months Ended
September 30,
 
2018
 
2017
 
U.S. (1)
Outside U.S.
Total
 
U.S. (1)
Outside U.S.
Total
Segment revenue—to unaffiliated customers:
 
 
 
 
 
 
 
Human pharmaceutical products:
 
 
 
 
 
 
 
Endocrinology:
 
 
 
 
 
 
 
Trulicity
$
1,786.5

$
487.8

$
2,274.3

 
$
1,090.1

$
290.7

$
1,380.8

Humalog
1,334.2

891.8

2,226.1

 
1,254.3

828.6

2,083.0

Forteo
529.7

608.8

1,138.5

 
661.5

574.3

1,235.8

Humulin
677.3

316.7

994.0

 
634.9

337.9

972.8

Basaglar
440.4

128.5

569.0

 
196.7

81.6

278.3

Jardiance
284.8

180.3

465.1

 
198.3

105.9

304.3

Trajenta
161.3

257.2

418.5

 
174.2

234.1

408.2

Other Endocrinology
199.4

206.9

406.1

 
283.4

228.5

511.8

Total Endocrinology
5,413.6

3,078.0

8,491.6

 
4,493.4

2,681.6

7,175.0

 
 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
 
Alimta
815.1

760.9

1,576.0

 
761.9

775.4

1,537.3

Cyramza
210.7

390.1

600.8

 
204.3

349.2

553.5

Erbitux
394.0

81.6

475.5

 
398.2

78.8

477.0

Other Oncology
321.4

157.1

478.6

 
128.4

104.3

232.7

Total Oncology
1,741.2

1,389.7

3,130.9

 
1,492.8

1,307.7

2,800.5

 
 
 
 
 
 
 
 
Cardiovascular:
 
 
 
 
 
 
 
Cialis
954.9

546.2

1,501.2

 
997.3

728.5

1,725.7

Effient
59.4

45.3

104.8

 
290.8

35.8

326.6

Other Cardiovascular
143.7

96.3

239.7

 
20.5

99.6

120.2

Total Cardiovascular
1,158.0

687.8

1,845.7

 
1,308.6

863.9

2,172.5

 
 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
 
Cymbalta
39.3

484.2

523.5

 
100.8

463.6

564.4

Zyprexa
27.6

332.8

360.4

 
49.3

379.6

428.9

Strattera
74.4

269.2

343.5

 
276.9

243.0

519.9

Other Neuroscience
72.2

71.2

143.5

 
88.4

72.2

160.5

Total Neuroscience
213.5

1,157.4

1,370.9

 
515.4

1,158.4

1,673.7

 
 
 
 
 
 
 
 
Immunology:
 
 
 
 
 
 
 
Taltz
495.3

135.1

630.4

 
343.6

43.1

386.7

Other Immunology
2.5

130.0

132.5

 
—

22.9

22.9

Total Immunology
497.8

265.1

762.9

 
343.6

66.0

409.6

 
 
 
 
 
 
 
 
Other pharmaceuticals
49.1

139.8

189.1

 
34.6

149.7

184.5

Total human pharmaceutical products
9,073.2

6,717.8

15,791.1

 
8,188.4

6,227.3

14,415.8

Animal health products
1,137.8

1,188.2

2,326.0

 
1,173.4

1,121.4

2,294.8

Revenue
$
10,211.0

$
7,906.1

$
18,117.1

 
$
9,361.8

$
7,348.7

$
16,710.6


Numbers may not add due to rounding.
(1) U.S. revenue includes revenue in Puerto Rico.
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Segment profits:
 
 
 
 
 
 
 
Human pharmaceutical products
$
1,514.0

 
$
1,242.5

 
$
4,751.0

 
$
3,765.7

Animal health products
162.6

 
121.9

 
461.9

 
422.6

Total segment profits
$
1,676.7

 
$
1,364.4

 
$
5,213.0

 
$
4,188.3

 
 
 
 
 
 
 
 
Reconciliation of total segment profits to consolidated income before taxes:
 
 
 
 
 
 
 
Segment profits
$
1,676.7

 
$
1,364.4

 
$
5,213.0

 
$
4,188.3

Other profits (losses):
 
 
 
 
 
 
 
Acquired in-process research and development (Note 3)
(30.0
)
 
(205.0
)
 
(1,654.5
)
 
(1,062.6
)
Amortization of intangible assets
(153.4
)
 
(155.8
)
 
(458.7
)
 
(510.0
)
Asset impairment, restructuring, and other special charges (Note 5)
(83.3
)
 
(406.5
)
 
(236.0
)
 
(670.4
)
Other, net
1.0

 
(5.5
)
 
(7.0
)
 
(32.0
)
Consolidated income before taxes
$
1,411.0

 
$
591.6

 
$
2,856.8

 
$
1,913.3

Numbers may not add due to rounding.
Schedule of revenue from external customers and long-lived assets, by geographical areas
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Geographic Information
 
 
 
 
 
 
 
Revenue—to unaffiliated customers (1):
 
 
 
 
 
 
 
United States
$
3,446.6

 
$
3,104.4

 
$
10,211.0

 
$
9,361.8

Europe
1,017.0

 
1,017.0

 
3,142.9

 
2,877.6

Japan
608.8

 
616.7

 
1,828.9

 
1,767.0

Other foreign countries
989.5

 
920.0

 
2,934.3

 
2,704.2

Revenue
$
6,061.9

 
$
5,658.0

 
$
18,117.1

 
$
16,710.6

Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Revenue Basis of Presentation and Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Disaggregation of Revenue [Line Items]          
Revenue $ 6,061.9 $ 5,658.0 $ 18,117.1 $ 16,710.6  
Payment term, minimum (in days)     30 days    
Payment term, maximum (in days)     75 days    
Contract liabilities 308.6   $ 308.6   $ 335.2
Product          
Disaggregation of Revenue [Line Items]          
Revenue 5,664.5 5,323.8 16,905.6 15,841.5  
Collaboration and Other Revenue          
Disaggregation of Revenue [Line Items]          
Revenue 397.4 334.2 1,211.5 869.1  
Royalty          
Disaggregation of Revenue [Line Items]          
Revenue $ 76.2 $ 36.7 $ 258.4 $ 105.5  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Implementation of New Financial Accounting Pronouncements (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Jan. 01, 2018
Dec. 31, 2017
Concentration Risk [Line Items]            
Accumulated other comprehensive loss $ 5,439.5   $ 5,439.5     $ 5,718.6
Retained earnings 14,408.7   14,408.7     13,894.1
Increase to deferred tax assets upon adoption 3,132.3   3,132.3     $ 1,166.4
Other, net (15.4) $ 49.9 90.1 $ 188.6    
Cost of sales 1,562.3 1,586.3 4,836.3 4,505.9    
Marketing, selling, and administrative 1,616.6 1,578.5 4,770.3 4,876.6    
Research and development $ 1,343.3 1,340.0 $ 3,853.3 3,870.4    
Accounting Standards Update 2016-01            
Concentration Risk [Line Items]            
Accumulated other comprehensive loss         $ 105.0  
Retained earnings         105.0  
Accounting Standards Update 2016-16            
Concentration Risk [Line Items]            
Retained earnings         2,500.0  
Increase to deferred tax assets upon adoption         2,500.0  
Accounting Standards Update 2017-07            
Concentration Risk [Line Items]            
Other, net   63.8   191.3    
Cost of sales   20.2   60.5    
Marketing, selling, and administrative   23.0   69.0    
Research and development   $ 20.6   $ 61.8    
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09            
Concentration Risk [Line Items]            
Retained earnings         $ 5.0  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Divestiture and Acquisitions (Formation of Elanco and IPO) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
Sep. 24, 2018
Sep. 30, 2018
Dec. 31, 2017
Sep. 30, 2017
Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Cash and cash equivalents   $ 8,960.0 $ 6,536.2 $ 3,724.3 $ 4,582.1
Noncontrolling interests   1,074.3 $ 75.7    
Elanco Animal Health Incorporated | Spin-off          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Cash Transfered From Subsidiary to Parent $ 4,200.0        
Sale of Elanco stock (Note 3) $ 629.2        
Elanco Animal Health Incorporated          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Percentage of ownership sold (percentage) 19.80%        
Cash and cash equivalents   300.0      
Noncontrolling interests   $ 1,020.0      
Elanco Animal Health Incorporated | IPO          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Number of shares sold (shares) 72.3        
Price per share sold (usd per share) $ 24        
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Divestiture and Acquisitions (Acquisitions) (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Nov. 30, 2018
Oct. 31, 2018
Jul. 31, 2018
Jun. 30, 2018
Apr. 30, 2018
Aug. 31, 2017
Jul. 31, 2017
Mar. 31, 2017
Jan. 31, 2017
Dec. 31, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Business Acquisition [Line Items]                            
Acquired in-process research and development                     $ 30.0 $ 205.0 $ 1,654.5 $ 1,062.6
Purchase of in-process research and development                         $ 1,578.2 $ 1,036.8
Boehringer Ingelheim Vetmedica, Inc.'s U.S. Vaccine Portfolio                            
Business Acquisition [Line Items]                            
All cash transaction                 $ 882.1          
Useful life (years)                 10 years          
Sigilon Therapeutics (Sigilon)                            
Business Acquisition [Line Items]                            
Acquired in-process research and development         $ 66.9                  
Purchase of in-process research and development         $ 62.5                  
AurKa Pharma, Inc. (AurKa)                            
Business Acquisition [Line Items]                            
Acquired in-process research and development       $ 81.8                    
Purchase of in-process research and development       81.3                    
Value of liabilities assumed       0.5                    
ARMO Biosciences, Inc. (ARMO)                            
Business Acquisition [Line Items]                            
Acquired in-process research and development       1,475.8                    
Purchase of in-process research and development       1,400.0                    
Value of liabilities assumed       $ 75.8                    
Anima Biotech (Anima)                            
Business Acquisition [Line Items]                            
Acquired in-process research and development     $ 30.0                      
CoLucid Pharmaceuticals, Inc. (CoLucid)                            
Business Acquisition [Line Items]                            
Acquired in-process research and development               $ 857.6            
Purchase of in-process research and development               831.8            
Value of liabilities assumed               $ 25.8            
KeyBioscience AG (KeyBioscience)                            
Business Acquisition [Line Items]                            
Acquired in-process research and development             $ 55.0              
Nektar Therapeutics (Nektar)                            
Business Acquisition [Line Items]                            
Acquired in-process research and development           $ 150.0                
Scenario, Forecast | Chugai Pharmaceutical Company                            
Business Acquisition [Line Items]                            
Acquired in-process research and development                   $ 50.0        
Purchase of in-process research and development                   50.0        
Scenario, Forecast | Priority Review Voucher                            
Business Acquisition [Line Items]                            
Acquired in-process research and development                   80.0        
All cash transaction $ 80.0                          
Scenario, Forecast | NextCure, Inc.                            
Business Acquisition [Line Items]                            
Acquired in-process research and development                   $ 30.0        
Purchase of in-process research and development $ 25.0                          
Subsequent Event | Dicerna Pharmaceuticals                            
Business Acquisition [Line Items]                            
Acquired in-process research and development   $ 135.0                        
Purchase of in-process research and development   $ 100.0                        
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Divestiture and Acquisitions (Purchased Price) (Details) - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Jan. 03, 2017
Business Acquisition [Line Items]      
Goodwill $ 4,358.4 $ 4,370.1  
Boehringer Ingelheim Vetmedica, Inc.'s U.S. Vaccine Portfolio      
Business Acquisition [Line Items]      
Inventories     $ 108.6
Marketed products     297.0
Property and equipment     148.2
Other assets and liabilities - net     8.2
Total identifiable net assets     562.0
Goodwill     320.1
Total consideration transferred - net of cash acquired     $ 882.1
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborations and Other Arrangements (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended 24 Months Ended 36 Months Ended 72 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2016
Dec. 31, 2016
Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue $ 6,061.9 $ 5,658.0 $ 18,117.1 $ 16,710.6          
Research and development 1,343.3 1,340.0 $ 3,853.3 3,870.4          
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Trajenta                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestones (deferred) capitalized                 $ 446.4
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Jardiance                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestones (deferred) capitalized               $ 299.5  
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Basaglar                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestones (deferred) capitalized             $ (250.0)    
Sales | Erbitux                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative arrangement, rights and obligations (percentage)     38.00%            
Royalty Agreement Terms | Olumiant                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative arrangement, rights and obligations (percentage)     20.00%            
Research and Development Exp | Olumiant                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative arrangement, rights and obligations (percentage)     30.00%            
Milestone Payments, Development and Regulatory, Expensed | Olumiant                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Research and development     $ 20.0   $ 30.0 $ 55.0      
Milestone Payments, Development and Regulatory | Olumiant                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestones (deferred) capitalized     130.0            
Milestone Payments, Development and Regulatory | Tanezumab                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestones (deferred) capitalized     350.0            
Milestone Payments, Sales-based | Olumiant                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestones (deferred) capitalized     150.0            
Milestone Payments, Sales-based | Tanezumab                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestones (deferred) capitalized     $ 1,230.0            
Profit and Development and Marketing Share | Effient                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative arrangement, rights and obligations (percentage)     50.00%            
Human pharmaceutical products                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 5,289.2 4,917.4 $ 15,791.1 14,415.8          
Human pharmaceutical products | Trajenta                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 135.7 153.3 418.5 408.2          
Human pharmaceutical products | Jardiance                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 166.9 127.2 465.1 304.3          
Human pharmaceutical products | Basaglar                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 201.2 145.7 569.0 278.3          
Human pharmaceutical products | Erbitux                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 159.5 163.5 475.5 477.0          
Human pharmaceutical products | Product                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 133.7 137.6 397.0 403.3          
Human pharmaceutical products | Collaboration and Other Revenue                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 25.8 25.9 78.5 73.7          
Human pharmaceutical products | Effient                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 45.3 55.9 104.8 326.6          
Europe                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 1,017.0 1,017.0 3,142.9 2,877.6          
Europe | Milestone Payments, Development and Regulatory, Capitalized (Deferred) | Olumiant                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestones (deferred) capitalized         65.0        
Japan                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 608.8 616.7 1,828.9 1,767.0          
Japan | Milestone Payments, Development and Regulatory, Capitalized (Deferred) | Olumiant                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestones (deferred) capitalized         $ 15.0        
U.S.                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 3,446.6 3,104.4 10,211.0 9,361.8          
U.S. | Milestone Payments, Development and Regulatory, Capitalized (Deferred) | Olumiant                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestones (deferred) capitalized     100.0            
U.S. | Human pharmaceutical products                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 3,062.7 2,751.3 9,073.2 8,188.4          
U.S. | Human pharmaceutical products | Trajenta                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 50.3 68.4 161.3 174.2          
U.S. | Human pharmaceutical products | Jardiance                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 104.2 83.8 284.8 198.3          
U.S. | Human pharmaceutical products | Basaglar                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 157.3 115.2 440.4 196.7          
U.S. | Human pharmaceutical products | Erbitux                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue 132.6 136.0 394.0 398.2          
U.S. | Human pharmaceutical products | Effient                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue $ 30.2 $ 42.7 $ 59.4 $ 290.8          
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Impairment, Restructuring, and Other Special Charges (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Restructuring Cost and Reserve [Line Items]        
Severance $ (5.4) $ 171.5 $ (25.3) $ 339.2
Total asset impairment and other special charges 88.7 235.0 261.3 331.2
Asset impairment and other special charges 83.3 406.5 236.0 670.4
Human pharmaceutical products        
Restructuring Cost and Reserve [Line Items]        
Severance 0.0 165.7 (24.7) 277.1
Total asset impairment and other special charges 3.5 25.0 2.0 25.0
Animal health products        
Restructuring Cost and Reserve [Line Items]        
Severance (5.4) 5.8 (0.6) 62.1
Total asset impairment and other special charges $ 85.2 $ 210.0 $ 259.3 $ 306.2
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments (Narrative) (Details)
€ in Millions, ¥ in Millions, £ in Millions, SFr in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
EUR (€)
Sep. 30, 2018
CHF (SFr)
Sep. 30, 2018
GBP (£)
Sep. 30, 2018
JPY (¥)
Dec. 31, 2017
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Maximum remaining maturity of foreign currency derivatives     30 days            
Description of derivative activity volume (percentage) 20.00%   20.00%   20.00% 20.00% 20.00% 20.00%  
Interest rate cash flow hedge gain (loss) to be reclassified during next 12 months $ 15.0   $ 15.0            
Cash payment     155.4            
OTTI recognized 0.0 $ 0.0 $ 0.0 $ 0.0          
Available-for-sale, percentage of nonperforming assets (percentage)     60.00%            
Amount of receivable derecognized 645.1   $ 645.1           $ 723.2
Buy Us Dollar Sell Euro                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Derivative liability, notional amount 1,400.0   1,400.0            
Derivative asset, notional amount | €         € 1,190        
Buy Euro Sell Us Dollar                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Derivative liability, notional amount | €         € 1,570        
Derivative asset, notional amount 1,840.0   1,840.0            
Buy US dollar Sell Japanese Yen                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Derivative liability, notional amount 426.9   426.9            
Derivative asset, notional amount | ¥               ¥ 47,940  
Buy GBP Sell USD                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Derivative liability, notional amount | SFr           SFr 234.1      
Derivative asset, notional amount 243.2   243.2            
Buy US dollar Sell British pound                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Derivative liability, notional amount 512.2   512.2            
Derivative asset, notional amount | £             £ 389.4    
Buy British Pound and Sell US Dollars                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Derivative liability, notional amount 466.4   466.4            
Derivative asset, notional amount 613.0   613.0            
Interest Rate Swap                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Derivative liability, notional amount 1,530.0   1,530.0            
Derivative asset, notional amount 350.0   350.0            
Foreign Currency Denominated Debt                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Long-term debt, including current portion 3,450.0   3,450.0           $ 3,700.0
Equity Securities                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Unrealized gain (loss), net $ (40.8)   $ (3.4)            
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments (Elanco Debt Issuance) (Details) - USD ($)
 1 Months Ended
Sep. 05, 2018
Sep. 30, 2018
Aug. 14, 2018
Senior Notes      
Debt Instrument [Line Items]      
Debt instrument, face amount     $ 2,000,000,000
Senior Notes | Senior Notes Due August 27, 2021      
Debt Instrument [Line Items]      
Debt instrument, face amount     $ 500,000,000
Stated interest rate (percentage)     3.912%
Senior Notes | Senior Notes Due August 28, 2023      
Debt Instrument [Line Items]      
Debt instrument, face amount     $ 750,000,000
Stated interest rate (percentage)     4.272%
Senior Notes | Senior Notes Due August 28, 2028      
Debt Instrument [Line Items]      
Debt instrument, face amount     $ 750,000,000
Stated interest rate (percentage)     4.90%
Secured Debt | Term Facility      
Debt Instrument [Line Items]      
Debt instrument, face amount   $ 500,000,000  
Debt instrument, term   3 years  
Proceeds from issuance of notes   $ 2,480,000,000  
Revolving Credit Facility | Line of Credit      
Debt Instrument [Line Items]      
Debt instrument, term 5 years    
Line of credit facility, maximum borrowing capacity $ 750,000,000    
Line of credit, outstanding balance   $ 0  
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments (Effect of Risk-Management Instruments) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Designated as Hedging Instrument | Effect from hedged fixed-rate debt        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Effect from hedged fixed-rate debt $ (19.6) $ (4.0) $ (94.1) $ 3.6
Designated as Hedging Instrument | Effect from interest rate contracts        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Effect from interest rate contracts 19.6 4.0 94.1 (3.6)
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss 3.7 3.7 11.1 11.1
Not Designated as Hedging Instrument | Foreign currency exchange contracts        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Net losses on foreign currency exchange contracts not designated as hedging instruments 0.7 16.3 76.5 79.2
Net investment hedges        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) (47.8) (58.7) 53.0 (332.0)
Net investment hedges | Cross-currency interest rate swaps        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) 14.7 (38.2) 52.3 (95.8)
Cash Flow Hedging | Interest Rate Swap        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) $ 0.0 $ 0.0 $ 0.0 $ 13.0
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments (Fair Value of Financial Instruments) (Details) - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities without readily determinable fair value, amount $ 394.7  
Noncurrent investments 2,005.8 $ 5,678.8
Cost    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 6,646.3 4,763.9
Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 6,646.3 4,763.9
Short-term investments, debt securities 76.1 1,497.9
Noncurrent investments 2,005.8 5,678.8
Short-term commercial paper borrowings (399.7) (2,696.8)
Long-term debt, including current portion (12,277.1) (10,950.3)
Estimate of Fair Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 6,646.3 4,763.9
Short-term commercial paper borrowings (398.4) (2,690.6)
Long-term debt, including current portion (12,542.2) (11,529.9)
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 6,646.3 4,712.4
Short-term commercial paper borrowings 0.0 0.0
Long-term debt, including current portion 0.0 0.0
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.0 51.5
Short-term commercial paper borrowings (398.4) (2,690.6)
Long-term debt, including current portion (12,542.2) (11,529.9)
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.0 0.0
Short-term commercial paper borrowings 0.0 0.0
Long-term debt, including current portion 0.0 0.0
U.S. government and agency securities | Cost    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 10.6 218.2
Noncurrent investments, debt securities 159.6 365.0
U.S. government and agency securities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 10.5 217.8
Noncurrent investments, debt securities 152.0 360.0
U.S. government and agency securities | Estimate of Fair Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 10.5 217.8
Noncurrent investments, debt securities 152.0 360.0
U.S. government and agency securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 10.5 217.8
Noncurrent investments, debt securities 152.0 360.0
U.S. government and agency securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 0.0 0.0
Noncurrent investments, debt securities 0.0 0.0
U.S. government and agency securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 0.0 0.0
Noncurrent investments, debt securities 0.0 0.0
Corporate debt securities | Cost    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 52.7 1,183.2
Noncurrent investments, debt securities 631.5 3,473.5
Corporate debt securities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 52.7 1,182.3
Noncurrent investments, debt securities 622.0 3,464.3
Corporate debt securities | Estimate of Fair Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 52.7 1,182.3
Noncurrent investments, debt securities 622.0 3,464.3
Corporate debt securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 0.0 0.0
Noncurrent investments, debt securities 0.0 0.0
Corporate debt securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 52.7 1,182.3
Noncurrent investments, debt securities 622.0 3,464.3
Corporate debt securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 0.0 0.0
Noncurrent investments, debt securities 0.0 0.0
Mortgage-backed securities | Cost    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Noncurrent investments, debt securities 114.1 204.2
Mortgage-backed securities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Noncurrent investments, debt securities 109.5 202.4
Mortgage-backed securities | Estimate of Fair Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Noncurrent investments, debt securities 109.5 202.4
Mortgage-backed securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Noncurrent investments, debt securities 0.0 0.0
Mortgage-backed securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Noncurrent investments, debt securities 109.5 202.4
Mortgage-backed securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Noncurrent investments, debt securities 0.0 0.0
Asset-backed securities | Cost    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 11.6 94.3
Noncurrent investments, debt securities 27.3 656.0
Asset-backed securities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 11.5 94.2
Noncurrent investments, debt securities 27.0 653.9
Asset-backed securities | Estimate of Fair Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 11.5 94.2
Noncurrent investments, debt securities 27.0 653.9
Asset-backed securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 0.0 0.0
Noncurrent investments, debt securities 0.0 0.0
Asset-backed securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 11.5 94.2
Noncurrent investments, debt securities 27.0 653.9
Asset-backed securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 0.0 0.0
Noncurrent investments, debt securities 0.0 0.0
Other securities | Cost    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 39.3  
Cost and equity method investments   66.4
Other securities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 137.4  
Cost and equity method investments   132.1
Other securities | Estimate of Fair Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 137.4  
Cost and equity method investments   132.1
Other securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 0.0  
Cost and equity method investments   0.0
Other securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 0.0  
Cost and equity method investments   0.0
Other securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 137.4  
Cost and equity method investments   132.1
Marketable equity securities | Cost    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 146.4  
Marketable equity securities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 287.9  
Marketable equity securities | Estimate of Fair Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 287.9  
Marketable equity securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 287.9  
Marketable equity securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 0.0  
Marketable equity securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 0.0  
Marketable equity securities | Cost    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable equity securities   131.0
Marketable equity securities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable equity securities   281.3
Marketable equity securities | Estimate of Fair Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable equity securities   281.3
Marketable equity securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable equity securities   281.3
Marketable equity securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable equity securities   0.0
Marketable equity securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable equity securities   0.0
Other securities | Cost    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 1.4 3.6
Other securities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 1.4 3.6
Other securities | Estimate of Fair Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 1.4 3.6
Other securities | Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 0.0 0.0
Other securities | Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 1.4 3.6
Other securities | Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments, debt securities 0.0 0.0
Cost and equity method investments | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cost and equity method investments $ 275.3 $ 584.8
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments (Risk Management Instruments) (Details) - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Effect from interest rate contracts | Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other current liabilities   $ (0.2)
Effect from interest rate contracts | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other current liabilities   0.0
Effect from interest rate contracts | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other current liabilities   (0.2)
Effect from interest rate contracts | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other current liabilities   0.0
Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other current liabilities $ (62.0) (208.0)
Other noncurrent liabilities (41.4) (45.2)
Carrying Amount | Effect from interest rate contracts | Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables   0.8
Sundry   35.1
Other current liabilities (2.7)  
Other noncurrent liabilities (66.5) (10.5)
Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables 30.3  
Sundry 6.9  
Other current liabilities (16.6) (33.4)
Other noncurrent liabilities   (26.0)
Carrying Amount | Foreign currency exchange contracts | Not Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables 6.3 26.8
Other current liabilities (14.0) (36.0)
Estimate of Fair Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other current liabilities (62.0) (208.0)
Other noncurrent liabilities (41.4) (45.2)
Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other current liabilities 0.0 0.0
Other noncurrent liabilities 0.0 0.0
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other current liabilities 0.0 0.0
Other noncurrent liabilities 0.0 0.0
Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other current liabilities (62.0) (208.0)
Other noncurrent liabilities (41.4) (45.2)
Estimate of Fair Value Measurement | Effect from interest rate contracts | Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables   0.8
Sundry   35.1
Other current liabilities (2.7) (0.2)
Other noncurrent liabilities (66.5) (10.5)
Estimate of Fair Value Measurement | Effect from interest rate contracts | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables   0.0
Sundry   0.0
Other current liabilities 0.0  
Other noncurrent liabilities 0.0 0.0
Estimate of Fair Value Measurement | Effect from interest rate contracts | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables   0.8
Sundry   35.1
Other current liabilities (2.7)  
Other noncurrent liabilities (66.5) (10.5)
Estimate of Fair Value Measurement | Effect from interest rate contracts | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables   0.0
Sundry   0.0
Other current liabilities 0.0  
Other noncurrent liabilities 0.0 0.0
Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables 30.3  
Sundry 6.9  
Other current liabilities (16.6) (33.4)
Other noncurrent liabilities   (26.0)
Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables 0.0  
Sundry 0.0  
Other current liabilities 0.0 0.0
Other noncurrent liabilities   0.0
Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables 30.3  
Sundry 6.9  
Other current liabilities (16.6) (33.4)
Other noncurrent liabilities   (26.0)
Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables 0.0  
Sundry 0.0  
Other current liabilities 0.0 0.0
Other noncurrent liabilities   0.0
Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables 6.3 26.8
Other current liabilities (14.0) (36.0)
Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables 0.0 0.0
Other current liabilities 0.0 0.0
Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables 6.3 26.8
Other current liabilities (14.0) (36.0)
Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other receivables 0.0 0.0
Other current liabilities $ 0.0 $ 0.0
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments (Contractual Maturities) (Details)
$ in Millions
Sep. 30, 2018
USD ($)
Debt Securities Contractual Maturities  
Total $ 985.1
Less Than 1 Year 74.7
1-5 Years 620.5
6-10 Years 135.4
More Than 10 Years $ 154.5
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments (Unrealized gain and losses) (Details) - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Fair Value Disclosures [Abstract]    
Unrealized gross gains $ 2.1 $ 184.7
Unrealized gross losses 24.4 47.5
Fair value of securities in an unrealized gain position 164.0 1,434.2
Fair value of securities in an unrealized loss position $ 816.7 $ 4,692.8
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments (Realized gain and losses) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Fair Value Disclosures [Abstract]        
Proceeds from sales   $ 951.5   $ 3,003.0
Realized gross gains on sales   9.0   82.9
Realized gross losses on sales   $ 0.8   $ 3.2
Adoption of ASU [Abstract]        
Proceeds from sales $ 52.0   $ 5,598.4  
Realized gross gains on sales 0.4   8.1  
Realized gross losses on sales $ 0.7   $ 49.7  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Operating Loss Carryforwards [Line Items]        
Effective income tax rate, percentage 18.50% 6.10% 26.20% 24.10%
Acquired in-process research and development $ 30.0 $ 205.0 $ 1,654.5 $ 1,062.6
ARMO and AurKa        
Operating Loss Carryforwards [Line Items]        
Acquired in-process research and development     $ 1,560.0  
Tax Year 2013        
Operating Loss Carryforwards [Line Items]        
Tax year under examination     2013  
Tax Year 2014        
Operating Loss Carryforwards [Line Items]        
Tax year under examination     2014  
Tax Year 2015        
Operating Loss Carryforwards [Line Items]        
Tax year under examination     2015  
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1
Retirement Benefits (Narrative) (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
USD ($)
Sep. 30, 2018
USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]    
Curtailment gain $ 28.0 $ 28.0
Pension contributions   35.0
Payment for additional discretionary funding   200.0
Estimated future employer contributions in current fiscal year $ 15.0 $ 15.0
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
Retirement Benefits (Components of Net Periodic Benefit Cost) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Defined Benefit Plan Disclosure [Line Items]        
Curtailment (gain) loss $ (28.0)   $ (28.0)  
Defined Benefit Pension Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost 74.2 $ 86.0 232.3 $ 251.6
Interest cost 117.9 103.6 342.5 309.2
Expected return on plan assets (212.7) (196.4) (636.3) (585.7)
Amortization of prior service cost 1.1 1.4 3.6 4.3
Recognized actuarial loss 79.2 72.5 261.2 215.6
Curtailment (gain) loss 1.3 0.0 1.3 0.0
Net periodic benefit cost 61.0 67.1 204.6 195.0
Retiree Health Benefit Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost 10.1 11.6 31.7 34.8
Interest cost 14.9 13.2 42.3 39.6
Expected return on plan assets (44.8) (40.2) (132.7) (120.6)
Amortization of prior service cost (19.3) (22.5) (60.2) (67.5)
Recognized actuarial loss 0.8 4.6 5.4 13.8
Curtailment (gain) loss (29.3) 0.0 (29.3) 0.0
Net periodic benefit cost $ (67.6) $ (33.3) $ (142.8) $ (99.9)
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1
Contingencies (Details)
R$ in Millions, $ in Millions
 1 Months Ended 9 Months Ended
Aug. 29, 2018
lawsuit
Aug. 31, 2018
USD ($)
patent
Jul. 31, 2018
company
product
Jun. 30, 2018
case
Aug. 31, 2015
plaintiff
Sep. 30, 2018
USD ($)
lawsuit
claim
company
patent
individual
plaintiff
demand
defendant
application
Sep. 30, 2018
BRL (R$)
lawsuit
claim
company
patent
individual
plaintiff
demand
defendant
application
Feb. 28, 2017
company
demand
Loss Contingency [Line Items]                
Number of companies | company     4          
Number of generic products | product     1          
U.S. | Alimta                
Loss Contingency [Line Items]                
Number of new application | application           10 10  
Number of defendants | defendant           2 2  
Number of companies | company           5 5  
Dr Reddy's Lab                
Loss Contingency [Line Items]                
Number of cases ruled in favor | case       2        
Japanese Administrative Proceedings                
Loss Contingency [Line Items]                
Number of companies | company               3
Number of demands | demand           3 3  
Number of patents | patent           2 2  
Number of demands resumed | demand               1
Number of demands remaining | demand               2
Product Liability Litigation | Cymbalta                
Loss Contingency [Line Items]                
Number of lawsuits | lawsuit           140 140  
Number of plaintiffs | plaintiff         4 1,470 1,470  
Product Liability Litigation | California | Cymbalta                
Loss Contingency [Line Items]                
Number of lawsuits | individual           40 40  
Employee Litigation | Brazil                
Loss Contingency [Line Items]                
Number of lawsuits | lawsuit           30 30  
Damages awarded, value           $ 125.0 R$ 500  
Number of Individuals | individual           105 105  
Agri Stats, Inc.                
Loss Contingency [Line Items]                
Number of lawsuits | lawsuit 25              
Adocia S.A                
Loss Contingency [Line Items]                
Number of patents | patent   2            
New claims filed | claim           2 2  
Amount awarded to other party | $   $ 11.7            
Estimated possible loss | $   1,800.0            
Gain Contingency, Unrecorded Amount | $   $ 188.0            
Plaintiff Appealing Decision of Court | Employee Litigation | Brazil                
Loss Contingency [Line Items]                
Number of Individuals | individual           305 305  
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Comprehensive Income (Loss) (AOCI) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]          
Beginning balance     $ 11,667.9    
Other comprehensive income (loss) before reclassifications $ 610.3 $ 141.0 234.5 $ 588.4  
Net amount reclassified from accumulated other comprehensive loss 49.9 26.7 140.8 62.8  
Net other comprehensive income (loss) [1] 660.2 167.7 375.3 651.2  
Ending balance 14,150.9   14,150.9    
Accumulated Other Comprehensive Loss          
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]          
Beginning balance (6,108.7) (4,742.3) (5,694.9) (5,225.8)  
Reclassification due to adoption of new accounting standard         $ (128.9)
Ending balance (5,448.5) (4,574.6) (5,448.5) (4,574.6)  
Foreign Currency Translation Gains (Losses)          
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]          
Beginning balance (1,671.5) (1,349.4) (1,233.4) (1,867.3)  
Reclassification due to adoption of new accounting standard         0.0
Other comprehensive income (loss) before reclassifications 60.6 135.8 (377.5) 653.7  
Net amount reclassified from accumulated other comprehensive loss 0.0 8.1 0.0 8.1  
Net other comprehensive income (loss) 60.6 143.9 (377.5) 661.8  
Ending balance (1,610.9) (1,205.5) (1,610.9) (1,205.5)  
Unrealized Net Gains (Losses) on Securities          
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]          
Beginning balance (18.1) 153.2 113.5 224.0  
Reclassification due to adoption of new accounting standard         (128.9)
Other comprehensive income (loss) before reclassifications 1.1 33.9 31.0 9.6  
Net amount reclassified from accumulated other comprehensive loss (0.2) (23.9) (32.8) (70.4)  
Net other comprehensive income (loss) 0.9 10.0 (1.8) (60.8)  
Ending balance (17.2) 163.2 (17.2) 163.2  
Defined Benefit Pension and Retiree Health Benefit Plans          
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]          
Beginning balance (4,190.6) (3,348.5) (4,340.7) (3,371.6)  
Reclassification due to adoption of new accounting standard         0.0
Other comprehensive income (loss) before reclassifications 548.6 (28.7) 581.0 (83.3)  
Net amount reclassified from accumulated other comprehensive loss 47.2 40.1 164.9 117.8  
Net other comprehensive income (loss) 595.8 11.4 745.9 34.5  
Ending balance (3,594.8) (3,337.1) (3,594.8) (3,337.1)  
Effective Portion of Cash Flow Hedges          
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]          
Beginning balance (228.5) (197.6) (234.3) (210.9)  
Reclassification due to adoption of new accounting standard         0.0
Other comprehensive income (loss) before reclassifications 0.0 0.0 0.0 8.4  
Net amount reclassified from accumulated other comprehensive loss 2.9 2.4 8.7 7.3  
Net other comprehensive income (loss) 2.9 2.4 8.7 15.7  
Ending balance (225.6) (195.2) (225.6) (195.2)  
AOCI Attributable to Parent          
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]          
Beginning balance (6,108.7) (4,774.9) (5,718.6) (5,274.0)  
Reclassification due to adoption of new accounting standard (105.2)   (105.2)   (104.8)
Ending balance (5,439.5) (4,609.4) (5,439.5) (4,609.4)  
AOCI Attributable to Noncontrolling Interest          
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]          
Beginning balance     23.7 48.2  
Reclassification due to adoption of new accounting standard         $ (24.1)
Ending balance $ (9.0) $ 34.8 $ (9.0) $ 34.8  
[1] Other comprehensive income for the three and nine months ended September 30, 2018 was all attributable to controlling interest. Other comprehensive income for the three and nine months ended September 30, 2017 consisted of $165.5 million and $664.6 million, respectively, of other comprehensive income attributable to controlling interest and $2.2 million and $(13.4) million of other comprehensive income (loss) attributable to noncontrolling interest during the same periods.
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Comprehensive Income (Loss) (Tax effect) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items $ (146.4) $ 19.0 $ (202.7) $ 142.7
Foreign currency translation gains/losses        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items 7.0 33.9 (11.2) 149.7
Unrealized net gains/losses on securities        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items (0.2) (4.2) 1.1 25.4
Defined benefit pension and retiree health benefit plans        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items (152.4) (9.4) (190.3) (24.0)
Effective portion of cash flow hedges        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items $ (0.8) $ (1.3) $ (2.3) $ (8.4)
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Comprehensive Income (Loss) (Reclassification) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Total reclassifications for the period (net of tax) $ 49.9 $ 26.7 $ 140.8 $ 62.8
Other, net 15.4 (49.9) (90.1) (188.6)
Tax (benefit) expense 261.5 36.0 749.8 460.5
Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Total reclassifications for the period (net of tax) 49.9 26.7 140.8 62.8
Prior service benefits, net | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Amortization of retirement benefit items: (18.2) (21.1) (56.6) (63.2)
Amortization of retirement benefit items | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Amortization of retirement benefit items: 80.0 77.1 266.6 229.4
Defined Benefit Pension and Retiree Health Benefit Plans        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Amortization of retirement benefit items: 61.8 56.0 210.0 166.2
Tax benefit (14.6) (15.9) (45.1) (48.4)
Total reclassifications for the period (net of tax) 47.2 40.1 164.9 117.8
Unrealized net gains/losses on securities        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Total reclassifications for the period (net of tax) (0.2) (23.9) (32.8) (70.4)
Unrealized net gains/losses on securities | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Other, net (0.3) (36.7) (41.6) (108.2)
Tax (benefit) expense 0.1 12.8 8.8 37.8
Net of tax (0.2) (23.9) (32.8) (70.4)
Other, net of tax | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Other, net $ 2.9 $ 10.5 $ 8.7 $ 15.4
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other - Net, (Income) Expense (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Nonoperating Income (Expense) [Abstract]        
Interest expense $ 69.4 $ 61.9 $ 193.9 $ 162.1
Interest income (32.1) (45.1) (118.8) (114.6)
Retirement benefit (62.9) (63.8) (174.2) (191.3)
Other income 41.0 (2.9) 9.0 (44.8)
Other–net, (income) expense $ 15.4 $ (49.9) $ (90.1) $ (188.6)
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Revenue by Product) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Segment Reporting Information [Line Items]        
Revenues $ 6,061.9 $ 5,658.0 $ 18,117.1 $ 16,710.6
Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 5,289.2 4,917.4 15,791.1 14,415.8
Animal health products        
Segment Reporting Information [Line Items]        
Revenues 772.7 740.6 2,326.0 2,294.8
Endocrinology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 2,837.9 2,560.7 8,491.6 7,175.0
Trulicity | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 816.2 527.7 2,274.3 1,380.8
Humalog | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 664.6 696.2 2,226.1 2,083.0
Forteo | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 390.8 441.7 1,138.5 1,235.8
Humulin® | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 322.1 300.5 994.0 972.8
Basaglar | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 201.2 145.7 569.0 278.3
Jardiance | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 166.9 127.2 465.1 304.3
Trajenta | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 135.7 153.3 418.5 408.2
Other Endocrinology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 140.4 168.4 406.1 511.8
Oncology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 1,064.2 957.6 3,130.9 2,800.5
Alimta | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 520.5 514.5 1,576.0 1,537.3
Cyramza | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 198.4 196.0 600.8 553.5
Erbitux | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 159.5 163.5 475.5 477.0
Other Oncology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 185.8 83.6 478.6 232.7
Cardiovascular | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 583.8 662.9 1,845.7 2,172.5
Cialis | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 467.1 564.9 1,501.2 1,725.7
Effient | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 45.3 55.9 104.8 326.6
Other Cardiovascular | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 71.4 42.1 239.7 120.2
Neuroscience | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 427.2 507.7 1,370.9 1,673.7
Cymbalta | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 172.0 183.2 523.5 564.4
Zyprexa | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 109.9 140.6 360.4 428.9
Strattera® | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 98.7 137.1 343.5 519.9
Other Neuroscience | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 46.6 46.8 143.5 160.5
Immunology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 319.5 167.6 762.9 409.6
Taltz® | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 263.9 151.3 630.4 386.7
Other Immunology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 55.6 16.3 132.5 22.9
Other pharmaceuticals | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 56.6 60.9 189.1 184.5
U.S.        
Segment Reporting Information [Line Items]        
Revenues 3,446.6 3,104.4 10,211.0 9,361.8
U.S. | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 3,062.7 2,751.3 9,073.2 8,188.4
U.S. | Animal health products        
Segment Reporting Information [Line Items]        
Revenues 383.9 353.0 1,137.8 1,173.4
U.S. | Endocrinology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 1,796.5 1,624.4 5,413.6 4,493.4
U.S. | Trulicity | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 645.9 412.9 1,786.5 1,090.1
U.S. | Humalog | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 365.6 414.9 1,334.2 1,254.3
U.S. | Forteo | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 182.5 234.1 529.7 661.5
U.S. | Humulin® | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 216.9 203.0 677.3 634.9
U.S. | Basaglar | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 157.3 115.2 440.4 196.7
U.S. | Jardiance | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 104.2 83.8 284.8 198.3
U.S. | Trajenta | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 50.3 68.4 161.3 174.2
U.S. | Other Endocrinology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 73.8 92.1 199.4 283.4
U.S. | Oncology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 619.8 509.3 1,741.2 1,492.8
U.S. | Alimta | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 288.5 260.3 815.1 761.9
U.S. | Cyramza | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 67.0 69.5 210.7 204.3
U.S. | Erbitux | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 132.6 136.0 394.0 398.2
U.S. | Other Oncology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 131.7 43.5 321.4 128.4
U.S. | Cardiovascular | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 365.8 367.2 1,158.0 1,308.6
U.S. | Cialis | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 295.9 319.6 954.9 997.3
U.S. | Effient | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 30.2 42.7 59.4 290.8
U.S. | Other Cardiovascular | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 39.7 4.9 143.7 20.5
U.S. | Neuroscience | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 55.8 108.4 213.5 515.4
U.S. | Cymbalta | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 14.5 19.6 39.3 100.8
U.S. | Zyprexa | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 7.0 12.6 27.6 49.3
U.S. | Strattera® | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 10.5 52.9 74.4 276.9
U.S. | Other Neuroscience | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 23.8 23.3 72.2 88.4
U.S. | Immunology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 211.4 131.3 497.8 343.6
U.S. | Taltz® | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 210.6 131.3 495.3 343.6
U.S. | Other Immunology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 0.8 0.0 2.5 0.0
U.S. | Other pharmaceuticals | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 13.4 10.7 49.1 34.6
Outside U.S.        
Segment Reporting Information [Line Items]        
Revenues 2,615.3 2,553.6 7,906.1 7,348.7
Outside U.S. | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 2,226.5 2,166.1 6,717.8 6,227.3
Outside U.S. | Animal health products        
Segment Reporting Information [Line Items]        
Revenues 388.8 387.6 1,188.2 1,121.4
Outside U.S. | Endocrinology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 1,041.4 936.3 3,078.0 2,681.6
Outside U.S. | Trulicity | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 170.3 114.8 487.8 290.7
Outside U.S. | Humalog | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 299.0 281.3 891.8 828.6
Outside U.S. | Forteo | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 208.3 207.6 608.8 574.3
Outside U.S. | Humulin® | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 105.1 97.5 316.7 337.9
Outside U.S. | Basaglar | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 43.9 30.5 128.5 81.6
Outside U.S. | Jardiance | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 62.7 43.4 180.3 105.9
Outside U.S. | Trajenta | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 85.3 84.9 257.2 234.1
Outside U.S. | Other Endocrinology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 66.8 76.3 206.9 228.5
Outside U.S. | Oncology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 444.4 448.3 1,389.7 1,307.7
Outside U.S. | Alimta | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 232.0 254.2 760.9 775.4
Outside U.S. | Cyramza | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 131.4 126.5 390.1 349.2
Outside U.S. | Erbitux | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 26.9 27.4 81.6 78.8
Outside U.S. | Other Oncology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 54.1 40.2 157.1 104.3
Outside U.S. | Cardiovascular | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 218.0 295.7 687.8 863.9
Outside U.S. | Cialis | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 171.2 245.3 546.2 728.5
Outside U.S. | Effient | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 15.1 13.1 45.3 35.8
Outside U.S. | Other Cardiovascular | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 31.7 37.3 96.3 99.6
Outside U.S. | Neuroscience | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 371.5 399.3 1,157.4 1,158.4
Outside U.S. | Cymbalta | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 157.5 163.5 484.2 463.6
Outside U.S. | Zyprexa | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 102.8 128.0 332.8 379.6
Outside U.S. | Strattera® | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 88.2 84.1 269.2 243.0
Outside U.S. | Other Neuroscience | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 23.0 23.7 71.2 72.2
Outside U.S. | Immunology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 108.1 36.3 265.1 66.0
Outside U.S. | Taltz® | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 53.3 20.0 135.1 43.1
Outside U.S. | Other Immunology | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 54.8 16.3 130.0 22.9
Outside U.S. | Other pharmaceuticals | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Revenues 43.2 50.2 139.8 149.7
Europe        
Segment Reporting Information [Line Items]        
Revenues 1,017.0 1,017.0 3,142.9 2,877.6
Japan        
Segment Reporting Information [Line Items]        
Revenues 608.8 616.7 1,828.9 1,767.0
Other foreign countries        
Segment Reporting Information [Line Items]        
Revenues $ 989.5 $ 920.0 $ 2,934.3 $ 2,704.2
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Segment profit) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Segment Reporting Information [Line Items]        
Consolidated income before taxes $ 1,411.0 $ 591.6 $ 2,856.8 $ 1,913.3
Acquired in-process research and development (Note 3) (30.0) (205.0) (1,654.5) (1,062.6)
Asset impairment, restructuring, and other special charges (Note 5) (83.3) (406.5) (236.0) (670.4)
Other, net (15.4) 49.9 90.1 188.6
Operating Segments        
Segment Reporting Information [Line Items]        
Consolidated income before taxes 1,676.7 1,364.4 5,213.0 4,188.3
Operating Segments | Human pharmaceutical products        
Segment Reporting Information [Line Items]        
Consolidated income before taxes 1,514.0 1,242.5 4,751.0 3,765.7
Operating Segments | Animal health products        
Segment Reporting Information [Line Items]        
Consolidated income before taxes 162.6 121.9 461.9 422.6
Corporate, Non-Segment        
Segment Reporting Information [Line Items]        
Acquired in-process research and development (Note 3) (30.0) (205.0) (1,654.5) (1,062.6)
Amortization of intangible assets (153.4) (155.8) (458.7) (510.0)
Asset impairment, restructuring, and other special charges (Note 5) (83.3) (406.5) (236.0) (670.4)
Other, net $ 1.0 $ (5.5) $ (7.0) $ (32.0)
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Narrative) (Details)
 9 Months Ended
Sep. 30, 2018
segment
Segment Reporting [Abstract]  
Number of operating segments 2
EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 803 265 1 true 149 0 false 21 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.lilly.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Condensed Statements of Operations (Unaudited) Sheet http://www.lilly.com/role/ConsolidatedCondensedStatementsOfOperationsUnaudited Consolidated Condensed Statements of Operations (Unaudited) Statements 2 false false R3.htm 1002000 - Statement - Consolidated Condensed Statements of Comprehensive Income (Unaudited) Sheet http://www.lilly.com/role/ConsolidatedCondensedStatementsOfComprehensiveIncomeUnaudited Consolidated Condensed Statements of Comprehensive Income (Unaudited) Statements 3 false false R4.htm 1002001 - Statement - Consolidated Condensed Statements of Comprehensive Income (Loss) (Unaudited) (Parenthetical) Sheet http://www.lilly.com/role/ConsolidatedCondensedStatementsOfComprehensiveIncomeLossUnauditedParenthetical Consolidated Condensed Statements of Comprehensive Income (Loss) (Unaudited) (Parenthetical) Statements 4 false false R5.htm 1003000 - Statement - Consolidated Condensed Balance Sheets Sheet http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets Consolidated Condensed Balance Sheets Statements 5 false false R6.htm 1003000 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited) Sheet http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityUnaudited Consolidated Statements of Shareholders' Equity (Unaudited) Statements 6 false false R7.htm 1003001 - Statement - Consolidated Condensed Statements of Shareholders' Equity (Unaudited) (Parenthetical) Sheet http://www.lilly.com/role/ConsolidatedCondensedStatementsOfShareholdersEquityUnauditedParenthetical Consolidated Condensed Statements of Shareholders' Equity (Unaudited) (Parenthetical) Statements 7 false false R8.htm 1003501 - Statement - Consolidated Condensed Balance Sheets (Parenthetical) Sheet http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical Consolidated Condensed Balance Sheets (Parenthetical) Statements 8 false false R9.htm 1004000 - Statement - Consolidated Condensed Statements of Cash Flows Sheet http://www.lilly.com/role/ConsolidatedCondensedStatementsOfCashFlows Consolidated Condensed Statements of Cash Flows Statements 9 false false R10.htm 2101100 - Disclosure - Basis of Presentation and Revenue Sheet http://www.lilly.com/role/BasisOfPresentationAndRevenue Basis of Presentation and Revenue Notes 10 false false R11.htm 2102100 - Disclosure - Implementation of New Financial Accounting Pronouncements Sheet http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncements Implementation of New Financial Accounting Pronouncements Notes 11 false false R12.htm 2103100 - Disclosure - Divestures and Acquisitions Sheet http://www.lilly.com/role/DivesturesAndAcquisitions Divestures and Acquisitions Notes 12 false false R13.htm 2104100 - Disclosure - Collaborations and Other Arrangements Sheet http://www.lilly.com/role/CollaborationsAndOtherArrangements Collaborations and Other Arrangements Notes 13 false false R14.htm 2105100 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges Sheet http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialCharges Asset Impairment, Restructuring, and Other Special Charges Notes 14 false false R15.htm 2106100 - Disclosure - Financial Instruments Sheet http://www.lilly.com/role/FinancialInstruments Financial Instruments Notes 15 false false R16.htm 2111100 - Disclosure - Income Taxes Sheet http://www.lilly.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 2112100 - Disclosure - Retirement Benefits Sheet http://www.lilly.com/role/RetirementBenefits Retirement Benefits Notes 17 false false R18.htm 2113100 - Disclosure - Contingencies Sheet http://www.lilly.com/role/Contingencies Contingencies Notes 18 false false R19.htm 2114100 - Disclosure - Other Comprehensive Income (Loss) Sheet http://www.lilly.com/role/OtherComprehensiveIncomeLoss Other Comprehensive Income (Loss) Notes 19 false false R20.htm 2115100 - Disclosure - Other-Net, (Income) Expense Sheet http://www.lilly.com/role/OtherNetIncomeExpense Other-Net, (Income) Expense Notes 20 false false R21.htm 2116100 - Disclosure - Segment Information Sheet http://www.lilly.com/role/SegmentInformation Segment Information Notes 21 false false R22.htm 2202201 - Disclosure - Implementation of New Financial Accounting Pronouncements (Policies) Sheet http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsPolicies Implementation of New Financial Accounting Pronouncements (Policies) Policies http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncements 22 false false R23.htm 2203201 - Disclosure - Divestiture and Acquisitions (Policies) Sheet http://www.lilly.com/role/DivestitureAndAcquisitionsPolicies Divestiture and Acquisitions (Policies) Policies http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncements 23 false false R24.htm 2206201 - Disclosure - Financial Instruments (Policies) Sheet http://www.lilly.com/role/FinancialInstrumentsPolicies Financial Instruments (Policies) Policies http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncements 24 false false R25.htm 2301301 - Disclosure - Basis of Presentation and Revenue Basis of Presentation and Revenue (Tables) Sheet http://www.lilly.com/role/BasisOfPresentationAndRevenueBasisOfPresentationAndRevenueTables Basis of Presentation and Revenue Basis of Presentation and Revenue (Tables) Tables 25 false false R26.htm 2302302 - Disclosure - Implementation of New Accounting Pronouncements (Tables) Sheet http://www.lilly.com/role/ImplementationOfNewAccountingPronouncementsTables Implementation of New Accounting Pronouncements (Tables) Tables 26 false false R27.htm 2303302 - Disclosure - Divestiture and Acquisitions (Tables) Sheet http://www.lilly.com/role/DivestitureAndAcquisitionsTables Divestiture and Acquisitions (Tables) Tables 27 false false R28.htm 2304301 - Disclosure - Collaborations and Other Arrangements (Tables) Sheet http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables Collaborations and Other Arrangements (Tables) Tables http://www.lilly.com/role/CollaborationsAndOtherArrangements 28 false false R29.htm 2305301 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables) Sheet http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesTables Asset Impairment, Restructuring, and Other Special Charges (Tables) Tables http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialCharges 29 false false R30.htm 2306302 - Disclosure - Financial Instruments (Tables) Sheet http://www.lilly.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.lilly.com/role/FinancialInstruments 30 false false R31.htm 2312301 - Disclosure - Retirement Benefits (Tables) Sheet http://www.lilly.com/role/RetirementBenefitsTables Retirement Benefits (Tables) Tables http://www.lilly.com/role/RetirementBenefits 31 false false R32.htm 2314301 - Disclosure - Other Comprehensive Income (Loss) (Tables) Sheet http://www.lilly.com/role/OtherComprehensiveIncomeLossTables Other Comprehensive Income (Loss) (Tables) Tables http://www.lilly.com/role/OtherComprehensiveIncomeLoss 32 false false R33.htm 2315301 - Disclosure - Other - Net, (Income) Expense (Tables) Sheet http://www.lilly.com/role/OtherNetIncomeExpenseTables Other - Net, (Income) Expense (Tables) Tables 33 false false R34.htm 2316301 - Disclosure - Segment Information (Tables) Sheet http://www.lilly.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.lilly.com/role/SegmentInformation 34 false false R35.htm 2401402 - Disclosure - Basis of Presentation and Revenue Basis of Presentation and Revenue (Details) Sheet http://www.lilly.com/role/BasisOfPresentationAndRevenueBasisOfPresentationAndRevenueDetails Basis of Presentation and Revenue Basis of Presentation and Revenue (Details) Details http://www.lilly.com/role/BasisOfPresentationAndRevenueBasisOfPresentationAndRevenueTables 35 false false R36.htm 2402403 - Disclosure - Implementation of New Financial Accounting Pronouncements (Details) Sheet http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails Implementation of New Financial Accounting Pronouncements (Details) Details http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsPolicies 36 false false R37.htm 2403403 - Disclosure - Divestiture and Acquisitions (Formation of Elanco and IPO) (Details) Sheet http://www.lilly.com/role/DivestitureAndAcquisitionsFormationOfElancoAndIpoDetails Divestiture and Acquisitions (Formation of Elanco and IPO) (Details) Details http://www.lilly.com/role/DivestitureAndAcquisitionsTables 37 false false R38.htm 2403404 - Disclosure - Divestiture and Acquisitions (Acquisitions) (Details) Sheet http://www.lilly.com/role/DivestitureAndAcquisitionsAcquisitionsDetails Divestiture and Acquisitions (Acquisitions) (Details) Details http://www.lilly.com/role/DivestitureAndAcquisitionsTables 38 false false R39.htm 2403405 - Disclosure - Divestiture and Acquisitions (Purchased Price) (Details) Sheet http://www.lilly.com/role/DivestitureAndAcquisitionsPurchasedPriceDetails Divestiture and Acquisitions (Purchased Price) (Details) Details http://www.lilly.com/role/DivestitureAndAcquisitionsTables 39 false false R40.htm 2404402 - Disclosure - Collaborations and Other Arrangements (Details) Sheet http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails Collaborations and Other Arrangements (Details) Details http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables 40 false false R41.htm 2405402 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details) Sheet http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesDetails Asset Impairment, Restructuring, and Other Special Charges (Details) Details http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesTables 41 false false R42.htm 2406403 - Disclosure - Financial Instruments (Narrative) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments (Narrative) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 42 false false R43.htm 2406404 - Disclosure - Financial Instruments (Elanco Debt Issuance) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsElancoDebtIssuanceDetails Financial Instruments (Elanco Debt Issuance) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 43 false false R44.htm 2406405 - Disclosure - Financial Instruments (Effect of Risk-Management Instruments) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementInstrumentsDetails Financial Instruments (Effect of Risk-Management Instruments) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 44 false false R45.htm 2406406 - Disclosure - Financial Instruments (Fair Value of Financial Instruments) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsFairValueOfFinancialInstrumentsDetails Financial Instruments (Fair Value of Financial Instruments) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 45 false false R46.htm 2406407 - Disclosure - Financial Instruments (Risk Management Instruments) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails Financial Instruments (Risk Management Instruments) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 46 false false R47.htm 2406408 - Disclosure - Financial Instruments (Contractual Maturities) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails Financial Instruments (Contractual Maturities) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 47 false false R48.htm 2406409 - Disclosure - Financial Instruments (Unrealized gain and losses) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainAndLossesDetails Financial Instruments (Unrealized gain and losses) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 48 false false R49.htm 2406410 - Disclosure - Financial Instruments (Realized gain and losses) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsRealizedGainAndLossesDetails Financial Instruments (Realized gain and losses) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 49 false false R50.htm 2411401 - Disclosure - Income Taxes (Details) Sheet http://www.lilly.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.lilly.com/role/IncomeTaxes 50 false false R51.htm 2412402 - Disclosure - Retirement Benefits (Narrative) (Details) Sheet http://www.lilly.com/role/RetirementBenefitsNarrativeDetails Retirement Benefits (Narrative) (Details) Details http://www.lilly.com/role/RetirementBenefitsTables 51 false false R52.htm 2412403 - Disclosure - Retirement Benefits (Components of Net Periodic Benefit Cost) (Details) Sheet http://www.lilly.com/role/RetirementBenefitsComponentsOfNetPeriodicBenefitCostDetails Retirement Benefits (Components of Net Periodic Benefit Cost) (Details) Details http://www.lilly.com/role/RetirementBenefitsTables 52 false false R53.htm 2413401 - Disclosure - Contingencies (Details) Sheet http://www.lilly.com/role/ContingenciesDetails Contingencies (Details) Details http://www.lilly.com/role/Contingencies 53 false false R54.htm 2414402 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details) Sheet http://www.lilly.com/role/OtherComprehensiveIncomeLossAociDetails Other Comprehensive Income (Loss) (AOCI) (Details) Details http://www.lilly.com/role/OtherComprehensiveIncomeLossTables 54 false false R55.htm 2414403 - Disclosure - Other Comprehensive Income (Loss) (Tax effect) (Details) Sheet http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails Other Comprehensive Income (Loss) (Tax effect) (Details) Details http://www.lilly.com/role/OtherComprehensiveIncomeLossTables 55 false false R56.htm 2414404 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details) Sheet http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails Other Comprehensive Income (Loss) (Reclassification) (Details) Details http://www.lilly.com/role/OtherComprehensiveIncomeLossTables 56 false false R57.htm 2415402 - Disclosure - Other - Net, (Income) Expense (Details) Sheet http://www.lilly.com/role/OtherNetIncomeExpenseDetails Other - Net, (Income) Expense (Details) Details http://www.lilly.com/role/OtherNetIncomeExpenseTables 57 false false R58.htm 2416402 - Disclosure - Segment Information (Revenue by Product) (Details) Sheet http://www.lilly.com/role/SegmentInformationRevenueByProductDetails Segment Information (Revenue by Product) (Details) Details http://www.lilly.com/role/SegmentInformationTables 58 false false R59.htm 2416403 - Disclosure - Segment Information (Segment profit) (Details) Sheet http://www.lilly.com/role/SegmentInformationSegmentProfitDetails Segment Information (Segment profit) (Details) Details http://www.lilly.com/role/SegmentInformationTables 59 false false R60.htm 2416404 - Disclosure - Segment Information (Narrative) (Details) Sheet http://www.lilly.com/role/SegmentInformationNarrativeDetails Segment Information (Narrative) (Details) Details http://www.lilly.com/role/SegmentInformationTables 60 false false All Reports Book All Reports lly-20180930.xml lly-20180930.xsd lly-20180930_cal.xml lly-20180930_def.xml lly-20180930_lab.xml lly-20180930_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 77 0000059478-18-000256-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000059478-18-000256-xbrl.zip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end

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�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